var title_f11_3_11312="Neonatal BP gestational age";
var content_f11_3_11312=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Neonatal blood pressure based on gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 585px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear regression of mean systolic and diastolic blood pressure on gestational age in 329 infants admitted to NICU on day 1 of life. The mean systolic and diastolic blood pressure, and 95 percent confidence limit (CL) for incremental gestational age are plotted about the respective regression lines.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted&nbsp;with permission from: Macmillan Publishers Ltd. Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol 1995; 15:470. Copyright &copy;1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11312=[""].join("\n");
var outline_f11_3_11312=null;
var title_f11_3_11313="CT of mucinous adenocarcinoma in situ";
var content_f11_3_11313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61743&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT of mucinous adenocarcinoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT of mucinous adenocarcinoma in situ; 2 cm predominantly solid nodule with air bronchogram (arrow) is noted in the left upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11313=[""].join("\n");
var outline_f11_3_11313=null;
var title_f11_3_11314="Patient information: Gout (The Basics)";
var content_f11_3_11314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?10/9/10386\">",
"         Patient information: Pseudogout (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?23/57/24467\">",
"         Patient information: Gout (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/15/34033\">",
"         Patient information: Pseudogout (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Gout (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/gout-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H482924995\">",
"      <span class=\"h1\">",
"       What is gout?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gout is a form of arthritis. It can cause pain and swelling in the joints. At first, it tends to affect only one joint &mdash; most frequently in the big toe. It happens in people who have too much uric acid in the blood. Uric acid is a chemical that is produced when the body breaks down certain foods. Uric acid can form sharp needle-like crystals that build up in the joints and cause pain. Uric acid crystals can also form inside the tubes that carry urine from the kidneys to the bladder. These crystals can turn into &ldquo;kidney stones&rdquo; that can cause pain and problems with the flow of urine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482925002\">",
"      <span class=\"h1\">",
"       What are the symptoms of gout?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with gout get sudden attacks of severe pain, most often the big toe, ankle, or knee. Often the joint also turns red and swells. Usually, only one joint is affected, but some people have pain in more than one joint.",
"     </p>",
"     <p>",
"      The pain from gout can be extreme. The pain and swelling are worst at the beginning of a gout attack. The symptoms then get better within a few days to weeks. It is not clear how the body &ldquo;turns off&rdquo; a gout attack.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482925009\">",
"      <span class=\"h1\">",
"       Is there a test for gout?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To test you for gout, your doctor or nurse can take a sample of fluid from the joint that is in pain. If he or she finds typical gout crystals in the fluid, then you have gout. Even without checking fluid from a joint, the doctor or nurse might still strongly suspect gout if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have had pain and swelling in one joint, especially the joint at the base of the big toe",
"       </li>",
"       <li>",
"        Your symptoms completely go away between attacks, at least when you first start having them",
"       </li>",
"       <li>",
"        Your blood tests show high levels of uric acid",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482925016\">",
"      <span class=\"h1\">",
"       How is gout treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are a few medicines that can reduce the pain and swelling caused by gout. When you find one that works for you, make sure to keep it on hand all the time. That way you can take it as soon you feel an attack starting. Gout medicines work best if you take them as soon as symptoms start.",
"     </p>",
"     <p>",
"      The medicines used to treat attacks of gout include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         NSAIDs",
"        </strong>",
"        &ndash; This is a large group of medicines that includes",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg; and Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/34/550?source=see_link\">",
"         indomethacin",
"        </a>",
"        (brand name: Indocin&reg;). NSAIDs may not be safe for people with kidney or liver disease, or for people who have bleeding problems.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"         Colchicine",
"        </a>",
"        &ndash; This medicine helps with gout but it can also cause diarrhea, nausea, vomiting, and stomach pain. Doctors and nurses usually give this medicine to people who cannot take NSAIDs.",
"       </li>",
"       <li>",
"        <strong>",
"         Steroids",
"        </strong>",
"        &ndash; Your doctor or nurse may suggest medicines called steroids if you cannot take NSAIDs or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"         colchicine",
"        </a>",
"        . These steroids are not the kind that athletes take to build up muscle. These steroids reduce swelling and pain. Steroids come in shots or as pills.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482925023\">",
"      <span class=\"h1\">",
"       Are there medicines to prevent gout attacks?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there are medicines that can reduce the chances of having future gout attacks. Most people who have repeated or severe attacks of gout need to take these medicines. In general, they all work by reducing the amount of uric acid in the blood. Examples of these medicines include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2277?source=see_link\">",
"       allopurinol",
"      </a>",
"      (brand names: Aloprim&reg; and Zyloprim&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/21/20820?source=see_link\">",
"       febuxostat",
"      </a>",
"      (brand name: Uloric&reg;), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?35/57/36756?source=see_link\">",
"       probenecid",
"      </a>",
"      . People with severe gout can also get a medicine called",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?39/29/40403?source=see_link\">",
"       pegloticase",
"      </a>",
"      &nbsp;(brand name: Krystexxa&reg;), which is given through a vein. This medicine can cause an allergic reaction in some people.",
"     </p>",
"     <p>",
"      If you take one of the medicines to prevent gout, your doctor or nurse will want to make sure that you use it safely. He or she might also want to check that your uric acid level gets low enough to dissolve the gout crystals.",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?2/14/2277?source=see_link\">",
"       Allopurinol",
"      </a>",
"      ,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?20/21/20820?source=see_link\">",
"       febuxostat",
"      </a>",
"      , and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?35/57/36756?source=see_link\">",
"       probenecid",
"      </a>",
"      can actually increase gout attacks when you first start taking them. To prevent these attacks, your doctor or nurse might suggest that you take low doses of",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?39/40/40580?source=see_link\">",
"       colchicine",
"      </a>",
"      when you start the medicines. This will give the gout crystals time to dissolve, and that will put a stop to the attacks.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482925030\">",
"      <span class=\"h1\">",
"       Can I do anything on my own to prevent gout attacks?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you are overweight, losing weight can help relieve gout. Plus, you can make changes to your diet that may help prevent future attacks.",
"     </p>",
"     <p>",
"      You should",
"      <strong>",
"       cut down",
"      </strong>",
"      on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Red meat and seafood",
"       </li>",
"       <li>",
"        Beer and hard alcohol, such as gin or vodka",
"       </li>",
"       <li>",
"        Foods and drinks that have high-fructose corn syrup (that includes most sodas, and store-bought cakes and cookies)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Instead, you should",
"      <strong>",
"       eat lots",
"      </strong>",
"      of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Low-fat dairy products, such as low-fat milk, cheese, and yogurt",
"       </li>",
"       <li>",
"        Whole grains and vegetables",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H482925037\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=see_link\">",
"       Patient information: Pseudogout (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=see_link\">",
"       Patient information: Gout (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=see_link\">",
"       Patient information: Pseudogout (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/3/11314?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15395 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11314=[""].join("\n");
var outline_f11_3_11314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482924995\">",
"      What is gout?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482925002\">",
"      What are the symptoms of gout?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482925009\">",
"      Is there a test for gout?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482925016\">",
"      How is gout treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482925023\">",
"      Are there medicines to prevent gout attacks?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482925030\">",
"      Can I do anything on my own to prevent gout attacks?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H482925037\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=related_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=related_link\">",
"      Patient information: Pseudogout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=related_link\">",
"      Patient information: Pseudogout (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_3_11315="Reduced overlapping fracture";
var content_f11_3_11315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomic reduction and long arm cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 484px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11315=[""].join("\n");
var outline_f11_3_11315=null;
var title_f11_3_11316="Urethral sling PI";
var content_f11_3_11316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Sling to treat incontinence in women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The urethra is the tube that carries urine from the bladder out of the body. A sling is a small piece of material that goes&nbsp;under the urethra. The material stays in your body and helps keep the urethra from leaking urine. In this picture, the ends of the sling are placed just below the skin in the belly. The ends of&nbsp;a sling can also be placed lower down, closer to the hips.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11316=[""].join("\n");
var outline_f11_3_11316=null;
var title_f11_3_11317="Ulceronecrotic skin lesions";
var content_f11_3_11317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HIV-positive man with ulceronecrotic skin lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 504px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH4AXEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCSSWRwg6HdgcVZv9NutLnlt9Rha3mK7gsvXHqKl8I/Yz4nsrjWLhYrSBvPfd3K8qvvkgVuePtW0rxBpljf211K17E8kMi3CqshRiWU4UkbQSQOa5Ula56kpNSseY+INrxsc8cfzqGw5jBwMe4qHxFdRRoIVbLOQvTqc07T2KBYy2ePkPqP/rViao6G32qmAfrWpbyRhdzNg9M9axrYk8Z981csXiDF9w+Y/KMjgVm2M6i0aSRcgGOP1IyT/hV2FETAwST6d6x7e6VY1UMFHb1NX4JUl3FSAMY61m2SXsskq9NrZH1PariqrYK459KzY43ZFC9QcrnoDWnDtKAg47H6+9MlkygluvPHWpAobkDb3OKRVDNksc+3FSJFtfOc5689apLqIbtyAV+8PbrVlNqgq2PWlCYHPIPpQ2FHI5PetBbjo0BBPTH5Yp3ODg/p1pAOMHjt9BSk464OBwRVIBQm5Tj7vak8sRjHJB7nmpoyOAcH2Bpd+D3AFUhXZCp2ZBYluMN6ChDvcqWAb3FPdQ2QFyvYUuw7CR24xmk7iuiNkOcnGfQdaawAAXncalcDdx+tQiIswc8n60WBMcQxKkDdjsOKjYAkKflHvUzYJJyRjr61C5UqNpyO/rSsgQ1mOwBQMenp9KoSTAFQRyDwcfzqxM4TdtGT/OqjYlJGTz2HUUrFIqTLIxVwFCgdMf1quybjx0z65NackeWxnjH61FbxqjFjjOc+lRJFqREsHlgHcCe9aEap5ePlGPTuahEW3DE4Hp6U5ZCCRzjualXE9SxsUHCtgjkYp8Y2DCAk5P41BC+Q2CenFWEXDHrjGfoK0jqSx4V3y+Rx+X1qYbggIHPrmhGAiOBuY8jjg0su4FNueDhue1aWJuIrHzDjBI6Y4zT5XDIFUDAyBjnn3qBiu09evJA6U92ZV4wPTHFMLEADlju4BHQHH4VFJyy7lIHp6VIsZBORnqcHmmzFsDLdOT2BpXYyrI205B6+1Rsxw2SqhvarAVTg55XkA9DmoJerMD1698GolqUinNKDgAYQjg+tRDODgcdqlnVlU5OO5pjudoIGA3HFZNFoikIOMnp0puBjOCQe5p8igc88DoKijyXwRhewPeoaH0HOGwSRkVUmDKcAdec1bbDA5PfAxSybNhJbpx7mmhbFPeff8qKXzV9FooLs+x5zc3m0krJk+5rmNY19bcO01yQBzgGti8srm5zuiFshH3V+Zj+Pasyfw1GsLuIg3HzbuSa3t3J1toZOhvPqt6L2bctup/dKepPqa6ssFjBUfOg3Kf5/nWTpqiNERMKqccdqtX8u20cscHHTFFS1rImF76hea8IXZIC0jEY2g4A/Gq39rStGNjsBnGB0xXN2kruzSZVf4T9PSug0rTp7u3MiEBP4cDljWbhbc2g09i7a6oxuEecybB2B49q6jR9cmJVFQbRzkk5x/kVyMVpMHCvjngHpkYq3aqBIPnwucZH15qHC2xrY9j0y88yFGYcPxmtcJ5gUAMv6Vxvhu7jiKW8bGUbc8jOK7GCYyJnGccA8/nTSOSas9C0gJULnPvVhO2Tz1xVWFsNyc5qdZBlScDnGDVmZZLHt1+lEeHBxk47GonOfTngZp6t2UcirGifAZQO3oKHAXO3dnj6CoTKfYKegxTxJuc8gALzVoVmSLnIPc9eKeVBwMEfjyTUOQSMN15wKeCATggbTyR0/OnsJocPQZJHp6UAZxyOPTsajZ8Z6Ed8+lBcmMjt/OmCQrFSeg46+5oZgGGQPlOOKhySQSfzpxwAckc/pSaBoTzQQTjrzmoZmyCQM9ulNdhkdVI545wO1E7AL8wwvTjvUthYrT7mkXH3eBj3poABDEjLenYU7cd5GeDgH2pVyF+YADqOc0mUEKDByAOufzofZkYGTjmnH5YizMAo5Gf61VMrR7nJz2ApMSVxzybztxyw5yO9RtG2zAJPQEU4gDBbaSeM0FWZ1ywXHI+lRYpaCxed5+xcLGBgDuDV5ZGK7SwDEZGR0qkNySKS2ew9PrVkeZszjORwatKwmWS3QBMgjnnip2USbPMC7u3PP4VVt1G1guc9MDjnuKsxbgp67cYAP+NapktDfLUJySmc8d8+uaazYB3YwAB6mpydpATC7R83NVbkMzZDDkc+49KGxojEu4E+pK5Xp+dQyygjOS2Ocr3qSNPlVcsVHtj8DTOFiAwRnpkVmPQhP3zxgEdT1B9qYxbauSOB6dan2YUHau48A1CQwkYEcAYwO59alsNytLjksfwqs4ACqOQTzViVWJ+UgnpnFROoQZyd/Q+lS9Shrjk9lpsu7ZhBjjpUTSguAc89ad5nI569h/WpZSuOwQVBY9eB0qJ0UrgDPPNSyFcKAefYVByGAQnikwHbI/wC4f++hRS7T7flRQFzPOjKgJdAT64rG1LTgoOAPTOa6vULwIm3cgwvFcxquohtyIvB53GuqSSJjJtnn+o262+oMI1I3HJAPeqGukmzIOT2BPrWt4hJGoISOuc9ucVSmT7UME8Lx+NZS8yranKWqJ5Snd8+cH8+9dd4e1BIgsJkC3EZxwe3r6EVzZh2SSrIuyQMcA8A0+NRGd0sLdeo4P4H0pyd9Sqb5Tf8AEV+dQ1NIbNEQoAXCHI/z7VYtSLdlc7dw5Kn6f54rBt2CO32WMxkfMWHLfXNa2lwz3Uz5Q4/vj+Y/xrOTbOhHZ+GWle4LhvlJwfUfSvQbabKc56Vxnh60FrCqbvmx29a6iKRhGPmwMYyaSuY1NWaaSuHxyAavRDcA3UjnnvWRDICRvfqOvetC2kAjBJyOoPWqMmi7z1Hf9KerEAAk+/vUCSg56E9RjpR5pDnkYziqTM7FrOQRnB6U2P7jDgtTd+XGCM55x6UrSqSABkHnHSrTBDiny5BJJ9+1ODbA28jpjg9RTN6OxIA69qjlYscoR1xnsKdyr9y0CCgbv6UjE8bBnPTIpnCAlSQDxyaQOMgtkY49TmmySQ4EfHHHRqiHzEAHjHPvSuwKghuvU1A7YdVXlTyc+tK4iZ0UL82cZ7VWlJGeO/cU2WdQjA7Rk8Y6momcMMgk89B2pPUYMpLFF7HPXrU0YO7Ljv6UxCQ+Bx/FnHT2FWGQngjB+v8AOgGyKfiM7Ac5GMiqbAyAgqMk8Z6065LGYIoPPOM09UIIAXcRwKlhHQZHjbggZB/L606OPfIAQx9KQKY8uY+QOQDToWwN+75gOmenNT1KZOyNhflHP6VOTwFLA9eR1/Co0fcvPY5p+QGB9sc8VRI8ZDjgjtyeQavLt3JuQFs/LnqT3qiCEIySxPtnNRX99HZwNNKFWCJCWJbkEDjAq1oFrmiD0xsRj0wd3P1qGdccoM4OGxx+YrltH8X29/qq2bYSRxhAhyDgZrqDNvVgS2CeAF4PuDRzKS0E04uzIckAAAgZwSTzmoJ3YrhR09utWH+UcA8/hioJFIB2nnpn29ahtopEUcmwHeD149qC6+YOcKecimlQhAU/LyQ2KTyiVLD5eT171DKsiGfadwQDHTioXC5HJJI6E9asOFweAB1znqaiG3OSOnfuam4yhLCCWyCMc/jTWIDANwR6VbmQBsE8DJFU3cgliDk8DPai49xr7kyxJ2scc0wSFDwMjHIodhluffmopn4749e9Jj3H+av90fnRUGfpRRZisZM0wIDSurE9e5rKu7lDuJwTnr6VSdlAyzg+vNc9rOsW9qGAZSw/hU5JreUrDTSGa1debqqKjZOC2P61LAoZWUnCr1GOtYuirLdTS3kw5c4UZ6D0robaMMwODycnNZSZN76kculx3CAuMP2aqFzok8TKIQrx46NzxXUWw5x1HapnChwCow3Ws7tbFrU5aw0h1lBnDeU3ysgbqfeuj05Y4CYYiVVRn602ZFVxj1B5qeJhxxlx0OK2jJPc7qUY21NqyZgwUHkd66CBxt6gjHNcnaH5sueceuK2rWfYARkgjn1olYzqxXQ34iAvGAwPHpVuJtgxke2O1ZcUny7dpyehFXEkwAdxz0qbnJI0I5SmeCfbtS+aOQcjPOKotOFXOcHuKckrEDP3sflQmRY0Y5F3Z61IJBtO489georOEmGI6Y70pkJU49McVVxcpfikLIuc43fXP1p3nbCxz1OAKz43+UcgDv70rT72wT09apNsTiaCyNIzdAfp0pxYE5BAC9z0qjCzqmS+7vT/ADPkJBJ9sU7hYm3AOwHHpz1pJHKxkDKk9x/npUK22ZRJjLtyWB4Aq3HCGfoBxwfanqJlYjdJwPoRzmpQhAAwqr6Af55qwbfouOeh56Gp44v3YOOTwMdPf6UxMgAO7KjAXjp+f0pSpOMg49B3q35W1TkFR39TUbr825mA9uuahsRnGHMrS7sMRjinCTv2PTip2VRgE4YnsajcAMCRjjANS2WvMrqrudwwpBz9frTTGhLDJBPOT2+lWyPLRSCPfcaruwaRGIPXpSTKuJZn5nRCxK/K3ufr3q2TlAeRgcE023CjoAo5wM9asNtXHPXpVLYmW5WyQVIOGPHXvVDXbI6jZSQo+MqcA5x+Iq1chlmBGAWPJPce1IXJxknPYD9KL20BX3OR8H+Cf7L1L7VcTeftGIUThVHQV6DFGysC24qSeh4//VVOE5iyHPf8asRl1jXbksO5YAj1z/hVw2FOTk7sc8R55IfoN3eo3XC8KRgY4qbeQ7Zxgckk0y5CmMBmwDyMHrSmgTKbMVIwCAeR0IHtTSGaI7tvtmpgTnKjGBTJxuXI29DjmsWVcqbW2hQABnBP61DgxgENwD3qXJH3icZ6iopHBjyeDUNlkE/PHQdh61nylw3I4q1K3JIIXHfFVpHLYyTn9KLlJWKzsVY8n5vWoZyxOQTyMYIp85LcHG0HrnrUUzrwuc0XGG1v7y0VDj2ailcR4PPdTIWtZ5ZGnB3Fs8FT0pkEPnyKvHqafqq7/Ec0ac8BRxWhFaCBARznrVz0d0YpczNrTlVIlQAYXvWrbqCwOOfesSychhk8VsQOGwM4JqLmljRtvvgADr2q75e89AAf0qnbDLLhsHHNasERljyo+Uc0MrYoPbbmyeR2pq2xXqT0/GthIc8kYOc082+W4wO3SmmbRqNFCGPsfmOe9aOnRrvG8kDtRFBtfnG3PHFW0OXUMmD2NVcUqjZcVyo45+lPWU5bdwMcZqFEYfxH8KVw2R8uB9aDEtJICRyfpUvmkZ5x6CqaFVzubPQGp42ByPemImWbnkjI49qmVhkuo6DkA/5zVFCxGxRnmrNuofAK7QPSmgZNGwIJBZsn0xU0QywJAH17VGvyn5gcnp9KlUBsgZwTxkdRTuSywqq6ttAJznPYCpYlVmI6DuSP0xUcTEjaBtI65HX6elX7VRjdnaTz83OPaqTJeghQoowAAByM5x7VJEwPCk8nPHJxSvgk7lVccjPXFLbRpG2VOCTgnHBqrivoTooZMAjrxnmpEQ+Wy/fP5ZqRF684/maejDJx2x17UEXIn5yEHA981UlIXqRxz0q6+Npbb97qc9apOGZcvxk84osNMrqRn7oDAcdzQUBJPI5/GoV3K5G45xx6H3NRTTfPtXJbsD2NZsv0LLHOQp49CODVfccgN1HHy81GTKNpyTnsRU0QJJ3EADgAjvQkD0LEXzR5jQkAfc6Zp8TmVQZEeNiM7GOcH0BHWiI7QOeGz07+9SFwFOxST3q7E3uVnU5VZBg8nAGc1UaUmUEHlRnaBxUs0nmErk+mcdSPegKR90g4IyuallR0Hw7otpU++Gxz35q8kajkpuV/vE9/8aznYM/l4G5vUcce9aEUuEfOzDDH+TVxE7krqFO4KNgxkdqjzkERMGU9P9mhpQwAUkYGCO30qv5isAFOcd+lU2SgMRjTGcfTvVG6kw7ADAX261db7yudxJPQn9arTnOeAGweQe3rWMkaRZT3BmILDPqO1Q3DgMRn1IAoueUJxkjv2qhJLknI9vrWTNFqRXNwQMdQOSDzVJJZGOWUr9KmmwzAjqKghnin3GBwwUlSRxz3qXoabIkJVskj6VUmk+QE9ueKdI/lsd2fSoZZBg4xgDpQRch+0H1H60VX8we35UUD0PH1icXqXEgIZm5b61vqoaPke9dvqemwT+E5GEKeYi7lbGCK4i0bcgGeDWteDg0mc9GfNcbECjjHStS1OUBqq8WAM4qxbAg44NYbG1zVtnYhcZ/xrWtZpeFXAHTrWNbuBjcOfb0rYtSDjFO4zXiYsoDKD71N5Q3FsnJ9KghOenOO9WQvyDcM0XEO8oMuCeQOe9SKu87SM4HUUI4OAFFXIlGSRj0qkFyIKAAACKl8rIw2SPX0p3l7nHOfwqQKdw449hTEVzCucg8ntUwh+RcEDnJOe3pT1A2kndk9iMfpT/KDpyuB/niqQthscC7iVxj61MqbX+TDNkcjimJGVIzgr6Cp1O0kFgFOMe1NCbJFC5yc8fhU6KpKEj6YPSmJGrY5AU9CetSoAECohUDrii4iUqd/y/jnmpYZWT7+W5POOlR87duO/c0m1gwJYOT0qkIsOykqHySOcVPERsAds56dsVBAmBjJI9KsRqo+Vevue9FxWLKMyNx17A9aVTiQr1553VHFkbsDk856U5xwQMnI6g1cdSWPYlsb8YJz+VVZnHT5mDMSM9RT5pBGhDN39az5pzlgAM9+KcmCRDdNgHBK46VWjPOWGQenPNE0gMgVSQw6j196d9xMknHb3rPctFjeWGB1A+lOifJAJIOOSOlMDB0yuEPUfLVhUwOgJPOCMVSBkqN8yDjOMDHcU4qrxgjJODg5wB+FRzyLbWzzSkgLz8g7fSo5bkgnavHHU9KpuxDXVELqzIACAF9TgfXFKHAi3ZG3HzZ6fgabMwMhJ2HjoBml+Yk7ZMqccEcUkVcfHxgnLA9c9AD2qaIllw6ADdu4x26Z/wAahBVxyd3dRilEmAEwm4kkhjzTtYV7jy+xvvcn5sn0pgdC2QBux3/rUJZjhmYDjaOM/iKVnBGFBJBzj1/GhtjJmY8YBJzwRVCZmXeTxx0xzVpmLAL2A5JOKhJViNpPPQCs2NaGdKzHOeR157e1U5osSKARk8kjtWtKByMA4PPpWe6KryKCVbr9RWcjWLuZ8kbA4RmIPXHeokt1hX5BjnPFabEMSEUAfSq0isSR6c1jIq7ehRljUAHbgAE5zmqM6DcdpOe/NaksZ2liMVRa3JU4J6856Ucw7FLYfSirmD7flRS5hDoovN8PToQTlce1eUacxRnjYcqxFekabqQgtXt5gXUjhs815tjy75+2Sf0Nb168KyjKDOTDxabNiAZTtk0pTY+e2abbnKZ61aT7oGBjOayOolt2GTkc9a1bMkHIbjPbvWVGoHqD7Vq2jjoeAKBbG3C+RnHtxV23ZuBsyvv2rLh/dkY5Hv2rVhkOFwCSfagCcoOUI+lWIUIAwoGai+VcFhke1TRyqoAA59BVJgyePcpPAFTqoJ65PXAFRnDe4Ipwyp5H68VVyWPZDkHoB260AjAyMDOT680sb5OPlGOtOO0jpx6jrQAFME8k4PFKv3yMAZ44FNJ64zgdzUiDcGyRnpg00JkzKpwB2HSpVIGQnp/niolQ7MA5GfSnMuCpOAcYz607gWUyWzggNTiArAnI+lRxSEqOccdug9qcHxjJCg9sU7kkiHD/ACev0xU4IUZY5559qgjJ3DIyvTmrBIBIyCcU1cTLEbBtu3GW6cUycoEOST7g8VEcb8njb/d5qGWUCQRAAN1x6VpexFtStcXBdmCLxjge9UmkdU+cEk84B6e1W5TgsC2ATwRxVYMGPJHy+2ahs1T0Kby/v9pDDPIA7D61cTa2AQfUGoJduc53MMYFTQBo8bhz1+XpSC5bjymQx3A4AJ6/gKmYgbush7jpk1W8wF1c4yfQf1pWnZRnks3IPSrTJZJI7MCpyD1z7VTmlyPlPHfI96gnnHvk+tZ1xN8uWAbnAFJsqxZnnEk4QEZ/2TUvmsq5ySOw3d6q6bBvPGMn3/StOSAbVXywBnpkc0RE0loQRzFUIUjp0HUVKrliGXkdM+1MMXzErtB6YHOPrViKEqobd29MD3ouwsBO50wVKn+8f0p7MykBeewwaeI49hPB6YAHQ1J5YUlWGCwOe/FFxXK5YDcc5bGevf6U1csTtzg98cU549gXgb+ck/zqNFwGxnr34pDQyRflbHzDvj1qo0Y7qRngmrjhQpYHj0BqFiSVwvbrmoY0RtHhCMnPPPpVeaNdu/HvkHNW0jwSN+c/wmmlBs5xmsWikZc4G0NySeTiqkjADbzj26VfuOSec5BBx61nup6KMnGcVDNUiHMnqPyoo2n/AJ5j86KRVjl+QR29K5C8XF056YkP86636GuY1JMXlwP9rNcmH+Jo5qe5ZtGBAz1q8gC/j+lZdmeAD1HSta3AY+9diNSWMg45HFaNtlXAIHI4NUggT+E/4Vbh+boOfr1ptgjWt3XJ9M1oW5bYTk1jQsVYkir8J5AyQOwpIdjU8wkcgj0p6YIJJANV1PzDGSRUzfwgYx696pCL0DnaCCA3TOP6VYzvQ5BH1FU4SPmVutWYiChU8+47VoSSqSrbQTgdz2oLKc9ePSkQoMqWOfShxkBkJ9efSgByuATzjHOKsQkHngjOOOtVzhlGMr35FPt8qcDBB6n0qhMvwkAkHd1p0jgM2OO5HrUKnDjBOOh5qZvmQ7Tk98UmIcH9MjPpSxBXPzNwO3So1UFtpOAPQZp8ceDnnGcZzinHcHYsb8E8D8OaarAq2AB7HvUTMQ42jA7+tTrIOgJJHXA4NaIhkkTqsYba2D69Kr3WDKr4yTxx2p27HKn589MZNVuCcjOM9etNsEupExbcC33hzkDP4VF1BIJOf0qcld5wT9D3pGDAkrnd3qRkCIXGAefSpdpEWM7mz26Uxdx2kZ6ipS+44/A/nQOxDnJIGQ3rjvSFHIx3AyzU8K0cuCSARknvT2dEG1QzOe3rQDKTwKiF2DE9l4FVordp7pmk4CDgA1caF55MuWAJyAPStCC38t1CjH4cUCEtbRY04wpbruHX6VKUBG593HYc/lV7ZgDGOO5NRgbpCSQOTznqfpViKwVFYnIUdQP8ammDMuAR09aUIoByScc5zn8acU4XjPuexrNOwEQUAdVVuccfrUTEEH+IAc/Wp2bnAUDsM1BMTyykegFO9gSIppSGwDyOSCufpVbdliGHGemas4fg5JOOh61Vdd0hHzBTngdKlstJCjGW2p15zSNCSPlHOOT3p/lnyzjrnA57etPjA8tuCwzzzSEyqYmUkjHt61CV3OxJAI754q3IOAoIwKoz79w64PYVLGiGYKXIzlsZ6VRkxt4/HNW5GIJ3HBJ4NVJIyVOT8prJo0TK2F9aKd5QoqbMq5z8ulMg3Kwx71yerwmPUHDDllBr0e7O0dq4XxIo+3RODyUI/WspU1CV0cdKTbMe34Y1q2jAsB0HTNZZGJc8jNadkuTyee1bI6jSA3HHXFSkdMjH1pIhlVzmp1RiP0zTkMmgOIyGPzDj61cBJGMVSUKOe/fircT7iBjr61KAuwblOM84rQhLEDoR3zVGP5SozjvVyMn+8ce9VcRcCqeowRzmiJsMV3YHembiOx56U4KGyRkH9apMViaMqQCDlv50+RguAc4J6VBGCDkk47GpDJjHYd89qpCsWU2FCABk/wANSxSEZyAR9agVU9OeoxxU0QAyONrDAAFMESWzEZyASDkE1d3YXkgLjqO1UQAOQMegJqQkLjoOM/jTtclonG5QSCSDyAD0qSIlRg53MeO+KrpIpQgHngGnod2SDwBjnoKaQn5lmTDLuQgkHBz3pYsdAF4Gc9qq79vIA2r2PNC3WzCsAwPBLEbR6CtELldtCdySBnBfvgcAVVJwCVU8cYznFQz3p2E7s4GMk9ap/wBoJtbzQCAOo9PpVWuXGm2aEZjABIIUdCx5J70+RlJUSE8YyBXOS6kVOYwHRT0Vc7Se9Dasdu9U2xDnnilY1+rvc6GRkSTHTgYNMEsauRu+U965VdUeXfiQHbn7xwT9BUcWouy5Jyw96TRqsM1udiZEYAK25SO3U0yN9jEkZft3wK5qDUmkkZ0VioA596kGqMrkSErxnaO1LQh4d7HUxyo8gjAw3OeMVdGCAAM7enbFc1a6ikrbmfJA47ECtq1uYwpO5stz0qdjGdJovQsGyRz25qVfmwTznPHNUUw0igrnBLFs8g+lW9xBZEGQOpNUmZtWI3VRkhR7d8UqMpIGRwOo4/CnyHAO7ZwM8VWDZkLEEoRxj/Cpa1Eh7uq8sxPPYVG4DA7flJ6Z4pkqyHYXk2jORjuPSn5OFBIxnuKTKDAEfGffnmq7FTnk5xwO9WJGxkkd+Mc1SkyrkhwB3A9am4JCqgK5OQcZC/40zcRyfl56DoKk807cBRx796bMUC4JIHXOKV+gyBnAYID8xBwetVpuXzljipnPJCjPHpVOcnGVxkHj2ouCRA4IbJzkjPPOKjlIw3A5HGaJWHbJJ61SkdkducZ7mpLJsf5zRVPz5PWip0HYbfEbTmuN8RnLRsOzYrr70kqelcjrfKHPbmorb3OGl8SMkj5QQetXLFsHnr61Wj5GDjHr7VLaAh/oaE+p3Jm/DhlFWUQhepx2J7VRgII4rSiYMcA/THNNgIqsNpOcVZjHzjd396jcgKGb5QfeqaazAk4iIG/pk+tLyLjBy2N2M7WGecVcjYZyCdvtVKzKTx71bqASKuJuBGRwO1VqtBNW0ZZV29OPX0p6MSg+Uj1yelNUAIuew5xViMJtwPXP4VVyVZCA4ypJ/wDrU6SEle/PenoN3TBPPUVMFHl4449O9MTdiOAAEZOSeM+tXQcE7cEVSjZgcLzjkelPhGx92SCeozmrFYsAE4wAOcetSDBf5kbB6+tRBcrknBPPWkWUAHL47AjmqRL8ibGTlDjAz9aN+DtyPm681VNx85bg57nt9Kp3V06yZTDBeoP61SLUW3YsXl1JC+Nu05wdoyTWVdakzHDsS6n7uefpx3xVK71aYtiIgyMCBkY6dhUcMHmzr9pljkOciMNgHPcYP4cmtorS7OlRVNXmSvqEs8RSCBsnjHU+mB3NW5LOOBlW/a3id+iSMePwHP4ZqjLfro8dxugjEmBGu1yCXxwMjkDryOprGiKxXCzvCn2xc7nBLSDjoScgHnOevalzpI5p4npBG/FHazNILaaZoA2wmP8Adgt/EfUgY71Q1aKGws0uICLwGQLK6P8AcGMltx4b36Vk3t9qFncSgwRbriMFo87gwU9T9T19aoarm/0G+u9SuWEuDCqxjbGg2k4x6HGOB2rJ1JXsZ+3ne9zpYZTdrJc2MAhg6BpnXD+uOcjn8KXzkEJfUPKgZh8odwGb0wAP1rxfSNUvGtRJDeyq20Iqo2COQB9f0rsLnSpIGgXXNQeRpMMYoXG5h3G7HHpTnzJ2uUqlR6pnoumHT7idza2zvFGMI7XIxJxy2ByOabK0UEe5LxHkUZZWwy/ga8+ubVNLtkk0Sd4LlN3nwSHIU9tuO+PryabBPrd/FCHspJ0xwLeRQ2PXDADvzStJvlWrF7acdWz0oJNNKHQGUSLk+UgAH0qW2v3jG3zEIHBGfm/KvN9K1LVLXUIrC5Sa0ed9saTkoXPqC3HsRnvwa6ldTEYk+3gQZkEe8spDMc4Ax16fp1qW3F2kjeFdS0Z29lqgZwCSGHB7fpWtazxkllJK9cnp+NcHBMj+QXeNieFKH7x+vbFbVle42kc4OMd6u1jSpRUleJ1wOO+QfSogu1xhmJxjP+NUYZ9wBJ4xwCcfU+9ThywGPmGckjt7UOxxOLRYyM7SSCM+/FQiTLN82AeAD2NDu21RgbvQdTVediiqS2Wx+NQCRJIzdiMdSF5qB85Yj61C0mBlSeeo704u3AGMYyf/AK9Q1qXYZvJOQM/j0pu44bBPH8RqORgwIYZHTg9aRnDbs47dKNhjZJOD3HSqm5nyv3s9RU7fMSW/Xt+FQHIcYcDI59KTHoQScc4wQfzqjcDPr+dXppASSBwOgNVZmDZA+vSoGU8r/s/lRUmR7UUgK12cjkGuX1bBVq6a5JIPrXN6qODRXWlzgg9TJgHyAj15qyilWypx9Kq2j/Njtkg1oxpwSB0FQtjuLFq2Bg9O1aNq21xt571mRYJz146VetpBu64IouUacqeZEVwMMp7dK5Kayliv8FcgnOa6yJyUOD+ApXhjkU7lG71pxdnc1pVORjPD8kjY81cKBgc9K6BRkHJ56cVnW8ISLAGD9a0ISuADkZH61TfMTUlzO6J0GRjuamSRR8oJ54zTI41Kg5PpjNAixKu0Z55zVIz0ZNCRGo+bcPXPNIpYE8k9qCAo4yfUe1KGX5VJyT1NWkK5IowxyD0yPenxSAjAVVx1z3qu8gGcHpxmoRclHy5B/DrTFZsss7F/9kHt61HPKcHbjPt3qpcXaRZxy2M57Cs2TVlwFbAPU7u9WkaRpuWqNZ7oKNzYbuewz7VhapeDHduv3e1Ml1ferLhmJxgMvSsS7uSzuN4CZGWxkj14q1HXU6qVKzuyeBhPcjzAgXuDycd6qajr09nJHb2n2dk2Da7Eh8noWHTP+FR3l4LeARwMqyKPmkc/KB1/D/69UdMNldabJqF1cIczPHJKvSFFHGFHJOCcZqakr+7E5sRUd9tDXi1sSmG7fEuqQqbcBT5YhxnL9+TnqPYCnR7rmETXokgiZdqiFwMIOvHbPpnJPUmuBt9d0yO9jeVXW3VtskzZDFQ3AbHt1/SvU49Ss7uFVht1njMTPwwEca46sW4A9utRLmWpx2V9CldXUkWrCLTmfyhF5iCfa0uwEcZHAH61H4ljGoWtlbzwvIoYyFpsbSW/iOB83XG32rn45f7WumEcpIEm5WiyrZ7AcYC/jXXW9p5MUDtLMWRCf3zFiuTggfSnTptvnehv7O+h5xJ4YubJbyHTovNEsaIMHGMMCTzjnjp2zWjcF7GCCPUrC6eEDMtwo+ckdBnn5c9+g969KsLdLpWAYYJ2gDrg9eemBT30sxJL5d1y6FEUjcWXPYniuvkUnfc1VPl0R5oHsGtXkjvntrgSYaNnBxj+72J4rDOpTwF7m4e5NvMwJkUeQuBwcAcc9M/WvT5fDmhpcmeSNrdTFvChskv2ZVAI/wCAmnQCezuF1aO0iuYIHB/0q2Vi4PBbH3d3XB9felCDi7imvmeVDUdPnjea8tzcrkBpTMfOzjgqfqB14HvVzUXvJ4bdrqSOQJ86l5MsEH8PGAT79f5VN9hvb9YpIpI1gR2lhMoIkVS5+baB85J79sdhTgLu4N08ghuLGzUiR3kXaFPIzgZzgHpTnBzsqZjJKn70jp9AulMavbGb7JhFcy8BSTjcD6KPzrqYpTHPgb8AAg9PMHqPY4rg/h9rFi0N3aX9wYbZY87GVm3yMpwuBzgZ69Mc11cZnit7KabdHujEMauc4/H1OPwrGMWrqR1YepfTodfptw+5WD/LjGD/ACrYEy+XtABcjBI/h9jXJaZeBI9pfdk44424/nWtBexuSQVOTjn2qWialN3NuLKqBklzwSO1QTzFg25dp6ZHX8qZGflLZLFmyOeKR18z5slXPJI55rK9jn6kTDDZwOnWmseMMOvJx0NLIofHXHcmmSPjknnp60m77DuRP8o3Ht2HamySgHljnHTsKVmAK4wSOM+lQlDtYnucc96LlepKrZU9N3Y1DIu7OOBio2BPDDGR+dDHnPJyPlGahsLEEi8k4yDgc9KhnwAV+mcVacDByecce9ZjknJ7Hr7VNyr3G7j/AM9Fopu4f3x+VFO4iCc/L15rntUHBGRXQyAlG64rB1JeDj+VVVWh50dzDtMecR75rahUFemc1ixjE2a3LXoOePX0rmiz0I6oVYyHGBwalUGJyT+FSqhZgAc45oZCc+mcHNMZNE20hv0q+rqe3Xv71mx/KwHJFW4ZMdcYoTBF6Bz90nIq/EOAw4z0FZkThDx0znFaEDh15JBHWrQPQvI2FwwyMfrUgdlBAIIPGBVZG2jvgnuaUyZ9j7VpElkpkKvnAJ70jMuQRgBugNQFiGwOT2BFJklvm4weM9KsNCwTkEgZwcdKhlPzlSGzj6VIZs5XvjtSKoODtOfpRcEyhdOnltHIuD3I71z17Im4AOFT1x275rpb+FSrMApY9jXM3whdTuDqQcHFaRZ20LPUoSzLGjbnYqTwG6fUioEQXQJkkkSR87cLkn04/WmXON4UEM+eCf8APSq9xLMjrdQnbEQUAA+4DwcfWitWVOOxrVkoIs3FlbWNs8v2qW6R2I+0MwDbBxllPv29K57UGsIbVprG0STzVKGR3wY2yCCSCAe4wR/jU0ouXlnniMDFeBC0ayIUxjcQe9Oi0+eKVRfSQeQ2SZoFVgSc4/4Dx0qsOouPN1OLlcvebOXv7S23NDBbXz3bBXUBDmQHBAx0A6kH6fWuj0CG+t7RbS/Ej2qnetoBuO7PCu3p32+1dLY6atkib4CIHAdghV0kbqDu74Bxj8Ola0mpPD5SpZ4U4woYAydhgYwDW9WXu7GTpWk5bi2CGBoobmSWPz/mi3YHloOuMfh6Y963LVY2ni8yN1EROS/PB6c54Pf+lY8eZpka4g8lPKPkhWBIHfcep/zzWpbgMm8ACSRfnzkcdAD7/wA6cLtJmkU7XFFyYJpTGQUfAxjPHPOB9OOnXNPDs+1nleLGQME9OmOOxzViKPzLiJstIu7JXPKkDv8A0q4qMqyW7GLauGU4xsJGMc1SjdmvMkcX9rv7PUhHJZR3KK+0wKmGH0PTFdBJ4htL/TDYtGSNhijUfKRn0b9cVU1WW2lt5IyVE+VQtzjPXBz9K5UzXFtcO0kC74QWTbICSjdZAuOO2c85NZpyg+VPQHBzaFGiy2dgIWuZJGRmjWNV2OkZ6kMeCcnoO1ZKaDcXs2o6fpaXBt96JLcebl2iGCyDAAYncue3HpXarY3DRW6QyATFcOznpu5wP7zE84rj45LyzM2s6fORdhwZVlBlWQkFSrZ6NyRgYxWkPc1FOn7ZNdiXSoYNN8QzWPnXEFqY0jm84eZIkmSAegwQoA44xnmt9TMXnRZvNTPnRbnztOcMc/j+NcbpKX0GqS3kplluthe7l6kHnCjPbAHT3rdh1NBB5RRY2KMwC9RuA4/SspyXNoKCd15G/bSlEVg5IzgccH/JrX0xt7fd4PGaw9OCsFPIGMKg5JOK29MDrIgJByTzWc2dFR2R1VvGqxZYfNgAgDpTiQDjgqMDFQwM5iG0n15qVS2TuX8awZ5rBlJX5FBGep7VVmRmBCcYH51dVgeBwRyarEclcfePfr9allRIFjOCSQ3H3fSkkOGAwBnk1PL8wYHp7VC67iCBwRzzSuURbFKjnOPmPHP5VXlBOcYGORmp5MHdzx7DpVZ2GDyc/wAqlsEQzk4xyBt6ntWfPNwRxjHpVm5dlyQc59qzp24I796ChvmH+9RVfK+tFIVi86/L6ViapHweK3m5rK1FcqcVtPY81bnLbcSsPQ8VqWJGzGOe4qgwxcMOmRV63bAByeueK4TvpvQ1YsFcgjNPUAk4/OoY3zwQMdanU4wOmfSrZbRFtK8gd+9SwHDf1NEgVlAB/KmIAMe1IC/CFBTIyKuxMASVJxWfC25c4GKuRA/eU4GOprWIMt5B4ycewpSwGOwPHXpTAcg4bkjj2qZSWCqckngYFWiQcbu+OOcGkZVyBuIYdOKkXgn1Ix0p5XkEtuz68VVwI4ioUD5sDpUxVN24c8cc5pgjVenT3705SGQjbx6GpGRzN8mFIY1zmpSqXI529cAVszo3Kx5yfUdazNQgkjRt+Bn2/StY2OqikjnhbeY7+WB5mOpbbt98+lT2NrJaWju0cU0ig5VkJHsN3QZ4Gfeql2rIcAD6Zxx/hW5axQzmUeZ8rKoUq+0B9ueOu7qODVVFF2kGLVo3ZwOjpeWd1qSXwkVp8YWNgE3Z5THv6j+tdeulQSTt813bTBBtjEYEcuegHr9KisNOGnavJczwPJIyuPLKjKcHDJuyM9+nrVmCWUNHDeR+XIrho5RIWU/QdAMdT710wSkrmNO8ouxuNo5hghdiY41YqTnLhuOAuMYPqOKW50W2WwYyErGxzuUltp69Oufam6dqzZntpmj3eZkkLmQL6j06Y9DXQSCCS3eDbtnTkqCGDZ56j605LmTsWlJLU46O3WFPMfc4KlC5cgse3HYe1dLZxLI0ao6s4Xcz53FvbHrxisO4tPNv1tryVjHHxsjG0A55AI+834100Ucem2rLbKvysG3H5Q3PfuTSpJpWY9WivepPHeWojiMTAhyu7YSc45qC9CNE/m5Xq46kg9QDzn8qvbre7gaWeSWQqQ4wcZYHgk+xqnc2qR36TvI23JEKM3yyt3Pvg1qurHBK+py0unG01K0uh5s86jc0MrAxmQ5xnBJIGQcfhxV2xsZYbm4unS5mKLsiZcfvN2S/UYCevUmt6GGAzMzMlxcA7mjjQjafbt7elQ2MkKyefeybZiDjAADn+BVUcf41MKaTujWUluC64dDijjSwE97Lku8bYWMHAzg8DJ4HfIrgPGN/Da280EJuNqzGVvm2M0nQkgnICkkD3zW14olt7e+W4nvBIuz9yxPmFCwBJxwSQeQOxxXnmvX9td3Trp0bMZMLF51yJMsQSzyFe/fB6ZrSzasjmqVI0486WrHWWqn7OYVXUJ71mQbjKrIqHduU45IOUOc9QfWti2jmCTPgbZBjZ0IGeBisbSYntbiGSGOW6Fu4llcxeWQ3AKkA/dB6f/XrtGdGuGQQbZOh3fwj0/MmuSs+eat0DCwlGyZo6NBIYoxzux2rqrGAwnuCBkAgY/8A11iaJEq4LMWB6kdq6tFCgZU5bgEjoKxcmzSvN3sSRNIpCgoFIwT3H0p0kwDk7cA8cmo3UEqM4Uj73UGnogJG3Bx0b+lSzmZKGzuwcg9s85pjsykBE3Atyc9KReq7QMjPXrT2OBjIJ7CpepF7MGcfKcjcenpVecqMkg/XNSSOAoCjvjGagOCM8hR60mNETZ24OcCq0mQOep71NJMN2AAeMZqpO3ynn5hUloqTSFiQORVGTJJ57VcmB4HQ45PrVSROuOBUjK2X/vr+dFLsX1aijUDROSMdqoaguVI5xV7OCQKrXa5TnFbvY8w5O5+WcdfSrMQ9uKi1JcNn3p9ucqp7fWuF7nZRehZupWhtvMRSQD+VasLCSNWIxuAxis4hZIWiI4YYqayJiHlk5A4q1qbvVF1VYjOPUUyNQMjnNWFwycYAqJlKgnAzRYRJHxkEAevvU8L84zx9aqI4A5PNTbgRkDOBjpWkQLqt8w9fXPWpo2II9Ceh6VRR+oHUd/SrEUgxgnj3q7iNCJt2Nrce9Sh/TnNUoJMAFV+XHQVPF1JAwDz0zRcRN1UHkZ6UwE7fmBY47cU4MCuAOR2xSt6dB6mkMRYwc54BGeDWff2m5M5znOMVpCQrGvQk9xVc2zTqxY49xVxNacrO7OPvomKiOXDqo2hjgEf/AFqg0y7W33mZQQmBsYkAjPBBHcZ/I1valYEbiBg47j9a52YGOTehRSDls8VsrSVmdcuWrBo6W0gScpPq0by2azkTQsrYCj7pBz255Hp6VFd363EbBy0lpEhRQOHKEYDYb0yOmar6Lr5trdbWMxxh3zvn5GMcKSffjj15ro73TRfWNtFJHbg8PHKYd20nqFO7sMfXPA7VvTb6dDyHelL3jg47W5F3Z3trEURMma4Rd6MpAIB7jHp0z3rqE8SWVrbNchhNsb584DE+lZEln5DziedmtlGEezRpIwpIJUqcEdSRnvxWPcXFpCzQWklvdxk4SNYXidjnO4q3f6HjFVGV1dHqwlGutDu7CVMebDvkMm3aIwfl5yAfUg+tW1thLcl7uQOhwxy5I3dDuB6EDv6V59B4iufNtYpJIreMruT7ykDP3sk4I+nPtXS2zX086xxRluCHLHaCT647cVdklZkaxlY6mNY/s/lwlFjJO1COT7isW8t0S+aW8lgS1XJXec7TjIz/ALXIIX0qBbiV3kRxEpBycLhR9COlYPiC4vrm5htbPylQ8AmLcBnIzyOep7EnND5UtSqafNZdTdl1mCyhT7M8gkZQJEIyxb3P0xz0rC1W9WVTc29zCJ7YCTLMTscHjaOjNz9Kz28Npp9rbw/a5WeSQt5bRYJUD+I7sjJxgVYtLCJ726WQWVo0UioYLgbkiJ4bEXcjryfzpNt9DVU6aTcmcJ4jvVN1vYXLQyt8kRTJce7jsTkn0qPwxply15Fd6eg+0h8ratDvt0XODuPf15z6c5r02XQ9Gn1ERWKSBWRhHM7ndMG4IyMBFyDnaM8YrQkn0/Q7JIVxJcsMSAH5lRcDHPqe/tUqdrxR51flqVU1d9kYc2ywsHZxM80o3StI2RId2SzjqSx6egHeq9l5k05km3EtyRnk/jVaa5l1G6aR1AR33BRxn2+lbelWzkqAvTnniuecjvp0/ZRbludNosa+WqkYPBIxW0GJI2A4A44JqlZx+WqhAcbcGriFyuOpz+dYo4Ju7uQud3zMduDjgZzUy5RB0yMc4/WoZYkdSCzKQcgmpFXMePwyRjNN+YN6EoYAjd82enY0krHAOMfWmAYwMgtnjPembgMtI3sBmkyBhcBcgc5zz/jUUjnZwSR161Bd3uZDEqnaepAoMgEWSRjueuKlqxXLbca5xyKrtkLtHX1J706R8Dnn37VVnc5JDHGcjFSVcZLyOuce9QSMWyeAD14p75Kg9feoXIGSMVIxuR6UUzP+1RQBeJ9ep6VFP938O9PJ4pkgJUj0FdLPKOd1NchuOaqWj4Ujn6UniHWLKyLrJKJJf7kZyazNE1AahE0sabMMVwTzXFOnJe9bQ6qLs7M6eAgYJP51aQLvHr2rLt3ORnpV+KQ5GT/9apidJoIRj5qbMBn196jSQHGccdKHbg4zz2rQQisDwD045qaEqMAnPoKrHK4PXsealibgE/nTWgFvueM9wKliXcQccgYx7VVQ8dSMHPvUykkf73NMZegKjAXgdeBUvmHOMMO/XqapQfJyc4z2qyDyAjdew4qhEsU/dCCD79KtGUbfnXHcZHeqSKEf5VO0elTBxzgNyMc0DepMr8Lxn2BqVGAB5+X8sVQRmVdxAPHQcE05J8rkKSD69BTSJaL9xGJkIOT24rmtU0tGYtHuz7DpW2pkdRwAMVE2XyrgqQcFiDzWidjSnNwejOCurWWK5G1/XII4P1HcUi65f29tNbxTiOJ8AhM9uQBjp7eldRqenKVLCIN755rmbzTpFAIXbg8dRWidzt5adZam9oepXl/aGKR48sQCjKFaXH8TEfNwe9LrEd7qFtHbX1hFHLCqCO6j2knDgjCZKv8AxAjjqelcor3MQUE5CtuGBgg/XrWnF4jvYAq210ybDlWdCTg/zppzi7xOOpg5J+6UtThvEvJrm/AWKQl1htrFUHm5ID4J2jAyARx7Gt3RmuIY57jzrhVcggzFV3jndjOOQT1HHHNKPFkzyq09ySqYAA6E5ySQeuavxePbmBtyWttuC+WrI44HfHHFa+2ndc35EwhVpq0Y7i3M1zdRiaD7LZAAF5bsZaRB0KgE8nA6c019SuZfJuPtVssgZWWSJWMgbp93rnjvx+NZ114oYs7Lp9onmHlgSWHtnt0HSkXxPc4dLWMW4cdFHykj2/yKftJM0SrbqJau7G41HUQbdW3qGeae4kO+Q9sdgPYZ6de1LLo0NnL5kz2nz8jyz+8kfIOCwO7HB5yPrWW2pXUyMrSzuCQcMRgn8KrpaTSzcDg8jtg1i+a/vM0VGpJe/LRDtS1CWaWRI2a0iZ87Yjk+n51V+zJmQx+afMbDKzFmOPVumPYVsQ6KHZcgHnoBWxa6SiRkYUY6AmpulqUpU6WxjaRp33S4zjsT/Kuot7LbkggevtUltYj5egYdlq8SI87ULtyMA4qNWYVKzmySAbVOB+PapmB6KCQTzjim27ZUDG3I7/ypzRlW3En2yTzQc+z1IGYI2JGJHTj0pwYnDDhSMnA60BQ8mSV24/M01nxlWXikUDuuTgk7e46/lUcnzA5znOfoKaWDgsT0H3aR2wnuBQ32DYqSwozBgWB64qKSQj34yAetSyMDL2JA9eaqMxyWPXPOTSY2xrtlckkj2qtJJn5WGBTpGJ5PJHYdhULn7pAO31qGNEbStj09PaoZHG3lvm6dKfMSSSTjHSq8g2rnPHXmpY1bqO3t/eH50VV3f7X6UUuVDsad/e29hCZruVY0Hr1P0FcFrPiebVJWtrVmt7U8Ajhm+tc3cXd1fzmW6meZz3Y8D/ConlWIYiPzf3v8K71BXscdKMbXGXUa25Pn5Mnp3/GtPwLciVr6PAwGUgemRWNqbie3W453Z2P/AI1J8PpsazeRZ+/ED+Rp1qX7mTe4/ae+kekQkFuetXFYjBHTNUUGRx1HerMZyg7nOK8lHSXkkBHYY6VYTDAA4/xqhEQDjpU6Z9cfStUJosSIWOT19BT0HQcD+dMRiw+bpT1GDkE4HOKaAkXj+76Zp6lcnkgk5xUfJGeAPrTA43Ejn+lOwy4GORkcnpUik7h0xn0qnG+Dwc1Mj/Ng5x1poZdDsWXHQE8+lOJHQDg8+lQxsGUDnHvTlYGXaVx3BPNMRNuYsN3X3qe1OCwyBntUIG0ljnmn7SSoUhiOmKa7ktlpugKttAODmnBC65yC2OtVirOqZOCPUY/SpI1dM5JPPcVQ0hHti/UqFA+nNQmxjfAI3Bv9mrqsdpDAAHkml3FSCpxTuCk0ZEujIRgKQAecjis+bw9HLLvIAUHPHrXVr93qc1GA2cEZ9yKpMpVpLqcdL4cBYk4z1I70xND7NyF9q7fDbiNvHvSGDJLY/wDrVTb6FrEz7nExaHkkLj8e9Tx6ESSzKCR711giVm5596ekYIIABOfypXbB4mbOai0Y5DYwcdM1ZisNjbcDGM81syKQfl25PHNNVAoJYkepFIn20nuVYIGAG8DB9KuKFBJIA7Y60qOCBtJPahiF4J/IYpGbbbHxnYTu+VTwc96ranqsdhEHZlAHoP8AGnM+9eCeenB5rn/EVpJfxbGDkdNpGKpNIujGLkufYpP4xM1xttgzOHKlQpHHrk9q6XTtVe6U7sjse5Fchpvh+SOXLvK7AYwxzj6V1FnbiCLgEMT1BBzSlK+x013SStA0gy7T8xJ9c4AqPzFVdxIzjGTURYBD5YyV6g8k0h3uVA4U9SazOSxZjB2A4wRzxTJjyQoyTwKa0pCks3A9+/vVeSTquQFP4VQCS4Lnge/POaqTThTnbyOhFSzupzgAnp1qjKwyQOp70gWo15h1JHfA9aZvG3J4z2FNY5ABHOO9QSDbyDjI5pD3HSuDx0Pt0qrNIW6npSufbbVeRywJ6DtU20BMTzB/k0VF5o/urRSuijy+6lABjj+VPbv9arq+RjOcUXDcFwR8vWqElwVwVGAK9eEEjy3Pkl5Ek8uLedCeOD+tHgu5EPim29JMxn8RVGVztkz1IH481VsZjbalbz9DHKrfrVyhzQcfIlz99M9yXI/Hip1GQNvQ9aqQSBlBByDzVqJgPug186ux6jJgeOTjH8qmjYAbgTUBJDg4zmnhiMkdR1q0xl2N8ZwffBqwHJBKY54PNZYcE8fpU0cxK8cVaFYujvkEA+9IGBY4H51CHJxzx7GlZsYwc/SmImRSQD3zk1NHnnP3s1VRiuCe1SmTng5NJMe5aSUZOW+lWkcgckZ5w3cVnIRg56VMh2pkNkDn3qgZoW8pZsHH41ab5BuXPX14rMjkzggcDkVY85iuOnv0xVk21LbTBHUEjOec9vyqZXyTjkZwADyaoLtZ/mDc9yKn3bgVyF/woTGWiF7EDtk/yoMYbguSv1xUXnLtHOVzgHOKcCWJ6g9+c1dxEojUtgbgOuD3qQEjOOnZT3qMNuOMgg8ZzTi3cYPpmmhMkGB83T8aeuQCMZ9yetViR3XGOSKeT8uQx5H5CqJsPIVmOQfbBox8uRke9RGQIQTkjHQCm+f1UZ7HFILDgc8ZGR3zTZFJ5Ixj0PNJKU8s5BBPHTFMLqRt9fWjcaFJZEPr7VXKuSCoLZ+8GJqTIZ8Fh+NKGC8AdBxUsdxHRiyAllA6DdUUkgdygyEUfe6j/wCvT2cElnYhe2Kj3hj0GBweBg0BcQoxH7vZ93njinLH5eN20DHGaUzBVJQ5UcYB4FIJCWGVzj1osO7HKkfzbfXk9TT24XcF6H0qNnCjkcnnA7VBJMw6ZJ656UWQEk7nOCQOpJzxVdpM/exg8ZAprMCWyM/pzVeRmYDOMA9zSYxbhzjKgluowKrGTkep60+VgAR07mq8uAxJ6dsUgBiMZKg8fjUL4IJYYwOOaJcBhn05qCUj1GB0pJXHYSZgFyapTPkMScetLM6lcZP0zVO4kCjHp6UNhYduHr+lFU/tH+cCipsFjzVmOeelVblCIyWyB61oqqrgHrVG/JYBVyTXspnlunpeRS25UYyemTUctswQu3yL6mrkQEcYOAXDD6Cor/cxDOxYGrQpR0uep6PNv062kBJ3Rqcn6VsQNzmua8NH/iR2X/XPrW5A+DivnaitNnqR1imaCt1x1/nQAfXrUSZLZ4p+RjBwf6Ukyx3zZx0NAYjoTijOCAcZ7UYPOegqguTxz8rznnvUu4OMrnHSqIBUngYqUOVxnqKYmi6GIwDyQOMc1JnC4BwapK5ZucYPrUu84+Y5B6UAWw/AHGT61IrnjsR0I6CqYzwCevQmpVZtgI5XpziqTAupIMcZPariAeXwecYrHDFSW25q1G+MEkjPSquTY0N3Qrn0NKjjO48MRwDVUXAA449zTo5wc4YEdT70wRfBxgHpjJ96lRiFH58HpWes4KnJ5HQHpUnnjoSAMf5FWkJl9mfb8ozjnpikWUj7wwx6VW89fr9Of0qEzfNl/vdhiqRPkaQIYDLgMev/ANajz9pOcgY4NUUkyDg8dyPWpCw5LsM9cn0oAtmQMSMnGP71NDgDliMHj2qqJC6HeRjsB296Zu5Xk/lnNA7EhkyzsXJ+p/lTHmygAU8nsOlN83aScKQR3ximu33t+TkdRQCJ0cZAH3vbvTvvEnOM+oqoJeyKQD79aGm5OAoPoM0rAy1u2E5OcDsKgiMvmbi52HkBuKhecgYbHPbOOKi8za3BOPQ+tMEWWmO/GTQZQV4LYB71UVyVYswPGeDUTydck7TyMetAy60nGWYnqKaSdoJbJPqearBsngcZ60Etxkj2OaTGSsckgZYj0GKhL+nQn0qN5OFywHrUU85yo6Y9+tKwCyMSGwdo9KiU4PPJz0qGWXBIOd1VnnK59fU0WAmmlAPGOfSqzS4ODx6VE83f7xFVJJWZgBjmlcomuJgowBz61mzSZHr7Usj5PLZx+tQs2OmDWb1ATzD/AHKKj8w+p/OilYm6OQeFIVJun2kf8s15NZF5d5DCECNfUdT+NevzfCyQgkbiT/08dfb7tUbj4SSliFUsO5+0jB+nFe4uVdUeLPEyf/LuX3f8E8pgObeTuRhsYpJ2MkJAGMA/WvUh8K7mH5ooJH4xzcA/pim/8Ksu1QA28gcjkG5XA/SqvHuifrMrW9nL7il4eXbotiOn7oVqxvtb/GtKz8G6taW8cHkAJGAAGkUmrD+GNRUlWhJIOM7xXkVMHOU3JNfedscxjGKXs5/+A/8ABKUMhGfan78jI61Zj0W75yuAOM7h/hUv9iXQOJCVwMn5f/rVDwc1vJfeVHH821Kf3L9WUlfPFSLKAODnPFWxok5JDSMoHP3KeujOBkyyD1yg6ULDNdV+P+RssS3/AMu5f+S//JFNWBzyKcDlSD06VcXSJCSFkf2JUYpy6Pck4y4J/wBgU1h33X4/5B9Za/5dy/8AJf8A5IqIfl6jFKGIXPOfUDNX08OakSR8qem7jn0qRfD2pbA5kh37sbc9sdc49ar6rLuv6+Rm8bb/AJdy+5f5lCJiemD7VKj8Y7/lU0mh6orlVELHHrj+lU7nS9dh81Y1t3dcbV4Gc/X0qlg59195m8yj1pz/APAf+CXPMyD2FTRyAkBcg59a5y4fX7Nx5tqSCOWWLK/pRFqOq+U0zQHyuhfyjj+VaLAVXtb7zGedYeHxRl93/BOsRsYbOSOgXjFPyvJGTXILrt4q7X2LnnlKkGuXQK5CHP8Asir+oVfIw/1hwa7/AHf8E67EcmTwvuRSlQinJ6eneuSXW7wcDYMd9tOOu3mFz5WcZwU/lVLAVfIX+sWD/vfd/wAE6sqGVs+YOOxpEgUKgXfx3JrlU1285P7oenyYqUa/ddCYl4xyuar6jV8hf6x4Nfzfd/wTq44wowGbOeSTQsaE5Y47Vyb69eDJUxjJ/ujmnjXr5hgmID+7toWBq+Qv9ZMH5/d/wTqyQADuOBxg96US4zjcvPHNcmutXLZJ2Z9lFPXV7ggAeWD/ALtP6jV8iXxLguvN93/BOlefnnbgdsU1rhRncAT9M1zJ1S4B5IyOcYFINTuCckqO4O0UfUKvkH+suC/vfd/wTovNUNkAdeM02SUgenqa506hORksuPpQNQlYckZA9KSwFXyB8S4L+993/BNpp+PlHJ46Co/MVEJAGfXFYj30+eoOOnArO1XVtQjt3ktPLEoHG5cgih4Gr1sXDiLBzdlf7v8AgnUyT5AHPTpgUB+PnYfTArhNF8UXl4hE3krIvUBK3odRd1DMVJY4NSsFVe1jSrn+FpPllf7v+CbjXBTowyOlRvOwxzjHXFVFnLDIIx3GBT2dgDj6nj/61X/Z9by+85v9aMCv5vu/4JM0wCd2qF3cnG36c1E1w+cche44H9KiaQnAJYEZ9P8ACksvq+Q/9Z8F/e+7/givuwckZPbrVebaMZJP4VY2r0y5J9x/hUb20bYJZ+oPLA4/Sh5dWfYa4owP977l/mU5JcgZHA9ef0qtLITwvWtT7BEecuSemGA/pWfOkYlZU3qF/vYOf0qHl1by+8qPE+Ck7Lm+7/glVgSfU/lUMzKikkg5q9HbyTMNscjA8cDqfyqSbRlZyJI7v6Bf64qVl9Xq195r/b+G/ll93/BML7UPRaK1/wCwLf8AuXf5f/Wop/2fV7on/WHDfyy+7/gnr/xE1mXwt4Q1DV7eCKZ7Yx/u3OA26RUIyP8Aez+FYvgLxNP4j1XVLCePTZVshGwutOuGlhfeD8o3AHIx/nv2fjXw3b+KvC97o1xO1tDc7MyoAWXa6v3/AN3FZ/hrwYmka5c63fapPqepTW4tQ7QxwqsW7dgJGoGc96E48uu56rUubTY03skJT5nQ+opTZxk5Vvwx+taZjVcDLZP94YGaYRsTDbc54rO5oZ7WcYAUgZI+8D1/CojZqAB5QOOMg5JrU+UkFhwBww5I/wAKQx7FBOC3UnPahhYyBZIxxsBbB7dqcdMXacjBI6MP1rXwmAxLHJ6gUydlRirkbAOo9KSHZmMdKIf5VX5Bk5H60+PTEbeXRShGdxPArSWdCGaPLjIUb8/kKYzNM52yOCvJwvGfTnrVJILMzTpsTMyRlTsHUA/1qCSBm2gxvHHnaWB5HpitkwyhUAjILYwWcDp3IqveyxxsFRnkkPLLGB8p9yT/ACpq1zWnC77lEwyJbxGU7ioIAcjP/wCqmwxXJhEgt1wR6kfjmor211OS3LQboJyAVl2iQkemM4Fa9jZRvBvvw6OcfKZDk+vGe9XydzeVOMVdmWbYmEyEDI4IjcE5qBreWSFo49jsQCSRuf6ZFdG1rBJIWjjgIA3Fim459BUQS4kkY/Kmc/P0LA9uuKVjLmj2OUj066jK74x1IyeTj8KeYEQnbFNHkYKhyM/UeldW8Mbq2Su/PzAKc49etUbyAbCTD5RJ4Ifdj04am0PmjPdHMXNssgybcng481A+R361my6PaKWZrWBVJOeq/wAq6qWOZYhHG6Oo5zkdfQjNV/MuQ0bAJtAwA2MA/Q01OUdmZTwOHq/FBP5HIz+GElZpopCkZIyoYMB/WqEvhu4VysUiuPQjn9K7uaPEaFkjY9/LXGPrVOWOIEsd4Geh71qsTUj1POqcPYKpqoW9GziZ/D16uc+XuUZwGGc1TOmX5VmNtIyA4O0Zr0NrKR0BjJc9fnXFNk0zKodyoeRwMZ/H1rT65Nbo4p8K4d/DNr7mebBJVyrowOejCpVbaATjHbmvRIbYLFsdwSp6MoP+TUf9n2zK3mRwc5AJiGfyqljl1R59XhSV/dqfh/wTgeNvVcmlU88gZ6ZrtX0vT9h81EB9VTBqI6TaM4Kopxzyuciq+vR7GD4UrdJr7mcdv5AIJFOD/Q8eldidFiIYNbpz09qYuixZwIlX/gHAp/XodiXwrXX21+JyZIxknk96YWI6jn1FdtHoEWQPJjkzzwCakTw+gGGtkG7ooXjFH16PYlcL1+s1+JwjknpnNVpQCPmAIPrXoJ0GFWz5EQB6/JT20GA/KsMWPXZx/Kk8dHsXHhisvtr8Tw25i/svWdwIWKQ9P6V0VpKBhlGcnIGentXph0CBsF7aBieR+5B/mKdJoYjJKQoOeoQD+lQsbFdDrqZBUqpKU9fQ4mCcMRtxg+p61ZV+xPsOa6r+xZCSEWPHpsGaBoczdAnqfl5q/wC0F2OKXCs3/wAvPw/4Jyvy5O4Y988D60yXacDjb2PrXXL4fcvtz9c1bg8LxuV8zJPfPah5guxUeFJX1qfh/wAE4ZXx90MSB2HOasQ21274WB9p5+fgGvRofD9pFnCrgd1qxHpqDlYwMdazlj5vZHZS4Ww61nJv8Dg7fTLhv9ZHjuQvStXT7BIWwLNBjvjJNdhDZAS4wAccACpBa/M3yc/pXJOtUqP3me1hsuw2GVqUEvz+8zLYIigiIZHpWnBHE5UmNQMdAOlEdmM5yCDwy4qdIPJxtbCjofSs7s7ORB5MPp+lFS7qKrmYchdD4b5hx6EjikVmyQAAw9D+v/1qi3ZBDEAZyFNMUjcPTpk9Ki5ZNvbawJI6Yy3+eKZkLtZjvK55PPJqFphvyQxBP1/nSozH5XyGPRcZIx3/APr0XESqW8tW3ZUfwng0xixClSUHXC4p0a7su7EseWLjr+VLkKzEKGyegXgelJ6ghFmQZRXB2jHJpsrLgJuRsgcgjH06U9IUb5/KGSc8YH5+9TiySSQkxYYjjPT601cbaK6PlgE3Y6cnIFPOxSAuQVPJBwMfT/OamUFJBGwJwvB7D8KYyN5gEiLyMhgRyKL9QuObysKWUMzDqRmljjOFaItjO77oAXt+NJDGdo2Iu9T64pwRlypkzzgbuRWieo0x8rKFO8AFTwe35UkkkZGBFvf1ODx9arNwvmcEkH5iecf57VHGzShfM54zgcce9NyY0riPI7qQQoUcjawDfnUTrgYMbYbneQOferICxkCMbDjK7lO7/wCtVO8ZZFcPuBHPUHP0pWLjG7HAGPManKcYO0k/h61BJcqq/u3Af+LePvfXj+tULm6lt2VEZoXGM722g/nWdqN3cSxF5Z90eew6U0jaNC7NE3sAcm4ERZABlefyB6+9U576OTISKMHOcqh3H6jOKxXkR2+bJCDdlOo9frVf7W0TrsTzNw5zjGO3Hr+daKLZr7BI3G1RAFL/ADyrkFXTAX6f/qp/262kUI8aqDwTjI/EVzn22YPlfMbdwVJDD64/zipJPtybm+wuuOGJjJA/wo5BumkdTbXNsC6xAFcYA3cj3FQXd1Cu1o5HQ91Pr/KuaS6LKkSbGkyeTjn2HvUi3gf92UVscdckH0zSce5KpamxMyTFCmckfMc55HoD/jSqpGRIhlU8BiNuKzbaYEZGCwOCjHkVqRzDymCu2Om3PA+tS0OUbFhbCCWLA5PTG7mov7OUsWwQfXdnj3FTWO4ll3bh0xntWiqkkMAuOlTdoxcnF2MFUntpykZDDdyCeQPpWtHAHbO3Dn1NW2VAw3JET79aRQWlypWNh6Dis5O4SkpalBIJo7ncWbYTke1asKbo8FMqeqk8UjLuIDtz2J6VMqkEAsCPbilqZztIj+yLKgRY5FI7bqRrJY+flYd+cbau28ynK+Y20HHI6VYZVcbFPsSe9O5la2hktYxHlYwT6Z/kaUWqhcEZJ45OcVoTRgAFgY9o4HrSwqWUlI+SepGc0l2HbQzvse9gqgZHbpTzYY6qQQevpWmkUjnDKo4znoc1IQVxkbmAxxTSEZyWuDlVyTTkiVXI2lWPTuKvqPnGBwfWnFRnaMbee1NIRRaIbiAhOccgVGbfoy5K55ya0Any7uSehIpip8wIOVOQRTsFyiBknAx71Ike5sHdjqR2qytsrNwuFHv1oEbpHlT7YosL0G/Z/wB4uwfKR0pfKixuzgKeg7mjEi7CzHjk4qYjK8hSG64p2AgzH/s0U/yk9KKVg0I54CoAeRjzkAH26ZpjQyeUobaSeORkGtJI9zBQM5HLZpTG0LAqMYAHTGPapUSb9DLhtpCSVRCO+3gVNHahfmlBx27nNatsidHRfz/lUjQA/wCyB79apJC5jMFqGJZlfAHQnvU6WSgAnAHr3Jq8iMkRXJJPzdaUQOFyWK4I4zzzTsJsomzzhQNuP4R61JsRWBIL4+7gjH41akAI8uIBSeAO/wBc1WkRUJEe1WHYnr/9ejYa1GOgGx4/mz7cUkqgyneqgEfl9KkgAVl2kEoeR0p11ksjbl69etUlpcduhRgZWV9pZFDYyVPb0ppaSE4jXap5+bkmrW1DGQT1Yn2qs8mJiCoKJ0OMZ9s0WNIq5AzoSu1w3OTgZ5qGeWUKwRoznrkdPxq5JDvO4MF9yeMVTlmWJCRGXB5LgD9aTizWKvsMeeNIjkup7EEc1j3VzAwKqI97cK7Ptyfc9B+NSz3XmNxtXPuDiqSRfaZsP5KuTkufuDjof7v16VrGLZ0Qhy6shnjkaZYGaQuckLH8wb1xnrj2qrNNbG63zSyiZBsVEXIcgdz0H0xWjPJI1jLHAgnAAi+YbZASeNsigZXP86I44LCyMt7I42NsbeTJtOMFeR0PGO3oa15VHUp1FFamDbafe318YreFI2BLPFnKKOu7B5x61U1jVLDT3mtY40uLlAFMkjbURcdUHXk/ypvijXtTntJLixhW1tY7mOH5QQ5YqSVc4xjHbOfmArH8ZJcQWSXM8EVuy3H2jyxGE2BjwCp5I+XgbiAAcgZ55qtRpNRLinOSc9ExdT1TUbdtyXFtZCaFVdVi+Uh+Bgds9M9jSWk+q2WRqTX8C5aNJ45RvUqeSMqSw7YBAODmqlhEftNuZgJy2yRhHllk3c4f0OB0rp/E1pdabqvm2SNFYcsr278Qq33lB75OcZz3qaS5veYTlFNQsi3odjquu6as8lnbXM5mPlz3DGH5MHYTtGcfKcnA6iqP2a2dN0az6eJSYw0jbopSBkhX7jjPPat34dx2TWMMEom/ta4TGYxtff0GASARgD0rX1ndclftdlbpAkO4pKfMDMrEMGB+6cs2QBzkYOBW0XzRucnt3Go0tjhWtru1Ks0XmxnhZY/mU9+GHFPEx2Blzs9+x9KuzCS6kSHSpksLszm38qPPkT4TKkL1yx4wPu4561KmlvJA19b7sbALmEEI8TkcgqcHrTSOyNZP4hltcqTG6gkAcrk8e9b1hclgV35Ge9cdbSi3bksCpwwIwfxFb1nMR86YKnof/rVlJDqU0dKVR1Djr0NU2ATJDHjkZ5zSQT5jUMccdzUMrbmJDcZ4ANZs5VAvRfvQCpIJ6mnb9pwGYt3xVZJ1J67SB371LGQ69evGaglxaLaBldXZjjOOD/OrIc/MwD/nVPynaH9yee/NTRyNs2uCrY+/TRLV9Rkl3sk2PLu749K0rG5jlUNG232B5rlNchlYMkXy5G0sDg+xB7VPoTSKxYjPHIZuTVuNtUbTw6dPmTOyzHgY5weOeaSYvuPTavPzHB/+vVGKYMMbVyO3tVsOsijKbW64oTOJxsLs/el1JPqBUnlKuQARuGQD609uCmwMPlycd6cSvyHcBxTJZXjY7SGwMcZphUMf4sk4PFPmwDiXAOetEhAHHGOoFCYIjOApbpirAKlCp6noaqqRvAkb5GHBPr6VP5m7G1eF4BBouNoZJGCVIyFxwKRc7COg7USMx2kcAdahmwAU3AdCDmgaVyXc/qtFQ7T6D/vqii4WRsRxjBb5DycnsKIUZFDk4OOARnipzGqxgyKXA/hK9aNsbkfKVXNO1zC4yPlNy7Vf0Bx+VSRbmAVlbd6Mc5/GpBHvyFYfTqPpTjAVUdQp6ZH50KIcyKs+5SG24HQ84pVIEeNrY/SppmB2FEHmDnGcEU+IFgwZvnB5OARVWuDehTlz8gVTj68f/WpNwXCGP5s4zU4BUfMCcHk7en4U2X5nXBOOmOaFHQtMgUEyYU4jDZIY9SKc2427MrsoYZ+6ce9E0ZWRXcEA5A2tyaJmcs7YJA44Ax+VUlYe5krNskWNUluHbgbOB+XelJCSIpYbuysMH9KnEcZwwBEoGSCvHXrmlnzHtmeQsORkODge2OapRXU3utikZGikKJIEB6gcY/xrOkW4unKW8S3hZgMCTBU+/FT3k8e9YHkjkMhyGgZT9FwcYP1pJBbw28qxiLdEgkfa+M9euMk4wegxnrVxgmap8qvbUri0WC7RmSMuMEwt8u8DnK5Hbj61JqVosdx5bQXC2z7WkdQGGWPAJBBU577T6Z5p9wkCh5DdtJEu0uqwsFRdpI4b04PXnNNTTreC1l1MPDcvIWdIYSsfGMbeODx1HvW6VkRKp1bMnUzBotpcT3tq43cGNGDb3zw2RgFSQOwI9a4i7vLzxPqMsl7P5cSFkGVVQrAZzleuPak8ST3mp6m4t0gawt4hIRHuO0EkENnr6ge2B3rGg1NbC0nt7hQQDuCmMH5SQAOO5yTjtiuKdR1HZbHTTptR5vtfkat1d3OnxLYXsXmIf9KkckBivRGGOxABOeeRWR4m1t/FN5IuqxfYBaxs1tCE3b12llBzyxPy9x3OKsav4g+ygM8YlnUAGNyCiYXOSO/0rnVkGr6gt492YvKPIlDzeaWX5i+OOhPAxxgAk0qcfab7Dfurntr3/wCAa3gy5u7rX7MxiOWQvCD5FuV+UMcSOc4DZO3kHt2rv9avfKGo2t9JFHdKVZJBEZFESOF3IBwGzncfcnHPHkmm202jJcPHctcWcjCLzoJzGwBw6EZwRuIH0xziu01mTUU0rTrpJpr2GIpNcEx4ld3+6jSDqRkryBxiuiMLRaOeq1OaZvyWaape6bNp1w7a0+WYAlvMO7JJ54OOfeujjnkk1n+y7p4dQSZC8ly8ZSQsvHlsp6eoPXtXN2Vo8Pid5rK7kmlWFWj2N8ykLu2jGOOpPHtWh4hvnudPW+0u4ErCeNHn2dVPzBh3PIIPcdcVKik7IxtzJL+kWoI4tP1W3htSk1xFbtLbiVRiFicBl9cZPWqBivrTU5ZZ5TdSSndLHGN5mwCM56cY49cYrR8N2S6zbTPcFPtDSfvn3ESKS3yqmM5BHGOMfjW1Fbtc3FsrRSowaRI8IFMbIMqVburDkde9TKi76kqqlc861Fll1FL3LtaXDbXUDBRu6/WktrkLJ5ZBCE9hgj3rrLqwgvLG9jLBSQJY3YBC6rk+YnYsScY9+a5+60uT7SnkN5zMN0m4bZC2Pm474Pp0p2urs9KlXjJWfQtC9UKRE+70DdcUltLH9omEsoYxoG8oK21sjs44BBx1rDJmhmeHA8wHBxyeKmeZlj85UUtnmNjwR9Pes+VJ6nVCmnoup0FszuvPOa0oYhHH8zZXqFPrXPWNxMY4WliYO2cnOQT6+xxWnC7yEFjwOxrGUOpz1YNOxt21xtjydyr+dSXFygyP4Sevp+FZsUbZBIJUn8qvCEAHI69BSRyOKTM29mdwdoO9CMFR2qTTmzEEaPDsffip5rTYDsV9zYySeMZqxFEgOJVYtu5c981bs0auXu2L8SbGHzHzB3FaCsd2QSGAyKowEpxyRj72KsFt2OcY6HpUHJLUsM7mRSH2nvUbSkuyqpJXkZHrTGPITBOBxmliY5J2twDuI9KpEj4z5yHdwc+nekc7kw6lfQipCquqvGT9QP50M6nCtkc8e9ArjCnyhFIOBnPrQrB/nC9ODmmMrDPlncemD1qKLcqPETj364FMZMuFQryV7ionhyXGcKB8p61NhgTl+vSnBWxubAwO3NAlKxBx/cNFSb1/vt+VFFkO5tpEEXD49cFuQKYGQMy4du+D1A/Cl812JDbMN171EsjLPtB2k9cjqPwp+hha5b4Kh/M5IwBnBFAZ8fOwBBIBzj9KgllwjBOecbhggfjQXBjUEAnvwadxJFjeMKQVDY6k9acqlD82za3zVnAqCMNjJxgVKIsFQpOAepIP5U0+o3ElALuWKglueGyAB3pm6V2VVkwp5Tfxn/GkiBz8j8n1Xj86BLtcnIQ9MNz+VNO4yM7hOsjnZjOcc8euKa9ukrMAJBx/Acsfw7UkEjNMMzAqTgZ7n64pLq4LbvmDseMr1x6Zqo2tqWr30Etpo4I1idFbdgFivP1qAtaM+5pYMnPyjgE++asOY2jWPcysF+4QN34VVYlR3SNeGJGeD9Oa0Lj3HW8dul5GloiTXLnAMCqqoepwdvoPWlRZ59QMmMxsJJYJI+qqO3AHXPrUOjRW63siRiGZJXxt8oqzA9twOOOvStALZul19kgijHlqu6M4Z1weAMfT+VbxWhE3yuxjxgWsdxJ5o+0SjzGKJuVXPQBjzkDAI6kniud8R6rJBp8sKJEWmIEoxgkEHoOgPHJHbPqK27sfY1kJfDrIQRE+7aWAOWPQntwO3tXmXjXUp7XVI4LHyr8DEUZiYHzGZvmdsn5fTk/XtXPiZSUeWO7NqMeeRe0rSw13M0KAO67pmjPCEjv68An2qbXPDEV6rXVnEzXMRLfvG+VUVMjI9MCuel1V479luJhbwWdwJ2t04MjsMBM9TgAYGMcknqK1ZPGVpO7FLidbiRSkDO22Ibs54H93tXC4ODSZvJVOZSizzWO+VvstxewxSW5nladVwxZ8YI4OdoUgg9M/jV5PDhi2tDDcQWdzE4kmDZXaACBxnbvJAwckfma7qXQrWO00axjs9kOr3Eck4jbdNOgf5ty8lFA/hHXOTyKw7vV7LfYWBuZba0huJWeQxh4R1EZUDnOARkjHXFelBe7aRPPzT5oFO9tdQ/sfU7q8gEsZEdsWUjKlY12oV7DA4PTryTWn9iWeC1e2j+zywuGZ5XkRmHYkZxkHkcHP4YrpfB3huG5urmfWvttncwusTedKgWRsBthABIYBl+U56kcHium1LT4ocoluJIGUhC4wA3UkcAgenFVyvqaQnBO27/A5nRNF1LS5Be2Msc11EU820DAtIqp8zKp++CCTleRnn2wNQ1KefVraeW4DyBy07BAqxoPmwVAGG7N1Nei+HbCWLUrOWzkWO4hlLs2cFVbghQfvAj+dY+p+EoNP8SSy28zT28423JWcjypGBIVnI75H3v72CaUoaaEKUfaNS7f1/wAA2rC2u1s7OTS3WG1niN1Ha42h0XBJVh1xu7889K6U39h+5OoQT2UyB9rM24vjGVDDjj5eBwMe1eb+Jvt9rYWdpDFOtxbybY1c8x5yGAK8beP0Nak2tG90W5vXgMrNGtreQyLtzkgbkI+5yMkkc4qY1U212OWeGbSl0E8eppqXdrcQWMkr3Cs9tFADlnzy7jHIPXI54JPrXP6Pa6n5cVyqBDKPMjOd8aJnlz6k8H+YrpZYZltrBpZ4o74OLNWjcgIhIBds8KCMA+vSn6NokAu7m4F8YtPjk22coi2xmTOTlR755zxWbj7TVFqooQtfY57UGWHVd13FG0s+TL5Hys4b+MY4BI7VQu/LDJ5aS+VIOTKAATnghvUdDXV6tYR2tvdyXk5SVt80LQRiPfKMruwBhueMjqKpTwTR2cSyNDcz23zNJIoeJ1ADcY56nBH/ANamk78rOmlW2aMWOdrdpoHGyLGGOd2MHgk+39a0oJGCkEDK9DWTfSme4PmRFSDnLnkDrge3tWvC4lcMjHDYJGOp7isqkTtnrFNrc19Pywy+QCcgitNYTh9nO3gqfWqFoAMZfvk5/wAK1FkCsw3deaxPPqb6D0QYCZ47hueKjnR1mTaBtA5OO1WgrPbBkVVIOKcgAPB5PPrTsY8w23fcoBIC9s1Jgsy7sfhUOR5ipjKk5Ge3tUjRbZMqxyew/lRYzb1JJZEB+cbSRtBFALRqcgE/d3djmmHbJjfghWwCeaniHzOAR+FVYV0hq7hhlxg80kihwTG3zDmpEXCB1445FMlQ4IB2t1zSUQ5tSRV3PliuCOfrVcgbmUcMR1NSBcbQVznjOaRuCAqk88nriqQk2LEOfmzngYpVysTZwSO1MC7WR1fgcnJqRWX95wSCBt/rSaB3D5v+edFN8xv7n60UWFqagCiM+ZEOBwOhNQsScBcpx2xz/hT2kBG5Ew3Xk8YqIgszPucZP3SM1N7AiZi/GCAOgPTNV3MqOXwxUDgqasY2xqXzjrgdKgm+RQV5x93cCcU7iWhJEyrn5goPTL1Mmxsu8m73ziqzRmUAjMjDkqpxxVUnyGZSJcN274J47Ux2vsXZGSOPC7goP13VWeRmYhckryD65/pTjIC46BiMdMn/APXSBdpAlzvDHHYj8KZS0LBmcxKR8uDx8p4qC4CGBsPESOemR9MimXBILbCzFeSBJg/zppk22+d4BJ2nc1VcEuqI5pfKQqZArN02/MR7c1nS3CGby5nmJb7uJSpH/fIP61aubiIR7nZfMHBIcKQfQZGDWTNsmnSKQ2zIrAky7UYKT1Ujk/Wqjc6Ka7mlprW+6a0tjDGQd375iCB9eORz+ddPbTafFaSEOsk9ugeNpmL7TyAc9jXATi3t0lSC2WSRwxjUSl2z64xkj2x7VsPcm30NrdrFYmYGUoT8rhV7dD948LknP5V1xdkY4iHNZo53xrdzyRNa6aPNeZhG0a4O4NwCMY53fpz1rktA1ldLcQvb2bmCZroq6dJVQqo3EHgZOOvNOn1iK9l869MluykhXkTaI2I3bCM/ezjgfdAHrXMazfRTwtAI2S2TcQ0XLSMRhck4ATOWPftXmVJylU93c64U0ockloZeo3EGo388jOi3EpAxv3cdeSev48mu0bRtLi8MrrKsgurV44kVyN08rEFnRB0UL0459q4vwxYCS4dIYjKoha5eV0wCin5n54/zivXNXt2iGl3VxbwrbyRbIGiGXAC7snuEAwzYHPfgV1UaPKr7lVavwwi7Igh0N/EHifUvsF8kkTxbvPWMgtuCl0Y8YdhkMoIbaMfLUGu+Fp9TubKwtnt/sqX8KTPa20cZTbkmKIL3UHcSTgZxkkGujhs2sbeCy3mNJVWeKcNuWXPIkOMcnJ5FSNZ3Gm7LLTzFcZyVRB90kex69T/OuprucyTTTUttv8yHTQdH17zFEksSh1kS4OWBzgNuHVsdW7jvWtdX6XUMr7CytwoYHcwzgY9Bk/U1lW9hKJUklRppZCCqMTtKjpk9wcY+lXniuoI/3ZP22TAEm5T15IHBAHOPal0Lly3T6mndwW7oxmRIZVChZ4uADjoO+eOmKfFOsGlNaRoJlnkAcT7R5rMeX44yc55qGAW9lbSR3M7PKo3ecQSzMe3PoePyrB1PULC1tikbql0riRU8snJ6YHoRnn6UN2Rkk56E+o/YpY5IxcyJPYsWZMlQ5I6hh0yR0/xrntUvVgt4ZtgWQKsjoU4ZT1DDuM+tQQ6ldLfXEC2rkyMN2xN+WAHHHUZA+lP8S6JefYJ4Lt2hmaIs/lyFGZcjhGHHTkj8+tZpKSfKb07RajI5zWNQ82FP7MuDPJd3IW4lY7SWOTwGx+FdRZxS6dHYS6hJf313cojw2ls7eYgB/wBYynK8gEDoDjp1NcWbW4u1jij2F1aKJFJEYj2j5XLNkdfX/CvUvB1nHYeDG1iCVr28kjSNUKPtw2MRpnliSAd3Tk8ClRsk7mOL9yyI2Z7rXIirTWmmwqzm2ltwrwuBkcN0444yv5ZrnZ8G5naNYrdmlHlwxIU3AnjK54JwP0rqNevrqZJNP1e3SzVkWWNUcM0T424fIPY9OnfNcjdXSHxnciK5Ui2tRJH/AAkgqCp6Z3Dioqu8vdHh7i67ZSWc13NOAZoZBG4dgBkgcKB/EOafFKpl+T5U4GOnaqs90txBfsYpJLm6UEtJj90wJ3Mv4fj15q9DEbi5MsiFWKrkAYGcVNTyPRjfkXN/WxsaeTM4wcbevfNa5DDD8ZA6VQs4fJUEtjjJ4rVRcxE4GCMDJ7ntWFjjqSV9CWCQsy4xgjOM9KuJHmMeuPzxVEAbhnjPOR6VehlQAAdxk59O1Uc8/IivEAYE4VgO1G4Rw5Ys3GST65pZQrMpxnPzHPcmhWUgK2OMYPp1/wAaDO1yRo1VPmAH+0PSiJGDYO3dyOOxxTiTIitjnsegpJXjBB6MvXHencVgD/uo9ynJPPtQ2Tzz8pwB6inQurjI4XOTnjAqT5SBgYA+bp2/zikncGrDQx27QBuHH04qHYVhfaDkjOB608MCzluA/T1pPMVg4B6YBHpxTGkMeIFN7Y3LyfcVSjuFickt8pJwfrU1y/7sYJBxjnuK5/UtRSwR3lC+XEu9ieNoBxRZ9DaEHLRGr9ob+5+tFcj/AMJton/P6f8AvhqKV/M2+q1f5WenRIAMAEE+mOacXMTYIb8QB1qBWLKpCZHfC849qid2T5sbSOoxg+1QcKV2WhKW2hXUj24I/Cq1y5UhVDkbjuwenqagMhOCzAN9M96WSTerbSjFTnuM/Wn0KsItwzFYj97oGenxyF2cLkEdSOcf4CqxQqxaXCY6DJ4/SmRyksW6A8ULzKsXizopJYllGcDPI9PeoUmSTLFSRnB6gj8ar8s2SOAM8envT3lX5W3AnoDgEA+/cGmgSLAkRosMp5Pylk/rWXdTuk4jZAuec5wOvXIP9KfPcHzN+RjHBDDg+1VLkib59rzBPvbACwU9z2NPc1hGz1H6ogTyHWR0B+5v+ZfwYZ/I1izStPIqSXqyW7EbY2kDhTng4YjA+hFWNVktrG2Jaef7G8oCwvGFj3tjOQ33B1yQeax1d5YI5LSxjazjuS37uUnjsDnqOmOa1SOmmtLk5uEi1NDGskEwOQGUkfg3HB+vHSpvGviYPp0qOqLGMIqGR8vwMqSvQnBAHfPNV9Iu3TU/NuFWJARvkaJ22lvqSBzkcmsXxjq1zd65JZW8h+w+buRFhCpFxt3DI5PJwM981pOSjAicVKaVtjHlu5Hu7W0k2JNbgoFb/lk7Pljz0JYc9eAPpXM+MdWsJNTWHT+bU/KTIeWOOT9Ca09Vli0mKCXSvnuo1WSRmfJM2M/gFHH1rzf7FPrus2yznyonbCsP4Is5LfQc1z0oKUrsyq1HCKlH+u52di9y+jajqU5klup54reJViLMw/55p/COccdemPWvR9f0v7S/hawikleUW7T3DuSMuW2kbiOEyOCc5468Z5E3KSaVY2WkM1tpsGJGXiRnm27DJz90kMeR0PTOAa9U8M273XhvSjdP9jaxMuJZVHmeUnyN67yD2OOR7Cu/R6GMHOk1U6N/oSww6hpltH9vle4DnC5l3hQM5z8oIwewA+ldBpEUSusjSxb3/eFmXOxMfXuTj8+lcrqmrNeKnl+c8uQib8F3BPJbtnGM1aS8VrZlAJ2tsYbss2P5D6UJpGtROUbvRmh5266lt0UyRyoQoRfmJPHDe3ZegzW5p11CtzBFMixTh/McRHccAHCj04J47Yrl4b0x4a4GN2duGwcVFFqFw5muLCKMb22tFgEGPAyuT2/XNNbGcoOeiOh1wrJcQ3GyIxFQxSTLhUA6BvcYP5Vz5SFwYjJPg7mRVQcDqee3aqMV2puovts80igASQdVjiByqqe/J9a6OCOwm0hpWjlW7mJMeDuJXIxz6dSenpU/EXZ00kxLO3tztVcwSud3+56/XqfoKt3GmRR3Kx3d+8SoQNzsvP8AsqPUj8aztN8uLVG/0e5uFYYhcjaA46jnsf0rE+IurGLRkktxKs7yBtpOA7cnr7H9cU0+VXM0nKfLcxPF1nZtc3VzayIymQl4gSccgjdn3/lXX6Lrl/rl+t54h8pYLVrVrTT1IAlkdGwRjndkFtnHb2ryN7y0vpYYbu7a3L7pZmjbdvAH3Vz1Y9s8Zr0nTYUllspmsZ3YOs7OreZIsoj2xx57mOPrgdT0yKyhUUrtG+MhHkinqzQ8XXTSrdRQIW1BrSQDaAVjBXknuWIBxj2964bw8sLzzXVmlvMVt1eQlAFkcn5gc+mQPw4zWrf6pLDBJdIzRXlyVLSZ2lQQcgcfKW65Hrjis1bqWfTLhXuFSMeUoYHDyFcnA9eTk/hWSkpSNMPBxhbuNVRFLN5vy+ZNnKjAHB+X15BrfjaJdQeGNyUULtxyMYHes2JQYbBlA+QSTu4HUg7cnk5Bx19SauWOWfcw27jnA5qKjsdUpXR00DYYZGFABLHoT2FXwMIoJAB5bPb149umazEIAAQHgAknpn0q7FlOSSQqheOhz2rJHBLcsPGzyZDAFiCAO2R/Qc0qjao3OeuQD24x+HFRRkkndtKkFie59/b0pwdUVVHzKG6evPT8TTIbLKFC2xiu4DOPfIGB+f6U2OIIxbg7efbpVeTiUZUDHfoM9OfqadagxoAWyzfMOKZm9C9HICsZI/h5UdQR0pdyMARzxiqrNuVtwxg4BB6/54FSrjbhR0AIA9aBD0JKlCcbumegp251BGe2Peq8zhOV59QOwqM3Cs2FbPPbvRsNInLbpAUGcDp/WhWRQVznJ4471UlmEb/IANn940puN6jjAUjGD+tA7D7skpuAztAGD3965/U7ZLhG81Q8bZBU9CK2/N3vuUkL1AP+FV7uDdGCDgAfd9aqMralQnys4r+zI/8An3h/75FFdT9mH90UUc7Or6zLubsYcqMM5AGRnJz60x1GPnY5A3fSqTXGbkZJIxlcr/Q1akuZsAJ91jhuMZNYpp6nHZiqDyPMIYncC2cU5cPuBI6dc8k/U1UKksdrZIwSCeR9KeoQyBy+0/dG7v8ASi9xiyDgBgMnquf14qIcljEBgD7x7H1HGPzqR+gAVsgdOmarGf5wYkKYOTjgUDJ5MhlDKWDAndtGKSZo/JO+Yg4xhlyp+mKia53N0wpBGDx+opktzxsJ3Kw2gNz+IoErg0gCKigxkc7lJP555/nWTfzLEwHlwkthQOGBzzuBGAauG3kIKEOUb5QC2D74NUb4JZxiKRHQqfuzJnH1FVF9zoha+hk3N3Zuklvf2k2wKPMRbg43A8MoPr6VWeZLSC5js3YxTyKCrx5CDGeO2fpUpuzeuVleMxbgDuGPl+oGePpSXksczNhXRkwFAO9ceqtjP55rdW3R2W1s0X/DF9F5ohSady27MEQG2Q7T68/pXC622oNqm0xLFLDlgo5XAywdjkgkg8Ae1dLYXmoWNzLeos0kYwJGeIjaPU8dPpXLfEK4nPiOeCOGXzJGDogAQDeAcA9/T0ArPEX5FYyhG1Z+ZjateR6mFuryMWtlDEF3QxZLsOOmeTzz0rntE1OLS7qWTdDIrZQb1DcMeBjv7/UirmraW91NeXpSWOyikEaWsbs4XjcQZMDcFwCeOSRRe6NbWL2TCSKWW+CuYIcv9nU/cJbpnrkZyOM8mtKUXCPmYTam7PRGtPZTNpc93bQIUTbhIUKKgBGfy4PJzk16B4d8QrqOmG0klYs+ZOWB80kk5475JPvXFWV/bArBc2jXTQT7Vs2fCzBfvFvY45A69B6160PDWgweH7G603T4BNc5kleAAnftJ2qT0TnGO2MHkVtCL3TKnWio8sl6MxnQ+ZDHHzvOdinHHTk/rSNA1tKyRyKqKu4EKGJz3H8hSvI8V9BNfoiWsZDBSVBdMjK4+ueTUc12rXZYlSFJdtox8ueM9hx+VEnoKDbBpzPdwB7jLCM/L0I5OB/WrljbSOivISwweW6cVGkAmDShMIx4ZsEj8anguGt4GTeEwCNq88dqSnfQ0vpZFi1sRhMOiSPlispwrEUS+bbMs5mVogQGTadoB44A/l2qB7vz0JkZlI4X16fpVVnERwieYkYO4Dvxy34Ein6Ds29TcuPEUEOnOLuBvt24eSEy2ehDn0yRj8K4Lxdqw1+ad5Fjhs7LZHFEoKIZHc5BUsdo+8N3C8fhXY6df3ElqfNurWKxY7fMcAmM9uB8xxzx7iuN1qOex025trNomF7KsRunUiZoAxYYB+XBOeDkjFNvTXY5VHllaK1J/DcOmXXi83XlQw2OnIqPcMdqq2OSOABuxtUdfmyBXZRakyNrj6Qy2en205LyTSrgFl+dYh/dLH36+9eaaVBqFvqyPCvkaXFiSMQv5jbkyEbPc84z78VtRvEyXUl7e+fJK7SLGF+UFh8xA6BsAD1rKN0rFTpc7u30RpX95LcCK4McUNgsZiDxKCSemRg9xxz6VnQTfaI88RG3TykjKk7yzc5btUrXEFzYlSBEzFVhjgGGjwST7fiecmo44gFWBZBHgEt5gzhevUdyf1pcvKddGKSs9C9IHggVQUKTooeSIYMir0H0BrR0YM4XePmxms61UXEkbsrJEg2xoxyRjua6G2AK/IAOeT0rnnPmegTkkuUvJII1IALBRk4qws77N2d7bsAEkEEjr+NVYSoO5CWXPbknFWdrMzFzzjI7UI45WQq7mPOeBu245/z3qwu0qGCqSuC2T+Q+tVI2zL97B7NjnP8A+qrAULuC9OPbP/16CJFnhi3JzgNg+tOYhRvBG7pnuPUj8ajQsVwSQSeMc5/z/WpZGP8AsgYxx2p3MpaEW8/MDhQDgH1/z/SltZj91SRg4OR1NULy4WPIz8wwfbPYZp6yBguCTgnvgUMfQtXDhl+Y/Nuzx29qqELsJRtqjPI60isJCTwNo/LNRMfLXhlVcdD6UXQJ20HSyKYwUPXv60RShNwb8c+tUJ3XZtVioxwfWqQnFzKRG37kfeb++fQe3qaLl7o11uwY142gjj8alFwCME47deorOmdUiK5y3pVXz8A7yeOhzzSbJsjf88f3T+VFYX2t/WT/AL6opXFZnQKgeVnJDOP4dxTGf0pw+8TzgnICZJH4dKqtKrMc7jhsnAC/l3/OprZx8qqzZC52524zUsvpclGQ2WIYD8c0yUeZtACYxyN3+PSla4Cq+9ic8FR2NQm4mkGM5BPAJ7elCEmSyEyQhUL78YKlR+WRVeUpJwUZjxuLf/WoYIqK+7516qFxj8aaszsxL5fJAbbg5FJjJXjJKCP5DjH3sg/gahkCvuEmxyG6qcY/yaesm0A5CDPAbv8ATIqCTcJWyGwwGPx9/SgF5liMkh08td7DhSuQf/11mXWZ43LxowPJjbLFPpk5H506S8CyeWCAT8oYnAz6H/69Zmq6qEnMjFSX4O4naR3/ANr8eo960WxvSpyb0M26NnBcEojouTkMcr7DPX06/nUkMllPZwpdxyJcIdoEaD5QT94NnB54wev61W1RI3EUsM8f75chFJO0Zxjd/F+lV4UzHICGZEG47cYUDv8ATNXB2djscU0nchad7O4fyZ5vMSTeokXKrj7ufQ9tpGKd4h1SOO4tZrJ4oNQkgKPK4BMbFSMg8g9TjA44708TtaMtvNaxMjIxP7xVcjsQfXHYg/jVHU9Nt7prUW/2izmlJZmKZBBJwEVRnHatZX5dDnqWbXMXokhsdI0KG1KTRWjLcOjBTsLqWYvuBDZ2nAxzxntXJ+MLrUNYuvMmt1SV3YrMjbE8scEhRhTzyT61pmy1y7+1ol3G8rAOsaQnbIBx8uf4sfh1xVG/WFJUilURy52CFssXwOTux3bov51Lk1oc8adm3LUt+HrdU0eCSRYpnjDRNDFE2+3UciViByDzzyfwrrNE1E29uTaRC6QqZGwpbYOQWIByAPU4ryXxnp95bXcRt5pGuwMjy22lEHUnJBU5OOnbvW3/AGj4q1nRzZ3muSxWkiAXCRgLJIo6+YwAZvfJ54reOiuwdZy92Kujvm1GLUbKWWGKFgNyoU/jYjjIPHPJquiGEi3dopmdVZzG2dvqp9cZrF0yBYbJILUHMahQwPA+nc/WtgvHHGHhjKyuBuQtu6HsewPp2qXqbpcuxuySwQQrGg6AEqewrNnkBIkLDJ6Y4pluxLt5gIHduuKZd3CogwAiEgA+tTvqOGmhoeaxhjR1BEhywByR6U24e2gtAEmYAHhy3rxj8s1QiuVlk2o43EEhnXIWqcmo3HmylXledwQZXw3B6gg1alpqNphcqiKzxKY/mBJIHJHr7Z7e9V7hxZXDLfwKCcSJtG5Qc9xnpj0/WnTI0nmAPlQF+9yWP19PfvVRLQszb+gHepbsU0pbstrrl6YZkiIUynbuSNU2r/dUAcCoorfzAFICoOuRgmrlnaFI4pztMZfZsLc5xnOPSpo4t0waQHOeABWcpjg4Q+EghtTHt+cg44B7VfjgVSu3ZyP85qVF3kMRgKc8D+VOUYmygBTHQdqzcgdVsnso+HaQMB2FXoGZiVZCI8cEHqapmQpGC+c9gKtQzFlBHB7Csn3MZSZpRkxxDy/lC/5wKnkcug3E8nkiqgbbGMkD1oRy5VGOD6jtVIwbvqXIWG7BHTj3I9P/AK9WRIjYABL+3pVJ5RvBGd3b3p73IBBVS277xzjFBDlc0AxG5iVLdznAxTHmOCzNhccDFZ6Tqj/Nyq/w9qpalqMRbaDjHQU/MhjryQSuxf7qkEA+vc1KbtRCMA5YZ9e9c/PqAKtg5bP51Gl2U+Y43Hjr0pPuUdCl2V3MTtqtLdB97Pycde9ZMl1tx84J6+9Uby7LjDMcHjHr9aEBo3Nz58nlqxEQ+8Sev/1qk8yJFJUhV6DFYn2oIoUkf7RHNQSXwTJY554p2C5vG5JCjONo5OetRfaSGG5j14rAbUgM5fGevGc0z+0flO4NnqD0osJux0n233FFcx/aTf3j+VFKzDm8z0OznZ5w0gYHruY9fwrQMirhkJbd0OSDWLa3tt5ZRSEk46N3p010Uk8xpFb0zzxQxs2JX3B3Y5PTAPP51UAYBjKxwf7vb86qrfySkhcDuGP8s1L5u7blM8fMM9T7VO446bkgnLIud20nnufzNG5mDDLsM9Tx/KoTJHjKE85xzkf/AFqh80qTtJx2GaRZNNIUIEb7RjBcE8+1MN4Niqpy44B7/n/SqMs7MzCUhhjg55NQedllVwQw79DQnqaKJYvbgSLLFcRM2RgMTyD2PB5/HNZMyQTo6SSvHJjB+XdGx/p9a0WeIANuAdv4iOCfb0NZOo3IS4VWTO/jCjOT6+1UdFFu9kRiJrZAFVSuOVOMH3B/rTIb57XzGQMC4wM/1HcVPJKyx7QAV7Z6iqTMASOv9KE7GjfNoxZ7h51O/wApVB+UouRH05C/gO9Vnn3JtfLyKcF9x6A5GCDUqOkDsxj3nptHemhUfdhSCecY4FbqZL5b6oqSXVyZMxhQgTBjLsAffrnPekS9nAy6icKCpZ0DMobryR39at+TlFBjQdfnVjlvr/8AWqB7YIjs/GetCmDVNrVFNrlJMrHZWwlbjzZF3EjPqen1pEjmvLkDMsrt8vygk4x09xT5dhyIiMH26iog8iq0asw45wccenFVz3MLRi/dRbRxbzRxqxGxcPuB+8D6dsVs2VzHJOXG1Sc7u5x0/KuZWKWR1csXVV3NxyD6e9adsu7HlfKevzHBJ+lNNoq1ze84xtlFOCMErgD25qusgndtoVZAMZYhuOh496p2wdpsB96HO49s1sWduhiWWaP7NERgsYiS7A/wjPI45P4daauxStFFB3mto5FdPMckBccgexH9KSOVXhC+V5TNgnacgcdOeefrV6KOW1uJ7qSRCqgv8gAGD7GqsBaeWYCEAt8yyrIQI8nq3976UtjN1EVp3NvO7LJI5zhRt+Qr271c+1l1865VNwBJkYFt5Ix39jxVeZiJjHJcW5VcELEoVc+wpVl8uMqVBjIxyM03djS5i3b3KwvuhiLnZtB6qnqatQ52jy89Oc1i2zOGJPRuQBWqJPlGCo7nFYSY5JItiQL8vduMdcVPDCFbn8aoTTI7ptOwZ7HrTXvCxxkBazbRF9DRuMLks3FRFlJVUOMck5qjLdLszkcdPeoY5wTuA4747+1LzJcrI35boblDLwB+tRG6CdyM/e57ViPeZQnOCeg6Yqs1yWJJfg9cVVzO50DaiQcg9Ovpio31clThsD16VzVxfADyweKom5G4gnA+tIVkdFNrUhb5D7ZPUmsuWeSZiXZjnrWc16q4UEbvXvVWbUwmRvHPcU0hXSOhNwiIAOnf1xVeS74O8jA6c1zMmqjaTkFhWbPqzbiSw+taKNzL2iR1txqgReMZ9O/41Tk1IkcE7h61yb6mOMc++etRNqpBJBUYGSc1SpsiVeKOpN3IejgdzVeW+QD55Q30NcTd+IolDBpcnHQHJrHuPEeciONmH+0cD8qtUX1MXiex6Bca2kSnByR2rHvNfmGWVtq+rHFcJcaxdzcBwi/7IqjJI8hzIzMfUnNbKkkZSqzfU7j/AISSX/n+j/76orhOaKvlRHNLufU54dWjcHPQ45/HtVhJyC6yyYduAPSs03Ln5W2nH93jNOWVc7wh3Y5I5FeRex7bNR/NhVcthT02DNSRXj7SC7Zzkdv/ANVYTXsqSqzdccAc8VdW4Vo9ykK+cE54/Ki4a7s1TdMoO5+T12n+dNF6zyAxHrwccqPxrMWcbmDuGOPwNSRSJswgUKT04BpofMupoxTlwVxuPrjOKSN0kBULl/Ws1pn3BBwFPftU0ThjzhT0DA80Xux8xI/zzKgUBifvFsAU5XTYPOKZGc8dKqTTiNXGGOc5bPBFZas7y5jf5QcEHvTRrCzvqbV0sMiglwCR8orNZGSYr8pX36/lQCxJVI2ZlGQFUtx3OPamXF08bDzmXaeenPtVWBNrRFtVXBLYB9e9ACNksQD3PrUBlTaCOvtUbzKnUHBpEcxadRksBx0HNZ9zhyVJJGPXpTjMJM9QR2BwKrSSBgcKPr61N+hPOMbykifEkYYcBT1P0qg0RbnJBJ47Z/8A1VNM6CTdj6ZFIs3zg4Vh/d9fatYMafUsWjGRiAY4UJ24ztJ4/h55NWwSpberKQAA3v8AWsopNcXVvHFGvl9RIRt2dvmPTGa3oba3+0Nbw3DSiJiBN5ZG5v8A6/auiLuKVTlFsJZsbHAAJyARjcfethZx5rySEs23G9jwuP6VieJbxvDunRsZFup5kPnIkg+QZ+UEdcHGc+uelebHxvfSXMluRJHbyk+Wu/OR7mtFoZyxEG9XY7LVvE9laSML5LlzncREVBxnk5Pf8KpRePLKUS/YraeKFTvidpAWHHG7Aw34YritUMl5GrMW3sc5znj3pNOtFEW21WS4lPZVPWlz2RnKUnU93Y6MazLdaubgtK+fmYP8wPvyetdhaX8V/pCyZxhtuSfT/PWvP7fTL0SRxtGxMgwoIP0/+tXRpKba0S0K7TFw5B3bm9f6VjB3ldbG8ZSfxbm1FdNCCQ25VGcjtzjNT216JTgHb6k981zbzZOFJwTnBFXI5gihnJH8zUS1Y5VEbjzkY9BwCTUbXirkAEk96xJdSLrgcDsTVSTUCHwpJPqR978KlRvsZOoupvvfM5Axz0wKc96qx7A6DPUk965R9XSHeAQXIxkt92s2fWY+fnz3wpzVKmzCVaJ2E16pY4PJ561UuNRAHLcGuPk1OVwTGuOepFUbjVCgHmTBSTVqi2YyxKOxl1ZUT92QD2B5rOn1ZSSS/J7LXHza1F83LP3GBjFUX1pip8pAD/tGtY0TJ4l9DtZdWbaVQjn15qjcalgEu/HvwK49tTupP+Wm0e1V3ZmOWYsfUnOKtUkjGVaTOnudYQn72T047VQn1gk4iRmz/fOKx1OB0/8Ar0rfh+NXypGbm2WZ9VumyQyqPYVQnuJpAPMkZgOxNDnGcd6iPQU0NDabTqPzplCUtWLazmnYCONm/Ct2y8L3MvM2UA7CnqzKpXp0tZuxze33ort/+ESX/nrRT5Wcv9pYf+Y9dVMZGSPTnrUwQYHBK9wD1/Cq/nKqkNknPTPakN2Ix714lz6ltksiHGHGFB44x+FIFCHbsIBGST1pom3gnjPr3oMwHIIGO9A1IGWFmViDgL64zTHwp3QnHYDr+dRGZM4JyCOSDxTGmjZSo5HQZNK4rlhrlV2HMmCASHP3T3x7UJexYIdyB0A9aoPJ1HyAAc5qAlQDsK4HXFHN2DY3ormInIfOASAearm8hjckKpHPt+lZFuA1yiQkiRm2DOSDmoJZ8gHG+IHgkfMatME0majXhmlPkNLE+CrFXK7l9OKgbYpyXdMnB54as03kTZYuwUcNzyKPOUkbZQQexPGPpWiaNVNGwsykAg/L7VHLK2MAnGeuagS4hC8ZwKe13bkADDEc59al6mbu9SZH59WPcimGWcL95cA8HFQNexk5CE+9MW7XgMUx1xip5WTexI8YkHJHFZ9yJEfMLNkc9eauS3cXHlYB71ny3iKzMVbrjcKqMQ50iF9QuRaSxR3E8UMpBkCDqQcg/oKk+0yxJgalI/mf8tHi+Xn17g/hVa5lV1Kq4VTzmsmeNt5K3Lg+o74roir7nPOtbY1NfZNQke/spHmkWNE8sgEqBxjHcfSsu606WVIrkI63CsPlkRgdpHUcYAqNri8E4l+0+ZMp3B3Hzce9SXF/eToGijs7QEBGSEMA/OdxBJrW2pg6ye6L+nWUzSROuY5M5UsdpHp9RV1kjjQCS5i3/edkX+RHBrmGvLvK7p9zA9d3I+lL9skLs0su+Qkkk96Xs09yvrVtkdImoQW8RW2JaQvzwdxBH3snj8KqrMSSxc4+vJrDkvV24BXP97OM1P8AJGpN7fRRKBnYhyf0quXSxm8TKRsNeCPI3E7e5qBtRKsCTn0yayJ9U02FRskeQ4C+2axtQ1tzjyVRWPIPXH1FCpozdaTOnl1VwcgqTyM9hWTc66iow80byOWXk9e3pXLzTyyuHkkZ2PcnpULcdOe9aKKM+Zs2pdXQNlVaXPcnGKrtrE4GIlRB245rMzigD8qqyEWpb66mzvmc+wOBUKkFst971NNHXkU6MHHHNAmKeASOpFRle+etSlcjdzjHHFNHyg4yeaBCkhV4HamFsnjpTiOeR17UKmc4BP0oQIAw46/WkeQn39KmisLmYgRxOfwrUtfDF5Ny6lFppXM51adP45JGAxzmlSJ5WxGjMfYV3dh4OhUq1wxY+hrbj0i0tRtijGfX3q1TZw1c3ow0hqcBp/h28u2GU2A+tdTp/hGCAK9wdzDt1rpoAAMEYPY4qdm3DkZz361oqaS1PIr5rXqO0dEUrfT4LeMeUijHXA6VI4wSG3AY5NWVXAOCcEetRkBuR9MGrSXQ872jk7ydyvsPqPzoqx+BoouHMKdYjJYhhk+3WqzawqtxJ8vpRRXz6gmfqTkwfX4em8BTx1zTZtejT5QQfQg4FFFX7NWMpVZIpSeJIkz84JAxUD+I1HRnPpRRWqoQMZYiaGf8JCdw4ZuvDUi66dpPPHH1oop+xiifbzZC+uvgbdytnjB5B+tRNrMzLycN0PrRRVeziuhLrT7kTanKxO9h+NLHqrowLLGwH60UU+RCdWXcmGsoUH7x19QGGM0xtZixIWdy+MLtYAZz3oopxgg9tPuQya9IQFFwgXPHzDmq51l25N0uR2yMUUVfIifaSfUQaoTnFwuemQ3X2pv9pEt812Of9uiinyoXOyB9QTBD3asc9iTUP9oQjJEsjEDOQKKKpRRJG+rn+BCWxj5jVdtSuWOQ+BnPSiinZCZE91M6/NM/4HFRb2I++x/GiimSBPGCeO9DOS2S5OepPeiigdhjFf8A9VGB2oooDZC43AHv3pvY80UUAmA64JNO2jHoaKKAYo6hgcc0L3GTj3oooETRQvIPlyfQf0rRtdFuLgjClfaiinFXOTFVpUo3ibll4S4HnNz781vWXh20hHKgv9KKK6FCJ8zWx9eejka0NlbwqBHGoPriiQFVAwAaKKuyOFScnqwwpXtUT4Ix1/GiiktS0QwsQxDcj3qdSBkg5T2oopIuSHrh8kc4qGZdrfKcEDnA60UU+hC+Ibuk/wAiiiiixZ//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Necrotic ulcers on the patient's abdomen (A) and arm (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yanagisawa, N, Imamura, A. HIV-Positive Man with Ulceronecrotic Skin Lesions. Clin Infect Dis 2008; 47:1068. Copyright &copy;2008 University of Chicago Press.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11317=[""].join("\n");
var outline_f11_3_11317=null;
var title_f11_3_11318="Droperidol: Pediatric drug information";
var content_f11_3_11318=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Droperidol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"    see \"Droperidol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/48/26372?source=see_link\">",
"    see \"Droperidol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2948709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Droperidol Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"      see \"Droperidol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage must be individualized, based on age, body weight, underlying medical conditions, physical status, concomitant medications, type of anesthesia, and surgical procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Postoperative nausea and vomiting (PONV):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention, if high risk for PONV: I.M., I.V.: 0.01-0.015 mg/kg/dose given near the end of surgery (Gan, 2007); maximum dose: 1.25 mg; administer additional doses after at least 6 hours with caution and only if potential benefit outweighs risks;",
"     <b>",
"      Note:",
"     </b>",
"     Previous reports suggested a higher dose of 0.075 mg/kg as effective; however, due to side-effects associated with the higher doses, doses &gt;0.05 mg/kg are considered excessive and no longer recommended (Gan, 2007; Henzi, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment (not first line): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer's labeling:",
"     <b>",
"      Maximum",
"     </b>",
"     initial dose: 0.1 mg/kg/dose; administer additional doses with   extreme caution and only if potential benefit outweighs risks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate dosing: Doses as low as 0.01-0.015 mg/kg/dose (up to 0.03 mg/kg) may be effective for breakthrough nausea and vomiting; maximum initial dose: 0.1 mg/kg; administer additional doses after at least 6 hours with caution and only if potential benefit outweighs risks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prevention of PONV:",
"     </b>",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer labeling: Maximum initial dose: 2.5 mg; additional doses of 1.25 mg may be administered with caution to achieve desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Consensus guideline recommendations: 0.625-1.25 mg I.V. administered at the end of surgery (Gan, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Specific dosing recommendations are not provided; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Specific dosing recommendations are not provided; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 2.5 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 2.5 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer by slow I.V. injection over 2-5 minutes; maximum concentration: 2.5 mg/mL (I.M. or I.V.); pH: 3-3.8.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F163619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, amifostine, azithromycin, aztreonam, bivalirudin, bleomycin, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doxorubicin, doxorubicin liposome, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, gemcitabine, granisetron, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, idarubicin, linezolid, melphalan, meperidine, metoclopramide, mitomycin, ondansetron, oxaliplatin, paclitaxel, potassium chloride, propofol, remifentanil, sargramostim, teniposide, thiotepa, vinblastine, vincristine, vinorelbine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, cefotetan, fluorouracil, foscarnet, furosemide, leucovorin calcium, nafcillin, pemetrexed, piperacillin/tazobactam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin, methotrexate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, bleomycin, butorphanol, chlorpromazine, cimetidine, cisplatin, cyclophosphamide, dexamethasone sodium phosphate, dimenhydrinate, diphenhydramine, doxorubicin, fentanyl, glycopyrrolate, hydroxyzine, meperidine, metoclopramide, midazolam, mitomycin, morphine, nalbuphine, pentazocine, prochlorperazine edisylate, promethazine, scopolamine, vinblastine, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Fluorouracil, furosemide, heparin, leucovorin calcium, methotrexate, pentobarbital.",
"     <b>",
"      Variable (consult detatiled reference):",
"     </b>",
"     Ondansetron.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light; store in carton until time of use. Solutions diluted in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W (20 mg/L) are stable at room temperature for up to 7 days in polyvinyl chloride bags or glass bottles. Solutions diluted in LR are stable at room temperature for 24 hours in polyvinyl chloride bags and up to 7 days in glass bottles.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures in patients for whom other treatments are ineffective or inappropriate (FDA approved in ages &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F163621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Droperidol may be confused with dronabinol",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F163618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, hypertension, hypotension (especially orthostatic), QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (dose dependent), tachycardia, torsade de pointes, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, depression (postoperative, transient), dizziness, drowsiness (postoperative) increased, dysphoria, extrapyramidal symptoms (akathisia, dystonia, oculogyric crisis), hallucinations (postoperative), hyperactivity, neuroleptic malignant syndrome (NMS) (rare), restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, laryngospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, shivering",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to droperidol or any component; known or suspected QT prolongation (ie, in adults, prolonged QT",
"     <sub>",
"      c",
"     </sub>",
"     is defined as &gt;440 msec in males or &gt;450 msec in females); congenital long QT syndrome",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired hepatic or renal function. Severe hypertension and tachycardia may occur in patients with pheochromocytoma. Use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems; may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention ); relative to other neuroleptics, droperidol has a low potency of cholinergic blockade",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cases of QT prolongation and torsade de pointes in patients treated with droperidol in doses within or even below the approved dosage range have been reported",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Some cases occurred in patients with no underlying risk factors for QT prolongation; fatalities have occurred. Droperidol should be reserved for patients who fail other treatments. Prior to its use, all patients should undergo a 12-lead ECG. If the QT interval is prolonged, droperidol should not be used. Droperidol should be used with extreme caution in patients with risk factors for prolonged QT syndrome, including: CHF; bradycardia; cardiac hypertrophy; any clinically significant cardiac disease; hypokalemia; hypomagnesemia; concomitant use of Class I or Class III antiarrhythmics, MAO inhibitors, or medications known to prolong the QT interval; age &gt;65 years; concomitant use of medication known to induce hypokalemia or hypomagnesemia [eg, diuretics, laxatives, corticosteroids (supraphysiologic doses)]; alcohol abuse; and use of medications such as benzodiazepines, volatile anesthetics, and I.V. opiates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The dosage of droperidol should be individualized; dosages should be started low and titrated upward. Not recommended for routine use in children for ambulatory operative procedures unless patient is being admitted to the hospital and other antiemetic therapies have failed (Gan, 2007). Continuous ECG monitoring should be done prior to treatment and for 2-3 hours after treatment to monitor for arrhythmias. I.V. fluids and other therapy to treat hypotension should be readily available; monitor patients carefully. Use reduced initial doses of opioids, if needed. May be sedating; use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Neuromalignant syndrome may rarely occur; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: Droperidol may enhance the CNS depressant effect of CNS Depressants.  Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Droperidol may enhance the adverse/toxic effect of Metoclopramide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Droperidol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     While teratogenicity has not been demonstrated in animal studies, a slight increase in fetal mortality rate has been observed in some animal studies. Droperidol crosses the placenta. Use during pregnancy only if the potential benefits outweigh potential risks to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to use: 12-lead ECG to identify patients with QT prolongation (use is contraindicated); continuous ECG during and for 2-3 hours after dosage administration is recommended. Blood pressure, heart rate, respiratory rate; serum potassium and magnesium; observe for dystonias, extrapyramidal side effects; temperature",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Droperidol is a butyrophenone antipsychotic; antiemetic effect is a result of blockade of dopamine stimulation of the chemoreceptor trigger zone. Other effects include alpha-adrenergic blockade, peripheral vascular dilation, and reduction of the pressor effect of epinephrine resulting in hypotension and decreased peripheral vascular resistance; may also reduce pulmonary artery pressure",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 3-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-4 hours (up to 12 hours)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: ~0.6 L/kg; Adults: ~1.5 L/kg (McKeage, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Rapid (Cressman, 1973)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 90% (McKeage, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, to",
"     <i>",
"      p",
"     </i>",
"     -fluorophenylacetic acid, benzimidazolone,",
"     <i>",
"      p",
"     </i>",
"     -hydroxypiperidine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Children: 1.7 hours; adults: 1.7&ndash;2.2 hours (McKeage, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine (75%; &lt;1% as unchanged drug) and feces (22%) (Cressman, 1973; McKeage, 2006)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cressman WA, Plostnieks J, and Johnson PC, \"Absorption, Metabolism and Excretion of Droperidol by Human Subjects Following Intramuscular and Intravenous Administration,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1973, 38(4):363-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/3/11318/abstract-text/4707581/pubmed\" id=\"4707581\" target=\"_blank\">",
"        4707581",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Meyer TA, Apfel CC, et al, \"Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2007, 105(6):1615-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/3/11318/abstract-text/18042859/pubmed\" id=\"18042859\" target=\"_blank\">",
"        18042859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henzi I, Sonderegger J, and Tramer MR, &ldquo;Efficacy, Dose-Response, and Adverse Effects of Droperidol for Prevention of Postoperative Nausea and Vomiting,&rdquo;",
"      <i>",
"       Can J Anaesth",
"      </i>",
"      , 2000, 47(6):537-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/3/11318/abstract-text/10875717/pubmed\" id=\"10875717\" target=\"_blank\">",
"        10875717",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McKeage K, Simpson D, and Wagstaff AJ, \"Intravenous Droperidol: A Review of Its Use in the Management of Postoperative Nausea and Vomiting,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2006, 66(16):2123-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/3/11318/abstract-text/17112307/pubmed\" id=\"17112307\" target=\"_blank\">",
"        17112307",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yaster M, Sola JE, Pegoli W Jr, et al, &ldquo;The Night After Surgery: Postoperative Management of the Pediatric Outpatient - Surgical and Anesthetic Aspects,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1994, 41(1):199-220.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/3/11318/abstract-text/8295803/pubmed\" id=\"8295803\" target=\"_blank\">",
"        8295803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13257 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11318=[""].join("\n");
var outline_f11_3_11318=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708711\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2948709\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052429\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052423\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163552\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163537\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052433\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163619\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052426\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052432\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163621\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163618\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052437\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052422\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052421\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299238\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163546\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163548\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163561\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052428\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052420\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052435\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052436\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13257|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=related_link\">",
"      Droperidol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/48/26372?source=related_link\">",
"      Droperidol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_3_11319="Anatomy of the penis";
var content_f11_3_11319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Anatomy of the penis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 572px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI8Ag8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKM0ZoAKKM0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUyWRY1yxwKAHk4phaqrXIJJphnzU8xagy5uozVMTU9ZaOYbgWs0uahWSnhqdybElFNzSZpisPzS1HupwNAWHUUgNLQIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvL/ABX418TW3xBv/Dnhyy0mYWWjDVma9eRWk/eFTGCvAPAwSK9QrjPEnw50bxB4gm1i7n1OG8ntBYTfZbt4Vlg3FtjBeSCSc80Aci3x98NQaHpN9dW12JbyyF9NBG8WbdN5Q/fdS53BsBAWIGcVr3Hxl8MReKYdFRppfMuYrM3SNFsWaRQVXYXEhHIBYIVBOM9a0rz4YeHZZ7SaxjudLltrUWSNYTGLMAOQh65wcnPXnrU6fDzR4dcfVLObULWWWVJ54obgiOaRQAHYHJyQozgjOOc0AZvh34q6VreuaVpyaZq9ouqNcx2V1cxIIZ3gLCRAVckEbSRkDNZ3xb+Ko8I22sWei6dc3+safZpdzP5YNvbK7hV807lPPOAoJq74A+GFr4eOm3mq3U1/qenyXb2v71jBb+fK7MY0PRirAE/Wr/i34Y6B4p1C9vNRN9FJfWy2t2ttctElwituXeB1IPSgCpc/FXSLTWTYzWeovbRXkWm3GpRxobaG6kUERH5t/wDEASFIBPWql58ZdFtNPvr2bStcS0tbprEXEkCJFLOJTHsWRnC9QTliAB1IPFbF18M/D9zrDX0i3flvdR30tms5FvLcIAFlZO7cDvg45FWpPAmlHw7NosMl5BZzXUl4/ly8s8js7A5BBUlj8pBHT0FAHP8AiD4v6VoOgWGsahpWopaXSO5xNa5QK204/ffvCeo8vdkVt+E/FcuveL/EOnosX9n2UFlPbSBSHdZ4y53ZPsMcCsV/gr4R+xQWsMN7BFHaS2TeVclTJFIxZw3/AAIk8Y9OnFddoHhbTdC1C8vLBZRNdQ28Epd9wKwpsTH4dfWgDm3+K2gxzRQzQ6hHO11eW00bRrut/sqb5pJMNwgXaQRkncOK5i++O+i3Og6pcaWtzbXdrbw3cRmjhuRJE8yR52RzcN84yrsrDOcHpXcJ8OfDa+J9Z142Re91a3e2uldyY2R1VXwvQFgi5I5OKzv+FTaA2h3Gjy3Gqy6ZLEkIt3uyVjRXV1C8Z4KLycnHFADL/wCK2lWXiVtIm0vWNsepx6TJfCFDbpO6qyAnfuwQw7V6IK5G9+Huh3k1xLPHcF59Vi1h8Skf6RGoVT/u4UcVL4qa90e+g8QWkksllCvlajabiVMGc+ci9nTJJx95cjkhaAOpoqOCaO4hjmgdZIpFDI6nIYHoQfSpKACiiigAooqOeZIInklYJGoyWPagB0jrGjO7BVUZJPQCuZuNVW7myhxEPug9/eqGsarLq4NvAGhs8/MT96T/AAHtVO0Nmkpid1Dr/ebg1zzqXdkd1LD8qvLc3o7gEcMKe04XGTyaypbyzt0yZEOOcKck1U02Sa+uWuZsrEvCr61HMaqnpc6IS09ZqxtRvltId3V24UepqnpeoNcXBjVtwUZY1ootrm6GMuW/L1OsSWp0krEgukZyqsCR1q7HNQpEyp2NMPSl6pLL70pl96vmMuQsmSno+apb896ljahMHEvKaeKgjNTKatGTQtFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFcl8W7q4sfhh4qurOaSC5h02eSOWNirIwQkEEdDXifhjxlf6RNaXPhLVr7xRAvhp9Q1e2nuWukt7pYwVAfkqxbIKA9B0oA+maK+fI/i54g/sjV3tLrRtVeCy067S8t4WEUEtzOkbW8gDnJAYkcg8citXxb8RPEnhXxfpuk6rd6TJbN5KTSWMKyTNJJIQFMDTCRU24+ZQ3OT7UAe3UV8/RfFnUtV8Z3OjW09vNpV0mowruiWG4gaBGIO1ZWYDjGXVc4yAO3U+HPE8mgfs66Rr93cymeLTIGMzR+exdiqgkMy55YZJYAdSeKAPWKK8C0T4p+KNSsHgibSGvx4it9HS42CSJo5Yy24iOQqSCOqtijVPGfibwpr/j57zV7PUr3TrK0mg03yWRZCYxvkiUyEhFOWbGc45IoA99orwC1+KXiqfS4vJl0Gaa41nTrC3uEkjmHl3IcN5iQyttIZOPmBIPSt6/8AGvi7TPH9p4MuEsJ9Qv3tprW8jtnWP7OAxumK7jyuw7ef4h1oA9hpCAQQRkGmpIju6K6l0xuUHJXPTNPoA43RlbwnrY0d/wDkB3zltNcni3kOWa3P+ycFk/FewrsqzvEGj22u6TPYXm4RyAFZEOHicHKup7MpAIPqKz/CeqXc4utL1rYNY09gsrLwtxGfuTqOwYA5HZlYdskA6GiiigAPSuH8Q6odQv2tod7W8LYwo+846k/ToPz9K2fEmptF/odscSuMuwP3F9PqawQjRwAJ8meFVfWsKsuZ8qOzD0+Ve0l8hkMCOMTFlX+6TjNWja2ZQI0cJA9QM1CulhuZpWJPUKMVm6msImS208M9wTg4OQPrU8sF1NlKpJ6ISO0jv70/Zo1jtI2wzjOW+n+fetKfUbW1URRncVGAkYzj2z0rGuklspfsvnbkKh2CkqBn1H4VmSXJlmFvbKzOeioMk1vTwya5m9DCrinflSH6pfTXE4wuZn+VEXnaPSr0kqeHtF2sc3s3Ycnd/gP89azbK9t7K/N1dchbfMY7lsgYHvWXdPeXz/2vdL/oyyqnsBnt7Dpn1P1qcVPltTjsbYCh7R+1mdxoFvJbWYe4J8+T5mBP3fatZZsd6qGQFQVIKnkEVC8uK5U7G0lzu7Ndbn3qRZ896wftHPWpo7nnrVKZDpG6kmatQtmsSC4z3rTtnzitIswnGxqxGrC1Vh5Aq2owK2RySFoooqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbJGkqMkiq6MMFWGQRTLe2gtkKW8McSE5KooUZ/CpaKAK0VhaQxPFFawJE7b2RYwAzdckevvSyWVtJcpcSW8LXCcJKyAsv0PUVYooArLY2iytIttAJGJZmEYySRgkn3FSfZ4TbG3MUZgK7THtG3HpjpipaKAK6WVrGAI7eFQCGAWMDBAwD9RTmtYGuBO0MRnC7PMKDdt9M9ce1TUUAVYdOsoU2w2lvGu/wAzCRKBu/vdOvvVKTw9p0vieHxBJEz6nDbNaRSFyVSNjlgFzgEkDJ61r0UAc54j0K4muhq+gzLa63EgTc2fKuUBJ8qUdxycN1UnjuDb8N67DrVvIDG1tf258u7s5CPMgf0PqD1DDgjkVsVz3ibw+99NDqmkyi0160UiCf8AhlXqYZR/FG35qeRzQB0Nc14u0m5lMGsaIANbsQTGCcC5iJy0DH0bHB7MAfWrXhzxBFq5mtp4XstVtcC6spTloyejKejIezDg+xyBt0AUND1SDWdKt7+13COZc7HGGRhwysOzAggj1FM1rUfsNuREBJcuMRpn9T7VyviK4PgrWZdXtwH0rU2xeQZ/1NxgBbgDsp4WT0wrf3stMksheaY75G+ZmJwP/wBVZVKnLojooUed8z2H28Eru0k7hpGO5j1JNXFhG9WY529BWVbvqNyu+EwxRH7pI6j8QaparLeQssD3hkmfAEca44PqeK507He4cztct395Le3X2KxbA/jkB7d/wpztbaPBtiXzLhh0/ib6+gqCMf2Pp+SqveTHGM8Z9PoKwb24mllEEBMt3OcFvX/AV0UKPP70tjnxFdU/cgQ3t3LNOYosy3Uzc7e5/wAK6HSNOh0ezee6dPOIzLKx4Ueg9v51FbW1r4c0yS5nO+cj537uf7q+3/6zXPK+oeKbwpvWK3jIJX+FAen+8ev/ANaiviOb3IbF4XCP+JMq3csWpXU0iQusCy7kJ4yD2z2J5OO2a7Syksr7TPIiRRDs2NCeqj0/+vUlpp1rZ2AtI4w0OPm3jO89yfeufvY/7L1INakgbdwBPUZ5X3HAqU1Wiov4kEr0pNw+FvbsWEe40U+VKWn04cJIBlovY+1XTcpKgeN1ZT0IOaU3CyxK6/dYZFYOoW6wSCeDKoT+8RCVz78VyN2O2KUjYMvPWlWfHes1NqgFHcg88sT/ADqO+e4+zEWqxyOSAyOM5Xvjkc0kwlGxsyajHAqqbiKKWVT5Rk+6SO59uRV3Rb7U9RRYWtkt5I5gk8qy5ChSCQo65YY/Bs15/p0LtLFZRWyyfNtNrLvjIBBG8MF4x3YbSRkEE81634M0YWGnQRnkIBvbJO9scnnn/wDUK6YI4K0tLnR2qbVBPU1PRRXUtDgbuFFFFAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwvEegf2lJb3tjP8AYtYtcm3uwm7APWNx/Ejd1yPUEEA1DoniUXEN1b6zCNP1axAN1bbtwKnpJGf4427HGc5BAIIro68v8fpD4gvYzay/Z7iyyILyMDcrHr/vJwAVPBxn0NRUmoK7NqNF1ZWRb1OcaxNM14geGVTH5TcgIeCD9e9YWhvLYXg8O38jvBs8yynY5M0S9Y2P95OPquD1zSaBqzTyNY6ki2+qwjLx9ElX/npGT95T7ZIPB99DWdKm1izEds8lvcxN5tvcqu3yZADhsnqOSCAOQSO9cXNrqelLlivd6HRru2fKvQcCs+208xXct3cEPM3T0X/PSs7w9JLrFpJ/aAEGoWzmC6tyu/y3HcFs5VgQynHII75rVOmNGP3Eij227c/iuP5U232MlViupmamjzStIcjAwo9BUXh3TzFJLeTj52+VM9l7n8f6VeJlhk2XCM6+h+9+B/iH60zUi13YvDaSAbhhtvUD0x2rb6w+TkRMKCc+c5y/kfxJrqWsLYs4STuHp3b6noP/ANdTSqfC+pPNDE0mn3ACkA5ZCPr+P5+1aeh2KaZaFcDzpDlz/Ifh/WpdTjjvrOW3lwVccH0PY1zne5a8q+Ekt9RgvEYwsQy8Mjjayn0INZepKLm/jjPRI2J/HijT5RPZRPMqmdBsZiOcjjrUbti/JP8AGmB+FClbVESprYgtppYoMMN0akjjqtPkdZIzyCrCmP8Au5iyn5X6j39arSzxwAtIwQE4x6n2FTJ3dzSEbIS9uRZ2MsxKDYvG84BPYE9snArLbUFudOa58pJo+rYc7Wx2DjlGGMgEdelJqrB4ZZDie3Y4CqSwLEYCkdVJ6ZHryK1vCemRwytcg4yNpJIJP/Axw49yM04qxnNtuyOl8FaNO0okvJnluGBUlm3BIwxIGcDJwRknvXpUUaxRqiDCqMCsvw3ZNbWIkkG2WU7sHqo7D+v41r13U42R5FefNKy2QUUUVoYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvi3xtZeHNU03SjZ3+pavqAdreysY1aRlTlmJZlVVHqTXVVw/jLwZfan4s0fxPoGpw2GsadFJbbbm3M0M8T9VYBlIIPIINAF6Xx94fsrawfXL5NFuLwEx2mokRTLhtp3Lk4Ge+ce9Wr7xr4asNQuLG81zT4b23UvLA8wDooTzCSOuNnzZ9K4PxP8LNX126vbubxBZtd6rpY0rUXksCVCeYX3wqJPlIBxgk9AetS638N2sfDnjxtPC6he6tYRwWaNGBKnl2ggC7yeS23PbrQB2Vl488K31rc3Fpr+nTQWzxxzOkwIRpCAgP+8SAPU1NqHjPw5p0d297rNlCtpOLWfdIMpKRkIR13Y5xXl9n8INS1HQbqfU9Vt7XWLuw0+2iSK0xHb/ZmSQCQbyXYsuCQR7Vbv8A4RajfQ6tLdavYy6hf6mupiZLeWDyHEXl/uyku4H8SCOCKAPW9Mv7TVLCC9064jubSdd8csZyrj1BqzWN4N0i50Hwxp2l32oy6nc20WyS8lXa0pyTkjJ9fUn1JrZoAKKKKACiiigAooqvf3K2dnNOwzsUkAfxHsPxPFDdhpXdkYfi7VDBB9htWP2qYc7eqp3PtmuQjS2tRE17dW9uJDhGlYDP+4D1/wB4/lWpaWz3dxLd3ZDtI2XPZj/dH+yOnvWH4puNGiuU1S/VXEKiNXckoxBJAVB945z7fWuK6qyvPY71zwj7KgrvqbGreHrXUbZMM8N9C3m216vMsMnZge47FehBIIwa5az+J2n2msnQvEKSW2qwv5Ms0SZt3OeGUk5APXBHHqetT2Hje21GbZDcXKPgkL9n64GfQ1SjuvDmv3Dand2tnLcWxUtJdJ5TDnAJOcH05zU20sjWOEmm3Vixvj/xdYeGfFNrdWwnm1GNBFe28S5WW3JJAJz99SSy/Vh346nwr4x0nxMn/EuldZdu7ypV2vj6d6wfFHhbS/El59ukllsb4qFMm3ej46HI9vX8qj8I+DLHQ9UTUJ9XiuJYwQiqQo5BHPPPXpXbyYd0r3fNb8Tymq8alnHQ6a18UeH9Tv302HUbWe5DbTCe5HYZ4P4VcudLRsNC2COgck4+jfeX8D+FcVH4D8K2niFNYt0u2njl85Ykb92GBznJA4z711K+KLA+YRLEUjIVyJk+UnoDzjJ+tcPK3uelKHK06F/mRTwzwuFbJJ6K55P0bofocGqbTZz1BHBB4Iq7rup3Rt4m023juhk+dbSKfMYdimOuPbNNu7N5LSK5ZWj3ICTIPmjyPuv6gevbvSnTcYqRpRxScuSaszEs2KNcIevmlvwNSSkMVPdTkVDOjJKSQUlX5WB/lTC5IrK56DjfUe53VR1GN1EN0ilxA+5gBk7SCDj6Zz+FXF+Y1etot6sp7imiJaIyJ7eG+lsjayKJ3YSebHgkIozk+ozgYPrXceEtMmu5Eku1QxRN87ICFdh0AB/M/lzUfhfww08K3EiJbwSckoAHlHr7D36/zrvbeGO3hSKFAkaDCqOgrrpUm9WebiMQleMdyTFFFFdR5wUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmPxK8Y6ppHjDR9Ds9R03QrO6tZrqTVNRi3xl0IAhX5lGT1POcdK9OqOeCKdAs8SSKDkB1BGfXmgDw3/haWsP8AEex0uzvrS606XUo9MnQ2yRlWaPJdCZDIwzyCUCkcZqCy+KXjBo9dhfTree/8MWV0+qJHAwWa4ErLAE5yFKDeeuRXvH2aDzTJ5MfmEgltoycdOaesaKzMqKGb7xA5P1oA+fNM+KPi+fQ55Vm0aaeS806G1nzG2BcPsdZI4pW2gEcEkHGeMipvG3xC8ceGrrxEhvNGmHh+1sLi4UWjj7SZ5NjBTv8AlHOe54r3mO0t4wRHBEoLbiFQDJ9frTngictviRt2A2VBzjpmgDxPUPibr8Hjea1SSwWCLxAmjLozRH7VLAUDG6Dbs7eSfu4wOtYcfxf8Srb+KGnmsmvbGykvIIYLdZrdUE6KGEySEkbCchlU5+nP0ObeEzicxR+cBtEm0bsemeuKRLW3QShIIlEv+swgG/6+tAHhur/FjWJtS1mHw9d6XPbQ6npVla3Hl+am25B8wkhhuwfQik8PfEPxgPFOm2WrXWl3NmfEd14enENq0byGNN4mB3kDqBtx26mvc1toFUBYIgBjACDt0/KnCCLOfKTO7dnaOvr9aAM3UPEmj6bdG21HUba0mABInfYMH3PFT2Os6XqBxYalZXR9IZ1f+Rq+QD2rG1LwtoGpknUdD0y6b1mtUc/mRQBs5rmvGFyFWCBn2x/6xznGOQAT9Mk/8BqE+A9Bi/48Y77Tz2FjqE9uo/4Cjhf0rmvEXha6GorbQeJdY8qSMIVuPJnGCH4yybj/AN9d6yrfCa0fiv2JtW1mzj0Q3FrL5lmsTSM0XdF4IH1PH51xyXN3dazcywSedp11Z+Zbh13Rxso6EdAc5yPerb6XNoen3NhqmoQXmn+SIEAg8iVi5PVi5B+8ewrMsI49Hmf+ytMubiRh5UnmXSFV/wB4LkDp1OKwkkn7ux6+CilSu17z+4jOsX0fh/Tzc3JikvXJjntY1CxYwArL3zz09O9SalELbSXh8QW9uZLucW8l3AADtxuDtgdiBxRc3UOl3kH9rTWkWjmXfZW0MW8tjneCvIwTkk9c4xzT59LmOpX8kkQvdIu0N0CHOA4GV6HPtx1BqdTt91a7Lf8A4C80T6fe32h3WlaZfIslnJEIxOvIEm5sAH027RitfxFeTxWckVhcW8VwF3yNI3MUXOXA79K57Tbq91Ce01HSW3WjGOO5snORCRgZUHtjByOePysX2kXF5qevwP8ALNeQxm3mIO0IpGUz26DP5009NCJRXNeWj6/f2IZmnudF024tdaltbSQmNzcje8rEke+fp0xVmyj02FbjQbq0jku44xLL5MWxZsDIxjvjFV7GWG51ayto2Bh0RH81CMeYwXG9R3wc+lWtIRtRdfEOoQNYyRAlDGciSHB+8Oc9TyMZ/KhDlotf67eYmnXN3cLa3unT2iaMkaiS2kba0GOvzYzkdQeP610M2pai11pr2LC7td+yZUAbzEYgbs/7PP8AnNcbaXJXXJGj0uG4sNSJQSwMwR4yeSy8jI5z07+tdB4RsZtFluowc2S3AeA7s5Q8H8h+opwlZ7XObGUFOD6PoaevWQh3FP8AlmAQP+mZ7fgc/gRWGK7fV4VkERYcNuib6MP8QK4mNT0b7w4P1rkmrMvBVOeFn0LEC5IroPD9j9svUhwdn3pD6L/9fpWTZQtJIiIhd3ICqOpNek+HdL/s2zIkwbiQ7pCOg9FHsP8AE963oU+Z36GOMrqnGy3ZqKoVQqgBQMADtS0UV6B4gUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5o+u+KPEPjvxNpHh6/03S7XQBAh+1WrTvdSSR+Zzh12IAcZGT39qjPxWEetJBLok39jnWRoH9pLcLzeEdPKxnZnjdn8K6XX/APhvXtVfUdS08teyRiGWSKeSEzIOiybGAcfXNNX4feGRrS6oNN/0lbn7YF86TyhcYx53lbtm/H8WM0Acfp/xfvL7QrHVovCF4trf38enWjNexATyvI6cdwAUHLAdfbNWvD/AMW49V1nT9Jn0Sez1Ca9vdPuY2uFcW81siuwDAfOCGHIxWzrvw50u+8PaNomnFtO07TtSi1ARxM+W2szMobcGUksfmByO1St8MvCTWdnbDStqWk0lxE6TyLJ5kn+sZpA25i2BnJOcUAcjP8AG+2j/wCEeH9jND/a9t9qWS7u1ghX96Y/LWQrtZ/lJwdowRzzXsKnIrg7zwR4Nik0vRJ7SdI3i8u3sluLjyZUibzMOobY2C2fnrvBhRgDjtQAtFGaTNAC0UZooAKKKgupNiBQcFjj8KG7DSu7C79zZHTtXP8AiVCl9az9iAM+mD/gx/KtlGqvq9uLyweMDMijeg7kjt+IyPxrKouaLRtT92WpxHiXT4727gExYBWSZcdyjdPpzXmWn28F1bazBpcUsGoPmMwmQFWTzBuOePxzXrkqm7sgV+aeHkerD/64/UVwWp29xPJqGnyzfYrGRlmimVMIE/5aIxGMEnJ56mubdHr4Oo1Fwb2/z7dSlrw0aSHTBqSXDW8MOyG9tDuRyOGQ+nKj/wCtzVaabSJ4V1Q3upxRW7pFDbIAPLIGQq9R0HXP1rVdpPsj6Xa2klrYyOBa3dsBOh+b+Mc8E1VnX+yLO1g1VYtRnnugYEVdsSY4JOABnnpQzri9La/f0/JeepIlzMselS2dt9gbU77fJGpySg/kCOePWneJMQa7i11prO7k2T/Z5srC5A2j5ugzt6HrWzpUeoya7qUt8c2aOFtlZRxx95fwOM1J4lso57Np/wCzob6eEZVH4JXuAR39qq2hkppTX9b+vY524nsfD2rC7SKe51G9j3fZ4TmMFiCcNjnJBx1q1ZaJqqeMZtQluw1oWLbfMJIUrxGU6cf0z1qlpeqT3Go250hFWKMhHsJI1Vol6MUbv79/UVbh0vy9X8QQ3nnoLxDKt1HnAj7r9R0x6CpWuxpK8dHvb1/4awybTbjSNG1lWT7THcS7xawSbfLiLHLZ6jI4OB2+uL/hjTLWws7lrOaXbPCsgtnbJhBBI/P19qy0sJFXTNW0a4F/LCRFI0XDSw54BBPUDj8vStzTrVtMfVNRv3ZxLIZ2AOSIUBIH1xxj6VUVd6IyrT5abbf9eh2mq/8AHmT/AHXQ/wDjwrjp0AuLj0Dt/M10FpqR1fw9BeGFoDO4Hlsc4xJjr+GaTw3pv9oawWkXMEbGV/Q8naPx6/Qe9ZTptz5Opw4OqoU3N7G/4P0b7LAt5cri4dfkU/wKf6munoFFd8YqKsjzalR1JOUgoooqiAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDxTXvCPiOT4xrr1nZvdWDXERd7108uCFIwC0DrKHU5z+7KFSckk5rh/AnhDxRq+h6fqfhyC60uZ9G1G2uL6e9z9ulkLLAFXcSuxudxC4/AV9R0gUKMKAB6CgD5tufhx4qn0nVLfRtJudIsp7bT4mspNQUtNcxzq004IchfkBGcgt6UvjbwpeeFbK8W4UR+Ej4ljuhYS6gyC6gMAyu8kkfvFJ2sRnH0r6SpGVWGGUEehGaAPm/wZ4b8Ta14e8M6joUc1jAi6/wCW0lwR5Pngrann5mAIGDjoM0lt8OfFB0u+t7PTtV0W2m0eGzvUg1CN5by8WVWeZQZNpG0MDuZSwJHGa+kgABgDiigD568PeD/GujzeG77+w4nj0/UL1ntbWZIHkhlhRI5HQyMitlTlVYgdepJMB+F/ia/0ixg1S0laS28L3dsirfbduoGZnhyVYbsZBycr69K+jKKAPLPhj4O1bwz4y1O5njmTTLzS7TzDJdmYveKD5rHcxOeevQ11smqeJ7ed1l8OWtxAGOx7TUgWK54JWREAOO2T9a6aigDnX8SzQJuu/DutxY67Io5v/Rbsf0rDn8e6I10xuprqyUfKPtdpLCPzZQP1rstWuRbWUjA4dvkX6n/OfwrnbdunpWVSVtDoowuuYfp/ibRL4f6Hq+nzn0juEY/lnNa9tJ5p8wHK+tcxrlhpd4YoLvTbK5kkP/LWBWOPxFNTwR4fjQeRZNaSf3rKeS35/wCAMKSdypQaVzQ1q2Npdi6hB8qTIbb2J6/4/XPrXE3j/wBmabt8SXUVyZ5CkUghLLcJgEFwBw3+ecZrqz4RMkbRW3iLXoEI+61ws4/8iqx/WsS50bWLOR7G71a1uoCdym8sFkByeD8rLj+hpO0Hd/CxJyesH7yM+08N2pja60uOeAXMJVXgkyuGx8wBPBqpDBZeH7d4LKMlx+8IZvMd8cEqoPPXqMVuTr4otLN4ra20O4hWMqqpJLbEDHYbXH4ZrhPENs019J51skNzc26SNvkLxhVGWRCFB4wD09eKybS1R6OFqTxDcZs1JvEu2ESGO+3g/vI2EcRjXsxBJ654qSXxGsF1PC4vx5cXmqxjRlkUDJxjHbvnHBrN0uexSzllE1nOqhIVkul2yHqcHcOccAey1b1a6C6RClzPHFsnj2pCOqn+EqP4SN35VPOzr9nFS5bGhFJYazagXEMEqXUe5sDy5doPUjOcZHUGoh4YS0juEtdQvLcTRGNFlbcqA9SOmeOBXP6ct01zHJbJBc6haTLbxmAnakR3D58cED1zn1r1bSQWtJ4g2ArlVOM7cqD/ADJp3urtGOInLD/C9Oxxui+E9NsriCW1Wae5jxhw56++OMexrtbTT0WGQXSpKZVKupGV2n+HB6j19ai0fTbqxlle51S4vA4wEkUKF9xirl3dJbrj70hGQucfifQe9Emo6R2POqYipiPiKWqSJbpDFEgCQrvCIMdtqKB7k8D2rqvDunjTtLiiZQJmAaU5zlsAf0A/Csnw/phu5hf3mSobdEpGMns2PQdh+NdVWtCFveZjVlZKmvmFFFFdBzhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFMldY4nkc4VQWJ9AKAOZ8SXRl1FbdT8kK5b/eP+Ax+dZsk9wq4tYC7f3mOFFNR2uJpZyMNIxbH1qjqgktyHkaNt3RSTmuVWm227HpJOEVGKuWNAMlzfS3Vw28oMZ7Z9vwrVbUF3ls/L0FYLCeBEWRPL81c4RsfgahsZDd61DAD+7iHmv9B0H54rohSSi5XOerWc5WtY7m2kIiDOcEjJz2qOQQarCyMRuGdr9Sv/1j6VzXi/U3trSC2gP765faOe3/AOsitzSYPsNmkRbfJjLt6n/Csea+jNHS5YqXUz90thMYLkHYOh9B6j1H8qzNU0hZ1DReY8GdwEUhUrkYOMHkcniuvn8q4h8uddy9R6g+oPasaWxntXLWkgkQ9jwfxHQ/UYrJxcdthwk07rRnnkvhmSLT7qBL4u0jhovtqbxEB6Bu/bOPwqsvh28aOELf2cU7Sb55Ik+ZgMbdvoR83THWvRjfSpxLb7T35Yf0/rTf7SA+7EM/U/0FTzLsdaxdbt+RhaXoEEF0ZrK2Mbkbd7Aqi5xnA98f/XrpoVisrdULgDqS3Vj3NUpL2Zx8g2fQY/U/4U2GLe26V2LHrgn+fX+X0obb0RhNTqazZPNeySN5dupBPGcZb8u31NXdK0kSzBrnDEkErnI49T3/AJUlsiIoWNQqjsBiuj0+DyogWHzNz+FaU6d3dmNSSpxtEtKoVQAMAdqWiius4gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArF8VXPlad5K/enbZ/wHqf8PxrarkPEUwuNX8tTlYFC/wDAjyf6VnVlaJth48015Fe0TAFZ9gn2/U5biXlIjhV7e3+NaFxILaxlk6ELx9TwKq6aDaaQ0p+/J8wz78CudK+h6F7RcirrE4eWR88J8i/h1/WqHhmULrVyCRmSEMp9g3P8xUiQG91FYDkwxDdJ7+34/wCNZniSOayvJZLU7DtJXb3RhhgPxz+ld7tyukt7HnxvzKq9riXxm8ReIpktZAqwIfLY9Pl/xJ611PhzWzfxPBdDyr+A7ZIz1OP4h/X/APVWf4R05bLTVmODNOA7EHOB2FGuaJ9tuEu7SY214vG8ZG78uc+9ecm0etPkn7nRbM6lpsd6hkuPeuO/tTV9OzBe2xujj5JUzz9cD/Cmx3NxIu+++3q57Rjai+2Bz+dPnMvq9jpZ7jnrVV5ie9Z0M3ynEzSL/t9RQ03vUORSp2LhkyetWIGJNZaSZNX7U9zTTCUTo9HhM86g/dX5j/hXSjpVDRrfyLJCww7jc2f0FX67IKyPKqy5pBRRRVmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFee/F3VtV09/Clpo2pPpr6pq8dlNOkaOyxsjk4DgjqBXoVZPiTw3o3ia0jtfEGnW2oW0b+Ykc6bgrYIz9cE0AePJ8WNY0P+0NJnEXiG+i1saTZ38cLBJQYhId6RKxZ1+6Qg5Ppg1av/AIxa7GNLsLfwlcf29PaXF3NayRTn5YpDGqoqxl/nxnLABQRmu617w/4T03w7ZaLceH7F9LnvI4YbKK3UKJXP3wOMEDJLdcA1Zufh74SutMs7C48P2D2loXaBDHzGWOWwevJ5PPPegDz3xD8ZNX0xtUuo/DtsNP0q30+5u47i5aO5AucAoqbCCyk9yOnSu3+IPi6+0HUvDuk6NZW11qmt3Dwwm7maKGNUTcxYqpJOOAAKii+FvhgeLJ9duNPguZTHbx28EsSmK18ldqeWMccY6+gro/EfhvRvEtrFb6/pttqEEUgljSdAwVh3FAHjXhv4peIU8N6Rapa2mo6y9jqGq3c95cGKPyYLiRAiFV5bCgAkAAAE10GkfFTVtc1ZotF8ORT2UekQavKZLvZKFkRm8tV24ZsqADkDnNdnefD7wleabZafc+H9Oeysi5tofJAWLeSXC46Ak5I6GtIeGtFEl240y0DXdsLKfEYAkgAIEZHTaASMe9AHlWm/GLULjQrya+s9N0/WY57eFNNuFuxMry7sRtH5O5m+XgoCDzyMcv0L4hav4i8VfD0PG2mpe3WrWmoWiZKyNbx/KfmUMMHnBwR0Nd6nw58IJp01gvh6w+yyyJK6GPJLp907jzxk454yfWr+neEPD+myWL6fpFnbNYvLJamKML5LSjEhX03DrQBxfxF+Jt54O8RSaR/ZMd1Pd20T6RiQr9rnaZYmiPHBG8Nx2qnafFTV77xpcaXZ+G57jS7TVDpF1dRRzMYnAG6Uts8sIGIG0tuxg98V6ZqWh6Xqd9YXmoWFvc3Vg5ktZZEBaFj1KnseB+VZ9x4J8NXGvrrc2i2TasrrJ9p8sbi6/dY+rDsTzQB5NpvxV1+28OaOtlp9vqV1NpF9q001/dlGCwTMCuUjwx2jA4HbJr2bwrq417w1perLEYRfW0dx5ZOdm9QcZ74zVSLwd4eijjjj0ezVI7aWzQCP7sMhJkj/AN1iSSK2LCzt9PsoLOyhSC1gQRxRIMKigYAHtigCeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCC9nW1s5p25EaFseuB0riLNXdi8pzI5LMfUnk103ipyulFB/wAtHVfwzn+lc0jyIoWCPfIfU4A+tc1Z3kkd2FjaDfcbrvzW0MI+9JIAB/n3IpNXlEapEvCxrvP8h/WozHMdYtftbq7YLBVHC4B/wrO124LLIV5aRtqj9BV4ePNMeJlywSL3h9CLJpm+9M5b8BwP5H8652OCXxB4guJ0kKW0GY1YdxyAPfJyT/8AqrqZdun6S2T8sEPX6CsnwPGF0ZnxzJKx/LA/pWU5tz5kdNKCjSaa8ijBNdaLctFjMXVoSeCPVTW3Bq9pOOJfLb+7J8v/ANan67arc2EnHzxgsp/mKxNM06zvdPDFXjmQ7GKOeSO+D7Yrok4VI88tH5HHFTpy5Iu68zakuIm+7Kh+jCqsrVkXWnm0fcym4g7kEhl/KnxxRMm+0lZf9knP5iuacIpXTOqnOTdmieVvzqLOTSbmPDgA+3SnouTXOzqT0JoBk10Ph20+13yKRmOP53/oPxP8jWJEoUZJAFd94ZsmtNOV5BiWb52B7DsPy/UmtqMeaRy4qpyQ9TXHSiiiu48kKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5TVR/aHxB0W0HMWnW8uoSf77/uo/0Mv5V1dcx4Wk/tDX/Emo4+VbpdPhb1SFAW/KWSYfhXT0Ac58QvFdr4I8I3/iC/gnuLa08vfHBje2+RUGMkDqwPWsux+I2mi91Ky8Q21z4fvLC2F7LHflNrQE7RIrozKw3fLjrntV/wCJvhJfHPgnUfDsl41kt55eZ1j8wpskV/u5Gc7cde9cprXwlPiOPWJ/E2vTXuq39pHZR3MNssKW0UcnmgLHk5y4ycnnpxQB0afEvwg2kNqZ1y3SyS4W0d5FdCkrDKqykZXIGQSMYqW0+IPhe81O10+01aOa6uVjaNY43YfvBlNzBcKWHQMQa5U/CVrq/l1LVNc+0alcatYapO8dmI4mFopVI1TecZB5Yk/Srmp/DD7Z4+TxNbat/Z8gmSV1s4GjklVV2iN28zYy/WPPbNAF+++KHhxNK1q6066+23OmWb3z2mx4XkjXuu9RkZ4yMit6TxNYWvha113UWe2tJ4YpcBGkZfMAIXCgknnHArzPT/ge0C6g154klu7i80qfS3uHtiZHEr7vNctIdzDpxgfSu38S+DZtX8E6d4ftdXmsvsn2cNMiEidYgAUdQynY2OQGH1oAWX4l+D4dJtdSm121jsrl5I4pHDDLxjLoRjIYehANU9H+K3hbUv7dJvJLWPSJzBPJcRFVf7oDJ1zksAB94nt0rN8J/Ce38P3WjyjUhOunajeagI/swVXNxHs2feOAvUHnNRa78JF1a38RWj6y0dlqupJqyILYF4LhQg5bd86YT7uAeetAHRzfErwhBpsN/ca3BDayzPbq0quhEqLuZGUjKsBg4IB5GOoq7ZeNvD16sLWuqRSede/2eihW3G4xkpjGc459MVyWkfCeCxvNGuXvbUPp+pSaiyW9kY0nZoRFg7pHOeM7iT6YFRaR4BuovjlqniV4Wg0RYVlt0MiFZbx0EckqqDlcIMcgZJOKAPVaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKDQBz3i2TC2kZOAXLH8B/8AXrOt8bMjpUeuXy3WsSJGGkMA8sBex7n8+PwqoILiT7zmPPYsTXM7Sk9T0YJwppWHowF5Ld3Hy4GyNe+PWsK4YG/sVc8CRSfzrRntpDIUhZnI6k8Cse5jM1ykW5QxO0HtmuqjGKT1OevKUmtDQ8ZSsukCJTgzSrGT7df6VN4dIt7VrBwFntTtYD+IEkhh7H+dZ92JpYo7XUgfkkDpL9PX/GtPU7OWaaG7sZFju4hgbvuyL/db2rinBwep6EKkZwUdjQkAZSD0IxXNaUwsZ7i3nOwnBBPQ9v8ACrP9r3iXK29zp+yRhlSsow/0yMfhmmzSw3zD5XhuE6LIuD9D6inGaScXsyJ0pXUl0LErcetZVxbqrl4DsbuB0NTou3lMoRwydR+FRyNzWTfK9DWK5lqRxsW+996rUKVXQc5FXouFye1SaGtoFiL3UY43GYk+eT0IHQfif61346VleHLA2NgvmDE8vzye3oPwrVrtpQ5Ynj4ir7SemyCiiitTAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqpq9/DpelXt/cnEFrC88h9FVST+gq3XLfEONr3SbPSEGTql7DauPWIN5ko/GONx+NAFnwBYTad4P0yK7GLySP7Tc/wDXaUmST/x92roKBRQAVzfiS+uW1/QtI0+ZopJ5Wurll6rbxDkf8CdkX6E10hrlvC7rqviHXdaC/u1kGmWz/wB6OEneR/21aRffYKAOpFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVXU7j7Jp11PkAxxM4z6gcVaPSuK8Taw9+s1hahVg3ANMTknBB+X8RUzlZGtGm6krIyUuhBCN5W3Q8kvy7n1Ipr6tbKM+Y7/jSW1jbKxdwZZT1ZuTWkqw7QDbp+Nc3Kz1W0uhlrrdttwGAz61UM9rIAySpvDhgc1uNDaOfmgXPqKa+n2EgIePr+NOPMtmTJQluiFpbe8hKMVIPv0p1rvhj8tzuVeAfaql1oUQ+a0kZD/sHB/LpWVLPqOnSfvgZoR/Go5H1FJtpWexShGTvF6m9ewx3UBjlGQeQQeVPYj3qowLKFmw0ifxY6+9QWurQ3A+8ATUkxJO5CD7etZsqzWjIpepPeqrHJqRpQ+R0YdQaiHWs2aRViWLrW94btPtmqwoR+7i/ev8AgRgfnj8jWHEK7TwLF+7vJsclljz9Bn/2arpLmkkY4mXJTbR1Q4ooor0DxQooooAKpa1qMOkaPfald7vs1nBJcS7Rk7UUscfgKu1X1Gyg1LT7myvIxJa3MTQyof4kYEMPxBNAHmWgfE3Vri68OT+IPDsOm6N4i3CwuIrzzpEbYXRZU2ADcoOME471q6P8XvB+qKXjvri3h+xvfrLdWksKSQocOyMygNg9cZqDRvhZbaZc6a8+t6rqVnpCuNLsrtk8u2JUqDlVBYgHALE4rnPAfwUhh8KWNp4zvLi9uotNl04WySL5NskjlmMZCgknjls4oA6uL4t+FHsbq5ee+i+zSQRyQyWUol/fnETBNu5g3bANb3hXxfpXijSbvUNINy8dpK8E8Mtu8c0ciDJQowBzyOPeuP0f4N6TptmLdb6VlW5tblWjtLeBs2771DGONS2T1LZPpiux8J+FrXw1LrUlpNNKdVv5NQl83HyO4GQuB0470AY0XxV8JS2UF2uosLaawfUvMML4SBX8sluODvBUL1J4FUrj4paXdRWn9kyCO4OrWmm3NvqEE0Mkfn5KYUKTlhypOF65IpkHwd8Nx2fia0kN1Lb65lWRnH+ip5jShIePlUSOWxzzUWlfB7SrC1toft0reRqNpqKtFaW9vlrcsUVvLjXcDuOSefTFAGlpnxX8K6jqqWEN1do7tcKs01pJHCzQAmVRIRtJAUng9BWv4N8aaV4whkm0Vb42yqHSee0khjmUkgMjMAGHH16etYdj8LdMso9NWC/vgbC7vbyJvkJL3KOr5+XGBvJH0Gc1N8N/hrp3gS81K6sLqaaa+CLIvlxwxgLnGI41Vc8nJxQB3dFFFABRRRQBh/2tN/wmp0bYn2caeLvfzu3eZsx6YxU1tqUsvirUNMZUENvZ29wrDO4tI8ykH2xEPzNZA/5Kw3/YEH/o81Zsf+Sja1/2C7H/ANG3VAHSVy13I198RbC2Q5h02ykupP8ArpK3lp/46sv511Ncp4I/02/8Q6yeRd3zQQt/0ygHljHtvEh/GgDq6KKKAMXxlq0mi+G727tkEl5tENrGf+Wk8jBIl/F2UVP4a0mPQ9AsNMhYyC2iVDIesjfxOfdjkn3NZOsuup+NdI0vaHisUbU7j0DcpCD+Jdh/uCupHSgAooooAKKKKAKOuavYaDpNzqesXUdpYWy75ZpDhVH/AOvAAHJJxXK2nxT8LXdvDNBdXeJrqCzRZbKaJi82fLOHUEq21vmHHFS/F7wlceNfAt7o9jPFBeM8c8LTAmMvG4YK4H8Jxiub8QaL408XWekDV9M0jTpLDV7K82Q3bSl0jLGRs7R6rtX65NAHqS3ELTPEsqNKnLIGBYfUU1bu3dJHSeJkj++wcEL9fSvBrX4VeIU1uOQ2unxvby6lLNq8d0yXOqLcK4jikIXK43AEknG3IFZNl8GvFEfhvUbGKPTrW3NzZyxWjPEZLhISxZJZUhCsDuBG9W5HNAH0bNfW0Nr9pknjEGMh9wwfoe9VNA12w13QbPWNPlJsLuMSRPINhIPAyD0rwmL4Sa5DFpLf2Pp97YwXV5JJo+o3wkhQzIgWUbYggwysdgTAzx149F0nwLcP8EIfB2q+SLwaabYsjbkSUZKMD/sttP4UAegSXEMYcySxqEGXLMBt+vpVGXWraPVraw2XDPPC06zpCxgCr/ek+6D6AnmvErv4U+KNQ8KC51Wa0uvE1zqqX+oQrKBHcRRxmOOMM6Mvyj5huUjJP1p2n/CjXLeC3jghgt4U0bUrFYJb3zjHJcNlAGCKNuckgAAZ4zQB7ylzA4cpNGwTliGB28Z59OKWGaKdA8MiSIejIQQfxFfP8Hwd1Ox0/U7WzsrNbW/0GysriC3u/IM11HKGkcnYR0B5IIboRgmvR/gz4Z1Xwr4VmstaWxjnku5JkjtI0QKhAAD7FVS3HJCigDvaKKKACiiigAooooAKKKKACiiigAooooArakzJp10yfeWJiPrg15vYruCg9AOK9OmQSQuh6MpU15pYrtO1uqnBrGrujvwT0kjSiTA4FSFM06PoKkxU2OhsrGM4qF0YdDVwimsvFSFygXdKjlnRwRIKuSpxWbdxcEii5okmYup6UrMZrQiOTqcdD9RVCG+mgk8m7yrDowNa7SNGx9PSq95BFeREEc/qPpWco31RrGVtJBJIsyDJAf8AhcUltKWfy5BiQfkaxHeW0fyZCSuflb1rQtZftSYBxcJ8y/7XtWTLtY3YVrv/AAjB5WjIx6yu0h/PA/QCuA0tjepGsIzK7BAPQnivU7OBba1igj+5GoQfhXRh463POx07RUSaiiius80KKKKACiiigArC8d+ePBWutaSSRXC2UzRvGxVlYISCCOh4rdqtqUAutOurdhlZYnjI+oIoANNnF1p9rcKciWJXB9cgGrNc98PJ2uPAnh+V/vGxhB+oQA/yroaACiiigAooooAKKKKACignFUptVsIGKy3lurj+HzBn8utJtLcaTexz4/5Kw3/YEH/o81Nayxx/EbWRJIik6XY43EDP726qhY3sF78VpGt2ZlXRQCShX/lufUc1m+IEdviPqIjghl/4lVn/AKx9uP3t10+U1nUqKEOcqMLy5Xodr4i1IaZ4e1PUI8O1rbSTKAfvFVJA/Eio/CGmHRvC+l6e5zJBbosh/vPjLH8WJNeY+LFkZdM09bGMSX17Eh8lwSUjzK45x1WMr/wKujj1CaDgSalAfTDyD9NwrFYuPU19gujPQqR2CqWYgADJJ7Vwg8QTJ11UL7Sqin9QKyfF3iedtDksotSt3m1F1sUKbdy+YdrOMH+FNzf8Bq1iIsTw8u6Om8AKb6HUfEEgO7V7gyw56i2QbIh+Kgv/AMDNdZXFWOqzWtpDbWs9qsMKCNFVBwoGAOvpVpdZv+vmQkf9c/8A69P6xAPq8zq6K5ca5fKeY7aQenzJ+uT/ACqzF4ixjz7KQe8Tq4/XbTVeD6idCa6G/RWXDr2nycNP5J/6bKY/1PB/OtKN1kUMjBlPIIOQa0UlLZmTi47odRRRVCMPxpeS2Ph+WS3kaKaSaC3R16q0syRg/wDj9bYrlvH58yHQbQf8vOsWg+vlv53/ALSrqqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAA151dr5Wr3aDjEzfzzXoprgdeXZ4iu8fxFT/46Kyq7I7MG/ea8ixByKsEcVXtTwKsnpSWx0S3IWptOem1DKRFJVK5XINXXNU5zwahmkTGuk5qi3ytWncDNZ069aEbEN1El1EVYDNZMPmW0+DkSocqf7wrUJINQX0Jmh3RcSIdy/X0qZRvqVF20O0+H0UM2tyXAIwYfMVOwfOCfy/nXo1eafClBLdXU3RY4xtH++ef/QK9Lrpo/AeRjf4rQUUUVqcgUUUUAFFFFABRRRQBzvw/QReFLSAdIJJoB/wCZ0/9lroq4vwrrVtZwataSMzzQapdr5cYyQGlMg9hw/erV1rV5PkQqlqnr99/14H61nOrGG5rClKeyOod1jUs7BVHJJOAKz59bsIuPPEh9IgX/lXHS3MVxL8zS3soPXl9p+p+VfpxTv8ATJD8kcUK9jIS5/75GB/49XLPGJGqoRXxM6KTxEP+WNnK3vIwUf1NQt4guz92zgH1mJ/9lrDFpM3+svJfcIqqP1BP607+z4j96W5Y/wDXdx/Iiud419y/Z010NY67fn7sVqv/AH03+FV59Uv3U+ZdLEvfy0C/qc1R/s62/iV2/wB+Vm/maVdPslORa24I7+WM/nUPGSfVjSgtokVxdW05JnuPtJ9C5l/TmhJn2gW9nMV7ZAQfkTn9KujaowCAPQVk+LbK71LQbm102cRXDgAHOMjuM+4/PoeDURq88knpfqxyqNLRC+E3kf4oXHmLGhGjgYV93/Lc9eOK4b42ade33xOzYxlimk22T0wfOuO+DVn4IaHf6J8R9Ti1GExs+lqVO/cCPO/Su61i8trT4i6obq5hgDaXZY8xwuf3t1617tL9xbkalbr0POm/bK81a5wHgQag3iQrrl35g0yyAiEkgYiSZueR3CxDvwH7ZxXov2uD/nqn51keCrm1uv7VvY7qCWa/vpJQFkBOxMRJx6bYwf8AgVdPXDWwiqzc27eiNoT5Y2Rn/a4D/wAtV/Oubae31TxsS8kbWukQYGSMG4lHP4rGP/ItS+NPiBpHhN/JvTLNdbQxiix8oPTJJ4+nWsP4YeOtH1VDbHzLfU765kuHEgG13YkhQQeoUKozj7oxWKwcE7c2p08lVx5+XQ7N200/fNn/AMC20iW2mTH91FZs3qgXP6Vs1FLawTf66GKT/fQH+dH1DtIx9t5FEWMSjCNMn0lbj8M002kyf6q7c+0iBh+mD+tWTplsP9Urw/8AXF2QfkDj9KYbO4T/AFV4W9pow3/oO3+tQ8JWj8LuWqyK+byP70UUw9Y22n8jx+tMhuYoJCwE1nJ1J5jB+pHB/OrQN2hxLbK4/vQyZ/MNjH5mm/bYd4SUmJycBZVK5+meD+FZP2tP4omiq30uXrTV72IKwmS6jPQSYBP0Yf4Gti0121mIWfNtJ6SfdP0bpXLvYQFi8WYJDzviO3P1HQ/iDTCbmDIlQXEf9+MYYfVe/wBR+VbU8Y1u/vE6cJ7qxseJj5/i/wAH24IIS4uLwj2S3ePP5zCuqrya0vWTx9YSWLK8Vrps7eU5O0eZLEMAfwn90f8ACvSdN1SC+JRMxzAZaJ+o9x6j3FehCrGfqc86Tjr0NCiiitTIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhvE4x4hk90Q/zrua4bxP/wAjC/8A1zT+tZ1djqwf8T5DrXtVuqdt0FW+1QtjqnuRSVGelSSVE54qZFIikNUrk8GrUrVn3LVDNoIpynmqU1WZmqhO/OKEakT9aWM9c0zdmnJ1qhnf/C+COHS71hzI1yQTjtgED/x412lcd8NQf7PvD28/H/jorsa3p/CeJif4sgoooqzAKKKKACiisjV9XW1Jgt8SXWOf7sfu3+Hf9amUlFXZUYuTsi7f30FjEHnbk8KgGWY+gFc3f6pc3asCxtoO6o3zEe7dvw/M1mXFw3nkktc3jDuece/ZV/zzSpZ+Z816wlbOQn8C/h3+p/SvPrYrodcKUaer1ZzfhiRhrPiW3sY1aM3qTLIxwgDW8QJHc8q3sfWuk+wrIc3UjTD+4eE/Lv8AjmsOymMfjvWobZPOaaztJMA4VWDTqcntwF966NLF5Mm8mL5/5Zxkqg/qfxP4ViqdWs9NEKVW25G1zBC3lJ8zr/yziUsR+A6fjSg3sv8Aq7ZIl9Zn5H4Ln+Yq9DFHDGEhRY0HRVAAH4U+uiGBgvi1MXVb2KRtbhgN10FPfy4gP5k0DT1P+suLl/8Atpt/9BxV2lrojQpx2iiHOT6lL+zLX+JHb/fkZv5moHh0eO4WCQWSzscCNyu4/geazPiMmrP4VuhoJkF1kb/K+/5f8W3vnp05xnFfNFroutvqKpJDcM5YbkCEl+em3Hf6UpyUHZI78JgliYuTnY+s/wCzbH/nzt/+/YqOey02GJpZ7e0jjUZZ3RVAHuTVfwnbXtp4c06DVJDJepEBIWbcQfQnuQMDPfFeF+PfEd7rWvzxLPItvC52KDjb6Y9DjBJ65J7cV2UKHtnbY8uvUVLzPZvBtzplx8T7n+yZrWRBo4Dm3YEZ88+lecftDef/AMLGY2zyBxo1uQqNjcfNuMVa/Z1Rk8f6rvd3Y6WvLMSf9aPWup+IPhMeJfiXcu1yIBBpVoDlC2cy3Pow9K2go0Ktm9EZSbq07rc8Q0/z9PhgWOd2aMAKrHOT7dwfpzX0R4GvbrUPDdtNe5MoLJvPVwDgEnv6Z74rJ0n4daPYyCScy3UnfdhQfy5x7E105vbG0jWKJ0wgCLFAu4rjthelPFV4VEoxWwYejOLbZ518QPhSfEuszala6gsbzEF4plOAdoHDDPGFHGPxpfAnwnj0DUor+/vRPLE4dI4wdu4dCWOOh5xgV3kl7dz/AOpjW3T+9J8z/kDgfmfpVZUiu0Ilna7CnDBnyufQqPl/SvNcYXue1CriXDkcrLbzsacup2UTlGuYzIOqId7f98jJqM6tB/BFdP8A9sGX/wBCArkvGHi2x8KW8MIga5v5gfIsoMBmA6seyqPWue8C/EafWfEDaTrNpbWs8wLWz28hdWI5KEn+LHORwcGn7TWxMcFdc2p6aNWi/jgul/7ZE/yzTxq1l/HKYh6yxtGP/HgK8u8TfEyTT9Yu7DS9MS4FpJ5MtxcXHlIZMAlVABJxnrWfB8XZ4SDf6ErJ3a0vFcj/AICwH86PapFfUG1dJntVvcQXKlreaOUDvG4b+VSOiupV1DKeoIyDXnHh/wAb+GfE9ykCOIL88JDdxeXIT/snofwNdcFuIiDb3LjH8Ev7xT+fP61SmmYTwko7F06eiEG1doP9kcof+Anp+GKhaeS2O29VUU8CZfuH6/3T9ePc0sOp7SFvY/JP/PQHdGfx7fjWP448XReFIrG4u7C4utOuXMctxDhhDkDGR3B5/Ksp4SFbZamDlKl8RWtLc3HjnXLiB/LeG1tYAccMcyudw78MnvW5DMXkCSBre7j+YbTyP9pT3H+SK5vwRcRahNr+raM6T2M18FSMDGUSCIfLnoc7vlP6V1LCG9hBDHg/Ky8Mjf0Psa4KkZ0JWlsdFOomtDotH1gyyLbXpVZz9xxwsn+De3ft3A2688R2D/ZrzaXPKOBgSe49GHp+IrpdE1Ulltbxvn6RyH+P2P8AtfzruoV+bRmdWj9qBvUUUV1nMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXB+KuPEbe8SH+dd5XEeNY9utW8vZ4Qv5E/wCIrOrsdWDf7wS15Aq4OlZf2qCys5bq7lSG3hQySSOcKqjqSav20yXFtFPFu8uVA67lKnBGRkHkfQ1MdjqnuJJVeRsVNKcZqlO/WokXFEUz4rOuJOTU1xLWZcS4zzWZ0RQyeQAGsyeXmn3M2apZLNVIuxZjJIqzEM1XiXgVt+HdNOp6lDbHhGO6Q+iDr/h+NPcUpKKbZ6B4HtDa+H4WYYacmY/Q9P0ArfpEUKoUAADgAdqWulKyseBOXPJyfUKKKKZIUUVn6zf/AGG1ygDTudsanpn1PsOtJtRV2NJydkVtc1Q23+jWuPtLDJY9Ix6+59BXKszu7W9sSZAcyytzszzn3Y/1yfQk0kgk8uNvMupiXZ25x6sf5AfQdOk4Edja9SQOp6s7E/qSTXk4iu5PQ7oxVNWW4IsFlbsc7EByzMclj6k9zWH4t1tdG0o3l4kgjc7ILZDtknYjOCf4V9e/8q6C1tXeRbi7/wBYOUjByI/8W9/y98bx14Zi8R2dv5l59je0YyLIVDLyOdwyPzzXThMJFSUq5y1akmmoHkR8S+I/+EkTUknitf8AQ3CwxRL5QRHUiM5/3zznNe7wXyf2bb3V2ywGWNXIY4wSAcV5FqujXGiW9vdSS/bLTzlH+q8sEjkcEnKnBGTjnHGOvounSWlzbxXsUnneaoZZZGy2PT2+gr1cVKlZeyWhnhcPVk37XQ031Msv+i20kmejSfu1/Xn9KgM1/J96eKIekUeSP+BMSD+VcXqvxF0y1meKygnvGU43ghIyfYnk/XGK1L3xRHD4Ri1tLdv3oULEx6MW28kdgfzrz/ap9T11gJQSbjvtc3tlwfvX1yf++B/JRRsuB92/uV/74P8ANTXmH/CWeJtV+bTLScxf37e1JU/8CO4frVSfWvGVi4lmjvkXv5ltuT8Tjj8xUe2XmdSy17NxT7XR64st8n3LqOQf9Nosn81I/lU0eozrxcWvH96F936HB/LNcl4L1/UdXt7iTVbEW0MSgrc4KI/XPDemOoOK39M1Kz1S2+0afcJPDuK7l7Edq0jO+px1cJGLcWtuxr2t9bXLbY5B5neNgVYfgea8+8WfDUX9/LfaVOkckhLNE524PXggHj2I/HHFdjNDFMoE0auB03DOKakc0X+ou5kUfwuQ4/8AHsn9a3p15U3eJxVcEpqxyvwd8PXvh/4j6hHf7C0mkhl2kHjzvb6V1Ov+afiLqQinkh/4ldnkoFJP726/vA0nhV5W+J0/nOrkaOMELj/luafrf/JR9S/7BVn/AOjbqnVqOpeTM6FJQmoMY1pHJ/x8NLP6iWQsp/4D939Kl/dwxfwxxoM+gAp9cR8Zrma2+Hmo+QzJ5zxQSMDghHkVW/MHH41ztnpxitkcR8QPHDeIGey0e5lh0JCUlniOx7xx1RD1Efqe/wBOvHeFdSPhrxJZahp4FtbmZIrqJCdkkLMA2R3IzkH1FQXpXzzHFgQw/u4wvQKP85/GqF/k2c4GSxQhQO5PT9a5nNuVz1lh4xptHc/FIOnj3WDITl7W28o/9M+cge24VyNpdtp+qabfKcNa3cUufbcAf0Jr1T4t+GLy70+x1yxhee6tbcQ3cMYyzR9dwHcqc8ehNeX6DpNz4pvEtNORjbhlNzdMCsUCA5JZjxnHQdaqSfOZUqkPYNNl3xpOkHijXYZWKyrqUrhccsHClcDvkVYsfBvii/gWa20O4WNhkGeRIifwY5/MV64+u+A38SwSG80ebWmZYY5lCyPnoBvAIB7dazvi74ln06C20fTp5Le6vFaWaeM4eKFeDtPZmPAPbmqcFq2ZQxFSyhBHDaf8M/FF3e2y3Vtb2EKSpI07XAdk2kH5QueePUV23jX4i3Wi+IptM03T7a4W0WM3MlxMUyzjcEXAPOOcn1rjfh/43n0DVYbTUbieXR7pwjNPKZGtnPAYMedp4BHbrR8V7Q2vjjUWP3b2C3ukPrtDRMP0U/jQmlG8QcZTqqNU9E8JfEjSdfuYrKZJdO1KT7sE5BVz6I44b6cH2pvi/wAUabpssuh2to2sXl0pWTSYk3Ic92P8Hr+uO9eB3+xbWR5CVCDcGBwVI6EH1zX0HoD6V4V8MWepa81npuoXcKSXs0pCvLMVBbryTnPA/KtKNRbyOfG4XltGL0Z51pOleKvBEH9tWsUUQQk3cMMrSBVySFnQ84x0kXOPWvXfC3iOy8V2bX2lfudRhAFzayNz04BI4I/uuP8AEVFpHiDQ/ErMdF1O1ubiMHKofmCnqGQ4JU+4x+NVvCvgzTtN8Vvq+myzWUgjaObT1IMXzc5XuFyMgevpyK6pzhiIONRanjTw8sPK8HodWfJvoGV1PBwynhkYfyI65qGNmDfZbknzMZR+m8DuPQjj+Yq3ewOr/abYZkAw6f8APQf4jt+X0ikSO9tlZWIzh43xyp7H/wCt9RXh1IPDyt0Z1U6l9TpdB1M3K/Zrlh9pQZ3f89F9fr61sV5/aXEu4MpEV5A3I7Z/qpH+ciu2028W9tEmUbWPDIeqt3FenQq86s9zGtT5XzR2ZaoooroMAooooAKKKKACiiigAooooAKKKKACiiigArlfHqKlra3TlVSJ2DsxwFBGck+ny11R4Fefa5HceO1nt7XKeG7ViWfvqMyH7i/9MQRyf4zwPlB3TJXVjSjLkmmc1pSv4ou47q5TGhwMGtoXH/H1IDkSsP7gIyo7n5vSu3LcVj2Eg2jHTFaTONuayTPSlHUjuG61l3EuM1au5Rg1i3UvJqJGtNEdzN1rKuZ+tPupves5iXapNxCxc1Zgi4zSQQnPIq9FH0pgNjj9a9O8F6R/Z9h58yYuZ8Eg9VXsP61geD9CN3cJd3C4tYmyoP8Ay0YH+Q/+t616FWtOPVnm4yvf93H5hRRRWx54UUUUANldY42dyFVQSSewrhtRvzPLJeShsH5YY+4XsB7k4/yK3fE92QiWUZ+aT5pMdkHb8Tx9Aa5uHNxeF/8AllASq/7T9z+A4/E1w4urbQ66EeWPOyS1iMETS3DL5rfNI2eB7D2H/wBfvUllCZ5BdTDj/lihH3R/ePuf0HHrTGQ3d0ITzBFhpf8AaPZf6n8PWtKs8HRv+9l8jOrPoMnmjgiaWVgiKMkmsdzJeuJblSsQOY4T29Gb1b+X15p003265Dg/6NESE/226FvoOg/E+lVo9Us5NWk0yOYNeRx+a6AZ2jIHJ6Z5HFdkpHRh6NlzNHL/ABL1Am1tNGtRvvL6VSFHZQ3H5tj8AfSll8H+FtOto5dWjiZ8ANJNKRvbHOACM/SsHxbqi6d8QYtUSNbqK0jEJTft+ba+QDg9N4P6UnxFc3+laPr0aywCeMxtGx+6D8w/kfrxWLq6Ndj16eFblT1tzdfMt3Vt4CdlYu9uE7KJlDe3I/lWtpPijw/qVzDoNtaObV18uMSxDymwM7cE57dxWXY+BNKbw9Zzalcy2t7Miu8vmhQGYZCYbjjOPU+ta3hrwLa6NqKXsl1JdTR58oFAiqSMZxk5OCR179KlKV9kVUlQcWnOTa2uV/HXiDUvD2oWX2IRfZHj4jaP5WIJyM9RgbcYqo/xHM/lR6fprtcvgbHO4lvRQvX6nH0rI8davL4i1i20vTVDxpKUjHeSTOCxPZRz+GTXU2WkWngrRpLyO2l1DUThC8aEsxPYYB2p69fx4FK8nJ2ehbp0qdGPtI+++n+Zo+J4tRv/AAlKtvDtvJERpbcNkkZBdAe+Rke9ZvgPS7rS/Dl3dyxyf2hd7pfJfjGAQgx2J/r7Vzj+KvEOmaot/qNpdCwc7XikhKR47bMj5T6ZPPftj0nR9TttWsI7yycvC/qMEEdQR2NXFxlK/U56kalGly6crd7r8jj/AAj42N5drp2rlBcOcQ3CLtWTPQEdie3Y+3fvK8q8H+FM+XrWvv8AY7eNxJHDIdhJByCxPQA9u+PTr6lFIk0SSRMrxuoZWU5DA9CKKfM17wsWqSn+6+fr5EXhX/kp0/8A2Bx/6PNP1v8A5KPqX/YKs/8A0bdUzwr/AMlOn/7A4/8AR5p+t/8AJR9S/wCwVZ/+jbquj7J5C/j/ANdij4k1q08PaNcalfsRDCBhV5Z2PAVR6k8Vn2s+l+PvBjEpIbC/jaN0bh42BwR7MrDP4CuI+N96ZNR0TTQf3caTX8g/2lGyM/mzU34H3szaN4h0y2dFuoZfPg38qPMTgkem5TWPN71j0vZ/u+fzMy8+FN1Y7nu/E9jb2KnAmng2tj3ywXNQ2P8Awg/hueO4ja/8T6lCweORU/co45BB4Tg98tXG3dzdXV1JJrbSXerwyPFcPdnzDE6sQVQH5VA7YFRNJLc3UUEay3N3M2yKFBudz6Af5FZcyT0R2KlOcb1J6Hqvh74marqvi7T9Ok0q1itLuQptjmMkqfKTuJ+7gY5rifGPiGfxHqN3Jdu0mmid47S03EQ7EYr5jKPvMxBPPSvSvhh4GPh3dqeslH1mddiorZW3Q/wj1Y8ZP4D38i8SaXceGtVk0m/XasAdreXtNAXYhvqMkEdiKqfNymdFU3Vstja+Gehf8JD4th8yJF03S9tzKqIFVpM/u049wWP+77133j3w3beN4xqHhvUbSXVLENAyiUMkgzkxsR9055BrF0kS+FfgxLeQjytQ1iQHzDx5ZmYIjZ7bUwfrXn+m3t14d1f7Z4ekFrLEPKKsNySoO0g75656g9KLqKsw5Z1pucOmxSuoJY5Z7LULaS3uY/klglGGX/EehHFd3qtleeJ/hdoWr20ct1qeku9tOEG55IgSjcDkn5Ub86tHV9D+JElrp+vWz6P4iGUtbuA70c9doJ6g8/I34HNaMetQfDfSn8Paef7X1ZGa5uJZP3MMRkORu6nOMYUZJ68URilfsFSrKXKre8jmPCHh77Lb3HinxTaSwaPpiGaG2mTa9xKPukqe2cYB6kisLWdUvNZv/wC1NWKy38oyiHlLWMniNAe/qepr1jRtQHxB+HGpnxMsVhB5jo81uxVVEZDCQbs4wR39K83tfDGn6hKyaP440e4PQLdwtAx/8e5/AUSi7WiFOrHncqu5z2ZEuo7uCV4LyJt8U8Zw6H1B/p0r3/4da/c+JfC9vqMgRdUtne3lIGFdlxn6Bhg+x+ledWfwuvriZEuPEmkxoxx/oyGRz9MsB/Ou+uL/AEL4YeHbGyK3Ukbu21YwHllbq8jcgfX8AKdNOO5OKnTrWUVqei2dyl1brLHkZ4Knqp7g+4qpOv2S6DjP2eZsMP7jnv8AQ/zx6ms7RdTtrlba/sZVl0+/VSrr03H7rfj90+4ArfniWaF43ztdSpx15rSpTVWHKzw5xdKZm3yGMi6jUloxhwOrJ3/EdR+XetLRL77LeJ8wNtcYUkdA38Lfj0/KqNnI7xFJf9dGdj+5Hf8AEYP41XhjWN5rNvuY3xj0Q9vwOfoMV5tCbpy5XujoVprlfU9EHSis/Q7s3enRs7bpU/dyf7w7/jwfxrQr2U7q6OFrldmFFFFMQUUUUAFFFFABRRRQAUUUUAFFFcnr2o3OsamfD2hXEkDrg6hfRc/ZU/55qenmt2/uj5vTIBFqs8/izUbnRdNnaLR7ZvK1K8ibDSP3toz2OPvsOmdo5zt6u0tYbO1itrWJIYIkCRxoMKqgYAAqLSdNtNJ06Cx06BILWFdqIvbuT7knJJPJJyat0AcZ4k0w2E7XcA/0eRsuB/Ax/of51li4JSvRJY0ljaORQyMMMGGQRXF614euLSRptPVpbfrsHLJ9PUfrWMo21R30K6a5Z7mReJKiZcEA1iXb9QKLm3kN3JcRXEqys2WRidp9iKWRQaz3PQirIzXQlqWOHBGaueXz0p8UDyyCONGeRuiKMk/hSKuRRR5OMV03hrQH1NhLLmOzU4Ld3Pov9T/kafh/wicrNqoAHaAHr/vEfyFdoiLGioiqqKMBQMACtIU76s4cRi0vdp/eNghSCJIolCRoNqqOgFSUUVueYFFFFABQelFZ2v3Bt9KnZDiRgI0PoWOM/rmlJ2VxxXM7I5TU7oyyXV2rAtK22LPTrtQfTPP4mkASwsOAWWNfxY/4k/zqEoHvoIVH7uFfMI9/ur/7N+QqeUCW7toTkjJlI9l6f+PFT+FeLO9WoodzuqPlWnQs2EBt7cK5BlYl5GHdj1/DsPYCodWmKwrbxkiWclAR1Vf4m/Lj6kVerGZjPqFxMfup+5j+g+8fxbj/AICK9fSKsjnow556md4hv/7H0OaeFVDoFihUjgMxCr+AJB+grn/hlZZsbrV5ctLeSFVZjliikgk+5bcT+FXfiLa3V34eEVhBJPN9oiISMZPX+WcVa8O20fhvw1ZWupXUEbpuLM7hV3MxYqCeuM4/CsNXPyPaTSoWW7f4L/gnGal4MvJvGMMDmWfS5WMzzsOFXJLIT/eJ4/4Fnsa9D1PSbLVLSO2vYBJbxurqmSACOnTt2xVp5oktzOzr5IXeXzxtxnOfTFeO6v4tvJvEFvqMbyCKCXfHEGIXYOq46EkdT2Jx2qXy0/mawVbFtJP4V/XzNj4t3Ba7gtsjCW+5VPq7EZ/JP1ruND1qw1KwtZLe5h3ug/dGQb1OOVIznIrM1jw/pPi+K31CO5k3GMKk0DDlck4IIPIJPoa4fWfh/qtpOBYql9AxwGBCsv8AvAn9Rmk3KMnJK6ZcFQrUo05S5ZK+6O48QR6f4ZtJ9WsNPtVvpHCeYVxyx+Y/lk8YzXLf8LKul/5ZWrnONvlsuT6Z3n+VddrJ0uw8O2tj4gc3ShETbyXkZQPmGDnr3yPc1Domr+HNTtE0iCKGJHBUWcqDDD2xkE9+uacr3snYzpOKhzTg5a7+Re0TV7TxF4de7uIUjgIZLiKUgquBzkngjHOfQ1Y8PDSY9OK6IYBZq53eWeA3U5z+H6VyXxBs5NH8P28ekxrBpauRNGmR87EbWb1Gcj6kde17wnYeb8OJIrU5ub2CYls8mRgwHPtwPwpqT5rMidKPs/aRejei/wAzMaI+OvEgaQsNFssNtzxJnpx6sBn2XA6k12lpq9jLq9xpML7bq2QEptwMYB+U98Blz6ZFcn8Kkvo01Jbu1lgiLIVMiFMtgggA+gC1U8UQzaV8RNIvYmPlXk6fgTticfTaVP4mlF2jzdzSpTUqjpJ6RWn5/ieg+Ff+SnT/APYHX/0eafrf/JR9S/7BVn/6NuqZ4V/5Kdcf9gcf+jzT9b/5KPqX/YKs/wD0bdV0/ZPEX8c8T+MLlvHcgPRNJiA/Gds/yrkdA1u78M6wmraeqyOiGOaBjgTR9Suex7g+tdx8YdC1e58YW17punXV7BPZJb5t03bXWRjhvQYYcnisWx8KabpjLc+PtWtbVByNKt5PMlf2fbz+Cj8a5XF810e5TqU1R5ZanZXfw+0fxZMviO11G+s7bU40u3iQIOWUc5IO0kYz75rmn1/SPDizW3gKyh3cxza3d/vC57iLPL/ov1r0HSte0jxf4c1XTPDryQtFatbrE8RiMYZCqEA/w8Y/CvDbXTNauJI7KPRtRe7hURNEtuwCbePvHCge+aqWmsUZUUpO1R6Ir6o1zqd6skk97qOozuI4mlkO9pGOFCgHC8+lev8Aim58K6Xo+h6P48ZtT1G2gjZmWN5HGBhnYrztJB69cdDVb4X+Ar+w1Ya14ihSCWFStra7g5QkYLsRxnGQAPU15zrFxcXGo6rPeZN3LqE6zluo2NtVPoFxgUtYK7NGo1qnLDRI+gNabRL/AMH3Mt+YptBa181mUEr5QG4Fcc8YBGOc4xXiSaV4JunIsPGdxp4PSPUbUnA/3iF/ma6j4ZTvrvgPxH4VkYGaGKRLfPaOVW2/k+79K84lkea3tzLuDBPLeNv4HX5WXHbkfrROSsnYmhSlzOKlZo9D8IeHfCNlrtleT+M7DUrmB98EKSxxLv7EjcSSPTNZXxW0+XSfGF7NKrG01gRzwy9hLGuxkP4c/j7Vwtxam6CWtvCslxcOIYl25yzHAr6G1/TdButBs/C+tX9utw0KJb+bKom3qNqyLk5zn8+RQrTjYdS9CopN3OE8Mltb+CGtaLp6k6jZCRXiX70g3+aMDvuXI+ua80u76yvZGMjQBQcLG+AUH93B9K9O+G+geIPDHxFktb21lazmtnSS7jX9zKFOUbPZuoweeav2PjvStX8Wzafr+i6etjLPJb2l3KiyFmVyg37hxuIOD+FDjzJXFCp7OUuVXR5n4N0NNb8V6da6bDH+6mS4uJ4xxDErBiSR0Jxge5re8f66PEHiG6vYnzZQj7HZ4PDqGzJIPYsAAe4FdB8SNZXR9Tl8NaLbW+lWBt1nufs0Sxtc7yRsBAGFwDk9e3FcZ4b0S48VasbSGT7NY267ru6AwlvEB91ewbHQdutJ6e6jSD5n7aeiWx6j8EIZJfAMyTbhbveT/Z/ZMjkf8D316pp07T2cbyY8wZV8f3gcH9RXz7F8TbvR0t49E0qzj8OW67YIG3ec8ION+c4BPJwQffrXuGgXcVxJ5kD7re8hW6iPrwAf0KfrW1NrY8vG05W52i5cJ5WoJIPuTLsb/eHIP5bvyFQakPL8u5H/ACyb5v8AcPDflwfwq1qyk2MkijLw4lXHU7eSPxGR+NDqk0LK2GR1wfcGvPxkeSqprqctKWhf8OT+TqUkJPyTruH++v8AiP8A0GuorgNMkeMWUrH95DIoZvodrH8t1d+OlehhpXjYnER96/cKKKK6DnCiiigAooooAKKKKACiisnxJdajbWKrotmLm+mkESFziOHPWSTvtAHQck4HfNAGd4k1i5mvf7A8PnOryoGmnxlLGJjjzW7FuuxO5HPAJrX0HR7TQ9MisbBCIkyzM53PI5OWd26sxOSTUPhvRYtEsnjEjXF3O5murpwA88p6sf0AHQAADpWtQAUUUUAFFFFAGTqugWOpMXljMcx/5aRnafx7H8RWBN4IYv8Aub8BfR4sn8wa7WipcEzaFepBWTOSs/BNqhBvLmWf/ZQeWp/mf1ro7CwtbCPy7OCOJe+0cn6nqfxq1RQopbEzqzn8TCiiiqMwooooAKKKKACuf8VyZezh9WaQ/gMf+zV0Fct4kYnV0HZIAR+LH/4msa7tBm1BXmjIsPmnu5PWQID7Ko/qWqayG/ULqT+4FiH/AKEf/Qh+VMsFxA3vJIf/AB81LpXMMz93nc/kdv8A7LXnYVc1ZvsaVnoWbiVYIJJX+7GpY/QDNYaSC00wzXTY8uMyyn043N/WtHXD/wAS2RP+ejLH+DMAf0JrH8SwTXPh3U4LZS80ltIiKOrEqRgV6M2a4OKerMTwD4ln8QLfi6jVXhkDJtGBsbOAfcYNcX8S9SF5r0kanMdsPJXnjI5Yj3z8p/3K7P4baNcaToszXsRhubmXfsbqqgADP6nHvVfRPAMFrfC71a7OoSo25VaPYpOc7mGTk559M1zuMpwSPbp1KFCvKa2WwzwL4o0y806y0aVDDOkIgVZMMkuBjg+/ocfjVP4svawadpllFEiSB2dFRQAiAYIAHuR+VdMmj+HptZW9ijtGv0bd+7l/i9SoOM/hVXxF4VGu+I7G7u3Q2EERV4snc7bsgfQ9/p703GThymVOrSjXVRXSWvzMr4S6ZNb6fdahKHRLoqIlPAZVz8/45x9BXfVyes+KDpPiWx0xYIvsjlI3boyFuBgdMDK/nWT8WvEF5pdvZWNhK0DXZPmSr94LlRgfmfy96cWoxt2IqxqVqnPJW5tfkaPj3wtc64Y7qwmUTxp5ZikOFcZyMHsf0PtXNfC6wCeJr5b2Ipd2kW0I45RicE/l39DXmeg+LNR0zV4prK5mG5wCJG3Bsn+IcZH+Qa+idKtba+ntPECI0V1c2SKyg8FWwwz6kdM1KipS5up0TqVKNF0W7p7DvFmmPrHh68soiBLIoZM9CysGAP1IxWD8NbXVdOt72w1O0lhgRw8LPjGTncBjqOAfxNZHjXWdW0DxOz2125imCypE/wA0ezAUrt7fMpORz8w5ro/BXiseIhNFLamC5gUM5U7kYHpg9jx0P5mnzRc/MzdOrDD3snF6+jLniXxDaaTazos6NqHlkxQr8zbscFh2Huax7i2u/EPhrw1fkCW9gure4kIAG5QwDn8vm/Cq/i3wN9r+0XejSsk8jGWS2dvklY8kg9iffj6Vz3gTxDqWnatbaPKryW8k3lGGQYeE98emOSQffpSlJqVpbFU6EZUeek7yWr9D1bwr/wAlOn/7A6/+jzT9b/5KPqX/AGCrP/0bdUzwr/yU64/7A4/9Hmn63/yUfUv+wXZf+jbqur7J4S/j/wBdjxT4g+L9S1PV9Q0+2u5rDR7SU2zC2O2a5cfey3VVzxgfjnpXDRNFagixgS3z1ccu31Y8/lina9cNYavqFnqpFvdLeTysJPl3b3yCM9QRjBqgt7BK4jt38+ZuFjhG9mPoAK4pttn0dCNOMEz1L4MPDYad4n166bEEG2Jm9o0Mjf8AoYrktd8Uavr0pn1HUbyGCX5o7C0lMMcaHkBiOWOOua6bXNMuvC/wRjtLlDHdahdI97/0z8x8lT9FVVNeeNcC8vzDZJJdXMjHZBboZHP4Crk2koowoqE5SqT2Lel6zd+HNQh1PTJbhRAweWAzuyTJ/ErAkjpnB7HFdv8AEjw9fXWrJq/h/Tpr3TtVijncQLuZZsY3Y7Bk28+o5pvhP4W3+pSRz+KALKyyD9iR90svs7DhR7DJ+ldf8UfEL6DpUNhp58hpIyWaPgxxrgAL6E9PwoStF8wnJSrL2O5y/wAPILbwbqF7qHiS8ihv54hAljBmZ4kB3EyFcgMTjjsKg8UeHNN8S6tNqPg/U7ZdQuG3zafdZiErd2QkZDHvwQfavOtRuyjeXKXeYjLorFUQnnHHJPqTVW11K4t5AQzOgOdjE8fQ9RU8+lraHQqCvzqTv3/4B6/8OPA1/pmtya34lgS1Syjb7PF5iv8AMR80hI4wF4H1Nef+KL6PxDq9/qsoLfbpAYQescCjbGPYnG78a9o8CeJE1PwbcXWrSBks1YTSvzvi2btzfhkH1xXlBHw/vpTJDdeINAjc5VZIfMix2xgPge2RVtXilE5oycardRXaPSPg/wCLZdYsJdI1SUyanYqCsjdZ4egY+46H8D3rxzVLbJvraYYMV7dQMPQiUn/2avWfhfoPhm21eXUNF8Rf2veCExbCyKY0JBJKAA9hyaPGnwxk1LUbzUtDv44J7l/OktbhMxtIQASGHK5xzweacotxIp1IQqN9GO0rTdH8dfD7TNQ8Rl/tNhE8ct3E+yVDHkPlh2IXOD61kX2saLffCfUbfwnbT2OmwXUVvdqy7ZPJd13yE5JO5TyTzjNWvh9oetWXgrxjperWUloZvNEIYghmaHaxUjquQMH61x/w71WGx8RW9reKr6VrkEdncxN93cyYQ/mSv/Avanfa5Cjfmt0OeumMjybwo/h2joAOAB7AcV798NJGHgfwpOx5SGOMn1VgUA/MqfwrzDWvhb4gtNSNnoqR3enSnEV1JKqtAp7SA8kj1Gc+1ez2GnxaJ4btrGHLR2NuqqT1JQAg/mKVOLi9S8ZUjVglE6o4IwRxWZpmRZRxnrFmLPrtJXP6Vpg5GR0rOthtubxewmyPxRSf1JrPHxvBM8Ok9StEhP26AHpIdv0ZQ38ya73T5vtNhbTf89I1b8xXDD5dUnHZoo2/HLg/0rrPDLbtHhX+4XT8mIFPBS6eRrXV4JmrRRRXecgUUUUAFMncxwu4UsVUkKOp9qfRQB88eBfiDquq3PhjVda8RalFLrl80KadbWET2UIEjoLd3PzrJhd2c5wRxVq0+LOraL4C0i6kW21fU3t729uY5Wl84wxXEihgI42VVAXG5iBx9a9ZTwL4Wj1/+208P6Yurb/N+1C2Xfv/AL+cfe9+tMvPAPhO9htorvw7pc0VsrpCj26kIrkswHHQkk/U5oA898SfGTUNMuNQmtNAgn0vT4dPubmV7srKEutuAq7SCQWHetvTPiTd3fxMm8M3Wmw2FsLiW3t5Lh5BJdBFyZI/k8thkEY37hjn0rsZ/CHh64iuYp9GsJI7lIY5laFSJFix5YPqFwMemKSz8IeHrPXZdatdGsItWlZne6WECQs33mz2J7nqaAOJ+IHxL1Pw34h1mw0/R7O7t9J0uPVbiWe7MTGMuysqDaQW44yRVOD4wXN74yOm6d4fnn02G+gsLiYLIZIzIB+8OE2BVLDgsCeorrNU+G+g6x44k8S6zaxahObWK2jguYleOIo5YOuRnPP0rVvPBnhu912LWbvQ9Pl1aJldLtoFMgZfunPcjAwe2OKAPNNF+Luqare2MN3okFpY6muoR21xDdl5RJa7skqUwAccdeaqaT8XdRtrLwrFPpp+yXtjbTzanqEshUvK+3y98cRUN05baDkdOtesw+EvD8H2bydHsU+zGUw7YQPLMufM2+m7Jz61UPgHwmbqzuD4e0zzrNUS3b7Ov7tUOUA/3T09KAOnHSigUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy3iL/AJDJ/wCuCf8AoT11Nct4i/5DJ9PIT/0J6wxHwG+H+MzLL/Uf8Df/ANCNS6R/yD4z6lm/Niag085gYeksg/8AHzU+j/8AIPiHpuH5Ma4sF/EkVWItaOVtE/vTj9FY/wBKzNc1OLR9MlvZ1Z1QqAq9WZiFA9uSOa0tY/1lj/12P/otq57x3bNdeEdTjQZZYxLj2Rgx/Ra7Zu17HVgknZPa5z2i+NNS1bXYLW1srd4Gb96E3Exp3YucDj0xz0rub23S7s57eTISaNo2x1wRiuD+D0a/YNSlAG5plXPsFyP5mukvdde18W2WkvCv2e5h3LNu5EnzcY9ML+tZU2+W8up6GKpxVVwpq1v0PHvsl1Lqy6S/lrL9oFtgoNqtu27gO3rxXs1jEvhvw6ft17NdJbIXaWU/MR6D+QGa5fX/AAjfS+NLXU9PVDbPPFPKSwUxsrDdx3yFzx3zXR+ONMudX8N3NpY4M5ZHCk43bWBIz+FRTi4XN8VXjX9mr2XXyfU8l1K8n1jxDFJ965nnXAXkBiRgD2AAGfbNemfETwqfE+nRC3kWO9tyTGW4DA4yM9uQpB9vemfD/wAMHRbR7m/iT+0ZjjsTEnZQfU9Tj2HapPG17rmmBL3TMPYxp++RUBZTn7xyDlcemMY59nCPLFuXUK9ZVKsYUdFHRHm3h74UamdWRtUCwWqtlmDqTj/ZAJ59zjHWva9PntJrcLp8sMkER8r90wKqQB8vHoMV5WfEuteJZIdJt7pYzdt5bGOHaQuMsS24nAAJ4xmu4vbqx8FaHZwW9s8kW7YqqQCxwWZmPrwacJR3WxniadW6jP4uiRzXxS0jUb3VbOeytZbiIw+UBGpba+4nn0ByOfauvsoLHwr4eGUEUUSqZSq5aRzgZ9yTgVX0zxnot/LHCLkwTuQFjmXGSegDcqfzqH4krL/wjTSxKzLDKssmOyjPP0BIP4Zp2SvNEuVSXJh6isk/zNa11/SrqNXj1C2G7+GSQIwPoVOCDUz2unx6lHdPDapfyAxpKVUSNxkgHqeB+VeT+A/C66/cSXF4+LG3YKyDrI2M7c9hjGfrXUSaomufEfTLW1ANtpYmdnH8bbdpx7AlR+ftSjNtJtDrYaNObhCV7LU7Xwr/AMlOn/7A6/8Ao80/W/8Ako+pf9gqz/8ARt1TPCv/ACU6f/sDr/6PNP1v/ko+pf8AYKs//Rt1XT9k8Vfx/wCux5D4l+IOrHV7+2gsdG+x21xJboL1Xd3KHBPHA5rpPhb4tXxE19az6ba2N7ahXP2YfJIjZGRxkcivKPGimLxt4hgPG29aQD/fRG/rXX/BbbYWvijXbji1gRY8+ojVnf8A9CFc0ZNysexUpQVFTW5Y8dfEG8TWb/T7Cx0280q0f7PcR3ilvtMmAXVewAyByDyK0tZ8Q2um/DvTdR8JWNtpravNHbKYoVUW5bduJAGCw2kDPfFeQl5JIIZJzm4nzcze7yEuf0I/Ku00SUXHwW1lH5bTNTWRB6ASRSf+zNQpttodSioQjI4jVruczHU0uLmTUbc+dHczTM8m5Tkck4HToOK9D+MbtevYX0SkxXFhHImO+HLEfkwrzjUGRba5OcIFb8sV72dEttT+Hmg2mqTx2l0lnAsUshAKy+WBt5xnPQipinKLRvUcaNSMraHzqy/abuTa4+bc+W74BP5/1qsCCoI6HmvSpvhvrOn6zb3CWZlijmWQiEh1YBgeOQQPqKqeFfh1fyhpJBHFBbTyW7T3DgIhjcoTjOSfl/8A1danldtjT20FOzkrWJrJ57D4Ta0mSrXktvZAe5OWH/fLVg3sriV4FkfyUwgTcdvHHT8K9W8c+C7+fwvo1j4YEU8VnObiVXkCNOxU4cN06knH0x0rjdN+HGu3k4OryWukWCnM0zXCySbe4UDgH3J49DVSg9EZQr005TYz4T2hfxa2suRDp2kwSvc3J4XJQjYT3wCWP0FReKPGes61qn9oWOoXmm2oP+hQRSFfkHSSQdCW9Dnj9fWU0TRNQ8DX3hzw7dWotXt3gDQSiTazD7zEHk55PrXg2sxXWmak1lrMBs75AAUb7r4GNyHoVOOPypyTjGyM6TjWqOUz3b4deL4fFWkGK5ZI9Xt12XUPTPbzFHdT+h4rxLw7pVzqXifTNEijYXdpdgXHH+qSKXcWPpwAB65FZi3BtLmG9trs2l1Ad0VxG+1kP9R6g8GvcfCfim7vfh1qPiK7sY49QtoJmMqx7VuvLQlXHfB6fgcU4vn3JqQeHb5dmY3xg8T3P2kaFpd01uiRiW+mibDfN92IEcgn7x9seta3wfu7i+8A3Ed1K83kXE1ujOxY7AAQMnk43EV4zIZDFG00jSzzAXM8rHJklkAZmP5gfhXtPwgh+z/DdJmGPPkuJ/w3sB+iinGXNJiq0lTpLuz0+xbfZW7nq0an9KgOBfzj1VG/mP6VPYrssrdf7saj9Kgf/kJS/wDXJP5vSxn8Jng0/iK0vGqJ/tQt+jD/ABrp/Ch/0CYf3Z3/AFwf61zM3/IUh/64yf8AoSV03hT/AI87j/ru3/oK1jguhvV/hm1RRRXpnGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcx4mXGqQN/fhI/Jv/ALKunrn/ABWmDZTejtGfxXP/ALKKxrq8GbUHaaOfsOJLtOyzcfiqn+ZNWNK4glTukzj82LD9DVa2+XUrhegeNHHucsD+gWp7M7NQuoz0cLKP/QT/ACH515+FfLWa7mlZaCa0MRW8n9ydf1yv/s1QkAgggEHqDV3U4WuLCeJPvlcp/vDkfqBWfBKJoUlXo6hq9CRrhX7rRU0fSLLSIpo9OhEMcshlZQSRk8cZ6DjpXEfFyR7VtKuodyyoXKSD+FhtI/rWj8UGuotOsp7SaSIxSlso2CGAyD+QatXwzqlt4o0KOW5hikkRgs8TqGCyDnIB7HqKxlZ+4epTUqdsQ9VezNuKQi1SScqhCBnOcAcc/hVLQ9as9bgmm093eKKUxFmXbkgA5HtgiqnjWC7uPDtwlkwBGGlXu8Q5dR7kdu/I71zfwq1GERXumyuPtRlM6n/nopABI+mP1puVpKJEaPNRlUW6Y2y8X6lqPjC2tLJVNpI/zRFRxH13E9QcYPpk49z2t/q2nWE8UF9eW8Es33EkcDd271ynhKwTRPGus2cu3dcRLPaserR7m3AfQkA/TNO+Ifh2W8STWLG4Mc8EGJY2OA8a7m49CMtx0PtSTkot7s0nGlOrGK92Nlqb2n+GtKsNUbUbO2EVwykfKx2jPUhegzVP4h2X2vwvdSKMy2w89foAQw/75LV5roXi3UtH8oRMJLUH/UvnaR3C/wB38Pyr1vSdRs/EWkGaD5oZVMckbdVOOVP50oTjNWRVehVw01OTvbqeU+BvDUmu3xmkby7C3ceY3d267B+HU9sj149nZkZjExUsVyUPcfT0rG8HaG3h/SGsnlWYmZ5A4GMg8DPvgCuU8eWt5oesweIdOORvAkZudpIC7T/skDHsT9KUV7OI61R4yva/p/XmdrHpcNhpV1a6NDFaNIrsm0YAcjAP8vyrmvhz4XutFa5u9TVUuZF8pEDBtqZySSPUgfl707wj43fXNTWxmsPKkZGcSRyblGPUEDFdrVrllaSMZurQ5qU9L2uV/Cv/ACU6f/sDr/6PNP1v/ko+pf8AYKs//Rt1TPCv/JTp/wDsDr/6PNP1v/ko+pf9gqz/APRt1W/2TyV/HPFfiv4W1Z/GhvdI0+4vI9TjjXdEmRHMo2fOf4VK7TuPHBrq9W8Ot4c+DGraXbN5lwljK8zgf6xyMuf5j6AV03jXxHF4X0Q30kLXEzyLBBCpwZJG6DPYcEk+1cboXxQgu786d4osrexSYFFnSbzYCTxsckDbnpnpWNkn6np3nOCXRHk1xIksm+IgxlV249MDFdz8K9O/t3w3410QSCM3AjKMRwrNGQD+aCsDxz4Wk8JaiPJ3S6Hcnda3HUR5/wCWTH+R7it74MyzQ3Pi57YEyrZQugHdx5uKygrSszsrzU6KlE1/C3wmkjvIbnxPd29zHEwdbS2VjG5HQuzYJH+zirfxv0G81Gz0/Ure3N7aWHmGe0AJOGA/eADrtx09DXksOoTXMEFxcXd5c3MiB5JXu5d249ejcYq/a+Kdc0lhNp2sXqKnzGG6nM8TexD5IH0NPnjsZuhVbVRu5Hp/iDUra3Qabq+pQW+PlSK6LIB7Bg2Kp+IJ2ub5vtctzcpdCO4jhaRn3yONrYQcFjIjngdTXqlz4N8O+I/D9r4lmkk8PvdQrc3BidViywySVYY/EYzXLwa94f8ACepafqukWV5rNrbxy2jXdyAjqciTfESOmDIOg781Si9mzOVWF4yhHX+v1Lt/Lr3hH4XaXpMqXaXepTyAiFWd7SE/N5QIz8x6e2T6V59PFbwTC3u9Ma1lYZWO7hdGYeuG617R8T/F95ZLplhoN0Lae8iN3Jc7AxjhHTAPGWJx+FL4H1iy8f6Fc6P4nt4Lq/tCPMDLjzUP3ZUxyp7HHQ/Whq7tcKc3Bc7jdHDfB0eR8QrdLYBEktJvOVRgFRtwSPrirl748vry8vrbWtO0e/hiuZYhaXVuVMQVyoG/5ucAfw119+/hj4ZKx0ywkuNXu1wkIlLyugPUsxO1B6/zrlDZ2XxKe9u9MiXRvFECh5bdn3xXSdAxIA57bsZHGc8UWaVk9Qcozm5yXuj7PxL4QssTjwNDFdLyPLa3kUH2JbP/AI7XofhTxJp3jjQ76GKCW22g21xbS4ygZcDGOCCCcfQ1893Pm2d3JZXsEkOoRv5bWpGXLdgo/iz2I61634Es7X4faLc6t4ru0tLzUimLYZZkVc7VCjJZuSTjpRCUm9R1qVOMU4u7Z49IZrS1ktpwTdWha1Ze5dGK4/PFfS/h3SjpHgqx0tz+8itFhY/7ZGD/AOPGsDSfCvhfxFrsXi7T5nuEkfzfJBxEZ143spGQwx0Pfmu4nXzbi0h/vzKx9gvz/wA1A/GqhCzMcRX5oryRtgADA6CqRIa+nPoqr/M/1q7WdbHdc3r/AMLTYH4Kqn9QazxrtSPHpfERPzqn+7D/ADb/AOxrqfCwxprt/emc/kcf0rlUO7UrpuypHH+I3N/7MK7Dw6hj0a1yOXXzD/wIlv61GCX5G9bSmjSooor0TjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACs3xFCZtInKjLx4lH/AAE5/kDWlSMAVIPINKS5k0OL5WmeeysEvLSYH5W3RE/72CD+agfjU87CG4t5znAby2Ps3H89tJe2pj+0WY4aFsIT2xhkP8vyoiZL6yw64WRSrr3U9CPw5rxZ3pzU+x3VFzfM0qxWU215JA33HJliPqD94fUE/kR71ajvvI024musl7RWMuBywUZyPqMH9O1cBaePm1LadQ04wQE+ZbzW7GRo27BhxwRwSPX8a9unSlWjzQVzjhXjQmubqb3jaz+2+FtQRf8AWRxGZD7rzj8QCPxry/wBe3lh4itjbQzSw3JEUqhDhlzjd/wE55+oroda1jWfFMkunaLbPFbn5XJPUf8ATRuij/ZGSffpWzpt5q3hvToLW+0NpbGFNvnafL5zD1LIQCe5JFctWk1JN6WPoMPibUZU0r8x2JGRgjINeSaPoN5pPxFtbZI3ESSvLHIAdpi2t3+h2n3rbi+JdnHHPLfWxSEMwhaKQMz8kKGU42k8DuBnnFdC2qz6Noi3mvEy3Mz5ENsoIjyMhFJwCAAcsSM8+wqWozSlfYUJVcO3T5fiVhvifSbi+1bQbu0XD2l1ulfOCsZHP1zgDHvVnxdp93qnh+6stPkSOebauXJA27huBx7ZpNA8SWGtExwF4rgDd5MpXcR6gqSCPoeO+KyfGXi5tGuvslrHG0oQPJI+SFznaoUdTwTyQBx1zTbik29iYQqupGCWq/4cvX/hTS7nQLXTJ8xx2wAimQhXVu5yeOe4PWqvg3wvdeHL283XyXFnMq7VCFW3A9SOR0OPeuN03R9U8czG5vrmRLBWKmVzkk9xGvQfX+ddh4i8a2mh6h/ZiWdzdXaopCrgA5HAz1P4A1KcX7zVjacKsV7CMuZvddvmamv+JLHRGVLnzXlZd+yMDIXOMkkgDPOPXBpHNt4s8LuIjLDBeRkKzqNykHg46HkVxun+GtV8T6mdR8Qxm0tXbf5J4dxwAoHVVwMc89eOc16VFGkMSRxIqRoAqqowAB0AqotyvfYyqxhSUVF3l17GL4V8NWvh23dYWM1xKf3kzKASOwA7D2rdooqkklZGE5ym3KTuyv4V/wCSnT/9gcf+jzT9b/5KPqX/AGCrP/0bdUzwr/yU64/7A4/9Hmn63/yUfUv+wVZ/+jbqtfsnAv45yfxasGvfBN3NEu6awdL9B/1zbc3/AI7urwa6WN5ZNuGif5lzzlTyP519TXESTwSQzKHjkUoynoQRgivmHXdKl8O65eaPcE7bY5gdv44TyrflwfcVzVV1PbwU0m4s9H+C0i6joOtaHqardabbshSOf5lVHBynPYFcj0zUNv4s8LeCDeW/g/SrjUA8oNzMsx8v5eAqyPndjJwBx71kaTFNpXwU1/U3LQy6vKFg7MYiVjX8xvP0NcfcqI3ESjEcYCKo6AAUOTikFOjGrOXY9M1XwFoWv6cPE2i6o+jWl1EbuYNGHiAxlm2kjaeucHHtXE2c2g6XItzY6ZL4jkQ5W71Rhb24P/TOEAlvq1a6X8h+Ac1qCQE1AWTH/YMwbH5HFcrqB/0uRB92M7FHYAcClOSWqHQpud4yeiO28cayPFvg3w/rIh8iC11L7NeWm7ciuRhW9wOMcfx1wt5Hc6lptzaRkySyTQ4JPTc/k/8Atauis2/4srrAAyRrkeT6fNDWZ4U0+91nV7m10zJkhs55nYDIVxG3lA+5k2EfSnvJE6Qoz8tjV+IF0s/ivVhF/qrMQ6bF7Ki72H/fTfpWHoGqyaB4i07VomKrBIFnA/jgY4cflyPcCpPEq3cWp3t3PaXIs9RnbUbadYmdJI5gHX5gCMgHGPapNC8Ka14mlWC00+5gspPllvLmMxRoh6ld2Cxx2FQ1Lm0NoSp+ws30Ol+LdjNbeMZL18m21O2jWCXsGj6x59xhh61z/g+9bRPH2jylxgypbzYzgpMikf8AoSH6ivUvGOr+CdS05fDeqa1brJlEjeJi7QSDhWLKCqn6ke9ecar4J8Q2XiPRLCWGOZpZhFFcwkBWWJxJ5jZ6HazDH/TMYzWjj710c0ayVPkl/X9M9X+IPia18Nm1aKxiu9buFcWu9QAiqPmdn6hRnoOT+teIarez6nfy32pXDXuoSDDTMNqRr/cjX+Ff1NevfGPRG1HR01WwO6/0gPI8anJeBh+8GPXA3D6H1rxS9kitobaYNmKW1FwWznnzJFwP++B+dTUuaYT2a1e5638Ay403XUH+oF4rL/vmNd3/ALLXqWnr5upyyfwwR+WP95sE/kAv/fVcH4BtYPA/w+S711zbPO/2u6JQt5bSEAKQATwNoPuDTfGvjq30zwYp8OX1tcavqJZkMEiyGEHlmOM4IG1RnuR6V00acpWSPKx1eK5tdz1N2CKzMcKBkn0FZ2ng/Yo3YENJmVgexYliP1pknnvo9rb3J3XM6JHMen8OXP5BvzFTXk32e1kkxllHA9T2H54rgx8rtQRzUV1KsKM8dyQfnnlYL9eEX+Qr0GFFjiSNeFVQo+gri9DtC17Y2xO4RfvXPrtxz/30VrtxXThY2i2PEPaIUUUV1nMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGB4msz8t9EOUGyUeqdj+B/QmubY/ZbnzMgQSnD+it2b8eh/CvQmAZSpAIPBBrjtV0/7BIY2UNZynahPIGf4D/T8vrxYqjfU66E+ZcjKdyjI/nxpv+XZLH/z0T0+oycfiO9eZa54S1KwklOhWxv8AS7jJhWNgHgz/AAkHqAe/bvXpNtIbZ1tp2JU8Qu3cf3SfUfqPfNSlJLaUzW43IxzJF/e/2l9G/n+tRgcdPCS5HsY4nDKqtdytYaQ1romnwQBIbm3hVCo+4xwNwOPfv1/kYp7+C1gmkvnFr5Kl5BKcbQO+e49xW3DcRTQ+bG4Kc5J4xjrn0rlUt4/Gd7FeThm8P2rbrVDlftUo/wCW2euxf4fU5bptrsfvalUqzprl6HLXHgyHxXNNrV4rWE8xzaRrGBsTn55V7u2cnoQMD1z0974eivPDEWkTzO3lRKiT45DKMBsf09Ca25LK7g/1LrcR/wB2Q7XH0bofxA+tRPM0RxNb3Efv5ZYfmuRWbh5HoQxN0kpbanlfg/R4dM8VXZ1m7S2l0weYq52rICCNwY9sEce9WofDV54vv5tZmuBbaddTFo1IJkaNcKpA6DIHf64qz8TbGK8n0+9h5ZybVjjGD1X8eWrvYHSGOOC3trjbGAiqsDAADgDJAFT7BKK7HXLHyc3NS961vT/hx9jaQ2NpDbWsYjgiUKijsKkkkjiG+RlQdMscUeTdyZ+VLWIDJkkIZgPYDj8SfwqlFbLO4lRpRHjiVz+9kHrn+BfZce/pV2scPtVJ2jqLLqSBikMbOw9fl/T7x/AVA1zfSSCNfIhZuiucMfpyT/47WHd+OtF0+X7Lbw3Mq7tu62jUrn1+8Cfy5rkdY8Pw2F9EdR8RQ2zkiRXW1cyg9nbB4bvkms3O2x108M5fG7dtHqeg3txJZui32sW9sz42q7Lk5OPQGpLk/YyovdYhgLdPMOzP5vXIa34fvNc8Y7UEh06QRTSXP8DoEUYU9CTg8ds5qr4m0bUb7Wb+61GVbPSopMPMXDEpn5QqjkkjAAPc+p5TnJdC4Yam7Xn0u/8AL1PQ/BEbJ8Srgmfzw2jqQ3bHnHpyaua3/wAlH1L/ALBVn/6Nuq534SX9lc+Pbm20yGSK0s9HSFN7BiR5x5OCf8+ldFrf/JR9S/7BVn/6Nuq3TvC55Tg4Ylxf9aEtYfiLwpoviOS3k1mxS5eDIRixU4PVTgjI9jW5RUHXex4j8X9Zjn12z0C2VV0/TFWWaNBgGUr8iY9FUg/8C9q4KOO51C/hs7KMz390+2NB3J7n0UdSewr2Xxz8NBr+svqmmaithczBRcJJD5iSEDAYcgg4AHocCuLn1C08C3F5pHhkC518jy77WLtcCLgHZGntkHHTOM7u2Mo3d5bHdRqqMOSmveO4bwxodt4LTwXd6rbRX06iXcZFEjT7g28KTk/MBx6DFeTa54e1zQ717bU7C5lIPy3FtE0kco9QQDg+x5rPlS2neZrtJL2WZt01xO5Mjt657frXaeAPG2paVrVhpd5dzX+k3Uq26faOZYGbhcN1K5wMH8KLxnoylTq0FzLXudP8O/Dtuvw0v4PFEP2ezv7l7p1nbyjGnyBWJ42nKAj8KoSeOdF8LWDWXgHTEuNrbmupMrCW9Sx+aQ/T86q/GXVBf+IoNK3brHTYhcXEf8Mk7/6tWHfCjP8AwKvOby4kKlyGllOFRAOSTwFA+uBinKfLoiKVD2ic5vQ9l8CeJRpHgzWJdWwmn6PevaWZjHzSQYUwqB3JV1A/CuC8TeKtX8QyzrezSxWpVm/s+B9saIASfMYcucAkjIWurn0TSNK8N3GieL9UNoRDZ6h56SAMswj8nCDB3Y8jpg9a462i8Ew34kvtU8TXEG7LMbZI42U9dwC7ipGc8cjNVO5hh+VJu17HMPZyaiV0zTbcSXdz+7ighUDrxkgdAOpJr6C+I1z/AGT4Uguo5o/7UsXSezDn/XSIp3J77ozIPxrm9F1DQvh7oN75NnFNNtWaynhxv1GGRsRkue6khW9MA45ArhNb8Q6lqWtJqGpSRvewnEaRj91bjPKIO5PdjyenSkrUty5KWM+FWSMvT9XudG1uPXobh5rsMJbuTdxdITmRT6gjOPTAr14eDvDx8baLLFZAWrWU13BDuPliRZY2B2+n7zIHQGvMfCPhSfxJrr6baRumk2so+0zuMAQnDKg9WZCv0zmvdNSh87xNoC2cgj2C4tmcDIQMivgdt2Ivw7+hqmnrcyxdSFoyjp3NyOJb24ZZArWkQIlDcq7Y+6fUAcn8PevGPAehWviLxtM2m2yRaJaXj3bsigAqHzDFn3I3Y9BXvSWsKWZtVTEJUpjJ5B689cn1rD0nRtP0DTU0PQofJgGWlbJJAPUlupY9B6D6AV1RrrD05Nni1k680zRib7Vdvc9YkBji9x/E34kfkPeopv8ASL1UBBigwze79h+A5/EVNdS/ZrcLEgLnCRp0BPb8P6CksLNnMVnCxMkhJeTv1yzn8/1FeJG9afOzthFRXkjofC9ttilu2HzTHan+4uf5nJ/KtymQRJDCkcahUQBVA7AU+vZhHlikcU5c8mwoooqiQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorx7SdW13xR4s8UzN4s/sG20PVBYQ6f5MRWVFCnzJC43HfuIGCPbNAHsNFeN2/xgvWubK4n0W3XSNTe/hsHW5Jn32ocnzU24UNsPQnGRmpdP8Aib4lvtJ8MXSeGtPhl8RSbLJZdRO3b5DSlnIQ45XGMdKAPX6K8X8P/GqTVII2l0mGB/7GvdRfNzlTLbytGUU45Vtuc/pS2/xhv5tY0G3l0WGysdRhs5Gu7mSXy2ecKTHGyRlQy7h98rk+nWgD2eigUUAFRXMEdzA8M6B43GGU96looA4vWNMNmDHNmazfgSHqp7Bj/Jv69aMc7WzLFdEtGcBJj6+jeh9+h9j17+RFkRkdVZWGGUjIIrzTxfFPLqUmheHmeTKb7+RBuNjCewPd2Gdq9QMtyMA8FfCp6rY64VlJWluZOpo3iXUrqwsCV02A7NQmDELcuCP9HGO3Z2HQHbzyB19hcROghWPyXiABhwBtHbHYr6Ef/WrI06zTSLOKDS4wbGMYWAHlfUqT1Oc5z+dXh5F6odCQ6HhhlXQ/zH0rnp15UHZ6xCdK/qalZviK7uLDQr67soPPuYYWeOPGdxA9O/0pY7qW3IW7BePoJ1H/AKEO31HH0q+rK6hkIZSMgg5Br0qdWM/ejqc0otaM8F+3ahr8Sz6jqc9xk7lVW2qh9VA6EV6D8N9Vv7m5v7G+upLtIEjkSSXll3FhtJ79M81s6h4M0O+ned7LyZ3OWkt3aIsfU7SAa0NF0ax0W3eLT4fLDtudmYszn1JPJr0a2JpTpcsY2ZyU6NSM+ZvQXWfniit84Ez4ceqgZI/HAB9jXnXibxLrtt4lfTNKtld8qYkMW7zFKg7ifTJYZ4AxXoGpHOqWwP8ADDIR+aV5tr13ruq+LJtDtLqW3QODuhJTy4sA7iRyevrjPFeVVZ9FlsFa7S2e5e8R6zceG77TLe3t7W2tXKS3AijGHJYiTH0GDnrlhWf4ss9M07WLi+1maTUpZG86Oxj/AHahegLtnnpgDvjoecXbvxJp98b03mmrdjTGSS1k3ZLZbbvY4+UZAY9RjB7VX0DUtP8AGGuzR6xpNo80cW+OUZwyqR8rA9fvd/fism03a5304yguflaS3t57B4rsNe1WW2m0llGlSxxtblZhF5AKg5YZH1yMnHFNt1uIviPe6fLbrd215CWmVxlHXaWV2z6N8n4/So7jw7Br3iW6ub7VoNQsIDuW3gbc4Un5YwBwo7ZHXFXrrxZbQaekOkQyC5jIhELxsiRIvbsT6de9TJpO5E6qhFR0ena2/wCbNH4QW89t8SNUS50mLTHOlqdkQ+Vv3x5ByQfwrf8AE7zp8R9Q8hGbOlWecIG/5a3Xq6/1rJ+F2qPqvxKvpDC0Kro6KFZyxz5vPJ7ZqD4q3og8bX9vHqY064l0yyZJGDbWAmusqWXleo5rpjL93c8nWtitOv8Al8zZNxfj/lgx+saj/wBqGk+33Cf621AH/A//AIjH61wuky+K0tdTtJVnZFtTNDOGL7mBBAR887lyPUcdKr+D9e1y5XWPJklu3gttyRuS+2TcAOpznG44zzis/aLTQ9J4OVpSUk7W/E9Hi1O3cEsTGB1YkMo+rKSB9CRXF+OPhva+ILuXVNLuvsWpyKC5I3QzkDALDqDgY3D8jUGjeItYu9Xt4NR0qSaFjgzyQGJ4l7vuwAABz2+tdbEtu8rDRtSiMv3jCsocH8P5nmmmpozlCpQl/keBav4Z8Q6I7DUtHuTGP+W9opnjPvleR+IFaPwz0S41rxfYXDW1wmn2DfaZZXiZFLr9xQSBk5Ofwr3q2u5iGE8Dbk+95YyV9yvXHuMirUc8UxIjkVmxyueR9RSVJJ3LeMlOLifMWqaj/al9e3xzvvLqSdvpnag/BVH51e8ILDbXF14l1CEy6ZopDRoP+Xi7PEaD6Egn0OK9S1v4VaFeR3UmnfabG8k3PGY5mMaueeUORjPYVzHgbTIda8Lal4F17fYapZXJnQpjcfm3B1z97BP4giiNKTbkVPFwUFTWlzj/ABLqN7ql3bapqkkcuoCaSBgqjbbhlVkjT6eXJz6k1kyOMF5G+pY11virwfJo076dJrJu7idUvHYWu0QKsqoZG+b+68n5V6Po/wANPDOkxJLfwDUbhCCZ75ty59k+6PypSpSdmx0cXThzRguv6HnvhLQbnxn8N76whH73S7rztJuG4Vjjc0Wf7ueM9sg9qp+EvA+reJIFvb9l0nSiT5ksjq0xIJDKFH3SCCDu5B7V7/b7mRYdOtgI1GAxXZGo9vX8BWO1onhrxLDdXISTTtTkAlk24W3vDwr46ASDC5/vAc5c1oqd7XOKeMdJvk69DP0PR4dC8RWWn2SzWmlalZ+Wgb77SwY5yeQXjc9ecQ9q6bXljsrrw2YlVI01HywB0w8Ey/zIpPHUONEXUU4m0mdNRVh1Cx580D6xGVf+BVR8fXaSaPaS2jh3t9QsZvMUblQG5jQk/wDAXJxWjairs82U5TZ0l5dMjrBbgNcMM89EX+8f6Dv+ZEcUaW0Lbm55d3bqT3JpYIVhU4JZmOWdjksfU1Ulf7Y5AOLRPvN/z0I7f7o7+v0znyKtaWIlZbHRTp29RI281zeTZVAMRLjkL649T6f/AF66/QLBraAzXCgXEuCR/cXsv+PvVDQdOaeVLy5XES8wow6n++f6fn6V0or0MNR5VzMivU+xEKKKK6zmCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmNW8LeEtS8Qxahqmk6RcazEFdJZokMuF6Hnk47E9K6evGh4A1218T+JbpNK0HU5tSu7i8s9ZvpmM1orw7EgMew5VTxw2NrHjPFAHdWfhnwcNTu9Ws9M0c3t1uinuY0Qs5fhgT6t39e9UfFPgnwvrNtodvqK2cWkaHKWWyIQQEGMoEYHoAGyOnIFeZeGfg/wCIYtN8TrqQ060udQsrZrQW0q7Y72Bi6yYSJFVdwXoCcEjJq1qfwo8SXGg6bcyzWV3rT6lcalq1r5irFO8q7V2NJG6/IoAG5D1OMGgD1C/8GeDL6DT7a90PRZobKLZaRPAhWJG7KPQn9fekg8HeDH1W2u4NG0dr+1SMwusaFo1jG1CB/s4AB7Y46VwXgz4TS2evaDda/a209npmj/ZYY5Lpp3huBdPKhDbFDBUYAHAwRgDjNZGnfBjV7K10f7C2n2F+NK1Sx1C7hkYNJJOGELZC5YLkemO1AHvEV7ayxSSR3MDxx8OyyAhfqe1LFe2syo0NxDIr5KlXB3Y649a+e2+EPiC60vUo/wCzNM0yKbT7WxawsNQKC6kikDNcMxiKgnGAGVs5OT3q9pHw48aaVJ4e1CK30Ca9spr5Xtlk+zqsU6KiMzRxbWcbTnCDPHuaAPdWvrVQpa5gUMAQTIOQTgH8+KlhuIZmcQyo5Q7XCsDtPofQ18+y/BbVrzSoYNQh0uee28JHSbcvIT5V8JmdZFO3gAN97r7V33w38C3HhPxfr97HFaQaZf2tmkcUDHJmjQiVmGO5Oc96AOm8U65NZyQ6Xo8aXGu3akwRt9yJRwZpPRF/NjwPa94b0aLQ9MW2R2nmdjLcXDgb55W5aRvcn8gABwBUtlpVtaalfX8Ydrq8ZTJI7biFVcKi+ijk49WY96v0AY2qaKlwzTWpWG5PJyPlk+o9ff8AnXM3loyXIWdXtrwD5WB6j2PRh7fyNd/UF5aQ3kJiuIw6deeoPqD2Nc9Wgp6rc3p13HSWqOGju2jKx3ihGJ2rIv3GP9D7H8zTvKktnMlngAnLQk4Vvcf3T+h7+tXtV0ySxVi4+0WRGGcjJQf7Q7j3/P1rLXzLIArvmth1X7zIPb1Ht19M9K82VOdGV4aM6HGM1dao07a5S4DbdyupwyMMMp/z36VPWa0aXIjuIJNrgZSVDnI9Pce1TWl3vkME4CXAGcdnHqvt7dR+RPdh8Squj0Zyzg46lfVEIvbSXsVeM/jgj/0E1wdz4ofR9Q8TLq5VltYxPAGwmY+gUNjkfMvqclvpXZ+MNRttO0sPMZHunkAtIIV3yzyjkIq9885PAAySQOa4y38Lza/run+I9feKK8tSVXT0USRxKN3yux+9ICclsYHYfxHWad7nbhKi5XFnP+HPEFtaeHLu/sNCjS0mZbd1mmaSXAU7jLx8qHICj6k4ziqmktpEun6qNDg1JtRmg2GBysgSEuokCFRk/Ke/PFbfh+80my8T6hHY2U1nfzRvHBDJL+5kbqFIx8pJHTkDJA54Muiapro1x7jU7WTTtNt0d7oG32RkBTgKcZY5x0J6Vz72PYV4KXyer38rdQ+HkNxBPqEt5EbeaV42gWceWzhd2QqnnAB9MVNq3h77LF9oiubi6vXmzKsoCZUg889Tnbzms3XLXS9c+1ayusvZxvN5DR3Fp5hDqg+UYOcY546ZNaFjJqOg+GILiwurnWxdyAIwheRYlAb7q/eGTgc8e3rLgZV4e1fO3q+lmvxNz4V2U1l8Rr1Z2hYtpCN+6fcB++6H3qr8RtPt9S+MIt7zS5ryE6PbkyxyMgixLcnnHBz065p/win1a4+I+pPrYCSnSl8uLCBkXzu4Xp+PNT/EPXRo/wATLhWjlYTaXZ5ZGUBQJrnJOQexro0VLU8qN6WKdn9z8jldA8R6jPc6zawsY7eHT5ZIIkRf9GZAAqrxk4zjnOSPwqLT9Y1HXtP1PS7qdUiVTL9udNqFFIykpGBhhxkc+oNdvDFp0pv30ye0M9yvlzXVqV8xGIIVjj3PX1/McvY6d4jubi40bWvO/s90JN2rbwCpDKykknkgfKaxTv1PXjUpyu0ktvXTt39Cj4ViuorK+sNYEc/hySNmeaGYFImBBwpXkZ/u4HOOOTnMW00w3cmo2+qag0Wnzx4hmjBkJJJXEgbCg7SCcZHvV7QtN0uaO8t28QT/AOlqgi3wGNQwYMpJJIJ6YBIPNWLOwsvDUOpadcSR6hqN1EPMRoyIVVMuRnOd2ws/4DpxlWukbuaTlZu7tola66vU6bwv4oXxAZnggWG/szuCB9yyIewJAPOMdODg12pitNStopZIYpo2UMhkQEgH69K8t+GVxo51G4S3tprbU2Qja0pkRkBGdp7duD+BPNel6Kdsd1F/DHOdv0YB/wCbGuijK61PHzKiqdRuKa9RW0mAf6mS4hP+zKWH5NkfpXIeO/A9zqKQ6tod9NH4isfmtpX2AOO8bEKMg89cj8Ca9ArhPiPpfi3VHt4fDl3BDp+0+eizmCVmz/fCn5cemDXRTXvdjyp1JctnqcV4LubTxFH4sPiTUItP8QXoeyks5CsYjjEe1QN4z94k8HrXf+A9Z0PWLCxNvcWsusC1SSeIyeZNG2AGBySRhjiuD0v4U6zKf9Ol0mzUvvLqHupSfXLbRn3ya6z4f6Ro2hXOuTqmdVGoT28kjfM7KWEqqi9htdDgfWta6pLVMzpzqNWZ6BWfrkdjdadPZamokt7lDG0XJZwfQDnPuOlBlurgHA+yxn6NJ/gP1/Clht44SSgJc/edjlj9Sa8urjYR0hqzpjSb3Oe8O3l3dpPoWrSH7TYKqSmQDzLyFshJPQBgCGxk7gw474M+bf4VeINNc/v9CimiPYkQDzYm/FBGfqa2/FCvJJBq2ixvPqenBziNflniPMkBPcnAK4zh1XOBmsi5ii1LU2mt2F1Z+JNKkjVo1O3zVQgHbzyY3IyeR5dYxc6zUpeRfJZaHYSyG9XdkxWWMkn5WkH9F/U+w67ujaQbgxzXKeXbLgxw4xu9Cw7D2/P0qp8PbFb/AMLaHqt6yyvcWUE6IPuruRWB9zz+H612YrpoYVQ1YVKyS5YABiiiiuw5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBCAQQRkHtXNato5tQZ7FC0I+9CoyV919vb8vSumoNROmpqzLhNwd0edENAxntBvjYkvEv8XqV9/5/WsvX9dhzHYaXH9v1iX5oYUOPI/6aSt/yzUc9eTyAD0rR8SXF1rWp3Nn4HEbXMTGO+vnANvA2OQo/jm6fL0HG4jpVPR9Eh0WBxpxkN0zFrp7g5e5k7tIf73uOgwMYAFeZVw7g+bqdaaqK8RPD2l/2fffbNcnN9rUilBfOMIFJz5ca9IxnHH8XUknpt31m7OZ7Qqsx++jcLJ9fQ+/+QyKaK6DwyLhsfPFIBnH8iP0ojM1mQE3T2/90tl0+hPUex59z0rSji7+7V3MXBwfNA5y40DTrzWo9TMLx6nB83llsAsOhYd8HuP1ridIv7+6ubvw9r1zeRrJH5wkcZljZMOcZHK8H+levOlrqcIOclDww+V42/mD7VUkhurY/vE+0RgcSRj5/wAV/wAPyFdMqd9Ud9DHKzjNa9PL0PM9BstH1rTJNGhmubT7K/2ppXKlpUYAEnsvAUe3HXmprBdPHii2MGvBLWHEVnbojrn5cBCx4Izz7muotPD2hf2jPd2sCJNLG8UsauVG1vvZTtn6Csy3+HunWkks8E9zJcrl7fznG2Jx90nABbBwec9Kz5GraHd7anK929fR6vcr/AyG7g+I+rpewTQyDTFyJVILHzeT75OTmr3xOs7i7+Jtz9nt2m8vR7Z22jOB51x+vtTfg/pWpaZ8TNU/tUReZJpSsGR9+799jJJGSfrU3xK8RxaD8TbgTwySpLpNqf3UxRhia56DoevcitJL9yedUi62Mahr6ehX8P6Pf6dKJRJGkF7FiSEriTODjjtgnOc+vFcv491u6HimNLVpFms5VESjI547f7RJHuMCuo1bUtYkt7W50CzAtbiJJPOkkTzXZuQvznjH45zxisizbWRLNd+I0sDdxws9itzHEZlcc7lC4JAGSfpxXOo2Vj0cPFU/flZ+V9fuMjVvDVjY6zcefrUKWSyHMUSPJKqZ+5hRgYHGTWzcaUt74r03V7XULI6ZdSh03ybXb5QrIFPUnG38cGsXRrbRfE2pGO+mvLHUZpGYxwuDFMSSxK7gSpJycZx6VPZ6RdXmrbR9kgj07MsVilyskjFCWRAAe7feJ5JJ9sNW6I6qjktJyd0rO6W3l39To/Cun6HpXiq8srBbh71IywkkIKouRlFx6ZHJ/Ou60XJ+2SfwtOdp9QFVT+oNcX4M0i6sbea/vIiNWvjsjR+qDk/N6ZOWavQLO3W1tY4UJIRcZPVj3J9yea6KS0PEzConLlvdk9Nd1jQu7BVXkknAFR3E8dvHvlOBnAA6sewA7mqQjkuZBLdgBVOUh6hfc+rfoO3rSrV40lruedGLkK9zNdHFtmKH/nqy/M3+6D/M/lWBp6Jp/jrWI2IC3tlb3m9jyWQvFJk+yrD+ddBcXSQMqHLyt92NRlj/AID3Ncvr8bp4j8NX92isHnmsTGgLbRLH5i5/vHfAg+rDHrXnqdTENqWx0KCWx0TXjSnbZx7/APpo3yoP6n8PzqNoBIdt5IZ2bnygPlP0QdfxzW5Z6Jc3BBuW+zQ/3VIMjf0X9T9K37KwtrJCttEEz95urN9SeT+Nb0sJ1eg5VYQ21Zztlo93cBd6i0g9xl8ew6D8fyrg/Glk3gO9S9sk/wCJX9qXUoGxzFKmftEOfSSFpmUf393qK9orJ8VaFZ+JdAvNJ1EN5FwmNy8NGwOVdT2ZWAIPqK7oUow2OedWU9zF+ETq3w40OONgyW8JtQVOQRE7R8f98V2FcL8E/DWp+D/h7Z6BrLI9xZT3CrIjZEkbTOyt7ZDZweRXdVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcT4h+I+maNr1xo8enazql5axLNd/2bZmdbVW5XzDkYJHOBk45roI/EmiSaqulrq+n/wBqFd/2I3KefjGc+Xnd056Vxt/4S8U6Z4z1zWfB2oaTHBrawtdRajE7tDLGmwPHtPOVA+U96wZPhRq0viVZJL7TP7MXxAPEJuREwvC4Ufuc9Nme+enagD0v/hLPDhiMo1/SDECAX+2x4BJIHO7uVYD6H0qez8RaLepatZ6xp1wt3vNuYrlGE2z72zB+bHfHSvG7/wCGN34d8A+F9L0zTtOvtZi1+3uLq4S2ykiCWRg0xA3FFDAHPSptP+EfiDSrrTNV03UtHXVo9Rvr64haGQWqC6RUKRAEHChRgHGc0AesXPivw9apZvc69pMKXn/Hs0l5Gon5x8hJ+bnjitqvB5fg5rkdt4fjsdR063u7CwjsZr9GlDlBKzsvlkFJFIbgMBznk17uoIUAnJx1oAWiiigAooqhrWrWOi2D3up3CQW6cZbksx6KoHLMewHJoAuTzR28Mk08iRxRqXd3ICqo5JJ7CuI+2X/jvfHpj3GneFzw1+hKT3w7iHukZ/56dT/DgfNT7XTL/wAYTLe+JI5LXQ8hrbRjwZRnIe59emRF90fxZPA7ZVCgBQABwAKAKul6dZ6Tp8FjptvHbWkK7Y4o1wqiq+q6THenzYz5VyBgOBw3sw7j9RWnRSlFSVmOMnF3RwN5bETeReRtDcJypU/qrdx/kio/PmtuLhTLF/z1ReR/vKP5j8hXd3lpDdxeXcIHXOR2IPqD2Nc3faRdWhLQ7rmDrx/rF/D+L8OfavPrYX5o7IVYz0lozNaKG5C3EMm1yPlmibkj+RHsaeLi5hP72ITx/wB+Lhh9VPX8D+FVvIjZne3doZScsU45/wBpT3+vNKLmeHi5i3p/z0hBP5r1H4ZrmjKrR+B3Q50r7lndp+otsdYZZB/BImHH4EZFB0my/hiKf7kjL/I1Fm0vl2t5U2OdrAEj8D0pxtygHkXE8WOg3bh+TZrojjo7TRj7OS+FlXwzbR23xPnWLfhtHB+d2b/lufU1yHxOQXPxg+xmxtL1ptEiMaXCAgOslyQc9R0wfrXXeGPOHxPnE8iyH+xhghNv/Lc9ea5n4jC8m+LE9nZ2ayi60KGFrgx825Mlzht/Yeo7/hXW5KdPmjsa4S6r6+f5HLaxa+Idc0swzaXLHNaSiKNNgRTG+Pu44O0xjkdm9qPEOn32oajajQLqK+uLWOIF1nUOrIMBiGIyM5ORnqaveHvD3iay1eA3NyLXTI2y8aXGYyg/hVPfp0Fa+l+FtJsri/k/tBpnuYWtwFcAxRkYIGOc4A59qwUXI9yVaNJ6NabWWmu9zEsTpT+Ngmi2CLO8MpSVXIVX2H51ToFPQfXOORmTwz4Mmtr2LVtdcwNburRW6NubI4GSPfoo6/jius0DQrXTN50ixkaWTh7m4JBP4nnHsBittIre0kWS7l+0XY5VVGduf7qjp9T+dWqa3kcdbHqF40nuref/AACXTrV/M+1XQ2ykYSP/AJ5r/ieM/l9Z7q8ET+VEpluMZ2DoB6sew/X0BqAtc3JG4m2i/uqcufqeg/D86Y0kFkPKiQtIfm8tBlmPqf8AE1jVxiXu09WeVySm+aQ9IT5vn3Lh5QOOyoO4Udvr1qE3T3J22ePL7zsMj/gI7/Xp9elMeNpRuvmG0nAgX7v0Pdj7dPat3TNGludsl6rRQdogcM3+9joPb/8AVXPCjKrK8tWb2jTV5GbpWnyXMjLZjcM4luZDkZ9Pc+wwB7U/xto0Fj4Ulvk3NcadPb6i0zfe2wyrI4HoCisMD1rtIYkhjWOJFSNRhVUYAHpiqmuWCapouoafL/q7u3kgb6MpU/zr06dGMPU5alZz0WiLoIYAg5Bpa574e6g+p+CdFupzm4a2RJs/89FG1wf+BKa6GtjI8j+N/iXxJo/iTwdpfhea6VtU+2+bFaxQvLIYo1Zceb8oxk55HGepxXK6P8WdTjsPDes6ldG9hXQdQu9QtoIhGJbiB1UDkcEZIJHHJNex+MfDfhjX0tG8WWNhdJAWWBrsgBC2MgZPfaPypIvDnhS3a1t4tO0qPyIHsoYQiALFIMvGF6YbGSMc0Aed3nxh1PSLK5TWdDszqj2tld2aWl2zQuty5RFkcoCpUg5wCCOlSt8WdW+3LoA0SxPic6wdJI+1sLPiISmTfs3fdONu3Ofyrs9N8F+Cbaz1HRrDSdK8m6AF3agBywX7oYEkgDsO3bFN/wCEL8DyaG+knStJfTbWf7VJEdpEcoH32OchscZJ6cdKAOV+Fvj3Urnwbor63p+s6rqF9czxtdWdp5sMOJ2QeY4xtAGOcdBmuU8KeMfFtxqthd65qLGO/wDFcmlLbWsqeVEkYk3LgxZK5A5zk4zx0Pt2jW2heHtEgt9KFjYaUCTEsbKsWWJJ2nOOSTTIPCmgRi3MOl2oEN22oREL924bO6Uf7RyefegDxbRfiTrVhB4f1LVbua9tho2r391AFUGdredhHyBxhRj+da8fxj12PS3lvPCjx3FzJaRafK4ngtpnnbbtZ5Y1Py8ElQQQeMV6hb+D/D1uLcRaRZhYIZreNfLBCxyktImD2YkkjvWbD8NPBsNhd2Ufh2wFrdKqzRlMhgp3KBk8YPIxigDM+D+t63rLeL18RyxPdWOuS2iRwtujiRY4zsRiqkjLHkjPNeh1leHfDukeG7Wa20HT7ewgmkM0kcC7Qz4ALH3wo/KtWgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPJNc+JWqab8UY9Alj0+DSnuYrWGTymnkmdkDMCySfumGeFZCCOcgGuY03416/5FtdXdnot/Hc6TfX/2XT/ME1q1vnHnZZsK+MdAfr39yfRdLbUW1A6dZ/2gRt+1eSvm4xj7+M9Pes3wj4O0XwrpUdjpdnGAqGNppEUyyqWLYdgBuHPegDyK8+MfiKw07VQ0fh/Uru3t7C6iuLISfZ1+0SqhikG8neA2QQenbtVzUvir4l0v7Tpuox+H7fUoteXSm1BxKtlDG0Kyh3BbdnnH3gK9gtvD+jW1rJbW2k6fFbSOJHiS2RUZgchiAMEg96o+KPCdj4gsJLWSS4sRJMJ5JbIrG8jAYG4lSG49R2HpQB5DF8TdSvJ/Cer3EEFxIYtddo7GaaOGcWiHZhN5Vt23gsGxnIxSwfGLxKLKcJbeHdTvZtJh1O2+yTNFHA0kqp5Mpd8FwGyMFSSMYGa9g8MeEtI8OaTY2Fhahks/MMUs+JJQ0hLSNvPOWJOcVYj8N6HFbXNvHo+nJBcnM8a2yBZT1ywxg/jQB5HoPxlu577Q4tTm0pLW6vL20u7h7d7UQtDCjquGkZQ258H5mBGMYOaqy/F3xVdaXY3Gl2ehiR/Ddxr8/npKV/cylSibW7qOM9znPavaD4e0Y2kFqdJ0/wCywP5kUP2ZNkbf3lXGAfcVMuj6YqhV06zCiFrcAQrjyzyU6fdPcdKAOB+HfjjXdc8U6npGtWmmoY9OttTtTaFxhJgTsct1I45AH0roNC8O3U+pJrvitoLnWFyLaCIloLBD/DHn7zn+KQgE9AAOK6SCxtIJzNBawRzFBGXSMKxQdFyOw7CrFABRRRQAUUUUAFFFFAFO+021veZ4gZAMLIvyuPoRz+FYtzoV1FzayrOv92T5W/McH8hXTUVnOlGe6NIVZQ2ZwV/ZhSBqFqy46M6ZA+jDgfnUKQMq5truUL2DESL+Z5/WvQiAao3GkWE7FntkDn+JPkP5jFc88JfY2WIT+JHC+FPOHxOuPPeNz/Y4wUQr/wAtz6k0uvixPxH1H7cyA/2VZ7QzkZ/e3WeO9aGnWMdh8VJUhaQq2jA/O2cfvzVLW7iKD4j6l5rEE6VZ4AUk/wCtuvSrk3Qo6K9jLSU/dHImlBgYdPR2/vC1/qRVo3MygLbWWB/00cIP0yf0qA3yH/VQ3Mh9PKKfq2BSefdv9y3SIesr5I/Bcj9a4niqz2Vjb2N9yRkuZv8Aj4n2L/cgG382PP5YppktbEeWu1WbnYoy7H1x1P1qKZXJH2m7Kg8BIxs3fTqfyNXtO0i5kH+i2ggjPWWb5SffH3ifrj61n7OpWfvO5agoK70Kbvcz5A/0aHu2QXP9B+v4VZ0zT5J0I0+EbCctM5O0n1J6sf8AOa6C00C3jcPdMblh0DjCD/gPf8c1sBQAABgCuylhOXciVdR0gZumaRBZsJX/AH1z/wA9WHT2Ufwj9fUmtOiiu2MVFWRyyk5O7CiiimI5D4f/AOiXPiXSTx9i1SWRB/0znAmH6yMPwrr64+L/AIl/xUmXpHq2lrJ/20t5MH/x2Zf++a7CgDyT44+BtX8W32kXWiWcU91ZxTJHJcTRGFGfA/eQyxurrx1GGHPXjHB3Hw/1vXvHniG2i0ixinjvdKl/tpsxm2EUSmT7ONuWBK4wGGOM+30vRigD5/t/hj4un+Ija1crp1jmfUQbyzaKMmOZGETBEjVywLZJd2Oaib4Wa/L4DttFg0LR9M1Cxe1e4u7a6UtrAicsyvmIgZzuBkD/ADdRivoWigD5u1P4SeIG0Czi0vSxHew3N1PCl5f21zFE0oQfPEbcRlSQxwoBXtnPH0FoNrNZaFp1rd+R9ogto4pPIXbHuVQDsHZcjgelX6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5If8AJWG/7Ag/9HmqN9ZXN38R9U+zLEdul2W4u5X/AJa3XoDV4f8AJWG/7Ag/9HmrNj/yUbWv+wXY/wDo26qZRUlZlRk4u6Gx6BeN/rLiCMeioW/UkVct/D8CHM808x9C20f+O4/nW1RUKjBdC3Xm+pWtLC1tMm2gjjY9WA+Y/U9TVnFFFaJJbGbbe4UUUUxBRRRQAUUVxnxitbu5+Guuvps00F9awfbYXhcq26EiTaCPUKVx70AdZJa28t1DcyQxtcQhljkKgsgbG4A9s4GfpU9fJA1TxZ4g1mFhc6lDp/j69j+zqsjqbOGC4G7GD8uYwScda7C78Zaroep6xbWc9rotnd+Lbi0uNVktTKsEawRspKk4LMSRnpxQB9D0V8taX478TeHvBHhey024itbe7TUpzqV0ihJZ1u5QkZMhwi4+Yj7xBAHSt3xL8SfG1vDq+pWV1YQ2+l2WlXb2os/NFw1wyrIqyEghfmz0J6cigD6IorwiX4keKx8T7nSz9jt7WDVvsK6dOER57YgbZkJO9mYnII+XHHvWX8O/E+p+Kfiv4Uv9V1SO4uHsL/z7GG2MIsG3KBCxz8xAHU8/nQB9F0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByQ/5Kw3/YEH/o81Zsf+Sja1/wBgux/9G3VVh/yVhv8AsCD/ANHmrNj/AMlG1r/sF2P/AKNuqAOkooooAKKKKACiiigAooooAKp6zqVjo+mXGoatcxWtjAu6WaVsKo9/5e9XK53x/wCGE8X+GZ9Je5e1dpI5op1UN5ckbh0JU8MMqMjuKAM2T4leDIdNhv31iBbRndFfyZPlKgFsjblcBl5OOoq/ceMfDEVrezzarZ+RaLBNO/3gFmAMTcD5g2RgjNcf4r+GviDxVaRR6x4sRiUnimiismjgcOoVW2CQZdcHBYsPmPFJL8HreXUfCU8uqObfRrK1s7u2EQCX/wBm5iZueMMScc+lAHWnxt4VfV30dtUtDeoXBhIONyLudQcbSwHJUHI9KpL8TvAslkbtfEWmvbb0jMgbI3MrMqnjqQrcdePWuYj+Daw+I7m9j1OB7KW8mvkjmtmeWF5A2Qr+Ztxlic7c44zW3pHw3j07Q/BOnpfBj4cuBOZBDj7SRG6YIzx9/PfpQBoXPxG8FwaZp+rTa5Y/Zb0ObaUZZnCnDkADcApzkkDHerMvjnwpb6lZ2X9r2bXd4sckKw5k3CQ4RiyghQ3GCSM1wdn8GbrSkt5tF8QpBfpFeWskk1n5iPDcSGQgJuGGUng557ipLX4MNYato9xpeuGzh09LWNpYYXS5mSEDKM6yBWVsHO5DgHHSgDr7n4j+HNmqxWGoR3WoWFrPdG1w0bSCIEsFLDB6YyM4rQ0vxZY3HgXTvFOoH7DZXVpDdsGJfyxIqkLwMk5YDgV5/ZfBy8TVJ73UfEsl9M9tfWolmhZpStwpUFmMhB254AAGBXV33gm7k+F1l4S0/W57G4tbSC2W+hUqWEQUHIDAgMFwQD0PWgC03xI8IJo6arJr1nHp73DWgmkJUCYLuKMCMq2BnBxWZo3xa8Kapqmt2i34t49KVZJLmf5YpEKgllPoMgc4JJ4zWHovwcGniz87Vo5TB4gGusq2xCsfKEflAM7HHfJJqx4m+Eza7d+LUbWTBpniEQSSQrb5khmh2+WyvuwV+XlSOfUUAdP/AMLH8Irpv9oS67aw2guPsjSTbo9ku3cFYMAVO3nnHFT2XjzwvfWYu7TWbWW3N1FZBlJ5mkAMaAYzlgwxXGaf8ImjNhJe6laPPb6rb6lI0FoyibykKhW3yMcnd1zxgDFJdfD+a7+O0evfZni0CG1iu5V3L5dxfxh442CDnKRv19QKAPWqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuK+NGt3/hz4Y69q2jzeRf2sStFJtDbSZFHQ8HgmvMb3xf4v0vwhFqE91r8FxNqthbA6vp9tDujkZt/l+WTkEY5OCOMUAfQdFeafHfxlc+EvDNlFpV9bWGrareR2lvc3JURwAnLyNu4wB6+tcWnxT1nVPh14JGm31vFrWtasui3uo7FkW3dWwzqv3SzDay9sNQB7/RXjvjO/wDFfhWPQtCi8Ufa7vXtWjs49TuLSMSWcZXLDauFZiR8uQPT3qL4rTeLfBHw4u9RtfGFxdXltdxbJZLOAMY5GRNj4XBwSzAgA847UAez0V4rqGoeLbn4onwrZeLJLKG18OJqRuHs4X82YS7CzgrwDkZAx04rsfgv4tvPG3gCy1jU4Y4rxnkhkMQISQoxXeuexxQB3NFFFAHJD/krDf8AYEH/AKPNWbH/AJKNrX/YLsf/AEbdVMNLuP8AhOzq/wAn2T+zRa/e+bf5pbp6YqW20+ePxdqOpNs+zXFlbW6c/NujedmyPTEi/rQBs0UUUAFFeKfGLxV4m034j6Bonh6fVBbXdhLPLDplrDPMzK3BAlwMY681y3xF+IfiTw74gsrKXWdYsYF8MDUZANNhlmN15rqPOUAqin5QSCADjnmgD6Uor598T+MvHEZ+H1qst4l/qumzXN7DotvBcO7qFKlfMO3GDk4PfjNbK6z4q1vxto3hGHW7zRNuhrqt1cT2kP2yaRpCmwryi4wM7c96APaaK8S+JM3jLw3c+EI7bxpO/wDa+rW+kzEWEAChgQZBkH5uM46ZJr2PS7ee1063gvLt724jQK9w6KjSn+8QvA/CgC1RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ3iHRbDxDo9zpWrwC4sLlQssRYruAII5BB6gVV8TeFtH8TaPHpetWn2ixjdJFj8xkwy/dIKkHj61t0UAcdY/DTwrZXdpcpppmltWd4TdXEk4QuoViA7EchRTrn4b+E7nT9QsZdHhNrfXQvZowzKBOBgSJg/I2OMriuvooA4xvhl4Tk0S40qfTGuLWeZbmQz3EskhlUYV/MZiwIHAwaiuPhZ4TutHbTLqwuJ7Rp/tDrLezs0kmANzMXy2Aq4z0xXcUUAcTqfwu8JapcQz3+myzTRWq2Qc3cwLQKSQjEP8wyT1zmur0nTbPSNOt7DTLaK1srdAkUMS7VQegFW6KACiiigAooooAKKKKAOY8U+BPD3ijUba/1qyea8tozFFLHcSRMqk5IyjCiPwH4cW6W4bThLMNOOk7pZHk3WpJJjbcTkEk8nn3rp6KAOIn+FnhKez0y1k06bydMR47TbdzK0KucsoYPnHHTNTap8NfC+px6cLqwk83T4zDbXCXMqTxoSSV8wNuI5PUnqa7GigDnZfBegy2Gi2clgGttGuEurFTI/7qVM7WznJPJ65roqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11319=[""].join("\n");
var outline_f11_3_11319=null;
var title_f11_3_11320="Clinical manifestations and diagnosis of adult Still's disease";
var content_f11_3_11320=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of adult Still's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/3/11320/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/3/11320/contributors\">",
"     Lisa A Mandl, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/3/11320/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/3/11320/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/3/11320/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/3/11320/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/3/11320/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adult Still&rsquo;s disease is an inflammatory disorder characterized by quotidian (daily) fevers, arthritis, and an evanescent rash. First described in children by George Still in 1896, &ldquo;Still&rsquo;s disease&rdquo; has become the eponymous term for systemic onset juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 1971, the term &ldquo;adult Still&rsquo;s disease&rdquo; (ASD) was used to describe a series of adult patients who did not fulfill criteria for classic rheumatoid arthritis (RA) but who had features similar to the children with systemic onset juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of ASD will be reviewed here. The treatment and prognosis of ASD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35174?source=see_link\">",
"     \"Treatment of adult Still's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of ASD is unknown. A variety of infectious triggers have been suggested, including numerous viral pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Suspected bacterial pathogens include Yersinia enterocolitica and Mycoplasma pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. There remains no proof of an infectious etiology.",
"   </p>",
"   <p>",
"    It has also been suggested that genetic factors are important. In a series of 62 French patients, for example, human leukocyte antigen (HLA)-B17, -B18, -B35, and -DR2 were associated with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9\">",
"     9",
"    </a>",
"    ]. However, other studies have not confirmed these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/10\">",
"     10",
"    </a>",
"    ]. Familial cases are uncommon, and there have been few reports of cases in twins [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective French study estimated the annual incidence of ASD to be 0.16 cases per 100,000 people, with an equal distribution between the sexes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/12\">",
"     12",
"    </a>",
"    ]. There is a bimodal age distribution, with one peak between the ages of 15 and 25 and the second between the ages of 36 and 46. However, patients older than age 70 have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific test or combination of tests that can be used to establish the diagnosis of ASD. As a result, at least seven sets of diagnostic criteria have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]. All of these sets are similar, differing generally in the number of major and minor criteria required for diagnosis, with some variation among the individual criteria.",
"   </p>",
"   <p>",
"    A comparison of these seven sets of criteria demonstrated that the Japanese criteria, often termed the Yamaguchi criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/15\">",
"     15",
"    </a>",
"    ], have the highest sensitivity in patients with a definite diagnosis of ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/22\">",
"     22",
"    </a>",
"    ]. The Yamaguchi criteria require the presence of five features, with at least two being major diagnostic criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Yamaguchi criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major Yamaguchi criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever of at least 39&ordm;C (102.2&ordm;F) lasting at least one week",
"     </li>",
"     <li>",
"      Arthralgias or arthritis lasting two weeks or longer",
"     </li>",
"     <li>",
"      A nonpruritic macular or maculopapular skin rash that is salmon-colored in appearance and that is usually found over the trunk or extremities during febrile episodes",
"     </li>",
"     <li>",
"      Leukocytosis",
"      <span class=\"nowrap\">",
"       (10,000/microL",
"      </span>",
"      or greater), with at least 80 percent granulocytes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The minor Yamaguchi criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sore throat",
"     </li>",
"     <li>",
"      Lymphadenopathy",
"     </li>",
"     <li>",
"      Hepatomegaly or splenomegaly",
"     </li>",
"     <li>",
"      Abnormal liver function studies, particularly elevations in aspartate and alanine aminotransferase and lactate dehydrogenase concentrations",
"     </li>",
"     <li>",
"      Negative tests for antinuclear antibody and rheumatoid factor",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of any infection, malignancy, or other rheumatic disorder known to mimic ASD in its clinical features precludes the diagnosis of ASD, at least for the purpose of research. Certain drug hypersensitivity reactions can also mimic ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria define the major clinical features of ASD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fever of ASD is usually quotidian or double-quotidian (two fever spikes per day). The temperature swings can be dramatic, with changes of 4&ordm;C (7.2&ordm;F) occurring within four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. Complete defervescence is not required with these fevers, as fever persists between spikes in approximately 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9\">",
"     9",
"    </a>",
"    ]. ASD can also present as fever of unknown origin (FUO) and may be a common cause of FUO in some regions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15431?source=see_link\">",
"     \"Etiologies of fever of unknown origin in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic rash of ASD is an evanescent, salmon-colored, macular or maculopapular eruption that tends to occur with the fever. The rash predominantly involves the trunk and extremities but can also involve the palms, the soles, and, occasionally, the face. The Koebner phenomenon may be present, in which the cutaneous eruption can sometimes be elicited by stroking the skin.",
"   </p>",
"   <p>",
"    The ASD rash should be sought in areas subject to tight clothing, such as at the beltline or beneath the breasts. The rash is frequently misdiagnosed as a drug reaction.",
"   </p>",
"   <p>",
"    The cutaneous histopathology in ASD reveals dermal edema and mild perivascular inflammation in the superficial dermis, consisting primarily of lymphocytes and histiocytes (",
"    <a class=\"graphic graphic_picture graphicRef56878 graphicRef72353 \" href=\"UTD.htm?37/26/38309\">",
"     picture 1A-B",
"    </a>",
"    ). Immunofluorescence of the skin biopsy may show slight deposition of complement component 3 (C3) in the blood vessel walls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of skin biopsies in ASD are nonspecific, but skin biopsy can be important in differentiating this disorder from vasculitis, Sweet syndrome, and other conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link\">",
"     \"Neutrophilic dermatoses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=see_link\">",
"     \"Hypersensitivity vasculitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Musculoskeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthralgias, arthritis, and myalgias are universal features of ASD. Initially, the arthritis may be mild, transient, and oligoarticular. These manifestations may evolve over a period of months into a more severe, destructive polyarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/25\">",
"     25",
"    </a>",
"    ]. Fusion of the wrist joints is characteristic of ASD, although it occurs in only a minority of cases.",
"   </p>",
"   <p>",
"    The most commonly involved joints, in descending order, are the knees, wrists, ankles, elbows, proximal interphalangeal joints, and shoulders. The synovial fluid is usually inflammatory, with a mean leukocyte count of 13,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    but with a reported range of 100 to 48,000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    Synovial biopsy reveals a chronic synovitis with slight cell proliferation in the synovial lining layers, moderate vascular engorgement, and a mononuclear cell infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9,17\">",
"     9,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myalgias can be severe and debilitating and can coincide with fever spikes. Muscle weakness is not present, but the serum creatinine kinase and aldolase concentrations can be slightly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9\">",
"     9",
"    </a>",
"    ]. Electromyographic studies and muscle biopsy are usually normal or show a nonspecific inflammatory myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pharyngitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe, nonsuppurative pharyngitis is common in ASD. In a literature review of 341 cases, sore throat was noted in 69 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/26\">",
"     26",
"    </a>",
"    ]. Pharyngitis can occur with disease relapses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concentrations of serum hepatic aminotransferases and alkaline phosphatase are often modestly elevated. These changes may antedate the use of nonsteroidal antiinflammatory drugs (NSAIDs) and may improve as the disease responds [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eight cases of fulminant liver failure in association with ASD have been described, with four fatalities [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. All patients had been treated with NSAIDs. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Reactive hemophagocytic syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lymphadenopathy and splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slightly tender, enlarged cervical lymph nodes are seen in about one-half of patients with ASD. Splenomegaly may also be present. Because of the frequent presence of fever and leukocytosis, there may be diagnostic confusion with lymphoma.",
"   </p>",
"   <p>",
"    Lymph node biopsy in ASD typically shows intense, paracortical immunoblastic hyperplasia, which is distinct from the changes observed with RA, systemic lupus erythematosus, Sj&ouml;gren&rsquo;s syndrome, or Kikuchi&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/29\">",
"     29",
"    </a>",
"    ]. These light microscopic changes may resemble lymphoma. However, immunohistochemistry reveals a benign polyclonal B-cell hyperplasia, which distinguishes ASD from lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cardiopulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis, pleural effusions, and transient pulmonary infiltrates have been observed in 30 to 40 percent of patients with ASD. Affected patients may complain of a slight cough, of pleuritic chest pain, or of mild dyspnea. However, severe interstitial lung disease has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/32\">",
"     32",
"    </a>",
"    ]. Some patients progress to acute respiratory distress syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Myocarditis is a rare complication that can cause arrhythmias and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hematologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASD can be associated with a number of hematologic disease manifestations, including the reactive hemophagocytic syndrome (RHS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Reactive hemophagocytic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RHS has also been termed the macrophage activation syndrome when it occurs either in ASD or in systemic onset juvenile idiopathic arthritis. This complication of ASD occurs in a minority of patients but may be underdiagnosed. A retrospective study of 50 ASD patients who fulfilled the Yamaguchi criteria reported RHS in six (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H19714867#H19714867\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'HLH in adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic hallmark of RHS is the presence on bone marrow examination of numerous, well-differentiated macrophages (histiocytes) that are engaged actively in the phagocytosis of hematopoietic elements [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RHS can occur at any time during the history of ASD, and simultaneous presentations of ASD and RHS are not unusual. Flares of ASD and the development of RHS are clinically indistinguishable. Pleuritis, acute respiratory distress syndrome (ARDS), and pancytopenia are more common in cases of ASD associated with RHS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other hematologic manifestations associated with ASD include pure red cell aplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/39\">",
"     39",
"    </a>",
"    ], disseminated intravascular coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/37\">",
"     37",
"    </a>",
"    ], and microangiopathic hemolytic anemia, including thrombotic thrombocytopenic purpura-hemolytic uremic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"     \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of laboratory findings are characteristic of ASD (",
"    <a class=\"graphic graphic_table graphicRef75048 \" href=\"UTD.htm?20/57/21403\">",
"     table 1",
"    </a>",
"    ). None is specific for this diagnosis, but the constellation of the clinical features listed above plus the presence of these laboratory features should alert the clinician to the possibility of ASD. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Classification criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Elevations in acute phase reactants (eg, erythrocyte sedimentation rate and C-reactive protein) are seen in virtually all patients with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9\">",
"     9",
"    </a>",
"    ]. These are typically accompanied by a leukocytosis, with a peripheral white blood cell count that exceeds 15,000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    There is a predominance of granulocytes. The presence of immature forms, including bands, may suggest a septic process.",
"   </p>",
"   <p>",
"    A normocytic, normochromic anemia with a hemoglobin less than or equal to 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is seen in the majority of patients. Reactive thrombocytosis is also common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Liver function studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in the serum alanine and aspartate aminotransferases, as well as lactate dehydrogenase, are seen in 75 percent of patients with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9\">",
"     9",
"    </a>",
"    ]. The liver biopsy findings are nonspecific but range in severity from minimally abnormal to fulminant hepatic necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9,28\">",
"     9,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serum ferritin",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASD has been associated with markedly elevated serum ferritin concentrations in as much as 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/5\">",
"     5",
"    </a>",
"    ]. This is probably an acute phase response, since hepatocytes responding to inflammatory cytokines can increase ferritin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/43\">",
"     43",
"    </a>",
"    ]. The elevations correlate with disease activity and have been suggested as a serologic marker to monitor the response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum ferritin concentrations exceeding 3000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (normal is 40 to 200",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    have been observed in ASD, with some patients having values above 10,000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/38,47\">",
"     38,47",
"    </a>",
"    ]. Serum ferritin values above 3000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in a patient with compatible symptoms should lead to suspicion of ASD in the absence of a bacterial or viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/38\">",
"     38",
"    </a>",
"    ]. This degree of hyperferritinemia is not observed with other rheumatic diseases, although it may be present in other hemophagocytic syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Glycosylated ferritin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The percentage of the ferritin that is glycosylated in ASD tends to be lower than in other rheumatic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/45,48-50\">",
"     45,48-50",
"    </a>",
"    ]. In one study, for example, the respective values were 3.7 and 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/45\">",
"     45",
"    </a>",
"    ]. The percentage of glycosylated ferritin may remain low both in the active phase of disease and in remission [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of both the total serum ferritin and the glycosylated fraction may provide more diagnostic specificity for ASD than does reliance upon either test alone. In one report, the combination of a fivefold or greater elevation in serum ferritin and a glycosylated fraction of &le;20 percent had a modest sensitivity for ASD of 43 percent but a relatively high specificity of 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both marked hyperferritinemia and a low fraction of glycosylated serum ferritin also occur in the macrophage activation syndrome as well as in various syndromes associated with hemophagocytosis, such as those due to lymphoma and to severe drug reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/37,51,52\">",
"     37,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Immunologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the absence of antinuclear antibodies and rheumatoid factor is one of the minor criteria for ASD. However, a low titer of either test occurs in less than 10 percent of patients and may obscure the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated serum levels of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, and interferon gamma are frequently present in patients with ASD but are not specific for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/53\">",
"     53",
"    </a>",
"    ]. IL-18 is also elevated in ASD, and the elevation appears to be more specific for ASD than for other systemic rheumatic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/54\">",
"     54",
"    </a>",
"    ]. None of these tests are available for routine clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fever and leukocytosis often leads to examination of the bone marrow to assess for occult infection or for evidence of a myeloproliferative disorder. In one series of 12 patients with ASD in whom bone marrow examinations were performed, hyperplasia of granulocytic precursors was present in all of the marrow samples [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/55\">",
"     55",
"    </a>",
"    ]. Other features that were less frequent included hypercellularity (75 percent), increased histiocytes (25 percent), and the presence of hemophagocytosis (17 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=see_link\">",
"     \"Evaluation of bone marrow aspirate smears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic radiographic finding of ASD is a nonerosive narrowing of the carpometacarpal and intercarpal joint spaces of the wrist, which often progresses to bony ankylosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Radiographic abnormalities are eventually seen in about 40 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ankylosis of the cervical spine, of the tarsal joints, or of the distal interphalangeal joints is a less common finding. An unusual complication of ASD is the rapid destruction of the hip and, less commonly, of the knee, which can require total joint arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/1,9,15,58\">",
"     1,9,15,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291599526\">",
"    <span class=\"h1\">",
"     DISEASE COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of ASD can be divided into three main patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Approximately one-third of patients fall into each pattern; in some studies, however, the chronic articular pattern is more common [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11320/abstract/59,61\">",
"     59,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monophasic pattern &mdash; Patients with monophasic ASD have a disease course that typically lasts only weeks to months, completely resolving within less than a year in most patients. Systemic features, including fever, rash, serositis, and hepatosplenomegaly, predominate in this group.",
"     </li>",
"     <li>",
"      Intermittent pattern &mdash; Patients with intermittent ASD have one or more disease flares, with or without articular symptoms, with complete remissions between episodes lasting from weeks up to one or two years. Although subsequent flares cannot be predicted, they tend to be less severe and of shorter duration than the initial disease episode.",
"     </li>",
"     <li>",
"      Chronic pattern &mdash; Patients with chronic ASD have persistently active disease, in which articular symptoms usually predominate. A potentially destructive arthritis may occur in patients in this group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adult Still&rsquo;s disease (ASD) is an inflammatory disorder characterized by quotidian fevers, arthritis, and an evanescent rash.",
"     </li>",
"     <li>",
"      There is no specific test or combination of tests that can be used to establish the diagnosis of ASD. A variety of classification criteria has been proposed, and the Yamaguchi criteria are most widely used. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of ASD include fevers, pharyngitis, a salmon-colored rash typically found on the trunk, arthritis, lymphadenopathy, and a number of nonspecific hematologic findings. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ASD is usually seronegative. However, a low titer antinuclear antibody or rheumatoid factor can occur and does not rule out the diagnosis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Immunologic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reactive hemophagocytic syndrome (RHS) occurs in a minority of patients with ASD. RHS occurring in the context of ASD or Still&rsquo;s disease in children is often termed the macrophage activation syndrome. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Reactive hemophagocytic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone marrow aspiration is the most sensitive means of diagnosing RHS. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Bone marrow examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ASD has been associated with markedly elevated serum ferritin concentrations in as much as 70 percent of patients. Serum ferritin values above 3000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in a patient with compatible symptoms should lead to suspicion of ASD in the absence of a bacterial or viral infection. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Serum ferritin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of ASD can be divided into three main patterns: monophasic, intermittent, and chronic. Systemic manifestations predominate in the two former patterns, while articular involvement predominates in patients with chronic disease. (See",
"      <a class=\"local\" href=\"#H291599526\">",
"       'Disease course'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374834104\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge John M Esdaile, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/1\">",
"      Still GF. On a Form of Chronic Joint Disease in Children. Med Chir Trans 1897; 80:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/2\">",
"      Bywaters EG. Still's disease in the adult. Ann Rheum Dis 1971; 30:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/3\">",
"      Huang SH, DeCoteau WE. Adult-onset Still's disease: an unusual presentation of rubella infection. Can Med Assoc J 1980; 122:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/4\">",
"      Wouters JM, van der Veen J, van de Putte LB, de Rooij DJ. Adult onset Still's disease and viral infections. Ann Rheum Dis 1988; 47:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/5\">",
"      Ohta A, Yamaguchi M, Tsunematsu T, et al. Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol 1990; 17:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/6\">",
"      Pouchot J, Ouakil H, Debin ML, Vinceneux P. Adult Still's disease associated with acute human parvovirus B19 infection. Lancet 1993; 341:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/7\">",
"      Efthimiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 2006; 65:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/8\">",
"      Colebunders R, Stevens WJ, Vanagt E, Snoeck J. Adult Still's disease caused by Yersinia enterocolitica infection. Arch Intern Med 1984; 144:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/9\">",
"      Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991; 70:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/10\">",
"      Sampalis JS, Medsger TA Jr, Fries JF, et al. Risk factors for adult Still's disease. J Rheumatol 1996; 23:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/11\">",
"      Kahn MF. Adult Still's disease. Still many issues unresolved. J Rheumatol 1996; 23:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/12\">",
"      Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis 1995; 54:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/13\">",
"      Uson J, Pe&ntilde;a JM, del Arco A, et al. Still's disease in a 72-year-old man. J Rheumatol 1993; 20:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/14\">",
"      Steffe LA, Cooke CL. Still's disease in a 70-year-old woman. JAMA 1983; 249:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/15\">",
"      Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992; 19:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/16\">",
"      Calabro JJ, Marchesano JM. Fever associated with juvenile rheumatoid arthritis. N Engl J Med 1967; 276:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/17\">",
"      Reginato AJ, Schumacher HR Jr, Baker DG, et al. Adult onset Still's disease: experience in 23 patients and literature review with emphasis on organ failure. Semin Arthritis Rheum 1987; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/18\">",
"      Cush JJ, Medsger TA Jr, Christy WC, et al. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 1987; 30:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/19\">",
"      Goldman JA, Beard MR, Casey HL. Acute febrile juvenile rheumatoid arthritis in adults: cause of polyarthritis and fever. South Med J 1980; 73:555.",
"     </a>",
"    </li>",
"    <li>",
"     Kahn MF, Delaire M. Maladie de Still de l'adulte. In: Les maladies systemiques, Kahn MF, et al (Eds), Flammarion, Paris 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/21\">",
"      Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset still disease. Medicine (Baltimore) 2002; 81:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/22\">",
"      Masson C, Le Loet X, Liote F, et al. Comparative study of 6 types of criteria in adult Still's disease. J Rheumatol 1996; 23:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/23\">",
"      Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/24\">",
"      Mert A, Ozaras R, Tabak F, et al. Fever of unknown origin: a review of 20 patients with adult-onset Still's disease. Clin Rheumatol 2003; 22:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/25\">",
"      Elkon KB, Hughes GR, Bywaters EG, et al. Adult-onset Still's disease. Twenty-year followup and further studies of patients with active disease. Arthritis Rheum 1982; 25:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/26\">",
"      Nguyen KH, Weisman MH. Severe sore throat as a presenting symptom of adult onset Still's disease: a case series and review of the literature. J Rheumatol 1997; 24:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/27\">",
"      Esdaile JM, Tannenbaum H, Lough J, Hawkins D. Hepatic abnormalities in adult onset Still's disease. J Rheumatol 1979; 6:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/28\">",
"      Dino O, Provenzano G, Giannuoli G, et al. Fulminant hepatic failure in adult onset Still's disease. J Rheumatol 1996; 23:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/29\">",
"      Valente RM, Banks PM, Conn DL. Characterization of lymph node histology in adult onset Still's disease. J Rheumatol 1989; 16:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/30\">",
"      Quaini F, Manganelli P, Pileri S, et al. Immunohistological characterization of lymph nodes in two cases of adult onset Still's disease. J Rheumatol 1991; 18:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/31\">",
"      Trotta F, Dovigo L, Scapoli G, et al. Immunoblastic malignant lymphoma in adult onset Still's disease. J Rheumatol 1993; 20:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/32\">",
"      Van Hoeyweghen RJ, De Clerck LS, Van Offel JF, Stevens WJ. Interstitial lung disease and adult-onset Still's disease. Clin Rheumatol 1993; 12:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/33\">",
"      Cheema GS, Quismorio FP Jr. Pulmonary involvement in adult-onset Still's disease. Curr Opin Pulm Med 1999; 5:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/34\">",
"      Suleiman M, Wolfovitz E, Boulman N, Levy Y. Adult onset Still's disease as a cause of ARDS and acute respiratory failure. Scand J Rheumatol 2002; 31:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/35\">",
"      Manganelli P, Fietta P, Zuccoli P. Adult-onset Still's disease with respiratory distress syndrome, polyserositis and disseminated intravascular coagulation: a case with a fatal outcome. Clin Exp Rheumatol 2003; 21:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/36\">",
"      Drouot MH, Hachulla E, Flipo RM, et al. [Cardiac complication of adult-onset Still's disease: from pericarditis to tamponade, sometimes a manifestation of the disease]. Rev Med Interne 1993; 14:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/37\">",
"      Arlet JB, Le TH, Marinho A, et al. Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature. Ann Rheum Dis 2006; 65:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/38\">",
"      Coffernils M, Soupart A, Pradier O, et al. Hyperferritinemia in adult onset Still's disease and the hemophagocytic syndrome. J Rheumatol 1992; 19:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/39\">",
"      Chung JW, Suh YJ, Song HJ, et al. Pure red cell aplasia and adult-onset Still's disease. Clin Rheumatol 2004; 23:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/40\">",
"      Boki KA, Tsirantonaki MJ, Markakis K, Moutsopoulos HM. Thrombotic thrombocytopenic purpura in adult Still's disease. J Rheumatol 1996; 23:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/41\">",
"      Diamond JR. Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) complicating adult Still's disease: remission induced with intravenous immunoglobulin G. J Nephrol 1997; 10:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/42\">",
"      Perez MG, Rodwig FR Jr. Chronic relapsing thrombotic thrombocytopenic purpura in adult onset Still's disease. South Med J 2003; 96:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/43\">",
"      Rogers J, Lacroix L, Durmowitz G, et al. The role of cytokines in the regulation of ferritin expression. Adv Exp Med Biol 1994; 356:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/44\">",
"      Schwarz-Eywill M, Heilig B, Bauer H, et al. Evaluation of serum ferritin as a marker for adult Still's disease activity. Ann Rheum Dis 1992; 51:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/45\">",
"      Van Reeth C, Le Moel G, Lasne Y, et al. Serum ferritin and isoferritins are tools for diagnosis of active adult Still's disease. J Rheumatol 1994; 21:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/46\">",
"      Akritidis N, Giannakakis I, Giouglis T. Ferritin levels and response to treatment in patients with Adult Still's disease. J Rheumatol 1996; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/47\">",
"      Kumakura S, Ishikura H, Munemasa S, et al. Adult onset Still's disease associated hemophagocytosis. J Rheumatol 1997; 24:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/48\">",
"      Hamidou MA, Denis M, Barbarot S, et al. Usefulness of glycosylated ferritin in atypical presentations of adult onset Still's disease. Ann Rheum Dis 2004; 63:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/49\">",
"      Vignes S, Le Mo&euml;l G, Fautrel B, et al. Percentage of glycosylated serum ferritin remains low throughout the course of adult onset Still's disease. Ann Rheum Dis 2000; 59:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/50\">",
"      Fautrel B, Le Mo&euml;l G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. J Rheumatol 2001; 28:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/51\">",
"      Esumi N, Ikushima S, Hibi S, et al. High serum ferritin level as a marker of malignant histiocytosis and virus-associated hemophagocytic syndrome. Cancer 1988; 61:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/52\">",
"      Lambotte O, Cacoub P, Costedoat N, et al. High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation. J Rheumatol 2003; 30:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/53\">",
"      Hoshino T, Ohta A, Yang D, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 1998; 25:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/54\">",
"      Kawashima M, Yamamura M, Taniai M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001; 44:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/55\">",
"      Min JK, Cho CS, Kim HY, Oh EJ. Bone marrow findings in patients with adult Still's disease. Scand J Rheumatol 2003; 32:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/56\">",
"      Medsger TA Jr, Christy WC. Carpal arthritis with ankylosis in late onset Still's disease. Arthritis Rheum 1976; 19:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/57\">",
"      Bj&ouml;rkengren AG, Pathria MN, Sartoris DJ, et al. Carpal alterations in adult-onset Still disease, juvenile chronic arthritis, and adult-onset rheumatoid arthritis: comparative study. Radiology 1987; 165:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/58\">",
"      Cabane J, Michon A, Ziza JM, et al. Comparison of long term evolution of adult onset and juvenile onset Still's disease, both followed up for more than 10 years. Ann Rheum Dis 1990; 49:283.",
"     </a>",
"    </li>",
"    <li>",
"     Pouchot, J, Sampalis, JS, Beaudet, F, et al. Adult onset Still's disease: Manifestations, disease course and outcome in 62 patients. Medicine (Baltimore) 1991; 70:118.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/60\">",
"      Kontzias A, Efthimiou P. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances. Drugs 2008; 68:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11320/abstract/61\">",
"      Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol 2008; 22:773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5611 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11320=[""].join("\n");
var outline_f11_3_11320=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Yamaguchi criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Musculoskeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pharyngitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lymphadenopathy and splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cardiopulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hematologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Reactive hemophagocytic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Liver function studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serum ferritin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Glycosylated ferritin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Immunologic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H291599526\">",
"      DISEASE COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H374834104\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5611\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5611|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/39/24176\" title=\"picture 1A\">",
"      Skin biopsy adult Stills",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/6/41056\" title=\"picture 1B\">",
"      Skin biopsy Stills dermis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5611|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/57/21403\" title=\"table 1\">",
"      Adult Stills laboratory tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15431?source=related_link\">",
"      Etiologies of fever of unknown origin in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13689?source=related_link\">",
"      Evaluation of bone marrow aspirate smears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30614?source=related_link\">",
"      Hypersensitivity vasculitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35174?source=related_link\">",
"      Treatment of adult Still's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_3_11321="Organoaxial gastric volvulus";
var content_f11_3_11321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83732%7ERADIOL%2F83734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83732%7ERADIOL%2F83734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Organoaxial gastric volvulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 386px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain radiograph of the abdomen (A) shows a large central gas bubble in the thoracic cavity reminiscent of a large hiatal hernia (between white arrows). A barium study (B)&nbsp;shows the greater curvature of the stomach (red arrow) superior to the lesser curvature (blue arrow). These findings are characteristic of an organoaxial volvulus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Mesenteroaxial gastric volvulus on upper GI study and computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 250px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD6AlUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+N7PTLy9tLy6tLd5YbNBJOyc+WpOAxHXGcDPbIzVKkpJtpPYD7V/4ar8D/APQK8Sf+A8H/AMeo/wCGq/A//QK8Sf8AgPB/8er4qopgfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVXp9fQZFkX9r+0/ecvLbpe97+a7HHi8X9Wtpe59Df8NV+B/8AoFeJP/AeD/49R/w1X4H/AOgV4k/8B4P/AI9Xxpqn/ITvP+uz/wDoRqrXh1afs6kodm0dUXzJM+1f+Gq/A/8A0CvEn/gPB/8AHqP+Gq/A/wD0CvEn/gPB/wDHq+KqKzKPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/Hq7D4X/ABr8OfEfX7jSNDstXguYLVrtmvIo1QoropAKyMc5cdvWvz6r6A/Yp/5Knqv/AGBZf/R8FAHuvj39oDwr4I8WX3h7VbDW5r2z8vzHtoYmjO+NXGC0gPRh2HNc/wD8NV+B/wDoFeJP/AeD/wCPV8//ALUf/JdvE3/br/6SxV6T4v8Ag18OvDXiNdEceOtQvf7PfU2+xz2W1IEJDEmQJyNvQZ9qAO3/AOGq/A//AECvEn/gPB/8eo/4ar8D/wDQK8Sf+A8H/wAerxv4u/DDwj4d+FWh+MfCN7rc6apdxRIuovHxG0crfdVFIbKAdSOvXg14dQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV8VUUAfav/AA1X4H/6BXiT/wAB4P8A49R/w1X4H/6BXiT/AMB4P/j1fFVFAH2r/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxVRQB9q/8ADVfgf/oFeJP/AAHg/wDj1H/DVfgf/oFeJP8AwHg/+PV88151qn/ITvP+uz/+hGvpM84f/smnCftObmdtrfqzhwuM+sNrltbzPsv/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq+KqK+bO4+1f8AhqvwP/0CvEn/AIDwf/HqP+Gq/A//AECvEn/gPB/8er4qooA+1f8AhqvwP/0CvEn/AIDwf/HqP+Gq/A//AECvEn/gPB/8er4qooA+1f8AhqvwP/0CvEn/AIDwf/HqP+Gq/A//AECvEn/gPB/8er4qooA+1f8AhqvwP/0CvEn/AIDwf/HqP+Gq/A//AECvEn/gPB/8er4qooA+1f8AhqvwP/0CvEn/AIDwf/Hq6DwF+0B4V8b+LLHw9pVhrcN7eeZ5b3MMSxjZGznJWQnop7HmvgqvVf2XP+S7eGf+3r/0lloA+wfHHxP03wh4gTSLrStXvrk2yXRazWHYqu7qoJklQ5zG3QelYB+O2jqCT4b8SgDr8tp/8kVw/wAfmx8VVHro1r/6Puqjh8I6Da+D/Bd/q2t+KrnV/ElvbtBY2AssyTPCJGC+ZEAqgnGWbjIyepoA71fjrpD/AHfDfiQ5/wBm0/8Akipv+F16d/0LHiT16Wf/AMkVwXiXwJbaP4JutdtrvxXZ3tpe21s1lq6WmGD3EUbHMUeGUrIcMjnn3BFY6DI4HTigD1j/AIXPYYz/AMIv4lx9LP8A+SKkt/jBaXDhIfCviRmPQf6GP/bivLYVyCOnFXtO/dXMZ7bqAPS2+K0Ss6t4S8ShkGTzZcf+TNVH+M9gilm8L+JAAMn/AI8//kiuWuH8y/uFHGRXL3AZhtAJOSpGKAPSv+F5aV/0LXiX/vm0/wDkinf8Lv0v/oWfEn5Wn/yRXl0OjzsnmT7beL+9IeT+FWY30+zOIYjdSD+OT7v4CgD1C3+MVpcHEPhPxO/0W0/+SKfP8XrWD/W+FvES+xex/wDkmvKp9SupgV3lE/uoMAVnOW35JJ9zQB643xt0xTg+GfEmfpZ//JFNX436WzAL4Y8SknoAtp/8kV5RBa3F9LshHT7zngKPc1aa7t9JUx2QE910adhwD/s0Aeo3nxq06yRWuvDHiOMN0B+x5/L7RmqR+P2hDr4d8Sf98Wv/AMfrxzUSZ2MrsS7dSeaypYyCcjH4UAe5zftC+HoU3yeH/EoX18u1P/teqD/tOeEIyQ+jeJRj/phb/wDx6vFri3EkJD88dK5PVtMwWwox2oA+nNP/AGkfC+oXIt7PQ/EkkpBbb5VsvA5PJnpkX7S/hOUkR6L4kJHX9zbf/H6+Z/Blq1vq91MwJENrK+T9KxLbhwQcZ5yKAPrgftH+GCpYaF4kwO/lW3/x+oJP2mfCUasz6L4lAUEn9zb8D/v9Xy/FcDyyjcf7RqlqsJ+yzleFEbHr7GgD9IaKKKAPAP21v+SWaV/2Gov/AERPXH/ATQdZ8Ufs3+J9D8O3Fpa3d/rDwSTXLMqrCYbfzMbVJJK5GPc812H7a3/JLNK/7DUX/oieviqgD7/8CfDLUPA/xCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXwBRRQAUUUUAXtG1S90XUYb/AEy4e3uoidrr6HggjoQRkEHgg4NdPc6RaeLLSTUfDVstrqkYLXekxg7WwMmS2zyVxktGTleSMr93pvAvwmee2h1Xxi8llYuA8VkvE849W/uKfzPoOtelvp1g+nw2VnbCysYn3Qx2/wAhjYdHDDncDzuzmuetQ5n7Sm7SXXv5PuvxXQafRngdr8P/ABLdRLLbacssTjKulzCVYeoO7kVdg+FnjKdXMWj7gnLf6VCMf+P17LAbnTL5TtV3nflVCxx3jHuo4WKf1XhJTyNrnB67STd2l/LaarFsuDGl1CCCpMMgyoI/vKQyN/ug/wAVRTxlOU1Rn7s+3p1Xdef6ppNxdrrY+cv+FReOPIM39ifuwu4n7XB0+m/NV3+FvjFEVm0fCtwD9ph/+Lr6yjkkNk0IXgqwIPbvWVdSM0MaN1XpXWSfKN94M1nTp44dSt0tHlBaPzHDB8dcFcjI9OtdXXsXiLRrbW9NktbvI/ijkX70bjoy+4/XpXlFxo+rWuuR6FNZu2syMqwwqMCYNnDqf7uAST/Dg56V91wjmGEw0KkKj5Zbtt6NK/4q/wAzycxo1JuLjqjlbTwRrniLXZrXQrVb26kLz+UjhdiZ+8zNhR1A5PJ6Vs/8KQ+If/Qv/wDk7b//AByvqb4ceEbXwbof2dSs2o3GJLy5A/1j+g9EXoB+PUmurMtfIY+rSrYic6CtFvS+56VKMowSk9T4t/4Uj8Qv+hf/APJ23/8AjlIfgn8QR/zL/wD5O2//AMcr7RMlML1yGh8Yf8KU+IH/AEAP/J23/wDjlJ/wpX4gf9AD/wAnLf8A+OV9nZozQB8OeJfhp4v8Naf9u1nRJ4bP+KaORJlT/eMbNt/HFcfX6J9mBAIIIIIyCPQjuK8Y+JvwM0zXhLqHhPytL1Q5ZrY8W859v+eZ/wDHfpQB8p0Ve1nSr7RNSn0/VrWW0vYG2yRSjBU/1HuKo0AFFFFABX0B+xT/AMlT1X/sCy/+j4K+f6+gP2Kf+Sp6r/2BZf8A0fBQByn7Uf8AyXbxN/26/wDpLFX1N8R/h3qPiH4i2fiCHS/DusWEOkvYGz1eV0AlLswkGIZBwD7HryK+Wf2o/wDku3ib/t1/9JYq8qoA+rP2h/Dl74S/Zx8KaJqmotqV5aarGslwc4OYrhgozzhQQoz2A6dB8p0VKtvMxULFISwyoCnn6UARUVO1pcoMvbzKM7clCOfSoKACiiigAq5ptg+oSmOKSJHAyA5Iz9MCoIoJZmRYondnYIoVSSWPQD39qnktb7T7xI5ba4t7ofMqPGVb8iPatsPKnGpF1lePVbaEzUnF8rsz0OuG8QWD2t3LLJJEfOkZ1RSdwBJOTxXSQ6t/oO6aGRbsDHkbSGY+oHpwfyrnpdK1zU53nGmahMzHqls5A9uBX3XFWZ4PFYanGm+aT1XkvPz6WPJy+hVp1G3ojGorWbw5rijLaNqQHqbV/wDCq7aRqS53afeDHXMLf4V+fnsFGirn9mX+f+PK6/79N/hS/wBk6j/z4Xf/AH5b/CgClRV4aRqR6afeH/tg3+FJcaVqFtbfabmwu4bfds82SFlXd6ZIxn2oApUUUUAFFad1oOr2ljaXt1pV/BZ3Y3W08lu6xzD1RiMN+FVTY3YjZzazhF6sYzgfjQBWr1X9lz/ku3hn/t6/9JZa8u8iXOPKfOM42npXqX7Ln/JdvDP/AG9f+kstAHuPx0tmuPiqdmMpotqeen+vuq6nTfCF/rngX4S69oc9qmraBp1tNFDdllhnSS2jV0LKCVOAMNg49Kxfi7EknxYkZ5GQLo1n0Gc5nu64uPwZovn4XSdLKluhtkP9KAPYviv/AGxN8LNQOvRafBcvqVh5cNlK8qRp9ttwAZGVSxzk52qOQMHGT5umlyhAflI9qq2PhPR4b1JYtI0yOWNg0bJaoGVgcgggcHPeustrK4HLgRpjkuaAOeW2MYY5GfrU0NtLI2I1Lt1G2tOeCzhJ3CS5IPToBTHvJivl2yCIY+6g5oAszwDfDNcyiIuANg5YmqF1cR2csyWkCq3DeY3JqpPJKwG9Gyp3DPWrWpxb0inII3ptIoAwrppZ5SZXZ+eMmmCHgEir5h56DPQ0LEvAOaAKJiNS2dgbpizsI7dfvyHt/wDXrQtbI3MwRcherMewqTUpEeMQWw2wIeB/ePqaAMy9vQ0f2ayTyrYHt1f3NZTW/BJPHpWsbfIGQOaQ2pzQBkGDOfl9iKq3Nr83OCBW29uwOOCfQVFJECCpHNAGE1vx0NUbrT1lRsjr7V0MkODwKgeIFOcZHvQBgaNpphsdeldeVtCo/E1wX2QxP8o6dRXtmnW0baBrQI5aID9a83vLN1Evy4OQOPSgDlLkcBe9JNJ/xLrpJATiF8H04NWtQtG+8R8w71m3BYWVwHP/ACzf8eKAP0pooooA8A/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqgAoop8UbyypHEjPI5CqqjJYnoAO5oAdbQTXVxFBbRPNPKwRI0UszMTgAAdTX0P4E+Hul+BIINW8WCK68QMA8No2Gjsz2LDozj8h7nmrvw98G2Hw10hNZ1xUm8UTR7kjYAixBHQf7fqe3QdzWFqN5Nr+rtLNI+1m+UA9aAOiOpXOr6s00zO+WPBNasSuxG/wD/AFUmiWcQUDaAwHXvitNoQrY/nQBSW2uFvory0uzFcQj5EliSaHOc5KMOD/tKQfer2u6treo3Gk3N3pVrPdWsu03NlNs3QvgSK0T9ACFfh2OUApkSsznaDkjtWnEjDYCD74FcVXLsNWrxxMo+/HZ7P/gr1KU2lboW4y+Mg8nOapzIdqgjtnNW4wVCjB61BcsdoX2xXaSRaRbrLfCRuUiIIB7ntXYJBA91FdvBEbqJGjSUqCyqxBYA9cEqM/QVj6JawCP5QTIQGJPStxOBQBY3570bqjWnCgBwpRSCloAWikooAXNOFMp60AedfGbwfpXijSYG1FPKu428uG7jX95Hnsf7y+x/DFfJni7wzqHhbVmsdTjxkbopl+5MnZlPp/KvuDxZZm70ltn34mDgevtXnes6FpnivRW0zV0PlbSYZ1GZLd/7y/1HQ0AfI9FbvjLwzf8AhPXZtM1JfmX5opVHyTIejqfQ/p0rCoAK+gP2Kf8Akqeq/wDYFl/9HwV8/wBfQH7FP/JU9V/7Asv/AKPgoA5T9qP/AJLt4m/7df8A0liryqvVf2o/+S7eJv8At1/9JYq8qoAK6HRZWlisY1XcY5WA46Zwf8a56t3wv5n2uLYDtMoyfTigDotaWePQvtDwSqoWRhIUOPmYKPp+NcBX0/canp+nfsu+ITeFTd6heLYxZHzO6lGA+ijca+YKAFUgEEjOOxo70lFAHqnwy0nRte8aWs9jDNZabo9stzM8zbpJpV5LHHAHUgDstcf4x1+fxR4xvdV+75suIVUY2RjhRj6AfjmtWA6hoHw/luoy9sNTkECjGCy7SWIPuMD8azfC+mLMhuJGAPYe1AG/pGnz3csS7N02MAnrz2r2rR/DN/YaUJJLPEe3JIbk1xfgCzkGoiV4GeJUZiWHB44wa53xF8QtZXWGWO8dYLfKhDyrEH8qAPQNXvALZ40k2Nkc7ug9hWDqLWf9mTJHHJC7LhZDgsDjr/8AWrOfxDoVxLAddc215cR+Y0ltkRqSOMj0961X01JtOjvNPu47u1f+JGyAfpQBzlpDK8aqXBkVQC2OJPf2q+qSjbtA+pqyqKrbVzkDpxxVpMEgkknHTFAFEQMGLAnJ596lHlz2VxY3qmSznGJEPY9mHuKuKoc5JP1xzTSgb7+cZ/KgDx3xT4dn0W+dBmS2I3xyDuvr+HesKvb9d046lo9xBE225iBltywzlh1X6EZry7xTpSWiafqNoqiw1GHzYwpyI3HDp+B/QigD3271zSPFH7MtvZ3l2sOtaTBbLBaMNr7o5SgkT+8GjbBx6V51qwaHw01qW3TsAM+ozzn8K1dQ8OX1n4Q8D6o9sG028gxHMvJD4O5W9M4yPoayvFaqbS2MnmhnfACjHHcn8qAOKmkK30rDOFwo+ldr+zB/yXnw39br/wBJpq4zTLd9Q1e1jdH8ky5lboAM5OTXa/syAD4/eHQvTdd4/wDAaagD6F+KUMs3xbkWKNnX+x7Pdjt+/u6qWFrbxyk3FyGcfN5cfJ/Op/i08w+KVzHFIUR9Fs9+O/7+7rH02JYzuJPTjFAG0btYQfskSpx94jJqk8ksqlpXZj7nrUUrEe9IzZwc8UAK0jZAyQPWq7TSJcN8xGCe9PwTSXEW4+YuORzn1oAj3l9gznJNa0ZE+nY64HbtWBJIweMAYAw3StfSF3BozkLncKAK4ClNxyMj9aWFDNIsUXzMTwCKkuYXVpI8E4bjHvTnkGn2gUf8fcoyx/uD0+tAEt5KkEJtrc5P/LRx3NZmxsruOVpmTnIyfenI7buvFAD5FGRgU0ZIx14pxm7EDFIJVYcfL/SgCPYcg4NRPGCvSrDbiODkVCQQcelAFV4AQRVOaAocEcdq1SM9uKaVycYzQBFpURbR9WHYxj+dcvPYghgwwcYrvrWFE0+7UfK0iqP1rn72zcOxK5B6EUAcDqOnABht4HPArj9bsWtobhsfIYm+gODXrNzZlgQyn8a5XxHYBdG1I4yFt5Gx/wABPNAH3ZRRRQB4B+2t/wAks0r/ALDUX/oieviqvtX9tb/klmlf9hqL/wBET18VUAFevfDqz07wPpEXi3XkWXVZ1zpdowz5Q/57MPU/w/n6V5nokdstx9pvwHtoPmMZP+tbsn0Pf2qzqOsXuu3jT3su5uwHAA7ADsBQB39z4wuPEGpGW+kby3OCM8Vv+HVzc7Swwv3a838PW6mQb2yew9a7zSzPLdxohdF6Zxxx0oA9S047NpVdwI5xWhN57x/JGEI9u1UtIkZLaLzcMxGMjvWm3LH2FAEFj5+7D4Bz9K05Ad+A4z7VQij/AHqvnmrRUB85oAsQqQNxfBziqkqkvzzg9fWrcZypHUDmopD856EdeaANLRZCixxxYYnIf/Z5rWchHxnrXO6exWVx93eAMj09a0BqEf2V3kcB4zyO+Pf3oA14zkVJ0Fc4/iKyijMhnTA6jPP5Vp6FqUWq2j3NvkxbyikjGcdaAL4OaUUGkoAdSUUUAFPU0wmhTzQA+ZN8Lr6g15lYqytexuCCpPB7HNenjkVwN5tOs3e3GHYjj6UAcz468MWnjLQksLorFexAtZ3RH+rf+6f9hu/p1r5X1GyuNNv7iyvYmhuYHMciN1VgcGvsGcFo1I6g15R8a/C66nZHX7JAL61QLdqB/rYhwH+q9D7fSgDwyvoD9in/AJKnqv8A2BZf/R8FfP8AX0B+xT/yVPVf+wLL/wCj4KAOU/aj/wCS7eJv+3X/ANJYq8qr1X9qP/ku3ib/ALdf/SWKvKqACtzw1I6zIFGQJN3T2rDrd8OSGNiy8ldz4HU4FAFnxBe3E+jwO9w/lTyn9xk7RsAG7HrXNV7n8RfhLc6Z4T8CT2935st7au9wCOFdtsgCjvw2OfStvwb8P9K0WBGntI7q/ABd5gHCn0APFAHzulrcOm9IJWT+8EJFOW0mVwZoJVjXBcspGBnGT+dfYMcACp5aIq8HCqMfTFc18R2ns/D0l9bPEkkfDI6BldfcUAc5+0V4fQ+F/Cmo6Ary6YkcqyhOVjclcZx/sj8hXnfhPRpmtleS4h2EE7c84ruPC3jC5vYZJYACAM3mlsNySKBjzIwfQdq3jY6XqdsbzQYIAjD70fG1vQr2oAzvDmsPpqf2ZPcFrSVflVjnZ9K07zRdHu4UiGnI6T/LlSABnqfTvWMujySXLLeov2h8bSwwp/EdKtXWt2vhPTpkuZ0aV/lSyT5tzdiPSgDgk8MW/neJkmnR7jTlzGjnkp03Z9uKrfDvVG0u7EEjkW0wDbc5Un6VJZXjWtxcXd5bs0lyd8yJnOP7rZ/CsGZS14TBC0ZkOEjXkjPQAUAey6pYQXKCawjMbHkpng/SsgedE/zpxn3zj8qy/C/iOVLI22osyqfkS4xkYHqOoxXS2tvE1ypbUkmhIyohG5mz6DtQBQub2CJ1UHLgc88CpIA1wdwZeR90Gt+98MhIHvPsN4sIXPzYyR64NSeCtPh8RaTPd6aiQpDMYCZjzuHXgfWgDCjRo5YiAhcMDkn3rx3xReOzLp6iL7LbzTSRFO4dv/rV9D6p4D1ia0cQXdlHuyrMiktj0Gen1rwvx94O1LQdUkLW0jWrY2soJ28dD6fXpQB6x4E8ZadrX7P+o+FtalMWp6S4m08sceaofeAp/vDLDHoa858R3BnSNkfJjjxyehNWNE02ObwZpUkbhX86RnG3ngnvWBJKYrT5JA2XySV554xQBz+oTyee0YYhFOSAeCe5r0n9l05+O3hkn/p6/wDSWWvMb87r24Oc/vG5/GvTf2XP+S7eGf8At6/9JZaAPo34o24n+KV2e66NZY/7/wB3WNGCmV7Cuk+ILBfinfFj/wAwax/9H3lYkzR7iQpz3AoAgZRwc+9MZTtBqyqoQCM4Pr2qSSNTgc46UAU/em8gYPQmrfkA/dkUfWh7ZwoOOvcc0AZ9xHuZSBzjbWzpgDpE46kbT9apSKApJ7Vc0CIzmRCSsafOT6UAaDQJFP8AaZj8owFH941ydxI008kjnLljXYa0POiidOFGdv5Vx+3rxQAwe1CLkmp0jyBk4zRgZwBQBCw49aTHWpSvNJgUAQjI6ZzT95OQwzT9uaYV60AGARwfzqxZWzTzhEGWY4FVtuce1aWh3Qs76OWQZQNz9KAOssPDcAt280l3OM84GR6VlazocUVu8sGdq/fRucV0lvPvi3W8kckTHOQ3+cVj+INQjjtJoEdZJpeH2nIQfX1oA4CeMhWXqOnNc14qt0XwzrDbRn7HN0/3DXXSKT1Fc/4yj/4pXWW6H7FN0/3DQB9dUUUUAeAftrf8ks0r/sNRf+iJ6+Kq+1f21v8Aklmlf9hqL/0RPXyJ4b0z7dLLLIuYohjHqx6CgDHLEqFzwOgq3YJvk2569K07vQWDjyjjIzzWc0E9tKMjDA8UAdjoEKxHdJ1zivRvD9u9xPEyriMDjJrz/wAJadNfui5Yd2b+7Xrum2cVpGFVuSAKANuzU/IgB64zWsWO8jnBNM0Wz3oD37GttNMXq7kUAZcQLOAoPFX7e08wgtuPsKtx2MXymPPB5PrU9xPFap83X0HrQAxYkgGFgQn35NVLuS3YncsKHuAMmqtzdvc7syGOIcYHVqrqBGDtxn1HJoAS4uRGvyAoO2fvH/AVkStISwRj83X3+tactuX5PQdqiaLA+UUAcvNpckt0oVSxdgB+Jr13Q9OXStKt7JTu8sHc3qx5NcZpxEWpWry/cWQE16C31oAY1IKDRQAtBNJQelABmlB5ptANAEymuH1O1FrrLKhyjNu+me1dsDXJ62o/tlznqR/KgDGPMP8AwKsu9T5jlQykEFSMhgeCD9a1nG2PHfNZtyPm56UAfM3j3QD4d8RT2yBvskn723Y90Pb6g5H4V67+xT/yVPVf+wLL/wCj4KZ8W9C/tXww11CubrTyZQe5j/jH8j+FP/Yp/wCSp6r/ANgWX/0fBQByn7Uf/JdvE3/br/6SxV5VXqv7Uf8AyXbxN/26/wDpLFXlVABWvoUJlnRVbG8lG+n+TWRW74Wyuo2+7G0uG57e9AH0to/iWfxZovhmO8iCDSrTyAM8PIoC7/pgL+tb0cQIzjGDnOK858ATx2MGkJcMFa588/MPfgV6PoZuNd1iPStLdFd/mknk6Io64Hc+1AFa+urWwtWkuZljjGSfwryD4keK5datTZWFrOlqDkFlxvr6i0zwn4es9TFpPA+oXO0+ZNccgfRegrXv/DXh75jPp1q3lrwqqM/l9KAPgSwurqwu47q2PlTwNlWxgn29xXUa5dNpl0NS0zzI0u0WYiF9uMjuOnXNfRvxW+Fui6z4Wub7SLaO2urZC6lBgHA/wr57g0me7TTNMkBGbJySOeh4oAxU8W6zc7EW+mTcdg5GMH0rY+HvhfUPFXiL/RkmEds2ZbyUbhGvbHueataT4bk062SBkiPmxEgzLhmYnoP/AK1fRXwi0P8AszwOdOsIYxcvdCe4ZP4wVxkk+mOlAENj4N0WxgT7RapckjEjT8s4968r+N3gLTNKstL1jRnmtrm4kfbAgzt2d1P1Ir6HXTriRXuJ8W0CKWe4m4UKBnP5V4d8YfF//CQ65p2geEITd3NtE0cUr8BQxG6U+mcADP1oA8av7S3t7j7RrSO10MbbO26ucfx46ZPPrXs3w9t9L0nwva6ldLHbXdynmSGRcCMZ+6M9MVzXg3wwIdZ1q0a9s4WsbdVn1G9jJy8gIkaId8dA3tXoXg3xT4W0GSLw8b+58TzAeUN8SlXOOBzx+dAHMfEv4iHTtOksdIRp5p1KCY/dGR2rL+A89zYRXlpfEm0vW82F8dLgffQ+5HP4VgfGazuYLqO6EVs+nrNvWOJ8+UM/dLDrnGK3/gZrNpf+JPEd5e2zWehXEkIjAJKW07cJz7kY/GgD2kIGiU4OccjNZ+v6Omt6Y8TKPOC4jYjIB9D6g1PYyPPGxkieKZGKvE/8JB9e4rRg2iRd24dvagDx/RfAaQfDrxTq9rJJ9q0ueSWKwx8gAQGVT9Rkj6V4LdXSyXEHACN8+MdDjIr6O8cX99pmreI9P0u4MVpqls32tMZB+TqPQnkZr50mjWa7hikkRCIyqluApxwT7UAc4xLMSep5r1T9lz/ku3hn/t6/9JZa8scBWYAhgDgEd69T/Zc/5Lt4Z/7ev/SWWgD6d8dMi/FPUA67t2i2OPb9/eVkOik7uOa1PHq5+Kt8T0Gi2P8A6PvKzGX0xigCOaMbflyAOuKhXBQ7pOR6ip36cVWSFpugJwaAHKhI4bIPpUpikiGQ2B67ulK1s0WDhhx3FFvbB1ZpmxHnk+v0oAijgkunIdtsSjLOegFXbK4T7bHbQfLbKDn/AGvc1U1K4ztgi/dxL29frVKBmilV1POf0oA6bWF8mzC5OFZh+lcuF7c10c8/2rSyX/1qEZ+nTNYYC+o4oAj2HjqQKTygamK4Y8jafSlMeFHHPtQBXaMgH0puzr6VZkjZQCckGhEABJHFAFbYcCkaM5q0FUHrxTHUYGM0AVhFxycUAAYx1qdVNN24oAA5UYzTWctwxx6U8DGcimMMCgCKRcHkisDxj/yKet/9eM//AKLat526A1ieMgP+ES1vH/PjP/6LagD6wooooA8A/bV/5JZpX/Yai/8ARE9eH+HNC+xeHbOFoczSL5sueuW5x+AwK+if2o9M/tjwp4YsT92XX4S/+6sFwzfoDXnMtk+SyqFzwPagDzu+0oR2zbRlyeBWDY6LLd6nFCyFjIcZI6V6+miGVSSOT3NTw6Tb2KgKuZuu/wBPpQBmaVoEOi2flx5kkJyzN3Na+nwtLMu9fkB+YevtVmTc6A/lk1f0W2We6RDk/MC1AHV2apFbKQmwEc07zBM23kLVl0THl449Kq3rJCuFADdqAFurpLaE7cZHQVhTTmU75fmbsM02cvICWOT2Bot7csMtnp3oAlt/m+ZkyP0qbyVJJUAHr9KeoEcHOABWbe3DBtvO0c/UUAXlUuCFKj/bbp+FUIvLu5WhaQpJ6n/Cqc95OLZpEyATgH3qrouoRJqYM4JZwPm6nNAHWaV4dgSaOaZ5J3Rtw3HAB+ldQTVawZXiBU5FWGoAQmjNNNHagB1BNJmkNABmlBpuaO9AEqmuZ1lP+Jq+OoAb9K6Va53X18rUVmJ4kULQBh3QAKH1zms66xuFaV4pDL/sk/rWbdD5gPagCrIiMhV1DIwKsPUHgisD9lXSm0X46+I7Ag7YdKm2H1QzwFT+RFdA3pWx8HrFIvjS1+vDXGgXETD3S4t8H8nH5UAeDftR/wDJdvE3/br/AOksVeVV6r+1H/yXbxN/26/+ksVeVUAFdBoZRdQsizKoO0EHnPWufrVtlIEbK/zbVI9qAPcr/RtQ0jwx4J8TOons5mkiRIgS4Zm2qMdyQOK9Os9H1fRNTsrkw+RMoFwFVf3mCPusOx56V574N+JNpL4e8C6RcW8sj6TrPnSoozujAYqR7gvn8K9h174keHbHU5bi1ie9uSeGJwo4oAh8QeJbzTLMeIbK9s7zTEKjUIYji5gyQN2D2HQj+dMu9WXQNAm8aww3F/pdz5dw1y8m4iMsFwV6hQDxXmPjLxe3iKZt1ta267GQlYwWO7qRXofwYe41/wCGer+EdSjFxZW8RtIJ48ZMUgOFYHoVyefT6UAXPiF8SdCsvh/qV7p97DKLiExQRIeXZhjGPxrwjwRday+v6VcaRaC6WGDypc9zjdt+vIr2Xxb8IfCXhP4R6yTZG5v4YTKlyzMzrISNoQZwBkgYqLR57TwhplnFbzqmseUMwiEFIGZQcsf4jz2oA6bRj4v1l7CDxD4O0w2gTbK02wPGCPvL6HpkAZrkPiP8RoPBeuarpVjpF1Y3Ue0LcxEqkq4GODxjnk1t6P4Z8Rajqb6lpfxYu21ojc9o1ssloFz90QkjjHG4c962NcW91zw1quhfEbTLezvBA5ttVsBvt5T/AAlN3zJJn+Buo6E9gDxLx78c9X1PRlt4Y7NN2D5EKkouOm9iefXHSvJ7bV9RXU7yWxVpbq55LouCeOenbNQeLVaDWp7YxRW/lsFkRfuswH3vauv+BGqaNpfi83PiUotr5fys65AOaAKVza+MbiwM8lreLAqbd3ILexrDitL6wsvPia4t7lmDM4BHlr9fWvsrX/HGkWWnM1naPecKRGsHCK3QtWzFZ6D9ghM9raXMciBt5jGDnnpQB8EhvtG6JbsvFjLB8gFvet7wtPqGmRajBYXjQid0UxjlHP8AeI9R2Ne7/HH4T6Nf+GLrxT4NtFtryzQyXVpGvyzRjqQOzDk+9fP/AIWvYbdZGlIIRlZWPQDNAH1N4Wjlh0ayg1CQzXfkqHlz94gcE+9bCqCwyD9ayfDUq3eg2U6MvzoOnOaj8feJ7Lwh4auL+5kHnspitov4pJSMDA9B1NAHm3ja/W71fVbgMPLbzEUeoVcV8/3nyvNuwCVP8q+h/i3p+naRd6VY2cqPcjRRLdtH0kdjxJ9WGf0r551HMl9c4UjCkj0xjNAGRXqv7Ln/ACXbwz/29f8ApLLXlVeq/suf8l28M/8Ab1/6Sy0AfT3jnB+KOog/9Aaw/wDR95WYwBOK0/HOT8VNQA/6Atj/AOj7yqIjJfpxQBDJF96tvQLZIrRpdoLltoJ7VmPGdvQ1Z0y++zMySgtC/UDqD6igDopbaKS2YTYkGOQRXG6rC9vdSR7iVBG3PpXStf2oQH7QWXrtAOTXN6ndfabpnC4z+lAGROcyNwTg0xWYHjj6VNcLiQ+jc0xF9enrQBo2twsiRpIQEYeWx9PQ/nUE0Qy2MLIpw6n19aiXoyjgEc1JcAuwcHkjBoAYoOMEcVLGcHIqBMiplYHqPxoAlABGMAjH0pvkrgkZ/GnL93g5FO5OOaAK+1uSBz61HjPf2q0cj+LiomCnocUAQYx/+qgrmnPxjr9abuHHXFADStMYcc1JuHemsV6Z5oArOmDWD4y48Ja3jobGf/0W1dC3sRzWH4zH/FI65kY/0Gf/ANFtQB9WUUUUAebfG0Zt/CQIyDrJH/kld1xPkr/Cox64rt/jX/qPCX/YZP8A6RXdcc/HJGPxoAqzALjjpVK5UElgPYVflG4mqsy7iOKAM1CxOPQ8Vu+GiqagFGPmFZjRBCOKfFI0FwkkTFXUgqfegD0EICxP61m6k6BsYBer2nzfaraOdV27xyvoaz9ThMbmVvu0AZmzksSWNOjJ79BSb42fbk5p8cJmeOEMFLtjIHSgB9lbz3pLAbYQdpz0Nal7pEE8cIZeYxgY71ftoI7WFYYQQi+pyTUp5oA8u1lxDfTQyMV2nCoFxxXMG5EGoblOdpGSa6rxtFIuos4x5bj8eK4uZZTdJGCUVwSSeh7fpQB7V4du1uLeMochh19a2Hrzn4e6jLeeI2tI+LS3gJGepIwK9IcGgCLNGaMHNGDQAtITSgUu2gBlKKcFp6rQAKOK5bxfcqtzbwD72M11cjpDE0krBI1GSxOAK8q1TVX1TXZbnIFvGSI/90dKANaZvMjU552A/kayr04Yfzq7ZSCa0Vsjqy1nXz5CkmgBo559q6T4S5/4Wnbj/qDXv/o+0rl4mwpOa6b4Rtn4qQe2i3n/AKPtKAPnv9qP/ku3ib/t1/8ASWKvKq9V/aj/AOS7eJv+3X/0liryqgAratV3JDgABowPyNYtaOny4jRSRw5/WgDu/AUPlasZEAAMRyT2J4GK7LCjbzk9z7153pDThJ7m1VmltVRioPUA84/Cu+s7mHU4UurJkZZRvK9CD34oAlMaljhVB75rpfA3ii88HtfXtnskZ9pELZAcDqDXNCKYsf3Z44OelMtCL7URaRSEsg+cjoooA7vxl4+1Xx/pV8n2Z9L0m3gZhGr7mmk2/eLeg5wBWnHb291ofg6ezHnGWzAkJO5m5wrH68/lWBLbx2+mvBtxE+EZFHJU/ex+Ga9j8K2vhfS9ctm0S6ju2vQotYhIPLtYlTgL78dOuc0AWfC/huWz1CO9v40hjSLD5IwxPQ57Vp6v4g8I6vMvh661jTrm6um2LZw3KtKzKc4wpyMY9queIdJ8P3Mb6jrtvBcRQjJM7F4xj/YJ25/Cm2H9jSLJBoMdja3TQlopIYUXAI6jAoA+e/2hfBemHWDFa29paXlxCz2f2cfeKAZDj15/WvLfBFzovhvVbG/vF86/gBjuLG5TKsp6vGf7w7Zr3D4saJfReIvCerarIr332RrScIcjIJy345U59q878V+F7XU4DJsTz1O5cjHNAHQ+EvG/h2y8M+Jm8cXEyWV9cO+mWADG5KepZeBzjGTgVh6Z451S6isLtdWtbbTluFt40uf9YyAgsZAO+Pzq/wCCvhFP4l8CzeIdS1CSOaXeLOz2gqAhKgMfciub+Hfh+xtfGkml+M7N0S4XyQAu5AT3z0DUAfSfha4il1FI2uVOm3MbBVU7o7gMMD6DFfKvi/4bah4a8a6vpaqBDG4mtj1EsLE7PyPy/UV9dQ+ELW3t7GLSmMdrAgRVJ+6B0rwr9qvWzp/xE8LpZSn7RbWZa4UHGVL/AChvyP50AZek+JdU8OeGtRgsBb3F5piqt0sjcQFhkD0J+leWSX2reNvGFncatdNOytuKnhI0HJwO1dB4s8SWlzZyWmlWsUTXbrdaiY2yZCBwK05tE0ez8PaVqPg15rm+vrZjfRSNg2r56LkdD6c9M0AULzUm1G6uGZ2dFQw7mOSFGQqjPYdq861QyGSSPjAUkj04rtrBHiSSJ8DKFW55yDmuL1Hab7bLEH4IPP60Ac/Xqv7Ln/JdvDP/AG9f+ksteV16p+y5/wAl28M/9vX/AKSy0AfUXjTn4pal/wBgWw/9H3lUwACfWr3jHH/C0dTyP+YLYf8Ao+9qkcZoAR3CgjrVQlhICCcelTS4JwG/Oo1T/aB70AISS2CM/TimGFWzg/hVhUZsAcmnNEyJkjH1oAy7mMCPc3BHSqobHFX5xu61WeLsPyoAYj8ipxkqMdqiEWBzVmGLcVyTtPpQA1VDdODSFMdamMDISG6g4NOA/vDIoAgUFRnrT95NOKA5wcfWoyuORzQAHr15pj9cY/GlOQcHg0jcnFADCOtRMnPHU1MV4600q2eKAICDnBpjgdzirXl/3hUUijOD07UAVXOOnIrD8ZSf8Ujrgz/y4z9f+ubVvNEM56Vh+NYv+KR1s+ljP/6LNAH1bRRRQB5v8a/9R4S/7DJ/9IruuOYc812Xxq5h8I/9hk/+kV3XIlc0AQstMaIY6Vb28e9BWgDNni4+lVljy30Na7RZ61BKip0WgDo/DJzYbc8BuParGrKTaybQCQKxtFuWhb5funqK1NSuAbc7TmgDmd/70HjrWvpilr2EjAwc8/SsaRcsSBWzo5PnwnBOaAOg70N0zSkcGuY8Z6+NO02ZbWRTdcL67Ae9AGN40dJJol3p5gypAPK+xrk9QimZVUR/MQOemB6CkF27277myzNuViOR61PPqBtNLSOZVnuXGQvQoh6c0Aafw98uy1cyuAMnyzIW4Gewr1hlrw+xVXmiZFk89CH8sHK+wz6etddpniPVLMeXPIt3zli4wq+wPpQB3pWjFcZc+M7jkQ2kK47sSaq/8Jlqe35be2J9Sp/xoA7/ABS7Djp+NedyeJdYf5zOkQI+6kYAHvzWfNf3twGE11O4bkguefwoA9C1PW7DTUJnm3uP+WcXzN/9asHUPHNogC6bC00h6tKNqj+pNce3AODj29aqm2BzjOfagDR1fWLjV3/0tztB+VBwo/CseeKVplMZIGemetXooC7ZbqO9WZIticjtQBP4ek32DKeqyc/iKqXh4+lWtLXy3lI6HGfw71QvH/1g/wBo0ALCcxEGum+Dxz8VYf8AsC3n/o+0rkopCIa6n4Mtu+Ksf/YFu/8A0faUAeB/tR/8l28Tf9uv/pLFXlVeq/tR/wDJdvE3/br/AOksVeVUAFWrIgPjPOQRmqtWLMAsxOOAP50Ael/DtELzBwuNx3fQDGP1qhNFPpXieTTNKzL5p3qoPTP8hTPBt9Baw6m00yopj+Vs/wCea7HwZLDrgK6JYzXmqzKFlES75B9T/CtAEGqaTqr6SWe+O4LzHG3Ru1dV4R0ODSdLjBPmXbgGaQ9SfSjU7LUNAeIatpV1YRyEpHJMmFkPfDVLp9y8kQZY8oO4Yc0AX9UPlwAoQHAJwD2IxWB4J0eSw1ayu7maSSSO6jkit4mJKHfkYHqelX9QvorCSOW7jaRFb5h0DexNe3fBzW9C1fTlS1sbe01ZAWddoZ2XPDbse+MUAWPi/oUeo+HzeXF1fQiMANDE+YxnuV74PevPfD2tWNldWKXLyK6KIozEAWY5wPxOcV3nx0nuLXwXHbWLMBcXI807skoASR75OK8L0a1ng1ewmlileOKVJm28tsBycUAeq/GTSZ7IaNf+X/ocUqxb9xYozcfN257Yrg5o2dmVmPynIzXqvxO8beG5/Dy6ZK8942pL8i26/wCrI+ZWYnhcEDjrxXldsWljDOBkrzg8EigDb+HXjW08L6nPoXiGQR6HqL7redj8lvK3VWPZWPIPY/WvR9T8LeeJJLLyLq2mA2uMH8c14Fr9pHqmhX1s6qZBG+0em3kGvPPBnxO8U+HLcQaVqEhiBCiGQ71UeozQB9xaRYromkIl7djbDl3kkbgD618U/G3XoPG3xG1nUtLcPZxpHDHj7zInBb6Zqr4q+IHijxXOba+1W5kthw8cR2ofXOOtc/4Qg+062mnq4guJTuBcDqAeM+/pQBreAfC/9rxXks1yFKtsDA54xwa6DwsJtN1S50i4feEG6KQDGB6Gr0nhw6JpE2oaJfBZbYFZ4m4DsDyB7iue8IX82pazLf3EThSMFu2aALeq2rQajKyqdjDeM8exrznVdw1BuMlSSTXqeuOn2tCcFvLcEdq8svSBfM4UkAOzUAYpr1T9lz/ku3hn/t6/9JZa8qr1X9lz/ku3hn/t6/8ASWWgD6k8YjPxT1LH/QGsP/R97VRxjGB0q34yP/F0tSHroth/6PvarKh2nPc5oAqsNx4owRwo4qRxt4pACOehoAUHaOPwNAYkYY5HvQRgA4pM4Vj3IoArugL5qBkBJNWdy56n8qT5C3DDJ/CgCuFHp9DViFA0TgdRyMVG6kH2zUkPyPx0xz70AExJAJH3sHNMBGDk4xWrFYfabYeWw8z72D0qtLp1xEM7A2PQ5oApshxnFRHg1MwZSQ2R3wajI+YZI56UAQOSARnAHc00cjNTmNSR81RSDa3HSgBvfinAY74poHBpC3uM96AJD057daiZexxUu5ccHk0zIzmgCF48AkdK57xsP+KQ13/rxn/9FtXStXPeOFH/AAh+ukcf6BP+P7tqAPqSiiigDzn40DMfhEf9Ro/+kV3XLlR0FdT8Zfu+EP8AsMn/ANIbuuZIxQA3AC5OBTC2TTpOTz0pAM0ANC5NMmQFasAAVHJzkUAFhHsUE9TVmYnZtzxTbYZX8OlDtng54oAzym1sDNa2kyLHMpPAxg1TKb5MZCn19asBBHAxLKTkDg5oA1L6/hgiLmReBnrXleolrm7upHz++JznnJ7Vv6zAXAmyFIO3p2NZk20Qx574IPfrigDnoULHewxxwB0qrfXDS6jIkYBOQijuOK0LgOsMo53Bj096o2o2zFig8w8Fu9AHQaSkdvEFViXx82RWyYwsYZRww6Vi2u3Ax1962rVw8RT+6KAKciAsSwA79KAgwBzVmZRjpTUUd+SKAIUXdkMKiePAyMkVbO/zPlwFxTXj9fzoAoMPXpTVXHSrUseASOvpUSj1oAliXAwfrS3DAqFPTr9KcmMZqvK4znHFAFrTh8zk9MVi6idk0q99xrSsZsMVJOCeP8KytcbEm/1JU/WgCOOT919K634JNu+Ky89NFu//AEfa1waXACkAiuy+A0vmfFluemi3X/o+1oA8S/aj/wCS7eJv+3X/ANJYq8qr1X9qP/ku3ib/ALdf/SWKvKqAFrXt7GOKCN5XjZ3PQHlaz7UsrAom5jwD6fSrjSbVAIJJ+8c/yoAtsqOFiAUA8YAwK90+AWpPoug+KNP05o4bmaFZPtCL+8AAwdp/GvEdPgaeN5GXkHKKM8V678CNJmv/ABBfQxq5QWTFto6knigD2PxXA978AIprmcPcQFZYZmOTkOep+hIr5y07xQZpI7e7hKtvCgLwDzz0r6W+JSMnw3sdLtwkUhA82EEDgd8fnXy1rdqLfUEdVY7WKrsGefagD6l0TQvDeuiybQHtpLSRP9KgmJZ0bvkdj6Gu48B6Fo2nJPd6Top09pf3fmyHLyoCRnrwMjOPpXx5oGr6xoGoLFaTva3F9Hsb12Z5zX0H8FbXxHCHn1XXZG0SNS3lSyhmdj0xnlFoA7/x8lmUga5sobiXorzcqi9+M81jeDrXTdXS4W70C1t5lIUPbggMPXrxxVL4g2174murZNJuraeNMoI45gDk+ua2bRr7wz4aZNRtLiZypd57VgdpxgD2xQB5l8XdHh0jS7/VbO7t723s5Yd9q4O9A5wqsehBIxWLbyq8ZwyKx27lQcIxA+XFdR8dfE1pY+FNM8NWtgz3OrwwzNM4wkaKwIy3dyc8dua8l8B6s1zdX0E0n79285QfXOD+RFAGzqfmR6vCqkBZAwJx6rXgUkMlndXCggyRSsrDPJGf5V9C6o8cokZ8JLC42k9OleB67Cw1a6KjcwkbPP5GgC94TtL7WdThtLK3kkMjBCE64Pp617/ffs1Sx2CXOka/GdaCeZHDcxbBnGduQc+2cVx3wasn0i0s9VCeXOZPMVuhAz1r6SldbzSW8STT7pLFGkRs42EYJ/SgD5Dnvdbm1x9H8VsYBZuYp4E+Uhx2b1/rXWWVgI4v3cccUIHyRrx+JrnfibqU/iXxLd6/OkYk3oHMa7QyLwpI+nGa25vFFidOEyqQ4jUKCODntQBj+K5fs8kkhZQegx7ivNLne0V1KWbCqF46HJroNf1ObULhiSNpOQK5ti5s7qPk/dbGemD/APXoAy69V/Zc/wCS7eGf+3r/ANJZa8qr1X9lz/ku3hn/ALev/SWWgD6j8ZDPxT1L/sDWH/o+8pmQF74p/jI4+KWpev8AYth/6PvarlsLQAx2BY00DcetNdstgYp6qMA0AP2bkAPaoJFIUjPOKtDJxzUTrigDO3EZqOc8Eip3X5jUTlejECgBscjAgqTj07VahdZGAPyn2psNhPLgqFC+pbpWpZ6ekBDzSbm/2RxQBo2gEQREGSByadfgvGwXIDelV0u1EuxQBxxSPcn7ucDsaAMqa0lZiyjd261m3RMTHI5HBFazXbxTfNyM4NZWublYyxkNHLzz2oAz/tTJJ147c9KnW4D8vjNY00jmQAAflUqS4YfrQBrM2OP5VG3JyO1EDiWE4PSg8GgBN2CMVIr5wOM0zG4/Sgqe9AD2PWsHxsP+KO17p/x4T/8Aotq3c5GDWH41BHg3Xh/04XH/AKLagD6hooooA87+Mn3fCGf+gy3/AKQ3dcxn2rpvjLyvhD/sNH/0hu65wAA80AMKZGc4oxipDSYoAZmmHp71KcAVGfWgCW1IAJIz2p0g+bI6UiR7Uye9OO3byTQBC2ckVIqlom9gDUZYA9Bn3qVZMhSe/FAGbejzFO4DAGenSsS7SJozjPyn9DW3eKQX4PAIxWNLGSrRg/eHegDJuYvk3p9CKoJGGY/LgjuK1bhSicLwf5ioobfcGIHOeKAIoHZOoDVuaVghiemKpR22TnGTW5p1tshYnB7CgCF0yOlII/arjJwRUbRcZFAFYpzjvSOPlwasEZNMZM+lAFUx5qu8OWx0PrWhtwPaoHIJJ/CgDPnLRjbiqUkhrSmAYnIyKoXEJHI6etAEBlKJuH3gRVDW5xJayMp+8olX8+au3C4jbPQc1iupktFQ/wALNH+DDIoAxlvDkj1Feg/s4S+Z8WZ89tFuf/R9tXlqA5GTivTP2Z12/Fm5/wCwLcf+j7agDyj9qP8A5Lt4m/7df/SWKvLY13OAenU816l+1H/yXbxN/wBuv/pLFXmUcP3CSDnnFAF5cRxqSSN3CipbNj5nmI3OckFc1XYOzL6rx7Cr2n27GNgxIY/MSOaANhNtnp6TkEs44HvX0P8AswWRPhnxTrrAiV2FpG4GMYUFsfiRXzhqbTFba1KnenJUHg+lfXv7OlhHb/BsWoEhlkupTKpGDvYjj6YxzQBznxWkxbXDOxZ7WD5T0O4DmvCLPWZG028n2hWiUP5nfJPQCvVvjhfPY3t1p84KS7sn0K44rxq2kgOiROwyn2vLjqWAX5RQBt+G5JfIhmvJt93M4ijeVuUjzk819hTXNnPpkEk1jFPpc0C5mgxlX6HOOw9a+MPGGl6jodzbnUUVTcpvjWNsg57fhV/wz428ZaFIkuh3s/2dwVa3KeZC4AwcqeKAPpafwjpWoy+bo+pPa53eahPI47VP4Y8Ja7aX9vLpniGaKzWZHuFZRIsyKeUAPTPqOa8htvjRb2djL/bXhW2XVCQM28ropUjrjsfanx/G3XU8OXc/h7wzFBaljbtc+a0jxsRwQOvA9qALH7TN9c634is9I0xrdp7PcUWI8qMj73vkdO1eaXsknh7xxYSSR+ULq2WaZB/AzcOPzGfxqt4Q12aDx9p+oX8nmpcSlJnbn73c/QkV6h8ZvDUGoaCurQxn7XppJcr1eBuGB+mc/hQBz2tpdXOqvYW4ZjIolDjjaMdc1lnwKzXE09xKjs4HC81e8G6r/aVjp8CB3njylzIRxlR8uPwrt9nIHBIHWgDOtraO1t7S0i4jjQCu90ye5v8A4PeJrKAkz2+T/vIcHH5A1xU20uvIyM12fhq6j0P4deJNTvI2aG4BgBXrgrt/rQB4deaSX3R5ys2F6+g6V53q1vNa3JsTOQFfCKTxt7flXrt06LbJcA7yBtjX1J7muB8ZWphWyu4l3ysGVgeSM85/DmgDlPM8wsG2hlOCM/rVcB4ZXyFKupVvoe1TE/6QrgAAKFOR1x0ouUeaJGDBQByccUAYk0flSshIOD1HevUf2XP+S7eGf+3r/wBJZa85uwssG8NuePCk+or0b9lz/ku3hn/t6/8ASWWgD6i8aD/i6eo/9gaw/wDR95VY/dPNWfGgJ+Keo4/6A1h/6PvKrlQcgCgCFVO/pnFSkEDkYpsa881YxxQBGGz0GBTbksE4qyqjbljyelVLjJzmgDPYkKxGc1nrvkl25289TWnIcYA54qq8jW7FkRCG/vCgDoNGgCrgvkYx0qzfRsEAVhXLWmrTm7RWPydgO1dG/mSgMMkGgDLkZ458kEDOasTN5kDMDyBnira2krj5lGPelGjvg7JCAf4cf1oAwpJi/XninC1a900qp5RjitRfDxEmXmIXuMda1rOwitoGjAG3OeaAPMpQ6F1lH3Tg+1QM27r8rHvXXeJtNjS58+DP77hwORn1rl54tre3rQBNpsmyQhu9aTqR15rJtk3MB6dD6VrvyoH60AMAGaUnaMAUYx1oP40AIAGHBwfSsXxrx4N17/rwuP8A0W1bIwee1Y/jbnwZr2T/AMw+4/8ARbUAfT1FFFAHm/xruorNPBsk7BUbXlhyemXtLpB+rCsI8dayv2yriS0+G2iXEDbZYddgkQ+hEM5FSaDqkeu6HYarByl5As2PQkfMPwORQBodT6UHgUmaglkLNsTk+1ADmf05qWL5UVnVSCaW0tzOAAD7D19eabOx3bRlNvG0UAT7/MTbwOfSon449KiDEdqeHDLznNADME+lOTOMYpgxnrT846UALLGsyf7YGM+tZF/bOnIXFa4xjnFV5pc7ldQyj1oA5idJHZg2QM5ogRlOCS3pW4IIS+W3c9sU5YoFl4ViewoAztKurO6vprOO5ga7hx5sIYb0yAeV64wRW28YUBU+6P503w5YaRc+L10/WrC3ubLVoisXmLkxXUQLBkbqrNHv+YEH90oro9X+Hl1p8Tz6BrIMCAsbXVmLoAOwnHzqPdxJQBzGznDDIoKcYqvp18948ySWzxSQsFLq6ywy+8cinDr78fSrjjjIoApleeOtIygnjrUrLk5B+tRFsZwKAILg7eKpM2AauSgbSXPPaqEmeo6UANbDUzaCcMOKATnI61IANuaAMnVE2JtHRqyFXCN/vqa37xRISDWQ8e1SDx8woA42aPZO6+jkfrXpH7NmB8WLgd/7FuD+Hn23+Brz69X/AEyT/fP866z9lq8F38cNb2HKQ6LLEv4TwZ/XNAHnf7Uf/JdvE3/br/6SxV50h2ShGBwvP+favRf2o/8Aku3ib/t1/wDSWKvM1dnfax78cUAX3zJICeWds4HTmrkbmO72pldpCgZ9KrWkWb4Dd/qwXPHAwKn0xGm1KBOXMjZPuaAJ55dmpxyIGZvMUrnndivtr9nQ/wDFvcLuEa3cm1WOSowpx+Zr5I8N6eJtaWaaM+XbttIYfLnGc/hX1X8Or2TQ/hlo10T5ZvLqSYKB95CxwPxABoA5z9prR7dLrSdYlMaCRWtW3nCu/BUMe3GRXmfw28GXPibXL/w1qmn/AGKyit1vHEBBlU5wpVj1JB6GvWv2srq2k+FFlKNjibUYPLJOOCGOf0rxzQvEV9pPgW9hgnZdV8RSJA8oyxSEfLkMOhA4xQBheNLOPw/4ju4dTv8A+1YdMbyrYt1nOM7ceijrj0rhb2TU72+W4WbyFlXdBGkmwKOowB0/xqnrtx51480c0i2hd0tgxJITJBx9araVa3Opy29pao80wfIX+FV7knsKAOu8I6ldarNPa6skckUK7/MkAEsfbg9x9elVk1W706+Z9NuZobpX4aM4HcHiuq8WmGzsLRFW2aRYhHPc264Z89EHt05ri71reQnymIZTgspyQwXLZPoPWgBtrIkWp27ahu2CVZZQo5K7skivrH7OWtzb3Dw3umXcTeRcROHWVCBlcj0BFfKGl2k+pEPEdzYD4zlh+HcV6f8ABoX9l4kltru+K2kEeILZv4i+clR7YyaAJPh3Cmn6jquhSqRe2Uz4Lfxx5+Uj3wa7xowVB6kD161xniO0k0r4sf2sD/osoRJcd9y4z+eK7UEOquANrfhQBz11KUnECKXu5JPLiiXqxJ4xXpnxogj8NfB200pCFlZ0Df7RALN+tYXw58Iz6j4wt/FepH7No2nsRbl+DPKTgED0BOB71J+1Re4k0XT2Y7JIZnIB6E4ANAHk3hQvNaC5u3DBuUUjgVh+JmaOYPHJiaRWMZHqvI/rVbSdSZVlshIdlvEp54JPpiofENyGexlVgWiKsw9gcEfzoA5SMmWeMEbmJJJz0PrUh2y6deASAlcNj9KkigFnqVwpLDyt5UAdeDj+YrFTJDFpMBlAIPQ0AQSsRGEB6kgj1r0v9lz/AJLt4Z/7ev8A0llrzmKP5WkLcKGP6V6N+y5/yXbwz/29f+kstAH1D40OPinqODj/AIk1h/6PvKhdhjdnqMVN41/5KnqP/YGsP/R95VcDcAOCKAHd89qkByRnoBmmNjOOn0p2DtP0oAA2W571VkJyfrU68fX3qOZSGYY5oApS9yagYZGD0qzIp4HXuaiKjOO9AGf5DRTeYuQT0IrtNIhmeFfOzt6gnisOylFvLvZc8Y+lbY1P93kMMfWgDXWJR0H50p+XOSAKwl1jzPuFgKdDqUhOJgGH97FAG1uQjqDShUccHNZryJKuFOM1JbI4OcmgCaaBEU7Y1Y9s9K5DxJaTSv5q23QfwJya7NmZRyM1SvLyJI8PkH0UUAefQwOsu1lKNnlWGK0mQBSuKW/u4ri9WWPcT0ORjA7VNgMARxQBUK8jI4phU7quEDHOTUcq4HyigCBgAcZ5rD8bf8ibr3/YPn/9FtW6c9QOlYHjU48Ga6P+nC4/9FtQB9Q0UUUAeAftrf8AJLNK/wCw1F/6InrzD9nDxILnR73w/cP++tG+0W4PeNj84H0bB/4FXp/7a3/JLNK/7DUX/oievkfwT4gm8MeJrHVYMsIXxIgP34zwy/iCaAPseaTb0ptspfJUt5noo7VUtrqG9toLm0kEltOiyxOP4lYZBrWtArPCph46Ehsbh60Aa0dobaEOjKZSPmIHGPp61kTbhuzk72ycr0ronZIIl8ocL0XPJrGuiXkZiNm7nA6N/wDXFAFZEzyTS/dHFOTAAFI+ABQBGc5570pPODTSw545oU8c0AS4LCq1yu0f4Vaz+7zUE43KKAKg+9ShCz5FBGSNoq1FG0YBaIsCeooAztTiuGtTJYkC/tnW5tiTgCWNgyg+xIwfYmtfXfENt4xnt76zzJpkcUZgV+nmEBnYjpuBITnlSjDuaBDG/rkHnjBH1qN4YrdVW2RAhycIMA5OT+tAEGCpyPSh2+XgZqUlSDjsccVC2AcdB6GgCMqcHNU3J384ourh1YDoO1NSTzQFY/N296AI5fmyT1qs/Q8VbdcVWkHYc0AV8AmmSPt5zyP1qZuAapXDcYoAY5zzVW+TaEfsOTT0f94Aehpl+2+Bkzy3FAHnfii+GnWlzdE/Pg7B6sen+P4Vv/sWMW+KurMxyx0aUk/9t4K8w+JOqC51NbGI5S2/1hHdz2/AcfnXp37FP/JU9V/7Asv/AKPgoA5T9qP/AJLt4m/7df8A0lirzqzQExucYPHPrXov7Uf/ACXbxN/26/8ApLFXnlnESIcNggFh9T/9agDUtYzFpt/OzDd8sS47ljk/oK2PAESyatPczgGK0t3mY+nGBWPqERt9Jsoc5aZ2nf8A9BX+tamjpcW3huS3toyLvVpfKUj/AJ5r1P0oA6TwBJceJL610yKNB59x5KSbsMxfj9BzX0/8R7i30fTdG8N6dIsQhjVEwuWXA2r9MjNebfs8eDFtNYl1m7AMWkx7beMjGZpBgZ9TjP5ivTrTwlda1rF1rl/I0ebgSLER82Y8YA9BxigDyz9qVZdO8F+AtIldfNEkjupPPyxgD/0I14tok0k+g30VvIUkgdHhfrsIPJx+Ve4ftfWZ1iz8NahakTWybwjI3Byw3AH8B+VeSanrEfibU7KTSdKt9A0u3tRYxW9uclj3kkfA3MSep5oA5q+u4xfWr3GjhJrYFHVSRG5Pcr29apa/rN7CPs9tHDZwzLkvbrtMo9C3UgV7dJq3g/xVbaZceNL7UNI1nTo1t72O1tQ41RE+6ysB8rEDBz6/jXm/ivSIPFV1Nc6MkWmRxOUtdOckjYTkfP6+uaAOBg1SVbL7HMS9vuLL6oT1x/hXQ+D7JrucvaOsi/8ALW3xkEepB7YrIbwtra3IgfTpxJn04H417N8O/CKeHLRp5QJ76YfvG/hVewFAHDeH7aTQfEEIv45re1IlzJGhPBBKj1x0Fdj4F8SWt94j0XdaSW9wbh3cyYG1BGVA/E8/hXfDVLfSLLUZb22LW72+DJGo82Eg5DJn34I7g15T4qvoP7ctLzStQh1KZ7ZZ5J44zCNx6x7T/Gvf6igDu/Gt1bz3OobmTcLiGNDnoMZNen/Dvwg+t2cV1e5isFYcDrNjqB6DPevCvBmkXnjzXNLsC8kIvL9hMwH3Io0yxPv2HuRX2TfFdL0GePTIUAtYSqRjgKAvA/KgDivEt3Nf+MvD2j6XGE06xu1eZVHBKjjj0HP415F+1Df29x47tbUSZa1sQsozwpZi38sGvZfh9f2+qXt/d3Fi9nc2ZO985jYMM7gTyDivk/4i603iPxjqWoshQTXciAZzhOi/oBQBjPpok1y9NvcfLIoELtx5mAPzGawtUEs6SeYMbcjYeCpFMa6uLTV7ZnLeRCxiUE5C881pyKZXu5GJIQ5560AUrrek4nTiSazSQM3rtwf5Gq+maeLyG7kZji3iHFTAefp9ruJ3RF7djjPB+Zf5mq1ncNZ2moqpAZ4NuAffGaAMaVwkbDJ38qPpXpX7Ln/JdvDP/b1/6Sy15VXqv7Ln/JdvDP8A29f+kstAH0745k8v4qX49dGsf/R95UEbbhkHNL8Qs/8AC1bwDHOjWP8A6PvKoeaQMAdz0oA0gcHgZqVfXvWfBPyAwP5c1ooVcZHSgBHj9+PSqt0xznuanllBwOeKpzuG7UAVZMhsjgUsUmeG/OmyctjmgDjpQBNuGcUyQZz/AEpqkjqeKcO/GKAISCDkfpTobmWLO059mGakZcqarqy5ORQBp2eoeaQjKqP2UnGfpW1Yzea2GyrDsa42RNw3L9c+lbHh25kM+JCWUfLz1FAHWFlC/N0qrLbxTg4wc0/ocA8Gub8RX0ttcKsDFWIwMdjQBky2wguZUdSCGOM1OhwnPQHmnz3H2mNHbAlI+bFQM2EwTQBMDls9qacdM8Gq5m2g5OAKozXDO3XigDSlK5IRc/Sub8bBv+EP17d2sLj/ANFtW3azdATWZ44GfBfiDJGRp8/P/bNqAPpqiiigDwD9tb/klmlf9hqL/wBET18V19qftrf8ks0r/sNRf+iJ6+KqAPfP2evFa3UDeGb11a5hzNYhz/rF6vH9R94D617nYz/OP3gVAOPk6+uK+GNPvLjT76C8spnhuoHEkUiHBVgcgivsP4f+KLbxt4ai1a1CJfR4ivrZP+WUv94D+43UfiO1AHYRIZGLSEjbkox5P0Iqq7f3SCpORin48s/MQGHXHaoJTl2z9OKAJtoHOajcZH0ojfkAnilbGeDxQBVk+U56jvUqjK8DmnOgK8daZu2OFxjNAEoUlAoqtOdrkdsVPJIEjOM5qkhE1wiMTgnnHXFAFqxtpH+dSB9a0Y47hVOFSYDqucVJaRpjHlhwDxxwo+vetAKoGFUAewoAznzGoMgVSeMMcj86zHwvmDBRs5A9K6KZAyEModD1BrB1WNYHVd3B5Uk849DQBAPmC7R8xI4H86zr7/XspJ+pNWlkRdm0nI681DMPNJYj5z39qAIIVEiEPjjjNRXELRjcvVTkYqwI2QHcAAfwp0jAxkntxj1oArv8y5HcZqB4ygyetTxjESg9R3pJXUgluuKAM6b5c1nz9etaFx1zWfLznrigClIduW79q57xj4hj0TRpboMDckeVboecv6/QdfyrY1K5jtoZZp3WOGNSzux4UV4B4s1yTXdWec5WBPkhQ/wr6/U9TQBkSyPLI8kjFnclmY9ST1Ne+/sU/wDJU9V/7Asv/o+Cvn+voD9in/kqeq/9gWX/ANHwUAcr+1EM/HfxKPX7L/6SxVwEZzPJsJyFCgD8hXov7TEZk+PniXGOPszHP/XrFXHeGtOW71KBGkjy0qAjB5GaAHapZy32uQWcA4SNYgzdAFHzMfYZNdn4Ztor3WhcWuVs4R9ltGbnKr95h9TmtvV/CV7HpzXbabMtpMfIFwnAlXOdgbsPU10fhTwZqV+wTTLZ/MMYhiCD93CO5J7fWgD3P4RNp9r4chsAwe8MhlkZwMu3Yj6ACvQJl3QyL6qR1x29a8hg0u28GeKNKL3AuLyRFSYF9qZ6fIvbHqa9WmZZS5jlVZYSR97gE9jQB4z480bT7nwFdadpc88smhXy3EsF0Pnihc5YZ7rySD7V816zZ29jqut2enTMbRHWWLn7wyD/AFr7G8RJHD490KMRIF1q0ubS8j2/eRE3Bj9DkZ96+RfEHhjUbXUbvUrENLp86GLcB90Zx+XHWgDNhvFvHUSsRswWKjNVH8S/ZdSETSJGITlmCk7z/dHYDGOaTQ4F/t0W28qZR5ZTphvrWDq99DbX1zZQ20ElpDIyxgg5BHGc9/xoA9D0/wAT29zdP/pCmUorEbgAAD+Wa73QdVi1DTUmt1HluuQxGM847189W91ptvdWtwbSbKoWZQ/HmZ4I9q9p0vUZZtCtTdwGG5vLcXOwHhUJwCT6kDNAHStZ3PiO7XTNNR5LlsE8ZCDvk/0rzX4reHZfCHiJ9KuUws8QmiwvKY4z9K9t+GviPTvDlu99fbI48k72PzOvqPrXi/xP8SS/EX4jPexp5VtKgt7ZT1Eak8/ieaAPVv2ZtM1CDwdqGswW5a6aQ6dZSKu4KWIMkzZ6BTgZ/wBnFfR2kWq2unQxee10wUB535Mp7sa8WRT4f/4QPw5AtyNFjtI57iGE4a5kkP8AFjqM5JHvXq3hTVv7SbUYfMjl+y3Lw+ZCDswDwB+GOlAFnXkSGCOcpdCGB/NkS0AJkGCCrL/EuD+lfGPjPQkjXVNS0l2MTTM8kJGSmD1H4YzX2N4yhLaRNdx3s9o1spdWhGST24r558S2gi1m2vIYvLttZt/OaI/89AxVyB2BIz+NAHgfjCwEM1reqQYLtVbI6buM11lnpaS2rtOyg7iT79Kg1myFzb6joPCzWcpltwe6dSKh8PveXFr9hY795IDHsP8AIoA5myd1i1SIqAUfzE5/utj+RrHumzM2FKhxg5rqbewH2B55GWM+YQzN/dJxXOatDFbu6QSmYK3PGDQBjupRip6ivU/2XP8Aku3hn/t6/wDSWWvL5cnnsOK9Q/Zc/wCS7eGf+3r/ANJZaAPpL4juF+LF1nvo1l/6Pu6xwdoUA474q38XJmh+KF0UPJ0Wz/8AR93XPWOoiVQrOCy4BB6igDegkOQASRWlDI3RfxrMsmSSQYPOOa1EGwDJwx5oAJCVI3cAiq8o/L1pdRmCxBgM4FVLa5SYEHj60ASgZ5pNtS47UqjkUARY9c08DAGetSbfagqeAOtADHGEJxVGUYJIq/Of3RB71Qbk89KAGDIIZeOeR61p6LIIrkpjhufxrMfjkfpU0LHaHUlXHQ0AdIb9DcCInaTxzWNrSmS8+bl1GKq5LSyM/JfkmpHB3EyEsx7k9aAKxGOBUUjMB8tWJEGM9CKozMeQOtAFS9udsWOeTzVGG43HrxUeuOVVAO4zWLFctCxJPBoA7GBwRkEVV8bMD4J10+unz/8AotqzdO1aMvjJHbkVY8WSh/A+vE9TYT9D/wBM2oA+p6KKKAPAP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqgArpvh/4w1DwV4ih1PTjvQ/u7m3Y/JcRE8o39D2ODXM0UAfbmm6zp+uaNb6xosnnafdj5ASC1vJ/FG47MP8A64q3GeBXyR8N/HV/4J1VpYB9o024wt3ZMcLMvqPRh2b+lfVPhvV9O8Q6ZDqGi3IuLOQfR4m7o47MP16igDXVehwKQtyeBUq4I46VEwGaAEye1RzLuAbceKk/i2gEk1L5KsjLk7sZwBQBUcEwnPaqe2SFllx8pyBWyIVjh+ZQx7f40kkKvakgEHGzHpzQBJa3azQRANnyhgrnH4471pwlmUNuDKRkYrJsbJSTORtAOxQOPzrTBFuCZTsXOE9hQBaH61i+JEjNuJDw4OPx9K2lcEEqc49K5vxCyvMhXIDffU+ooAx0yDU8bhByM5qErjpTlyOO1AFs/OBzx3qCaCNJQ2T07U6LP8I/KnONwBIOR0FAFCcgL8owBVZjkc1cuQfK5A69RWc2QTgUARTA81m3Z2qegUcnJwB71qSssaO8jKihSxZjgKO5J7V4R8TvHn9qSS6VospGng7Zp14NwfQeifz+lAGd8SPFv9sXJ0/T3P8AZ8TfM4/5bOO/+6O351w1FFABX0B+xT/yVPVf+wLL/wCj4K+f6+gP2Kf+Sp6r/wBgWX/0fBQBz37TIb/heHi0qSOLQZHobaL/AArnvAcDXXijR7dnVIHnRGcdgTgn8q6b9pTn42eLV3bQWs8+/wDo0Vc94EWO28XaPI0geNZVYn1AyTxQB9c/FPxXc+Dp9K0zR0tWiaDIt5Iw42rwOP8APSsDwv8AEvVL7TtSh1KKG3dEL25s08piwH3eeK9B8V+FNN8Z6fDqlsNt6Yf9Hn6ZQ87T7HNeN6/osttZy6Klsy3VqHkaYfed/Y+nagDmvAkt9rXxH05BJM01xdb2Mrlyqrljn6AV9EeKtR0LRTHZ3+oSQTS3Iu5Ai7jjdkb/AEX/AAriv2evB0lpFN4l1BAHuF2WisPmVf4m/Hp+deWeMNXk1jWtYub9pVe6mkaFGI5jVtqhT9AKAPXfCHjzSfEnj3xXqd9Pb22n6ParBaSzMFBjJJlk59SFH0xXA2Mq3FhGYnjeErhGU8MmeCPwrzy10/SbzTjEIfJlYZYuCWzWz4bOo6RAlpIBPZLnbIvLL9aAMHxv4djF4J4d0cbn76HGw157c+C9S+3GOBo5IXBdJmbgj396911RnvrUQ2yrI8h27W71m6Vp0sFsh2lWP8B/h+lAHmejeENY1y9so9ZieDTbZNm9FALL6D1J9TXoWv7LG2zDETFFGESMnqFHC5+ldNGZijbUGE4bd3zWLrOg3OruVaYQ26qS2OlAHnET32v6sloZWllccRRAhEGOOfSu5uvD1to/hxLCyg8zU55FXz3Hz7hyzZ7AAHgVL4St7TRba6mD+Uc4WWQfO6jqcdhnoBUU8F34h1EXUpktLCJGjhH3S4bq2O2fegD2Wbxtov8AZnw+8TySxG1nY6bcNn5o0aMqxcfw7XA+gb3rtdbvX8Pano0VrEkHhhtqlrZOBITxkj+Ej86+Um8JWNyLiRLydZWBB/ucetbnhn4peItCiTTNKnmuI41EawPtlVcf3d2SKAPr2e3jureUId8dwoB54Ax1Arwn4n/2dBrtja6e4lTTYPLchv49xJ/HnmrMHxR1a+soEE0RWePBljQKQ2Oa4nXJXTTrm62fvGXgHqxNAHj/AIn1SaPxZNdxcYkzuzXW+Gnhbz5YSis4Dpn3HNY+jeHZNZv7pb1WVd5MjDovoM1Z1LSm0mxW2jkZRGxCP0I7jn0oAZHElzpM4EaNkFiT3IY1wfiKAw6tMFAUMobb+lei6DAg8P264k3ZdGZvXJ7VxHi9P9OWRRj+E0AcqDt4OME/pXp/7Lv/ACXfwzjp/pX/AKSy15hKS0xwMV6f+y5/yXbwz/29f+kstAH0N8WIRL8U7oN0/sSz4/7b3dcW9n5cxZPu9Miu6+J4z8U7vH/QFsh/5Hu6w7e2JIz9TmgCTQywzu7D8a3cGVj6ZxVK1SFCMD8hWwoUW5dMgj1oAxdVYLA65AYYGT2rHtpwknB47e9Ta3MRuJ/irHRjnigDqredSdpPXkVcHtXO2jkkVqW1wVOD92gDSA5oIxikQhgD2PNONAEd0P3RrKYndWtPzD7VlSr82aAHKA/BHFTxx7YuORmoIhitKNQUUe1AFEZyPSrO3cnvSyW+DlRSoCq47UAVJVO0kZqiyEt/jWu5BGPSqky/Od3SgDmtftyyxvjgZFc61q8h9EHeu9liV1KSAEVlXFgfuxqMelAHNxW6RjGCT61Y8TFovBWrrk7TZT4H/bNqttYSK4DZGe+Kg8XDHhLWVHRbGcdP+mZoA+tqKKKAPAP21v8Aklmlf9hqL/0RPXxVX2r+2t/ySzSv+w1F/wCiJ6+KqACiiigAre8HeK9V8I6oL7RrgxsRtlibmOZf7rL3H6jtWDRQB9jfDnx/pHjW0CWjrbaoq5lsZG+cepQ/xr+o7iuwNs3Jdtozw2M18HW1xNa3Ec9tLJDPGQySRsVZT6gjpXuvgH493EEcVj40iku41wq38AAlUerr0f6jB+tAHvQjjVvm2uvY96uwyB5sqNpKke1Y2hazpmuWovNGvre9tu7RNkr/ALy9VP1FacZjF0Nxwvc56UAWRb+ZLschSV4AHH4VEsSwSmHqnTJ9evNW0miZ49jjGPxp0gQTSBsAnD4PtQBBEscI8oEmQHfjr07VHqNyiwvKCSAwXHuf61R1GRknMw8zb1yvDIemR/hWJfatJN8nntKDyxxgEjpgetAG5b6qsNycJ+4JJOOprO1G5F3ePIF2qegJqpbSGQc1KRzQAgpyR7uaapJHNTJJsHAoAbH8rg9MVOzgKS/IIojYMfmA561Xu5khhkeQokKrku5Cqo9yelAENww2EZyK57XdXstHsnvdSuI7W3UY3N1Y+ijqT7CuP8afF3SdMV7bQlGqXgGPN5ECH69X/Dj3rwvxBruo6/fG71W5eeX+EHhUHoo6AUAdL8QPiBeeJXa1tN9rpKniLPzS+7kfy6D3rhqKKACiiigAr6A/Yp/5Knqv/YFl/wDR8FfP9fQH7FP/ACVPVf8AsCy/+j4KAOf/AGlTn45+LU77bVx74toeP51xHh+8Ww1Wyk43mQKRngKf/wBddh+06+z49+JGPT/Rgfp9lizXnUQEUwUscp0J780Afcn7OfiSbVfC8mnXkm6azYmPPXyySMfgR+orjPFHjr+yPirrVrd7VDBkRpVDIpC/KD9apfAe9/s7XdLdjlbsvbsAf7/zD9QK5j4/aVInxK1M5WMPtmDE9QVH9c0AfWeh3drc2EK2jIVSNMqv8OVBAr5j+NfgS2sNZXTtEuWVkSbWXDtzGm4/IvtmvQv2ZtXN34Y1pJ2fdZXCqxYk8eWDmvG21yfxx8TNV1243rCc28UQ7Qq3yrj3xk0AY3gua71i0F3NCYNowknd/wAK3rq6vIrfAgZJVP3oujD1rRsYBBAMIkfJKxgcKSelX2iAjZi6gqOmKAO5+F/g7RvEGii4vJbttSTBlYEIq5/hA/rWT460ez0DWTaWV5FM20EoWG5AT0IHese++J40Hw79h0O2axl2/v73gsw9EHY5715avjKwtZUnkSWRp3Jkl3bnz/ebPWgD04BCXBz8/PHQ12vw10HSdcnn/tS5ikkHC2O7BdeuT3I+leb2l0txp6XEMyGB1DiTPG3+lctD4y09dSN3Y3EsV9YSblcZUkg44PegD1z46Wmk6Ze6KmlW6LIhkWaOOPP93B/nXBvNM8Qb7LMV6AMMEn6VOnjqbxdfm8vtgKgR5Ax8x747Zq6zJ5oBLYJwfpQB59q1lqGsX72kN+beFG/eJGMZXuB71d8OaXaeGp5NVGl3RuIR5YXfuDR9Wf644rpPD9rGWvrs/wDLMhVGO9asMhz93p2oA4f4eao+seINSlKCK3abzYIh0TJwP0rsvHqyw+H2aBgkvmRhWUZP3hXE6dbjw94xvIlYpbm4imjHYo2ePwJrr9Ve58TO1vZgra28mXmPAB6AD360AZ/h+48281KGBwLSIoVUc5kyQzH1Jqp4/tRPZooznYScexzW9pGkJpUt1bwxoEcK4dTy+PUH+dR6rA0k1sW+ZVYhs+hFAGFZwRnT/lwQyeYCOhOOteX+J5CsmSAWGW5+uK9Did9O1KbR5mOOZID6oecfhXm/idxLNMQchG8vPvkk0ActI4aXK8Zr1D9l3/ku3hn/ALev/SWWvMduJiAe9enfsu/8l38M/wDb1/6Sy0AfSvxEkjj+KN8ZRn/iTWOD/wBt7ysUTQucBiDVz4ryiP4o3YIPzaLZHj2nu6wovmII70AbttLAufvHaMmpI7nzPNAJI28A1VhgLR4XrjtRApVnx2oAw9WzLMwHQVWtY+qt68VvXltvO5VyaqNaFDlhz3oAS3QqvoTVtBkU2Fc9etWlQZ96AJ7Rjwpq1nI5qrGNrCpz3oAWbmEjNZrjPBBrRbmI4qmRQA2MYHt71cU4AGO1QIuSM81Zx2oAejZHuKHHcflTQcfWl3cYNAFaY8VCDvBVufQ1PL8x+X8RVdkO7jg5zQBFKMHpgVnzytuOCAM1rTjdbtkDcax7qHahK8c0ARtIXbHY96xfF+R4R10DHNjOT/37atlMHZuGAD69KzvGxA8Ja7txzYz5/wC/bUAfVVFFFAHmH7Qvw/1X4j+C7LSNDuLGC5h1BLtmvHdEKLHIpAKqxzlx29a+ev8AhlTxx/0FfDf/AIET/wDxmvtSigD4r/4ZU8cf9BXw3/4ET/8Axmj/AIZU8cf9BXw3/wCBE/8A8Zr7UooA+K/+GVPHH/QV8N/+BE//AMZo/wCGVPHH/QV8N/8AgRP/APGa+1KKAPiv/hlTxx/0FfDf/gRP/wDGaP8AhlTxx/0FfDf/AIET/wDxmvtSigD430r9mj4jaReJdaX4g0K0uF6SQ3dwp/SHmvVtA8G/FO0hEWtzeEtUwNvmrdTwSH6kQFT/AN817lRQB5ZF4f8AGsfl/wDEp8Nkqc5Osz8/+SlMvPD3jm5ZD/ZvhtNpPTWJzkHt/wAelerUUAeO3nhLx1cWwgFl4bVA27J1acn6Z+y9Kzf+Fe+Nu1p4b/8ABrP/API1e6UUAeKQeB/G8Q5svDbf9xacf+2tTf8ACG+N/wDnw8N/+Def/wCRa9looA8a/wCEN8b/APPh4b/8G8//AMi0o8HeOP8Anw8N/wDg3n/+Ra9kooA8Vv8AwZ8QHtiun2vhSCc9JJ9SuJVH/ARbr/OvNPE/wE+KnieXdrHiTQJowcrCLmdY1+iiHFfWtFAHxX/wyp44/wCgr4b/APAif/4zR/wyp44/6Cvhv/wIn/8AjNfalFAHxX/wyp44/wCgr4b/APAif/4zR/wyp44/6Cvhv/wIn/8AjNfalFAHxX/wyp44/wCgr4b/APAif/4zR/wyp44/6Cvhv/wIn/8AjNfalFAHxX/wyp44/wCgr4b/APAif/4zXp/7PXwU8R/Djxpe6vrl7pE9tNp72irZyyM4dpI2BIaNRjCHv6V9C0UAfMHxm/Z/8VeN/iVrHiHStQ0SGyvPJ8tLmaVZBshRDkLGR1Q9zxiuRP7Lnjg8/wBp+Gt20Ln7TP8A/Ga+zaKAPnvwz8LfHWhx2YVPDcz2zo6v/aU65KkH/n2PpV34k/Djxn401+DU/sXhqyKQiJ4zqs8ofBJBz9lXHX9K93ooA8W+Hngnxx4O0PWrAWXhu7m1J2czjVp4/Lym0Db9lOcdeorlvCPwZ8YeHLaOOOHw3PKMmSU6nOpcnr/y7HFfSVFAHz7J8LfGzXUkqQ+G1VjkJ/ac5x+P2apG+GXjdh/x7+Gv/BnP/wDI1e/UUAfL2o/AzxxfzM88vhva5w6i/n5Xso/0fiuak/Zj8bM0uL/w0EY5UG6nJX8fJr7GooA+aND+C/jjTNBXTXPhqcgEeZ/aE68H2+zn+dck37M3jjdKy6h4aV5H3bhdT8D0/wBTX2JRQB8waP8AA3xrpV5HPbt4a+5smQ38+JPQ/wDHvwfetCX4P+ODcvPCfD0bMQSP7TnI4/7dq+j6KAPn3T/hb43tLWeDyvDbCWUyZGpzjHGMf8e1Sp8M/G6DAg8N4/7Cc/8A8jV77RQB8y698FPHGq3qXCv4cgIULgahOc4/7d66HRPht400vS4LIWfhmURkszHVJxvY9WP+jV7zRQB4bc/D/wAbzzRSG08NhowQP+JrP3/7daqT/DPxvKCDb+Gx/wBxSf8A+Rq99ooA+ZfEfwU8cavLbTRP4btZ4QQHGoTtken/AB7iuXvv2aPHN0u0aj4bQHlv9LnOTnOf9TX2FRQB8Xr+yx43DEnVPDh/7eZ//jNdl8Gv2f8AxT4J+JekeIdVv9ElsrPzvMS2mlaQ74XQYDRqOrDuOM19PUUAeT/EnwJ4i1zxqdY0MaRJbPp0NoyXl3JC6vHJMxICxOCCJR3HQ1g23w78cQkZtvDbAdv7UnH/ALbV7tRQB44ng/xuqgDT/DX/AIN5/wD5Fo/4Q7xtuz/Z/hrPf/ibz/8AyLXsdFAHjjeD/G5GBYeGx/3F5/8A5FqGTwT44f8A5cvDY/7i0/8A8i17TRQB4kPAvjcHiz8N49P7Wn/+RalXwV43X/lx8Nn/ALi0/wD8i17RRQB42vg7xuOth4bP/cXn/wDkWn/8Ij43/wCgf4b/APBvP/8AItew0UAePf8ACI+N8Y/s/wAN4/7C8/8A8i1EfBnjfP8Ax4eG/wDwbz//ACLXs1FAHjieD/G6nP8AZ/ho/wDcXn/+Raf/AMIn43/6B3hv/wAG8/8A8i17BRQB49/wiXjf/oH+G/8Awbz/APyLSN4Q8bn/AJh/hv8A8G8//wAi17FRQB44PB/jcf8ALh4a/wDBvP8A/ItMPgzxuf8Alw8Nf+Daf/5Fr2aigDxhvBfjhlwbHw3/AODaf/5FqF/AnjZgc2Xhrn/qKz//ACLXttFAHhJ+HXjcsCLbw2ADnH9qT/8AyNVTWvhf441PSb6x8nw3F9qgkh3/ANpztt3KRnH2YZ619A0UAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 64-year-old male presented with medication-resistant gastroesophageal reflux disease. Mesenteroaxial gastric volvulus is noted on a barium swallow fluoroscopic examination (A). The distal esophagus (yellow arrow) is in normal position. The antrum of the stomach (thick blue arrow in panel A and B) has rotated 180 degrees in a cranial direction and the fundus is positioned&nbsp;caudally (white arrowhead A).&nbsp;The mesenteroaxial volvulus&nbsp;is&nbsp;shown on reformatted CT study. A follow-up barium swallow fluoroscopic examination shows normal anatomic positioning of the stomach after the patient underwent fundoplication and gastropexy (C).",
"    <div class=\"footnotes\">",
"     CT: Computed tomography",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11321=[""].join("\n");
var outline_f11_3_11321=null;
var title_f11_3_11322="Psychiatric illness in dialysis patients";
var content_f11_3_11322=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychiatric illness in dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/3/11322/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/3/11322/contributors\">",
"     Rebecca J Schmidt, DO, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/3/11322/contributors\">",
"     Jean L Holley, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/3/11322/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/3/11322/contributors\">",
"     Jonathan M Silver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/3/11322/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/3/11322/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/3/11322/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric illness is common among patients with chronic disorders, particularly in those with end-stage renal disease (ESRD). A review found the following mental disorders were frequently observed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Affective disorders, particularly depression",
"     </li>",
"     <li>",
"      Organic brain diseases (eg, dementia and delirium)",
"     </li>",
"     <li>",
"      Drug-related disorders (such as alcoholism)",
"     </li>",
"     <li>",
"      Schizophrenia and other psychoses",
"     </li>",
"     <li>",
"      Personality disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders account for a 1.5 to 3.0 times higher rate of hospitalization among dialysis patients compared to those with other chronic illnesses, thereby resulting in significant morbidity. In the previous study of approximately 175,000 dialysis patients, 9 percent were hospitalized with a mental disorder during a one-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/1\">",
"     1",
"    </a>",
"    ]. A subsequent study from Japan reported a one-year 10.6 percent incidence of psychiatric disorders in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/2\">",
"     2",
"    </a>",
"    ]. Dementia, delirium, and major depression were the most common disorders in this four-year follow-up study.",
"   </p>",
"   <p>",
"    Patients maintained on hemodialysis are more likely to be hospitalized for a psychiatric disorder than are those treated with peritoneal dialysis. This difference may be due to patient selection for a particular dialysis modality or the increased incidence among hemodialysis patients of disruptive behaviors that may lead to hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/1\">",
"     1",
"    </a>",
"    ]. Overall, the type of dialysis modality does not appear to have a significant impact upon symptoms related to depression, sexual function, and life satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a paucity of data relating to the effectiveness of therapeutic interventions in the treatment of psychiatric disorders occurring in patients with ESRD. It is unclear if the management is less successful, and thus hospitalization is more common. Resistance to therapy may also contribute to higher hospitalization rates.",
"   </p>",
"   <p>",
"    Although few studies relating to the treatment of depression or other psychiatric disorders occurring in patients with ESRD exist, general recommendations for treating such individuals based upon outcomes among those without chronic kidney disease can be made. The types and treatment of psychiatric disorders in patients with ESRD are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression among dialysis patients may adversely affect mortality, possibly independent of dialysis adequacy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. It is the most common psychiatric disorder requiring hospitalization in this patient population, and can usually be successfully treated via the judicious use of medications, with or without counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence of depression in dialysis patients is unclear, reportedly ranging from 10 to 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4-7,10-22\">",
"     4-7,10-22",
"    </a>",
"    ]. This wide variation is based in part upon the different criteria utilized for assessing mood disturbances. In two studies of 210 and 380 peritoneal dialysis patients, scores consistent with a possible diagnosis of clinical depression were observed in 42 and 49 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/18,23\">",
"     18,23",
"    </a>",
"    ]. Of the patients who agreed to further testing, 87 and 84 percent, respectively, were diagnosed with clinical depression based upon standard psychiatric criteria. In addition, some patients may overemphasize their somatic symptoms, and may deny any mood disturbance or other symptoms directly attributable to depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression may be present at the start of dialysis. This was suggested by the finding that 44 percent of 123 incident dialysis patients scored above the validated cut-off on the Beck Depression Inventory [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, depression was most likely among Caucasians, patients without previous acquaintances on dialysis, and those with lower self-rated quality of life. A subsequent study of 272 consecutive patients at a Veterans Affairs Clinic found a 21 percent prevalence of a single depressive episode in patients with chronic kidney disease without a difference in episodes by stage of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/24\">",
"     24",
"    </a>",
"    ]. This suggests that screening for depression among CKD patients may be beneficial before the start of dialysis.",
"   </p>",
"   <p>",
"    The most powerful predictor of depression in a long-term follow-up (16 months) study of hemodialysis patients with depression and anxiety was the degree of depressive affect at the time of initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/25\">",
"     25",
"    </a>",
"    ]. In this study, 20 percent of patients had chronic depression or anxiety.",
"   </p>",
"   <p>",
"    Anxiety may be common in hemodialysis patients and difficult to diagnose. One study found anxiety in 46 percent of 70 patients studied [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/26\">",
"     26",
"    </a>",
"    ]. The Hospital Anxiety and Depression Scale, a commonly used instrument, had a poor predictive value for anxiety in ESRD patients. The anxiety disorders negatively impacted the dialysis patients&rsquo; quality of life and were not simply manifestations of depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Association with morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting information exists concerning the association of depression with survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/5-7,9\">",
"     5-7,9",
"    </a>",
"    ]. The effects of psychosocial factors on mortality were assessed in one study of 295 dialysis patients that used the Beck Depression Inventory to define depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/6\">",
"     6",
"    </a>",
"    ]. Although variations in depression scores were not associated with survival, lower levels of social support, decreased compliance with the dialysis prescription, and increased negative perception of the effects of illness independently correlated with enhanced mortality.",
"   </p>",
"   <p>",
"    In contrast, other studies suggest poorer survival among depressed dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/5,7,27-29\">",
"     5,7,27-29",
"    </a>",
"    ]. In a study based upon over 5000 hemodialysis patients with or without depression in the United States and Europe, the adjusted relative risk of mortality was 1.23 for those with physician-diagnosed depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/28\">",
"     28",
"    </a>",
"    ]. In a second report, utilizing depression as a time-varying covariate resulted in a significant association between mortality and the presence of a depressive affect [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suicide is significantly more common among ESRD patients than the general population. Independent predictors include male gender, white or Asian race, recent hospitalization, and alcohol or drug-dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depression is also associated with an increased risk of hospitalization. This appears to be independent of other comorbidities and demographic variables [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/31\">",
"     31",
"    </a>",
"    ]. This is consistent with the finding that major depression independently predicts hospitalization in patients with chronic kidney disease who are not receiving dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/32\">",
"     32",
"    </a>",
"    ]. However, it is not clear whether these findings are due to poor compliance with medical treatment or other health-related behaviors that are associated with depression, or the physiologic effects of depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general criteria for evaluating and diagnosing depression apply similarly to patients with and without chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To ensure the identification of depression, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines suggest that every dialysis patient should be evaluated by the dialysis social worker upon initiation of dialysis and at least biannually subsequently [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/33\">",
"     33",
"    </a>",
"    ]. However, screening for depression in this patient population is controversial, in part because there are no data showing that screening improves overall patient outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this, given the increased prevalence and morbidity associated with depression in dialysis patients, it is prudent to assume that actively screening for depression may lead to better outcomes. Some suggest using a screening tool, such as the Beck Depression Inventory (BDI), as the initial screen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/9\">",
"     9",
"    </a>",
"    ]. If the BDI score is greater than 14, further evaluation should be performed. However, the utility of this screening method remains uncertain.",
"   </p>",
"   <p>",
"    It is imperative to exclude uremia and assure adequate dialysis before diagnosing depression, since the symptoms of depression and those originating from a somatic process or disorder are similar:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms of under-dialysis, including anorexia and failure to thrive, may mirror those of depression.",
"     </li>",
"     <li>",
"      Correction of fluctuating blood pressure, nausea, or other gastrointestinal complaints may improve quality of life and lift spirits in chronically ill patients; thus, such therapy may effectively treat psychosocial markers suggesting depression.",
"     </li>",
"     <li>",
"      Common complaints in the dialysis patient, such as chronic fatigue, weakness, and constipation, may reflect a psychosocial disturbance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, an accurate assessment of such symptoms and signs relies upon the recognition that depression or related emotional concerns are additional diagnostic possibilities. An emphasis upon the cognitive aspects of depression rather than somatic complaints may be diagnostically helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, a mental status exam is required to help distinguish an encephalopathy from depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The request to withdraw from dialysis may also suggest underlying depression, as well as other disorders. To optimally assess this situation, it must initially be determined that the patient is competent and fully comprehends that the consequences of withdrawing from dialysis include death, usually within one to two weeks. In patients who appear to have intact decision-making capacity, the nephrologist must exclude the subtle presence of factors such as situational depression, mild dementia, and uremic or toxic encephalopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=see_link\">",
"     \"Withdrawal from and withholding of dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is also confounded by patients who do not realize they are clinically depressed or who deny \"being depressed\" even when directly asked; this is due in part to the stigma long associated with mental illness. Among 30 peritoneal dialysis outpatients, for example, 46 percent were found to be in a \"state of hopelessness,\" 50 percent had anxiety, but only 13 percent met the criteria for depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/34\">",
"     34",
"    </a>",
"    ]. The vast majority (93 percent) \"accepted their illness,\" an assessment that appears incongruent given that nearly one-half felt hopeless. By contrast, 55 percent of peritoneal dialysis patients eligible by Beck Depression Index criteria screening for further assessment to confirm the diagnosis of depression refused [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of depression in dialysis patients is similar to that recommended in the general patient population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .) Although studies among ESRD patients are few, combined treatment with antidepressants and counseling in the non-ESRD population results in greater success than treatment with medication alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]. Because psychosocial support and compliance are associated with reduced mortality in chronic hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/6\">",
"     6",
"    </a>",
"    ], psychologic counseling may be an important component to the treatment regimen. A randomized study from Brazil found that cognitive-behavioral group therapy was effective in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The urgency of treatment is primarily guided by the clinical circumstances and presentation. The patient must be questioned about suicidal thoughts and plans, and psychiatric referral made immediately if necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When there is no need for emergent psychiatric referral or hospitalization, treatment is dictated by the patient's needs and acceptance for medication and psychiatric referral, and the nephrologist's",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    primary care physician's comfort with prescribing antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]. The dialysis unit social worker's assessment may also be helpful in categorizing depression and directing therapeutic options.",
"   </p>",
"   <p>",
"    When treating a dialysis patient with antidepressants, the following must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antidepressants appear to be effective in approximately 75 percent of patients.",
"     </li>",
"     <li>",
"      Antidepressants usually require four to six weeks for full effect, although patients often begin to respond earlier.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the choice of antidepressant is principally guided by cost and side effect profile. Since many antidepressants (regardless of class) are hepatically metabolized, dosage adjustment is sometimes not required for chronic kidney disease. However, there are exceptions, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (Paxil) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    (Effexor) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inadequate dosing of antidepressants is the most common cause of therapeutic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]. Regardless of the class of antidepressant prescribed, full therapeutic doses should be anticipated for at least six months to one year in all patients to reduce the likelihood of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]. Subsequent survey data suggest that depression is undertreated in dialysis patients despite being common [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Japan, the use of benzodiazepines for the treatment of depression is more commonly observed than in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/38\">",
"     38",
"    </a>",
"    ]. In a study using data from the Dialysis Outcomes and Practice Patterns Study (DOPPS), benzodiazepine monotherapy was associated with an increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although selective serotonin reuptake inhibitors (SSRIs) are significantly more expensive than tricyclic antidepressants, they are generally well tolerated and effective in the doses initially prescribed; unlike tricyclic antidepressants, no dose titration is required with SSRIs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4,36\">",
"     4,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an increasing amount of literature about the efficacy of SSRIs in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/9,16,18,22,39,40\">",
"     9,16,18,22,39,40",
"    </a>",
"    ]. Although not proven, the safety and efficacy of SSRIs in dialysis patients is generally expected to be comparable to that observed in the nondialysis population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following is a survey of some of the studies that have evaluated these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/16,18,22,39,40\">",
"     16,18,22,39,40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 14 dialysis patients with depression were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/22\">",
"       22",
"      </a>",
"      ]. Psychological testing revealed improvement in mood at four and eight weeks with active therapy.",
"     </li>",
"     <li>",
"      In a second trial, 34 hemodialysis patients with depression were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and psychotherapy for eight weeks, with another 28 similar patients assigned to the control group [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/40\">",
"       40",
"      </a>",
"      ]. Antidepressant therapy significantly decreased symptoms of depression and increased normalized protein catabolic rate and serum albumin levels; by comparison, there was no change in the control group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most SSRIs are hepatically metabolized and highly protein bound (95 to 99 percent). Some exceptions include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , (which is 77 percent bound) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    (which is 80 percent bound) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36\">",
"     36",
"    </a>",
"    ]. Despite these properties, the pharmacokinetics of SSRIs may differ in patients with and without chronic kidney disease. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The half-life of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , normally 10 to 16 hours, is 30 hours in end-stage renal disease.",
"     </li>",
"     <li>",
"      The half-lives of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      , 24 to 72 hours and 12 to 15 hours, respectively, are unchanged in patients with end-stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36\">",
"       36",
"      </a>",
"      ]. However, when discontinuing fluoxetine, one must consider that the half-life of the active metabolite is seven to nine days [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dosing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    in patients with end-stage renal disease (ESRD) is the same as in those with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36\">",
"     36",
"    </a>",
"    ]. By comparison, the dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    should be reduced by 50 to 75 percent in patients with reduced renal clearance (glomerular filtration rates of 10 to 50",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and should not exceed 10 mg daily in end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized study comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    in patients without chronic kidney disease found no significant differences in the efficacy and tolerability of these drugs in anxious depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In non-renal patients, the reduction in or loss of sexual drive is a common side effect of all SSRIs, except for possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/43\">",
"     43",
"    </a>",
"    ]. Additional common side effects include restlessness, skin rash, hives, and itching (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ). A myriad of other less common side effects have been observed with these and the other SSRIs. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blurred vision (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Changes in urination (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Confusion",
"     </li>",
"     <li>",
"      Fever (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mental, mood, or emotional changes (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Menstrual changes, skin rash (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Itching, trouble breathing (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Joint or muscle pain (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Agitation and fast or irregular heartbeat (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these side effects have been described in patients without chronic kidney disease, their incidence is unlikely to be less in patients with end-stage renal disease. Cardiac arrhythmias and orthostatic hypotension are uncommon with SSRIs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less expensive than selective serotonin reuptake inhibitors (SSRIs), the tricyclic antidepressants are generally less well tolerated, particularly due to their anticholinergic effects (dry mouth, constipation), potential for causing orthostatic hypotension, and effects on cardiac conduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .) While these effects limit their usefulness in dialysis patients (particularly since these individuals have a high incidence of heart disease), their sedating effects and potential efficacy in treating neuropathic pain may be beneficial in some individuals.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     Nortriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    are the usual preferred agents in such cases.",
"   </p>",
"   <p>",
"    Because tolerance to tricyclic antidepressants is best achieved by gradually increasing the dose, initial prescribed doses should be low [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]. The dosing ranges for some selected antidepressants are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .) Blood levels of tricyclic antidepressants should be measured and followed, at least initially, on a monthly basis to reduce the likelihood of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]. In patients over 40 years of age, electrocardiograms should be obtained and monitored before and after starting tricyclic antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For nephrologists who prescribe or plan to begin prescribing antidepressants for dialysis patients, it is generally best to become familiar with one or two medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , beginning with the lowest dose and increasing to approximately two-thirds the maximum daily dose [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/4,9,44\">",
"     4,9,44",
"    </a>",
"    ]. If no clinical response occurs by eight weeks, a trial of an alternate SSRI or a tricyclic antidepressant may be prescribed. Upon failure of either the first or second choice antidepressant, psychiatric referral should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DEMENTIA AND DELIRIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with chronic kidney disease (CKD) over the age of 65 years, dementia, delirium, and other organic disorders are the most common mental disorders leading to hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/1\">",
"     1",
"    </a>",
"    ]. In younger patients with chronic kidney disease, they are the second most common psychiatric condition (after depression) requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dementia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high incidence of dementia among dialysis patients is likely because of the high number of older patients who are started on dialysis who are at high risk for dementia due to vascular disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report of 338 hemodialysis patients aged 55 years and older found that 14, 36, 37, and 13 percent had mild, moderate, and severe cognitive impairment or normal cognition, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/45\">",
"       45",
"      </a>",
"      ]. These findings were based upon the results of a battery of nine cognitive tests. Only 3 percent had a documented history of cognitive impairment prior to this study. Severe impairment correlated with a history of stroke, a",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      greater than 1.2, and a lower level of education.",
"     </li>",
"     <li>",
"      In one study utilizing SPECT imaging, 14 of 17 older dialysis patients with cognitive impairment had discrete cortical defects suggestive of multiinfarct dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other studies of CKD patients suggest that a decline in cognitive function likely begins with early kidney disease and before progression to ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. As an example, in a cross sectional analysis of 23,405 individuals, estimated glomerular filtration less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 was associated with increased prevalence of cognitive impairment (odds ratio 1.23; 95% CI 1.06-1.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/48\">",
"     48",
"    </a>",
"    ]. Furthermore, each",
"    <span class=\"nowrap\">",
"     10-mL/min",
"    </span>",
"    per 1.73 decrease in glomerular filtration rate below 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 was associated with an 11 percent increase in prevalence of cognitive impairment (odds ratio 1.11, 95% CI 1.04-1.19).",
"   </p>",
"   <p>",
"    Thus, the as yet unanswered issue is the degree to which the observed cognitive impairment is related to the dialysis process itself versus the metabolic and uremic processes seen with chronic kidney disease (CKD), the common cardiovascular disease in those with CKD, or neurodegenerative disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major dementia syndromes in patients with and without chronic kidney disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alzheimer disease",
"     </li>",
"     <li>",
"      Vascular dementia",
"     </li>",
"     <li>",
"      Dementia with Lewy bodies",
"     </li>",
"     <li>",
"      Frontotemporal dementia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with ESRD may be particularly susceptible to vascular dementia, but this association is unproven. Dialysis patients have a greater risk of stroke than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/49\">",
"     49",
"    </a>",
"    ]. Leukoaraiosis, a finding of high signal intensity in the periventricular white matter on brain magnetic resonance imaging that is associated with vascular dementia, has been found in some studies to be more prevalent in dialysis and predialysis patients, compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dementia associated with aluminum intoxication in dialysis patients is now uncommon due to increased awareness and the adoption of alternatives to aluminum-containing compounds as phosphate binders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of dementia in the dialysis patient is generally the same as in the nondialysis patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .) However, certain features unique to these patients deserve some emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As with depression, the occurrence of dementia in a patient with chronic kidney disease necessitates an evaluation for a medical condition, particularly a metabolic disorder. Uremia, as well as disturbances in fluid and electrolyte or mineral balance, may result in dementia. Thus, hyponatremia, hypocalcemia, hypoglycemia, and hypercalcemia should be excluded. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"       \"Acute complications during hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The central nervous system dysfunction that is universally observed among patients with severe untreated uremia is termed uremic encephalopathy. Depending upon the degree and rapidity of onset of chronic kidney disease, symptoms may range from irritability and restlessness to seizures, coma, and death. Central nervous system dysfunction should abate shortly (within days to weeks) after the initiation of adequate renal replacement therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"       \"Indications for initiation of dialysis in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain drugs can accumulate because of the lack of renal excretion. Thus, exposure to agents cleared by the kidney that affect CNS function must be excluded. This includes illicit drug use and aluminum exposure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"       \"Aluminum toxicity in end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Confusion, whether acute or chronic, may be due to a subdural hematoma,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      another structural lesion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"       \"Differential diagnosis of transient ischemic attack and stroke\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dementia due to structural and",
"    <span class=\"nowrap\">",
"     metabolic/electrolyte",
"    </span>",
"    disorders may be reversible with appropriate therapy. Similarly, discontinuing or lowering the dose of medications that are possibly contributing to a decrease in mental status should also be performed, if possible. As an example, antiemetics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , may cause neurologic effects in dialysis patients, thereby requiring dose adjustment in end-stage renal disease (ESRD) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36,53\">",
"     36,53",
"    </a>",
"    ]. Opiates, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , may also accumulate in ESRD, resulting in mental status changes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dramatic advances in understanding the pathophysiology of dementing illnesses have changed the management of patients with dementia from a conservative, symptomatic approach to a more biologically and medically specific one. Current management of patients is still frequently limited to treatment of behavioral disturbances, environmental manipulations to support function, and counseling with respect to safety issues (specifically the need to provide safe dialysis); however, the near future promises disease-specific, and hopefully disease-modifying, treatments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although cholinesterase inhibitors, such as tacrine (now rarely used due to hepatotoxicity) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    may be helpful in treating dementia, there is no information concerning the pharmacokinetics or effectiveness of these agents in those with renal impairment. As with all medications, the accurate use of medications in patients with end-stage renal disease depends upon close attention to proper dosing and whether there are contraindications to their use in individuals without renal function.",
"   </p>",
"   <p>",
"    The patient with dementia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delirium due to aluminum toxicity is administered the chelator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (DFO) to remove excess aluminum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"     \"Aluminum toxicity in end-stage renal disease\"",
"    </a>",
"    .) Patients may improve with such chelation therapy unless the dementia is significantly advanced [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/54\">",
"     54",
"    </a>",
"    ]. However, DFO can occasionally cause an acute worsening of neurologic symptoms. This effect may result from transiently increased levels of aluminum in the cerebrospinal fluid due to passage of the DFO-aluminum complex (mol wt 600) across the blood-brain barrier.",
"   </p>",
"   <p>",
"    Raising low hemoglobin levels to current target levels with epoetin therapy may also improve cognitive function and attention span in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of evidence addressing the effect of dementia upon survival among dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. A retrospective study using the United States Renal Data System database reported that two year survival was only 24 percent for those with dementia versus 66 percent for patients without dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium (acute confusional state) is one of the most common mental disorders encountered in patients with medical illness, particularly among the elderly. It is associated with many complex underlying medical conditions and can be hard to recognize.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many of the causes of delirium are similar in those with and without chronic kidney disease, some are specifically related to patients with uremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drugs, which can accumulate because of the lack of renal excretion. Thus, exposure to agents cleared by the kidney that affect CNS function must be excluded. This includes illicit drug use.",
"      <br/>",
"      <br/>",
"      An increasingly reported intoxication results from the ingestion of star fruit (Averrhoa carambola) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/58\">",
"       58",
"      </a>",
"      ]. This fruit, which is popular in the Philippines, Australia and elsewhere, can result in severe neurologic symptoms, delirium, and death if eaten by those with chronic kidney disease. Common symptoms and signs may include mental confusion, psychomotor agitation, intractable hiccups, vomiting, paresis, and seizures.",
"      <br/>",
"      <br/>",
"      The intake of the mushroom Sugihiratake may also result in acute encephalopathy. In one study of 32 patients with chronic kidney disease (24 undergoing regular dialysis), disturbed consciousness, convulsions, dysarthria, ataxia, paresis or paralysis were reported, with death occurring in nine [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The dialysis disequilibrium syndrome, which is characterized by acute symptoms, including headache, nausea, disorientation, restlessness, blurred vision, and asterixis, that develop during or immediately after hemodialysis. This syndrome, which is now rare in adults, is thought to be due primarily to cerebral edema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=see_link\">",
"       \"Dialysis disequilibrium syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemodynamic instability, whether hypotension or hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"       \"Hemodynamic instability during hemodialysis: Overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cerebrovascular disease, such as hypertensive encephalopathy, infarction, hemorrhage, and subdural hematoma [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/49,60\">",
"       49,60",
"      </a>",
"      ], which may occur in increased frequency during or shortly after the dialysis procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"       \"Overview of the evaluation of stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link\">",
"       \"Etiology and classification of stroke\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=see_link\">",
"       \"Etiology and clinical manifestations of transient ischemic attack\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysis dementia due to aluminum intoxication, which may rarely cause an acute encephalopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link\">",
"       \"Aluminum toxicity in end-stage renal disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Dementia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrolyte disorders, such as hypercalcemia, hypocalcemia, hypoglycemia, hyperglycemia, hyponatremia, and hypernatremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"       \"Acute complications during hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin deficiencies, particular thiamine. In one series of 30 consecutive dialysis patients with altered mental status, the diagnosis remained unclear after initial evaluation in ten [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/62\">",
"       62",
"      </a>",
"      ]. All ten had thiamine deficiency as evidenced by a marked response to thiamine supplementation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a low serum thiamine concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=see_link\">",
"       \"Overview of water-soluble vitamins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alcohol withdrawal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"       \"Management of moderate and severe alcohol withdrawal syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures, which are relatively common in dialysis patients. Rarely, nonconvulsive status epilepticus is the cause of confusion [",
"      <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"       \"Seizures in patients undergoing hemodialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A structural lesion, such as a tumor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a subdural hematoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link\">",
"       \"Classification of gliomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=see_link\">",
"       \"Differential diagnosis of transient ischemic attack and stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Uremic encephalopathy, which may present as acute confusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"       \"Indications for initiation of dialysis in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors, either alone or in combination, may result in severe central nervous system dysfunction. Many of these factors may also cause seizures and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"     \"Seizures in patients undergoing hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A related subject is that cognitive function among all dialysis patients may vary in relation to the timing of the dialysis procedure. One study, for example, found that global cognitive function was worst during dialysis and best just prior to dialysis and the day between dialysis sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of delirium in the dialysis patient is generally the same as in the nondialysis patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .) However, the clinician must also consider those unique causes of delirium in the dialysis patient delineated in the previous section. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=see_link\">",
"     \"Acute complications during hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=see_link\">",
"     \"Seizures in patients undergoing hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of a dialysis patient with delirium is based upon the presence or absence of a behavioral disturbance and the need to provide safe dialysis. If an underlying cause is found (as above), management should be tailored to the specific underlying disorder or abnormality.",
"   </p>",
"   <p>",
"    If required, parenteral or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , a typical (conventional) antipsychotic drug, is the treatment of choice to avoid the respiratory depression that may occur with benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .) No dosage adjustment of haloperidol is required with chronic kidney disease.",
"   </p>",
"   <p>",
"    Benzodiazepines may also generally be used at the usual doses; some exceptions are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    , which should be dosed at 50 percent for those with creatinine clearances less than 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Use of anxiolytics'",
"    </a>",
"    below) for further discussion [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36\">",
"     36",
"    </a>",
"    ]. There are few pharmacokinetic studies of these medications in patients with chronic kidney disease or on dialysis. Respiratory depression is certainly possible with benzodiazepines and necessitates careful monitoring of patients who receive these drugs. There are few data on the use of the newer atypical antipsychotic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ) in dialysis patients.",
"   </p>",
"   <p>",
"    For the acutely delirious dialysis patient, the recommended treatment is the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      &mdash; 0.5 to 2.0 mg PO or IM for mild agitation, 2.0 to 5.0 mg for moderate symptoms, or 5.0 to 10 mg for severe symptoms",
"     </li>",
"     <li>",
"      Elderly patients should receive lower end doses",
"     </li>",
"     <li>",
"      Although not approved for intravenous use,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      is commonly administered by this route and is generally thought to be safe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OTHER DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After depression, dementia, and delirium, the most common disturbances leading to hospitalization among older dialysis patients are alcoholism and other drug-dependence disorders, schizophrenia and other psychoses (including bipolar disease), and anxiety and personality disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alcoholism appears to be particularly common among patients with ESRD. In one study of 163 patients undergoing dialysis in an urban center in the United States, 28 percent scored positive according to the Michigan Alcoholism Screening Test [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/65\">",
"     65",
"    </a>",
"    ]. Such patients were more likely to be young, HIV-positive, and male.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with ESRD and psychiatric disorders other than depression or dementia are principally treated by a psychiatrist; some nephrologists may be comfortable prescribing antidepressants and often short-term anxiolytics, but the treatment of psychoses and personality disorders requires a psychiatric referral.",
"   </p>",
"   <p>",
"    Few pharmacokinetic studies of antipsychotics and anxiolytics in ESRD are available.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    or a short-acting benzodiazepine are the treatments of choice for acute agitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delirium in a dialysis patient as in non-dialysis patients (see above). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=see_link\">",
"     \"Assessment and management of the acutely agitated or violent adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Use of anxiolytics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since benzodiazepines are hepatically metabolized, dosage reduction is generally not needed in patients with chronic kidney disease; exceptions are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    , which should be dosed at 50 percent for those with creatinine clearances less than 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/36\">",
"     36",
"    </a>",
"    ]. No dosage adjustment for chronic kidney disease is needed with the benzodiazepine antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Although dosage adjustment of benzodiazepines is not generally needed for dialysis patients, one study of 12 patients (seven on hemodialysis and five on CAPD) showed increased sensitivity to the psychomotor effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    compared with healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/66\">",
"     66",
"    </a>",
"    ]. A marginally increased sensitivity to the memory impairment effects of alprazolam in the dialysis patients was also noted. The degree of sedation that occurred with the 2 mg oral dose of alprazolam was similar among controls and dialysis patients.",
"   </p>",
"   <p>",
"    Thus, a greater degree of memory impairment and an increased sensitivity to psychomotor impairment from benzodiazepines may occur in dialysis patients. Confounding variables that may have affected these findings in the previous study included patient age and gender (more women and older patients in the dialysis group versus controls) and the presence of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/3/11322/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Use of lithium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among medications used to treat psychiatric disorders,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    is unique in its effects on the kidney. Disorders of water handling, protein excretion, and possibly renal function may all be associated with lithium use and are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link\">",
"     \"Renal toxicity of lithium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    intoxication may also occur either acutely or as a result of chronic use and a superimposed loss of renal function; hemodialysis will readily remove lithium and is an integral part of the management of lithium intoxication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9225?source=see_link\">",
"     \"Lithium poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260812396\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with end-stage renal disease (ESRD) commonly have psychiatric illnesses, including depression, dementia, delirium, substance use disorders such as alcoholism, schizophrenia, and personality disorders. These illnesses account for a 1.5 to 3.0 times higher rate of hospitalization among dialysis patients compared to patients with other chronic illnesses. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is the most common psychiatric disorder requiring hospitalization in dialysis patients. The exact prevalence of depression is unclear, and ranges from 10 to 66 percent of dialysis patients. Depression may adversely affect mortality, possibly independent of dialysis adequacy. In addition, suicide is significantly more common among ESRD patients than the general population. The criteria for diagnosing depression apply similarly to patients with and without chronic kidney disease. Depression can usually be treated successfully with medications, with or without counseling. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Depression'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A high incidence of dementia among dialysis patients is likely because of the high number of older patients who are started on dialysis and are at high risk for dementia due to vascular disease. The major dementia syndromes in patients with and without chronic kidney disease include Alzheimer disease, vascular dementia, Parkinson&rsquo;s disease and related dementias, frontal lobe dementia, and reversible dementias. The evaluation of dementia in the dialysis patient is generally the same as in the nondialysis patient. Dementia due to structural and",
"      <span class=\"nowrap\">",
"       metabolic/electrolyte",
"      </span>",
"      disorders may be reversible with appropriate therapy. Medications that impair cognition should be reduced if feasible. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Dementia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although many of the causes of delirium are similar in those with and without chronic kidney disease, some are specifically related to patients with ESRD. These include drugs that can accumulate because of the lack of renal excretion (including illicit drugs), ingestion of star fruit (Averrhoa carambola) or the mushroom Sugihiratake, the dialysis disequilibrium syndrome, hemodynamic instability (hypotension or hypertension), cerebrovascular disease (such as hypertensive encephalopathy, infarction, hemorrhage, and subdural hematoma), aluminum intoxication, electrolyte disorders (such as hypercalcemia, hypocalcemia, hypoglycemia, hyperglycemia, hyponatremia, and hypernatremia), vitamin deficiencies (particularly thiamine), seizures, a structural central nervous system lesion (eg, tumor or subdural hematoma), and uremic encephalopathy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Delirium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of delirium in the dialysis patient is generally the same as in the nondialysis patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of a dialysis patient with delirium is based upon the presence or absence of a behavioral disturbance and the need to provide safe dialysis. If an underlying cause is found, management should be tailored to the specific underlying disorder or abnormality. If required, parenteral or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      is the treatment of choice to avoid the respiratory depression that may occur with benzodiazepines. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"       \"Prevention and treatment of delirium and confusional states\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among medications used to treat psychiatric disorders,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      is unique in its effects on the kidney. Disorders of water handling, protein excretion, and possibly renal dysfunction may all be associated with lithium use and are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=see_link\">",
"       \"Renal toxicity of lithium\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/1\">",
"      Kimmel PL, Thamer M, Richard CM, Ray NF. Psychiatric illness in patients with end-stage renal disease. Am J Med 1998; 105:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/2\">",
"      Fukunishi I, Kitaoka T, Shirai T, et al. Psychiatric disorders among patients undergoing hemodialysis therapy. Nephron 2002; 91:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/3\">",
"      Iacovides A, Fountoulakis KN, Balaskas E, et al. Relationship of age and psychosocial factors with biological ratings in patients with end-stage renal disease undergoing dialysis. Aging Clin Exp Res 2002; 14:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/4\">",
"      Fishbein, LJ. Depression in end-stage renal disease patients. Semin Dial 1994; 7:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/5\">",
"      Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 1993; 4:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/6\">",
"      Kimmel PL, Peterson RA, Weihs KL, et al. Psychosocial factors, behavioral compliance and survival in urban hemodialysis patients. Kidney Int 1998; 54:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/7\">",
"      Peterson RA, Kimmel PL, Sacks CR, et al. Depression, perception of illness and mortality in patients with end-stage renal disease. Int J Psychiatry Med 1991; 21:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/8\">",
"      Klein O, Korzets Z, Bernheim J. Is a major psychiatric illness a contraindication to chronic dialysis? Nephrol Dial Transplant 2005; 20:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/9\">",
"      Cohen SD, Norris L, Acquaviva K, et al. Screening, diagnosis, and treatment of depression in patients with end-stage renal disease. Clin J Am Soc Nephrol 2007; 2:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/10\">",
"      Beard BH. Fear of death and fear of life. The dilemma in chronic renal failure, hemodialysis, and kidney transplantation. Arch Gen Psychiatry 1969; 21:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/11\">",
"      Kutner NG, Fair PL, Kutner MH. Assessing depression and anxiety in chronic dialysis patients. J Psychosom Res 1985; 29:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/12\">",
"      Israel M. Depression in dialysis patients: a review of psychological factors. Can J Psychiatry 1986; 31:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/13\">",
"      Christensen AJ, Smith TW, Turner CW, Cundick KE. Patient adherence and adjustment in renal dialysis: a person x treatment interactive approach. J Behav Med 1994; 17:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/14\">",
"      Kimmel PL, Peterson RA, Weihs KL, et al. Behavioral compliance with dialysis prescription in hemodialysis patients. J Am Soc Nephrol 1995; 5:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/15\">",
"      DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 1997; 30:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/16\">",
"      Wuerth D, Finkelstein SH, Ciarcia J, et al. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am J Kidney Dis 2001; 37:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/17\">",
"      Watnick S, Kirwin P, Mahnensmith R, Concato J. The prevalence and treatment of depression among patients starting dialysis. Am J Kidney Dis 2003; 41:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/18\">",
"      Wuerth D, Finkelstein SH, Kliger AS, Finkelstein FO. Chronic peritoneal dialysis patients diagnosed with clinical depression: results of pharmacologic therapy. Semin Dial 2003; 16:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/19\">",
"      Lopes AA, Albert JM, Young EW, et al. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 2004; 66:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/20\">",
"      Hedayati SS, Bosworth HB, Kuchibhatla M, et al. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients. Kidney Int 2006; 69:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/21\">",
"      Cukor D, Coplan J, Brown C, et al. Depression and anxiety in urban hemodialysis patients. Clin J Am Soc Nephrol 2007; 2:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/22\">",
"      Blumenfield M, Levy NB, Spinowitz B, et al. Fluoxetine in depressed patients on dialysis. Int J Psychiatry Med 1997; 27:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/23\">",
"      Wuerth D, Finkelstein SH, Finkelstein FO. The identification and treatment of depression in patients maintained on dialysis. Semin Dial 2005; 18:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/24\">",
"      Hedayati SS, Minhajuddin AT, Toto RD, et al. Prevalence of major depressive episode in CKD. Am J Kidney Dis 2009; 54:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/25\">",
"      Cukor D, Coplan J, Brown C, et al. Course of depression and anxiety diagnosis in patients treated with hemodialysis: a 16-month follow-up. Clin J Am Soc Nephrol 2008; 3:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/26\">",
"      Cukor D, Coplan J, Brown C, et al. Anxiety disorders in adults treated by hemodialysis: a single-center study. Am J Kidney Dis 2008; 52:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/27\">",
"      Kimmel PL, Peterson RA, Weihs KL, et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000; 57:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/28\">",
"      Lopes AA, Bragg J, Young E, et al. Depression as a predictor of mortality and hospitalization among hemodialysis patients in the United States and Europe. Kidney Int 2002; 62:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/29\">",
"      Boulware LE, Liu Y, Fink NE, et al. Temporal relation among depression symptoms, cardiovascular disease events, and mortality in end-stage renal disease: contribution of reverse causality. Clin J Am Soc Nephrol 2006; 1:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/30\">",
"      Kurella M, Kimmel PL, Young BS, Chertow GM. Suicide in the United States end-stage renal disease program. J Am Soc Nephrol 2005; 16:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/31\">",
"      Hedayati SS, Grambow SC, Szczech LA, et al. Physician-diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis. Am J Kidney Dis 2005; 46:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/32\">",
"      Hedayati SS, Minhajuddin AT, Afshar M, et al. Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. JAMA 2010; 303:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/33\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/34\">",
"      Lye WC, Chan PS, Leong SO, van der Straaten JC. Psychosocial and psychiatric morbidity in patients on CAPD. Adv Perit Dial 1997; 13:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/35\">",
"      Duarte PS, Miyazaki MC, Blay SL, Sesso R. Cognitive-behavioral group therapy is an effective treatment for major depression in hemodialysis patients. Kidney Int 2009; 76:414.",
"     </a>",
"    </li>",
"    <li>",
"     Aronoff, GR, Berns, JS, Brier, ME, et al. Drug prescribing in renal failure. In: Dosing guidelines for adults, 4th edition. ACP-ASIM, Philadelphia, 1999. p.91.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/37\">",
"      Andreucci, VE, Fissell, RB, Bragg-Gresham, JL, et al. Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. Am J Kidney Dis 2004; 44(5 Suppl 2):S61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/38\">",
"      Fukuhara S, Green J, Albert J, et al. Symptoms of depression, prescription of benzodiazepines, and the risk of death in hemodialysis patients in Japan. Kidney Int 2006; 70:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/39\">",
"      Levy NB, Blumenfield M, Beasley CM Jr, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry 1996; 18:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/40\">",
"      Koo JR, Yoon JY, Joo MH, et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci 2005; 329:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/41\">",
"      Kimmel PL, Cukor D, Cohen SD, Peterson RA. Depression in end-stage renal disease patients: a critical review. Adv Chronic Kidney Dis 2007; 14:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/42\">",
"      Fava M, Rosenbaum JF, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000; 59:119.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. National Library of Medicine. Medlineplus Drug Monographs. www.nlm.nih.gov/medlineplus/druginformation.html (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/44\">",
"      Fabrazzo M, De Santo RM. Depression in chronic kidney disease. Semin Nephrol 2006; 26:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/45\">",
"      Murray AM, Tupper DE, Knopman DS, et al. Cognitive impairment in hemodialysis patients is common. Neurology 2006; 67:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/46\">",
"      Lass P, Buscombe JR, Harber M, et al. Cognitive impairment in patients with renal failure is associated with multiple-infarct dementia. Clin Nucl Med 1999; 24:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/47\">",
"      Kurella M, Chertow GM, Luan J, Yaffe K. Cognitive impairment in chronic kidney disease. J Am Geriatr Soc 2004; 52:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/48\">",
"      Kurella Tamura M, Wadley V, Yaffe K, et al. Kidney function and cognitive impairment in US adults: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis 2008; 52:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/49\">",
"      Seliger SL, Gillen DL, Longstreth WT Jr, et al. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 2003; 64:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/50\">",
"      Kim CD, Lee HJ, Kim DJ, et al. High prevalence of leukoaraiosis in cerebral magnetic resonance images of patients on peritoneal dialysis. Am J Kidney Dis 2007; 50:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/51\">",
"      Fazekas G, Fazekas F, Schmidt R, et al. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. J Neurol Sci 1995; 134:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/52\">",
"      Martinez-Vea A, Salvad&oacute; E, Bardaj&iacute; A, et al. Silent cerebral white matter lesions and their relationship with vascular risk factors in middle-aged predialysis patients with CKD. Am J Kidney Dis 2006; 47:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/53\">",
"      Neely KJ, Roxe DM. Palliative care/hospice and the withdrawal of dialysis. J Palliat Med 2000; 3:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/54\">",
"      McCarthy JT, Milliner DS, Johnson WJ. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity. Q J Med 1990; 74:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/55\">",
"      Pereira AA, Weiner DE, Scott T, Sarnak MJ. Cognitive function in dialysis patients. Am J Kidney Dis 2005; 45:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/56\">",
"      Rakowski DA, Caillard S, Agodoa LY, Abbott KC. Dementia as a predictor of mortality in dialysis patients. Clin J Am Soc Nephrol 2006; 1:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/57\">",
"      Kurella M, Mapes DL, Port FK, Chertow GM. Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2006; 21:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/58\">",
"      Neto MM, da Costa JA, Garcia-Cairasco N, et al. Intoxication by star fruit (Averrhoa carambola) in 32 uraemic patients: treatment and outcome. Nephrol Dial Transplant 2003; 18:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/59\">",
"      Gejyo F, Homma N, Higuchi N, et al. A novel type of encephalopathy associated with mushroom Sugihiratake ingestion in patients with chronic kidney diseases. Kidney Int 2005; 68:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/60\">",
"      Sood P, Sinson GP, Cohen EP. Subdural hematomas in chronic dialysis patients: significant and increasing. Clin J Am Soc Nephrol 2007; 2:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/61\">",
"      Toyoda K, Fujii K, Fujimi S, et al. Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis 2005; 45:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/62\">",
"      Hung SC, Hung SH, Tarng DC, et al. Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2001; 38:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/63\">",
"      Chow KM, Wang AY, Hui AC, et al. Nonconvulsive status epilepticus in peritoneal dialysis patients. Am J Kidney Dis 2001; 38:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/64\">",
"      Murray AM, Pederson SL, Tupper DE, et al. Acute variation in cognitive function in hemodialysis patients: a cohort study with repeated measures. Am J Kidney Dis 2007; 50:270.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. National Library of Medicine. Medlineplus Drug Monographs. www.nlm.nih.gov/medlineplus/druginformation.html (Accessed January 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/3/11322/abstract/66\">",
"      Schmith VD, Piraino B, Smith RB, Kroboth PD. Alprazolam in end-stage renal disease. II. Pharmacodynamics. Clin Pharmacol Ther 1992; 51:533.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4855 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11322=[""].join("\n");
var outline_f11_3_11322=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H260812396\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Association with morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DEMENTIA AND DELIRIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dementia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Delirium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OTHER DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Use of anxiolytics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Use of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260812396\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8343?source=related_link\">",
"      Acute complications during hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13125?source=related_link\">",
"      Dialysis disequilibrium syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/37/36439?source=related_link\">",
"      Differential diagnosis of transient ischemic attack and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40678?source=related_link\">",
"      Etiology and clinical manifestations of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=related_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9225?source=related_link\">",
"      Lithium poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/62/28650?source=related_link\">",
"      Overview of water-soluble vitamins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=related_link\">",
"      Patient information: Delirium (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/32999?source=related_link\">",
"      Renal toxicity of lithium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/58/22440?source=related_link\">",
"      Seizures in patients undergoing hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8072?source=related_link\">",
"      Withdrawal from and withholding of dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_3_11323="Skin testing protocol LA";
var content_f11_3_11323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Skin testing protocol for patients with histories of possible IgE-mediated reactions to local anesthetics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Step",
"      </td>",
"      <td class=\"subtitle1\">",
"       Route",
"      </td>",
"      <td class=\"subtitle1\">",
"       Volume, mL",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dilution",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       Puncture",
"      </td>",
"      <td>",
"       _",
"      </td>",
"      <td>",
"       Undiluted&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       Intradermal",
"      </td>",
"      <td>",
"       0.02 cc",
"      </td>",
"      <td>",
"       1:100",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Prick (epicutaneous) testing is performed initially, with appropriate positive (histamine) and negative (diluent) controls. Results are assessed at 20 minutes. A positive result consists of a wheal 3 mm greater than the negative control. If prick tests are negative, then intradermal testing is performed by injecting 0.02 mL of a 1:100 dilution of the local anesthetic in question.",
"    <div class=\"footnotes\">",
"     &bull; The concentration of the local anesthetic (usually 1 to 2 percent) to be used for the procedure.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11323=[""].join("\n");
var outline_f11_3_11323=null;
var title_f11_3_11324="Features spasmus nutans";
var content_f11_3_11324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features distinguishing spasmus nutans from congenital nystagmus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Congenital nystagmus",
"       </td>",
"       <td class=\"subtitle1\">",
"        Spasmus nutans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Features of nystagmus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Waveform",
"       </td>",
"       <td>",
"        Often mixed with jerk",
"       </td>",
"       <td>",
"        Strictly pendular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amplitude",
"       </td>",
"       <td>",
"        Large, always &gt;3&ordm;",
"       </td>",
"       <td>",
"        Small, often &lt;3&ordm;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amplitude asymmetry",
"       </td>",
"       <td>",
"        Minimal (&lt;25 percent)",
"       </td>",
"       <td>",
"        &gt;25 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frequency",
"       </td>",
"       <td>",
"        Slow, &lt;7Hz",
"       </td>",
"       <td>",
"        Fast, &gt;7Hz",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phase relationship",
"       </td>",
"       <td>",
"        Conjugate",
"       </td>",
"       <td>",
"        Dysconjugate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duration",
"       </td>",
"       <td>",
"        Constant",
"       </td>",
"       <td>",
"        Intermittent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Other features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age at onset",
"       </td>",
"       <td>",
"        &lt;6 months",
"       </td>",
"       <td>",
"        &gt;6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Associated strabismus/amblyopia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        More frequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Head nodding",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Larger and more frequent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Horizontal OKR",
"       </td>",
"       <td>",
"        Absent or inverted",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Gottlob, I, Zubcov, A, Catalano, RA, et al. Ophthalmology 1990; 97:1166.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11324=[""].join("\n");
var outline_f11_3_11324=null;
var title_f11_3_11325="Desensitiz for chemo hypersens";
var content_f11_3_11325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77173%7EONC%2F61477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77173%7EONC%2F61477&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Premedication regimens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Intravenous premedication regimen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Premedications (last dose immediately prior to infusion of chemotherapy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dexamethasone, 10-20 mg iv every 6 hours for 4 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cimetidine, 300 mg iv every 8 hours for 3 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diphenhydramine hydrochloride, 25-50 mg iv every 6 hours for 4 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ondansetron hydrochloride (Zofran), 8 mg iv every 6 hours for 4 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Albuterol nebulizer, 2.5 mg every 6 hours for 4 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Oral premedication regimen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Premedications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dexamethasone, 20 mg po every 6 hours for 4 to 8 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cimetidine, 300-600 mg po every 8 hours for 3 to 6 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diphenhydramine hydrochloride, 25-50 mg every 6 hours for 4 to 8 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Albuterol multidose inhaler, two puffs administered every 6 hours for 8 doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Immediately prior to infusion of chemotherapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dexamethasone, 20 mg iv",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cimetidine, 300-600 mg iv",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diphenhydramine hydrochloride, 25-50 mg iv",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lorazepam, 0.5 mg iv",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ondansetron hydrochloride, 8 mg iv",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       May continue dexamethasone, cimetidine, diphenhydramine during infusion",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Note: Patients with delayed reactions may continue dexamethasone, 8 mg po every 12 hours for 5 days as outpatients.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robinson, JB, Singh, D, Bodurka-Bevers, DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecologic Oncol 2001; 82:555. Copyright &copy; 2001 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Desensitization protocols",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Platinum administration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mix calculated total dose in 100 cc D5W.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Administer 0.1 cc of this solution in 100 cc D5W over 1 h (1:1000 dilution).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If tolerated, administer 1 cc of the solution in 100 cc D5W over 1 h (1:100 dilution).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If tolerated, administer 10 cc of the solution in 100 cc D5W over 1 h (1:10 dilution).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If tolerated, administer the remaining solution over 1 h (1:1 dilution)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       OR: Administer at 25 percent of usual rate for 1 h.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If tolerated, administer at 50 percent of the usual rate for 1 h.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If tolerated, administer at 75 percent of the usual rate for 1 h.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       If tolerated, administer the remaining at usual rate.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Robinson, JB, Singh, D, Bodurka-Bevers, DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecologic Oncol 2001; 82:555. Copyright &copy;2001 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11325=[""].join("\n");
var outline_f11_3_11325=null;
var title_f11_3_11326="CRP troponin mortality";
var content_f11_3_11326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    C-reactive protein and troponin T are predictive of mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the TIMI 11A study of 630 patients with unstable angina or a non-Q wave myocardial infarction, an early positive troponin T level (cTnT) and C-reactive protein (CRP) level &ge;1.55 mg/dL were both associated with an increased mortality at 14 days; the mortality was highest when both levels were elevated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Morrow DA, Rifai N, Antman EM, et al. J Am Coll Cardiol 1998; 31:1460.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11326=[""].join("\n");
var outline_f11_3_11326=null;
var title_f11_3_11327="Hemat transcription factors";
var content_f11_3_11327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76779&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Transcription factors essential for normal hematopoietic development as defined by gene targeting studies in murine embryonic stem cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 407px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The primitive hematopoietic stem cell gives rise to nucleated erythroid cells at the yolk sac stage of development. Subsequently, multilineage hematopoiesis is thought to be derived from the the definitive hematopoietic stem cell. The origins and relationships of the primitive and definitive hematopoietic stem cells remain controversial. Experimental evidence suggests that a common precursor to the primitive and definitive hematopoietic stem cell may exist (blast cell colony-forming cell). The precise hematopoietic pathways remain to be defined.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from Nature, Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature 1997; 386:488. Copyright &copy; 1997 Macmillan Magazines Ltd.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.nature.com\">",
"      file://www.nature.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_3_11327=[""].join("\n");
var outline_f11_3_11327=null;
